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Abstract
Historically, cannabis has been used as a pharmaceutical drug for a variety of conditions
including rheumatism, depression, convulsions, and malaria. Since the 1970s,
randomised, controlled clinical trials have shown cannabis to be effective in the
treatment of debilitating medical conditions including nausea and vomiting resulting
from cancer chemotherapy, wasting syndrome associated with HIV/AIDS, and chronic
pain. Despite scientific evidence, as of 2011, when the material for this thesis was
collected, only 17 states of the United States (U.S.) and the District of Columbia had
enacted medical cannabis laws allowing patients with specific medical conditions to use
cannabis without being criminally prosecuted. This thesis examines two components of
the medical cannabis policy: the medical cannabis policy process in five representative
states of the U.S., and the factors influencing the formation of such a process. The first
part of the thesis chronologically documents the passing, attempts to pass, and failure to
pass medical cannabis policies in five U.S. states; two with a current medical cannabis
law; one where attempts to pass a law have been made, but a law has not yet been
passed; and two states where no or few attempts at passing a medical cannabis law have
been made. The second part of the thesis used a questionnaire to elicit the factors
influencing policies as perceived by three groups. Group one comprised individuals
directly involved in the medical cannabis policy process in at least one of the five states
referred to above and group two comprised individuals participating in research in the
alcohol and other drug field. Group four comprised members of the International
Society for the Study of Drug Policy (ISSDP). The study found that, despite the
expectation that the same rules would apply to cannabis as other medicine, the medical
cannabis process appears to be less medically and more politically driven, with
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scientific evidence having limited influence. The results suggest that there are a number
of interlinking factors which played a role in the passing or failure to pass medical
cannabis laws in U.S. states, and the level of influence of these factors can vary
according to context or conditions placed on them. Three major themes emerged in
relation to the factors influencing policy: the role of scientific evidence, the political
process, and the interaction between factors. It is hoped that this thesis will be viewed as
an observation of the medical cannabis process, not only from the researcher’s point of
view but from the views of those who participated in the process, researched the
process, or observed the changes in medical cannabis laws over the years.
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Chapter 1- Introduction
Studying the origins, development, and implementation of policies allows us to
enhance knowledge of the policy process and examine factors influencing policy
creation and implementation, as well as the effects of policy (Birkland, 2005; Sabatier,
1991; Weible, Heikkila, deLeon, & Sabatier, 2012). If the process by which policies are
enacted is not analysed, important changes and improvements cannot be made (Burch,
1999). Anderson (2003) defined policy as “a relatively stable, purposive course of
action followed by an actor or a set of actors in dealing with a problem or a matter of
concern” (p.2). This definition of policy will be adopted in this thesis. Policies may take
various forms such as legislation, executive orders, or others official acts (Anderson,
2003).
The policy process is complex and inherently political and does not have one
single theoretical foundation (Birkland, 2005; Choi et al., 2005; Ritter, 2011). A number
of theories of the policy process offer insight into the process including “Institutional
Analysis and Developmental Framework”, “Multiple Streams”, “Advocacy Coalition
Framework”, “Policy Diffusion”, “Punctuated- Equilibrium”, and “Social Construction
and Policy Design” (Nowlin, 2011). Because the policy process is complex and
multifaceted, Weible et al. (2012) argued that a single framework cannot explain all its
facets and it is difficult to reach consensus on which is the “best” or most satisfactory
approach (Anderson, 2003). To enable the reader to understand the process for the
development of medical cannabis policies, this thesis will adopt the approach of the
Institute of Medicine (IOM) (1999) study which looked at medical cannabis by
describing what happened with no predetermined framework identified. By taking this
approach, this thesis will provide an account of the medical cannabis policymaking
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process, analyse the evidence and arguments offered in support of the major claims
made for and against the medical use of cannabis, capture what happened in the states
with medical cannabis laws, and describe and analyse the process of development of
medical cannabis policies.
Participants in the United States Policy Making
Birkland (2005) outlined two categories of participants in policy making; official
and unofficial actors. Official actors are involved in public policy and given
responsibilities in laws or in the Constitution and therefore have the power to make and
enforce policies. Unofficial actors include those who play a role in the policy process
but do not have a legal authority. Unofficial actors are involved in the process because
they have important interests to protect and promote. Interest groups are very important
unofficial actors and the impact that they have depends on how powerful the group is,
the control it has over resources, the influence it has on official actors, and access to
information. The decisions in the policymaking process are the cumulative result of
interactions between the many actors involved in the process (Wolf, 2000). The political
process in the U.S. will be discussed in Chapter Two of this thesis.
There is a complex interaction between the actors in the policy process and
mixed evidence on what influences policy (Birkland, 2005; Noel, 2010). There are
normally several actors involved in the process, involving a number of complex
interacting elements over time (Brownson, Chriqui, & Stamatakis, 2009; Choi et al.,
2005; Sabatier, 1999). The policy process can also be long and occur at different levels
of government (Sabatier, 1999). Public policies do not just happen through one isolated
event but are the result of actions or patterns of action taken over time by the actors
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involved (Anderson, 2003). One element in the mix of influences on the policy process
is scientific evidence, which is discussed next.
The Role of the Scientific Evidence
Evidence-based policy is encouraged in public policy and is occurring in some
public sectors (Brownson, Baker, Left, Gillespie, & True, 2011; Davies, Nutley, &
Smith, 2000). The key characteristics of evidence-based policy making in public health
include making decisions using the best available peer-reviewed evidence, using data
and information systems systematically, applying program-planning frameworks,
engaging the community in decision making, conducting sound evaluation, and
disseminating what is learned (Brownson et al., 2009). Ideally, scientific evidence
should always be incorporated in selecting and implementing programs, developing
policies, and evaluating progress (Brownson et al., 2011). However, as the policy
process is a political rather than scientific process no policy process relies solely on
research evidence (Anderson, 2003; Brownson et al., 2009; Brownson et al., 2011;
Pentz, Marers, Schinke, & Rohrbach, 2004; Ritter, 2011). Birkland (2005) and Ritter
(2011) argued that in order for the study of public policy to be useful to the community
as a whole, it is important to bridge the gap between what research tells us and how
citizens and government officials use that information.
Weiss offered seven different models of the use of research in policymaking
(Weiss, 1977, 1979). These are (1) knowledge-driven; (2) problem-solving; (3)
interactive; (4) political; (5) enlightenment; (6) tactical; and (7) intellectual enterprise
(Weiss, 1979). Weiss suggested that the “enlightenment model” was the way in which
scientific research most frequently enters the policy arena (Weiss, 1979). In the
enlightenment model, the impact of research on policy is not direct, but research is
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instead seen as one of several sources of information available to policymakers (Weiss,
1977, 1979). Weiss’ enlightenment model indicates that research utilisation develops
through a gradual shift in thinking and that the accumulation of research will influence
policy by educating the policymakers.
Weiss also identified ways in which the results of policy research enter the
policy field and influence policy decisions (Weiss, 1991). The three ways described by
Weiss are (1) research as data and findings; (2) research as ideas and criticism; and (3)
research as arguments or briefs for policy action (Weiss, 1991). The implication of these
for policy research is that policymakers have to get something out of research if they are
to use it. When research is used as data or findings it is assumed that these meet the
users’ needs and that there is no conflict between what the goal of research is and what
is required by policymakers. Research is likely to be influential when there is consensus
on values and goals of research and policy. When research is used as ideas, the findings
are generalised and diffused into a simple story, altering the way that issues are
conceptualised and problems framed. The ideas from research became absorbed into
conventional wisdom and bring new insights into the policy process in terms of what
needs to be done and what solutions will achieve the desired outcomes. Research as
arguments represents research to which an advocacy position has been added; a decision
has already been made and the policymakers and/or interest groups use research to
support their position. When research is used as arguments, the data are selectively lost
in order to make an argument more persuasive (Weiss, 1991).
Weiss (1991) suggests that research as data is more likely to be influential in
situations of consensus on values and goals, when research has been explicitly designed
to test a limited number of alternatives and findings are clear-cut, when nobody knows
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what the situation is or if the present conditions are unacceptable, and when decision
makers using data are skilled in analysing it so that data are not applied beyond their
generalisability. Research as ideas is more likely to be influential at the early stages of
policy discussion, when existing policy is in crisis and a way out of the situation is
needed, when there is uncertainty around what will work and ideas are needed, and in
decentralised policy arenas where many separate bodies make a decision. Research as
arguments is more likely to be influential when conflict is high and different sides are
seeking justification to strengthen their own case, in legislatures where argumentation is
the prevailing mode, and after decisions have been made and there is continuing need
for legitimation (Weiss, 1991). In practice, while research can be used for different
purposes by policymakers, there are also several barriers to effective use of research in
decision making.
Barriers to research utilisation. Weiss listed the reasons for the limited use of
research in policymaking as weaknesses in the research itself, conflicting demands on
policy, and the discrepancy between what knowledge is needed by policymakers and
what is provided by researchers (Weiss, 1977, 1979). More recently, Black (2001) listed
these reasons as (a) policymakers having their own goals for policies other than
evidence and clinical effectiveness; (b) the dismissal of evidence as irrelevant and not
applicable to a particular sector; (c) lack of consensus about evidence and its
interpretations; (d) focus on other types of evidence such as personal experience; (e) a
social environment not conductive to policy change; and (f) poor quality of knowledge
purveyors.
In terms of public health, Brownson et al. (2011) suggested that the potential
barriers for use of evidence-based decision making are lack of resources, lack of
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leadership and instability in setting a clear and focused agenda for evidence based
approaches, lack of incentives for using evidence-based approaches, and lack of a longterm view for program implementation and evaluation. Brownson et al. (2011) also
suggested that external (including political) pressures can drive the process away from
evidence, as well as inadequate training, lack of time to gather the necessary
information and evidence, lack of evidence on the effectiveness of a specific
intervention, and lack of information on implementation of interventions. Possible
approaches to overcoming these barriers and improving the use of scientific evidence
are discussed next.
Improving the use of scientific evidence. To improve the use of scientific
evidence by policymakers, it is necessary to consider which arguments are likely to be
useful to policymakers (Weiss, 1991). Researchers need to understand the policymaking
process and that their research may not be used in the way they intended, as the
policymakers consider other factors in deciding policy. In order for research to have an
impact, it is necessary to consider the values of the policymakers and the factors other
than research evidence which play a role in the policymaking process (Weiss, 1991).
Davies et al. (2000) believed it important for there to be some agreement on what counts
as evidence in what circumstances, that there should be a strategy of creating evidence
in priority areas, that such evidence needs to be disseminated where it is most needed
and made available for wide use, and that strategies should be put in place to ensure that
evidence is integrated into policy and utilised in practice.
Bacci (2009) suggested that what needs to happen for research evidence to be
used effectively in the process is for researchers and decision makers to collaborate
more instead of working in isolation, and for the decision makers to be involved in all
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stages of research. Decision makers also need to be more transparent about their aims
and objectives and clarify what sort of information they want and how they want to use
it, while researchers also need to make their expectations clear. Bacci (2009) also
suggested that there needs to be more of a synthesis and summary of knowledge rather
than a focus on single studies.
In terms of public health, Brownson et al. (2009) argued that to overcome the
barriers to the use of evidence, potential solutions such as increasing funding, increasing
the understanding of the value of the evidence-based approach and identification of new
ways of shaping organisational culture to support evidence-based decision making need
to be considered. Brownson et al. (2009) also believed that systematic communication
and dissemination strategies need to be implemented as well as wider dissemination of
new and established training programs. Other solutions suggested include enhanced
skills for efficient analysis and review of literature, increased funding for applied
researched and dissemination of findings, and greater emphasis on building the evidence
base for external validity (Brownson et al., 2009). It has also been recognised that
policymakers draw lessons from the actions of their counterparts in other jurisdictions
which is referred to as policy transfer and learning. This is discussed next.
Policy Transfer and Learning
The policy transfer process is described as “the process by which knowledge
about policies, administrative arrangements, institutions and ideas in one political
system (past or present) is used in the development of policies, administrative
arrangements, institutions and ideas in another political system” (Dolowitz & Marsh,
2000, p.5). As different jurisdictions are subjected to similar situations, policymakers
are increasingly looking to other jurisdictions for knowledge and ideas they can apply to

Medical Cannabis in the United States

8

their own jurisdictions (Dolowitz & Marsh, 2000; Wolf, 2000). According to Wolf
(2000) “the most important trend for the future of public administration is the trend
towards global learning processes among practitioners and experts” (p. 696).
Wolf (2000) noted that currently there is no such thing as “best country” in
terms of public administration, but there are instead good and better practices which
need to be identified on the basis of national needs and the requirements for its
adaptation to the political and administrative context in which they are to be applied.
According to Dolowitz and Marsh (2000), policy transfer can occur at international,
national and local levels of governance. Policymakers can also look within their own
political systems to find possible policy solutions. In terms of what can be transferred,
Dolowitz and Marsh (2000) refer to “policy goals, policy content, policy instruments,
policy programs, institutions, ideologies, ideas and attitudes and negative lessons” (p.
12). Peachment (2001) suggested that for each policy consideration the possible courses
of action should focus on what the policy must do, what it must not do, and what it
could do.
A range of actors is likely to become involved in the policy transfer process,
including elected officials, bureaucrats/civil servants, political parties, pressure groups,
policy networks, policy entrepreneurs and experts, think tanks, transnational
corporations, and supranational governmental and nongovernmental institutions and
consultants (Dolowitz & Marsh, 2000; Wolf, 2000). However, policy transfer is not an
“all or nothing” process and the type of transfer likely to occur is subject to a number of
factors such as the actors involved, the resources and time available, and the nature of
the problem faced (Dolowitz & Marsh, 2000). Policy transfer can be direct and indirect
and the reasons why it occurs also vary and are affected by a range of factors,
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illustrating the dynamic and complex nature of the policy process. Peachment (2001)
noted that one of the constraints on policy transfer is that the historical record of policy
development is often unclear, with much policy inherited and many statutes being very
old and never having been tested in law.
Overall, there appears to be a gap between what research shows as effective and
the policies that are enacted and enforced (Birkland, 2005; Brownson, et al., 2009;
Davies et al., 2000; Hanney, Gonzalez-Block, Buxton, & Kogan, 2003; Ritter, 2011).
Evidence can impact on policymaking, but not necessarily in the immediate or direct
way that would be expected by the researchers, as evidence is only one of many factors
that affect policymaking (Black, 2001; Brownson et al., 2009). It is also not enough for
research to be available as it needs to be research that is wanted and can be used by
policymakers. Evidence-based policy is difficult to achieve and policies created do not
necessarily reflect evidence (Hanney et al., 2003). Evidence can be used to make
evidence-based policy but evidence itself may not necessarily be used by the
participants in the process (Birkland, 2005; Brownson et al., 2009; Hanney et al., 2003).
The extent of the involvement of researchers in the policy process has also been
questioned. Pentz et al. (2004) argued that researchers were reluctant to get involved in
the highly political policy process and that the lack of attention paid to evidence
reflected historical precedent rather than deliberate inattention. In order for research to
have an impact on policy, researchers need to have an understanding of the policy
process and the political nature of policymaking and that science is just one of many
elements under consideration (Davies et al., 2000; Schenkel, 2010; Pentz et al., 2004;
Weiss, 1998).
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Overall, it is important to analyse policies in order to obtain a better
understanding of how the policy process works, how problems and issues are identified
and placed on the political agenda, how and why governments choose to act or not act
on policies, and what the effects of the policies are. One policy that has ignited debate in
recent years is that of medical cannabis. For the purposes of this thesis, cannabis will be
the term applied to all products derived from the plant Cannabis sativa, which has over
400 compounds (Institute of Medicine [IOM], 1999; McPartland & Russo, 2001; Ryder,
Walker, & Salmon, 2006).
In 1996 California became the first state in the U.S. to legalise the cultivation,
possession and use of cannabis for medical purposes (Marijuana Policy Project [MPP],
2013; Zeese 1999). It was the first in a string of state medical cannabis movements in
the U.S. Since 1996, despite federal opposition, when the material for this thesis was
collected, 17 1 U.S. states and the District of Columbia have enacted medical cannabis
laws (MPP, 2013; ProCon.org, 2014). In order to understand what happened in the
states that enacted or did not enact medical cannabis laws, it is important to look at the
history of drug policy in the U.S., and medical cannabis in particular. The following
section will provide a background to the history of medical cannabis in the U.S. and
recount the events leading up to the passage of the medical cannabis laws.

1

Since 2011 when the material for this thesis was collected, , six more states have enacted medical
cannabis laws. As of November 2014, 23 states and the District of Columbia have enacted medical
cannabis laws.
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History of Medical Cannabis in the United States
The U.S. has a complex history of drug control policy, but the restriction of use
and distribution of drugs at the federal level goes back approximately 100 years
(McBride, Terry-McElrath, Harwood, Inciardi, & Leukefeld, 2009). Previous to 1914,
any restrictions on use and distribution of drugs were at the state or local level, and it
was thought that federal control over drug use and prescription practices by medical
professions was unconstitutional (Musto, 1999). Drugs such as heroin, morphine, and
cannabis were readily available and sold as part of medicines. The U.S. history of
medical cannabis began with the first American Conference on the Medical Use of
Marijuana in Ohio in 1860, where physicians reported its effectiveness in the treatment
of conditions including chronic cough, gonorrhoea and pain (Grinspoon, 2000; IOM,
1999; Ruiz, Strain, & Langrod, 2007).
Gradually, federal commerce and tax powers were broadened by Supreme Court
decisions and occurred in the context of major social reforms, such as the shift towards
safe food and drugs which led to the Pure Food and Drug Act of 1906 and the Harrison
Act of 1914 (McBride et al., 2009; Musto, 1999). The Pure Food and Drug Act required
that any quantity of cannabis, as well as several other substances, be clearly marked on
the label when sold to the public (Musto, 1999). After the passage of the Pure Food and
Drug Act in 1906, campaigning for federal anti-drug laws gained momentum.
As cannabis became widely used as a medicine, recreational use of the drug also
increased. While cannabis use was mostly supported by the public, in the 1920s the
federal government started giving more attention to drug use and there was political
pressure for the federal government to regulate cannabis, amongst other drugs (Musto,
1999). The passage of the Harrison Tax Act saw the federal government not only
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collecting taxes and ensuring registration of drug users, but also the prosecution of
doctors that prescribed the drugs. Since it was brought to the U.S. in the 1800s, cannabis
was recognised as an effective medicine, and by the 1930s at least two American
companies were selling medicines containing cannabis (Grinspoon, 2000; Mack & Joy,
2000; Ruiz et al., 2007). During the 19th and 20th century the drug’s recreational use
increased and it became popular among minorities, such as immigrants and AfricanAmericans. Fear of cannabis was seen in areas with concentrations of Mexican
immigrants, who were feared as a source of crime and deviant social behaviour (Musto,
1999). The end of the 1920s saw the emergence of reports of negative effects of
cannabis, including crime and death (Mack & Joy, 2000; Marshall, 2005).
Consequently, the U.S. Congress passed the Marihuana Tax Act of 1937, which
imposed a $1-an-ounce tax for industrial and medicinal use of cannabis and a $100-anounce tax for the drug’s recreational use (Eddy, 2010; Koch, 1999). While cannabis was
not made illegal by this act, the prohibitive tax imposed on it made it difficult to get
cannabis, including for medical purposes (Gieringer, Rosenthal, & Carter, 2008). As a
result, the use of cannabis reduced significantly and doctors eventually ceased to
prescribe it. By 1942, cannabis was no longer included in the U.S. Pharmacopeia
(American College of Physicians [ACP], 2008; Koch, 1999). U.S. states also started
passing laws making cannabis illegal and by 1937 cannabis use was prohibited in every
state (Gieringer et al., 2008; Musto, 1999).
The use of cannabis increased in the 1960s, which was also a period of
economic growth in the U.S. (Musto, 1999). Cannabis also became a political issue,
associated with anti-war protests and the use of the drug was no longer associated only
with minorities (Musto, 1999). However, cannabis remained legal under federal law
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until the Controlled Substances Act (CSA) of 1970 (Controlled Substances Act [CSA],
1970; Eddy, 2010). The act was signed into law by President Nixon, at a time when
drug use and its associated harm were increasing (Musto, 1999). The act classified all
drugs into schedules, and cannabis was placed in the most restrictive, Schedule I
category, together with LSD and heroin. This classification implied that cannabis had no
accepted medical use, had a high potential for abuse, and could not be used safely even
under medical supervision (CSA, 1970). Figure 1 outlines the history of medical
cannabis in the U.S. since the enactment of the CSA. 2

2

The chronological account in the original thesis ended in 2011; all events from 2011 leading up to 2014
have been subsequently added.
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1970
1971

14

• U.S. Congress passed the Controlled Substances Act. Cannabis classified as Schedule I
substance
• National Organization for the Reform of Marijuana Laws (NORML) founded
• The National Commission on Marijuana and Drug Abuse created by President Nixon and
led by Raymond P. Shafer

• President Nixon declares a "War on Drugs"

1972

• National Organization for the Reform of Marijuana Laws (NORML) files first ever
administrative petition to reschedule cannabis for medical use, under the Controlled
Substance Act
• The Shafer Commission recommends that cannabis should be decriminalised for personal
use. President Nixon rejects the recommendations

1974

• National Institute on Drug Abuse (NIDA) established, placed in charge of contracts to grow
cannabis for research purposes
• The U.S. Court of Appeals for the District of Columbia Circuit orders the Bureau of
Narcotics and Dangerous Drugs to process NORML's petition

1976
1977
1978

• Federal court rules Robert Randall's use of cannabis a "medical necessity"

• President Jimmy Carter endorses the Shafer Commission’s findings and endorses cannabis
decriminalisation

• Federal government IND Compassionate Use Program supplies patients with cannabis
• New Mexico passes first state law recognising medical value of cannabis

1981

• Robert Randall forms organisation to help others obtain access to medical cannabis

1985

• Marinol approved by the Food and Drug Administration (FDA)

1988

• Drug Enforcement Administration (DEA) Administrative Law Judge Francis Young rules in
favour of NORML to make cannabis a medicine
• The Reagan administration and Department of Justice appeal Judge Young’s ruling seeking
to uphold a total ban on cannabis
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1992

1994

1996

1998

1999

2000

2001

2003

2004

15

• San Francisco becomes the first city to pass a medical cannabis ordinance
• Federal Government suspends IND Compassionate Use Medical Marijuana Program

• IND Compassionate Use Program officially terminated; existing patients continue to get
government cannabis

• The U.S. District Court of Appeals makes a final decision in favor of the Drug Enforcement
Administration in NORML vs. DEA

• California becomes first state to legalise the cultivation, possession and use of cannabis for
medical purposes, laying the groundwork for future laws across the country
• Arizona voters pass a medical cannabis initiative which proved ineffective

• Alaska, Oregon, Washington, and the District of Columbia pass medical cannabis laws
• Presidents Ford, Carter, and Bush urge voters to reject medical cannabis

• Maine voters approved a medical cannabis initiative
• Institute of Medicine (IOM) conducts comprehensive study on medical effects of cannabis
• Marinol moved to Schedule III to increase availability to patients

• Nevada and Colorado voters approve medical cannabis initiatives
• Hawaii legislature passed medical cannabis legislation

• Supreme Court rules that there is no medical necessity exception to the Controlled
Substances Act in U.S. v. Oakland Cannabis Buyers’ Cooperative

• U.S. House of Representatives rejects amendment to stop federal raids on medical cannabis
patients

• Montana voters approve a medical cannabis initiative
• Vermont’s legislature passed medical cannabis legislation
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2007
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• The U.S. Supreme Court upholds the power of Congress to prohibit and prosecute medical
cannabis even in the states that permit it
• The States’ Rights to Medical Marijuana Act introduced to 109th Congress

• Rhode Island legislature passes medical cannabis legislation
• FDA confirms opposition to smoked cannabis for medical purposes

• New Mexico legislature passes medical cannabis legislation
• DEA Administrative Law Judge recommends allowing new source of cannabis for research

2008

• Michigan voters approve medical cannabis initiative
• The American College of Physicians calls for cannabis reclassification and supports nonsmoked forms of medical cannabis

2009

• DEA rejects judge's ruling to allow new source of cannabis for research
• Deputy Attorney General says raids on medical cannabis clinics will not continue
• The American Medical Association calls on the federal government to reconsider cannabis'
classification under federal law

2010

• Arizona voters approve medical cannabis initiative
• District of Columbia City Council passes medical cannabis legislation
• New Jersey legislature passes medical cannabis legislation

2011

• Delaware legislature passes medical cannabis legislation
• First ever cannabis legalisation bill introduced into the US Congress
• U.S. Attorneys send letters to states with medical cannabis
• DEA denies petition to initiate proceedings to reschedule cannabis

2012

• Connecticut legislature passes medical cannabis legislation
• Massachusetts voters approve a medical cannabis initiative

2013

• New Hampshire legislature passes medical cannabis legislation
• Illinois legislature passes medical cannabis legislation
• The Justice Department announces that it will not challenge state cannabis laws
• U.S. Appeals Court upholds rejection of the cannabis rescheduling petition

2014

• Maryland legislature passes medical cannabis legislation
• Minnesota legislature passes medical cannabis legislation
• New York legislature passes medical cannab is legislation

Figure 1. Time chart of medical cannabis in the U.S. since the enactment of the CSA.
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The 1970 CSA authorised the creation of a National Commission on Marihuana
and Drug Abuse and President Nixon appointed Raymond P. Shafer, formerly Governor
of Pennsylvania, to head the commission, which later became known as the Shafer
Commission (Bonnie, 2001; Gieringer et al., 2008). Its purpose was to to undertake a
two-year study on cannabis and the causes of drug abuse in general. The commission
reviewed the available literature on cannabis use and its effects and also sponsored its
own research (Bonnie, 2001). In the same year, the National Organization for the
Reform of Marijuana Laws (NORML) was founded by Keith Stroup, a public-interest
attorney (NORML, 2014a). The NORML was founded as a non-profit public-interest
advocacy group to oppose cannabis prohibition and favour an end to the practice of
arresting cannabis users.
In a special message to the Congress on Drug Abuse Prevention and Control on
17 June 1971, President Nixon said that drug abuse had assumed the dimensions of a
national emergency and that he was therefore “transmitting legislation to the Congress
to consolidate at the highest level a full-scale attack on the problem of drug abuse in
America” (Nixon, 1971). The movement later became more commonly known as the
“War on Drugs”. In 1972 the Shafer Commission issued its first report which found that
“there is no evidence that experimental or intermittent use of marihuana causes physical
or psychological harm” (as cited in Zeese, 1999, p. 344). The commission therefore
recommended decriminalisation of possession of cannabis for personal use and casual
distribution in private of small amounts of cannabis, but that growing and selling of
cannabis remain a criminal offence (Bonnie, 2001; Zeese, 1999).
While President Nixon immediately rejected the recommendations, the
publication of the commission’s findings reflected a shift in elite opinion. The report
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was followed by the National Conference of Commissioners on Uniform State Laws
supporting amendments to the CSA based on the commission’s recommendations and
the endorsement of some forms of cannabis decriminalisation by various national
organisations (Bonnie, 2001; Caulkins, 2012). In 1977, in a message to the U.S.
Congress, President Carter endorsed the findings of the Shafer Commission and
decriminalisation of cannabis (Bertram, Blachman, Sharpe, & Andreas, 1996; Bonnie,
2001). However, political and legislative support for cannabis decriminalisation was
decreasing and the more permissive stance on cannabis decriminalisation during the
Carter Administration led to an increase in public resistance and opposition from lobby
groups (Bonnie, 2001). In 1982, the National Academy of Sciences came to similar
conclusions as the Shafer Commission in relation to cannabis, and the findings were
rejected by President Reagan (Bertram et al., 1996; Gieringer et al., 2008).
In 1972, the NORML foundation filed the first ever administrative petition with
the Bureau of Narcotics and Dangerous Drugs (BNDD) to move cannabis to Schedule II
of the CSA (Koch, 1999; Zeese, 1999). This schedule encompasses drugs that have a
strong potential for abuse or addiction but also have recognised medical use (CSA,
1970). Substances placed in this schedule include morphine, cocaine, and oxycodone.
The petition was rejected by the BNDD and the NORML appealed the decision. In
1974, the U.S. Court of Appeals for the District of Columbia Circuit ordered the BNDD
to process the NORML petition (Zeese, 1999). It wasn’t until 1986 that the Drug
Enforcement Administration (DEA) initiated public hearings on whether cannabis
should be rescheduled (Clark, 2000). The hearings lasted two years, and in 1988 Judge
Francis L. Young recommended that cannabis be moved from Schedule I to Schedule II.
However, as his ruling was a recommendation only, the final decision was left to the
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DEA administrator (Clark, 2000). In 1989 the DEA administrator John Lawn overruled
Judge Young’s ruling to reschedule cannabis and stated that there was no scientific
evidence to support claims that cannabis is better than other drugs used in the treatment
of any medical condition (Koch, 1999; Werner, 2001). Cannabis research projects are
rarely approved due to a complicated federal approval process and the difficulty of
obtaining research-grade cannabis; this makes it difficult for scientific evidence to be
obtained (Marshall, 2005). Martin and Rashidian (2014) note that “the federal
government has never approved a plant in its entirety as medicine, and it’s unlikely it is
going to begin with the controversial cannabis plant” (p. 17).
In 1974, the National Institute on Drug Abuse (NIDA) was established as a
federal government research institute “for research, treatment, prevention, training,
services, and data collection on the nature and extent of drug abuse” (National Institute
on Drug Abuse, [NIDA], 2014b). It is the single official source of cannabis for
medicinal research. The institute funds a wide range of research on cannabis and also
supports a drug supply program which provides research-grade cannabis to researchers
(NIDA, 2014a). The NIDA contracts with the University of Mississippi to grow
cannabis for use in research and it is there that cannabis is grown, harvested, stored and
made into cigarettes or other purified elements of cannabis. To obtain research-grade
cannabis through the NIDA, the research must be approved by the Food and Drug
Administration (FDA), the DEA, and the NIDA (NIDA, 2014a).
The FDA approval process. In the U.S., before a drug can be prescribed, it
needs to undergo the FDA’s approval process. Under the federal Food, Drug, and
Cosmetic Act, to be approved by the FDA, the drug in question first needs to be tested
as an Investigational New Drug (IND). Sponsors of the drug need to complete
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preclinical testing in laboratory animals to demonstrate its effectiveness and safety and
outline what they propose to do for human testing, following which the FDA decided
whether it is safe for the drug to be tested in humans. This stage is followed by clinical
trials in humans and after extensive testing showing effectiveness and safety, a potential
manufacturer is required to file a New Drug Application with the FDA. It is then up to
the FDA to determine whether the drug is safe and effective for its proposed use,
whether the benefits of the drug outweigh its risks, and whether the methods used in
manufacturing the drug and the controls used to maintain the drug's quality are adequate
to preserve the drug's integrity, strength, quality, and purity (Federal Food, Drug, and
Cosmetic Act, 2000). The decision is made based on clinical trials, where the drug in
question has to be proven safe and effective for human use (Federal Food, Drug, and
Cosmetic Act, 2000; Joy, Watson, & Benson, 1999). If the FDA determines that the
benefits of the drug outweigh its risks, it will allow it to be manufactured (Federal Food,
Drug, and Cosmetic Act, 2000). For cannabis, the process is made more difficult due to
cannabis’ Schedule I classification and the fact that cannabis for research can only be
obtained through the federal government (ACP, 2008; Joy, et al., 1999).
In 1976, Robert Randall, a glaucoma patient, became the first person to use a
medical cannabis necessity defence to defend himself against cannabis charges
(Gieringer et al., 2008). With the support of his doctor, Randall argued that cannabis
was the only drug that would prevent him from going blind (Gieringer et al., 2008).
After the charges were dropped Randall successfully lobbied the federal government to
allow him access to medical cannabis under the IND program, becoming the first U.S.
citizen to receive federally supplied cannabis under the IND program. Randall also
lobbied for cannabis’ rescheduling and in 1981 he formed the Alliance for Cannabis
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Therapeutics to lobby state legislatures to protect medical cannabis patients from arrest
and prosecution (Gieringer et al., 2008; Werner, 2001).
The IND program was established in 1976 and the patients were considered to
be participants in research on medical cannabis (Gieringer et al., 2008). As part of the
program, a limited number of patients were approved by the FDA to receive
government supplies of medical cannabis grown at the University of Mississippi. It was
difficult for patents to qualify for the program and it was expanded to approximately 30
patients until suspended in 1991 and closed in 1992 by the Bush Administration, who
believed too many people were seeking access to medical cannabis supplies and they
did not want to send the wrong message to the public (Clark, 2000; Werner, 2001). As
the decision proved unpopular, it was decided that already approved program
participants would receive cannabis for the rest of their lives while others would be
prescribed dronabinol (distributed in the U.S. as Marinol), a synthetic form of Delta-9Tetrahydrocannabinol (THC) (Gieringer et al., 2008; Werner, 2001).
First medical cannabis IND program. In 1978, New Mexico became the first
state to pass legislation recognising cannabis as a medicine (Koch, 1999). By 1983, 34
states had enacted legislation which allowed their health departments to conduct
research on the effectiveness of cannabis as a medicine under the IND program (Koch,
1999; Werner, 2001). The cannabis required for research was to be supplied by the
federal government. However, due to its classification as a Schedule I substance,
cannabis could only be distributed to patients through the NIDA (Werner, 2001). The
process proved to be difficult and only six states (New Mexico, California, New York,
Tennessee, Michigan, and Georgia) obtained research-grade cannabis for medical
cannabis research; the other states received oral THC pills (Koch, 1999; Werner, 2001).
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In June 1985, dronabinol (Marinol) was moved to Schedule II of the CSA
(Werner, 2001). Marinol was approved for use in the treatment of the AIDS wasting
syndrome, and nausea and vomiting associated with cancer chemotherapy (ACP, 2008).
The rescheduling followed research which indicated that THC was effective in the
treatment of nausea. Marinol was reclassified as a Schedule III substance in 1999, after
a study found that Marinol had low abuse potential. However, it has been suggested that
the federal government decided to make THC legally available after political pressure in
support of cannabis and in an effort to stem medical demand for cannabis in its natural
form (Gieringer et al., 2008; IOM, 1999; Zeese, 1999). Access to cannabis remained
limited, and as Werner (2001) states:
Despite the fact that a synthesized and concentrated version of cannabis’
most active compound was rescheduled, the source plant was not. With
marijuana withheld, and synthetic THC available by prescription, the
state medical marijuana research programs slipped into dormancy. (p.
22).
In 1991, San Francisco activists succeeded in getting “Proposition P” on the
ballot which passed with 79 percent of the vote (Zeese, 1999). The initiative was in
favour of patients having access to cannabis for medical purposes. The same year,
following an appeal to the U.S. Court of Appeals by the Alliance for Cannabis
Therapeutics and the NORML, the Court rejected the DEA’s 1989 findings that there
was no scientific evidence to support medical cannabis claims and reschedule cannabis
and ordered the DEA to reconsider their position. The DEA did not change their view.
The decision was again appealed, and after 22 years of litigation the final decision was
rendered by the U.S. District Court of Appeals upholding the DEA’s decision to keep
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cannabis in Schedule I (Pacula, Chriqui, Reichmann, & Terry-McElrath, 2002; Zeese,
1999).
After the failed litigation to reschedule cannabis, a national movement emerged.
In 1995 activists in California gathered the required signatures for a medical cannabis
proposition and in 1996 California became the first state to legalise the cultivation,
possession and use of cannabis for medical purposes when it passed Proposition 215, a
ballot initiative, with 56 percent of the vote in favour (MPP, 2013; Zeese 1999). This
was at odds with the federal law which prohibits possession, sale and cultivation of
cannabis. In the same year Arizona voters also passed a medical cannabis initiative but
it was ineffective because it required medical cannabis patients to have a doctor’s
prescription. It should be noted that using the word “prescribe” made the law
ineffective, as doctors cannot legally prescribe an illegal substance to their patients
(Delaney, 2010a). In 1998, voters in Alaska, Oregon, Washington and the District of
Columbia (D.C.) passed medical cannabis initiatives similar to California (MPP, 2013).
However, the DC initiative did not take effect until 2010 as Congress was able to
prevent it from taking place because D.C. is a district and not a state (MPP, 2013).
While the states were passing medical cannabis laws, in 1998 former Presidents
Ford, Carter, and Bush released a statement urging voters to reject state medical
cannabis initiatives (Mack & Joy, 2000). The presidents said that the state initiatives
bypassed the FDA approval process and believed that medicine must be based on
science and not political appeals (Mack & Joy, 2000). However, medical cannabis
initiatives continued to be passed and in 1999 Maine voters also approved a medical
cannabis initiative (MPP, 2013).
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In 1999, the IOM published the findings of their comprehensive study on
medical effects of cannabis (IOM, 1999). The study was requested by the White House
Office of National Drug Control Policy (ONDCP) as a critical review of scientific
evidence pertaining to medical use of cannabis (IOM, 1999; Mack & Joy, 2000). The
report recognised that cannabis has therapeutic properties and recommended that the
drug be made available to individuals requiring it (IOM, 1999). The 1999 IOM report
outlined both positives and negatives of cannabis use and found evidence that cannabis
can offer “broad-spectrum” relief from severe pain, nausea, and appetite loss associated
with AIDS or chemotherapy patients; offered moderate promise for alleviating
symptoms associated with muscle spasticity; and was least promising for movement
disorders, epilepsy and glaucoma. It found no significant data showing that cannabis
was a “gateway” drug, leading to other drug use. The report concluded that:
The critical issue is not whether marijuana or cannabinoid drugs might
be superior to the new drugs, but whether some group of patients might
obtain added or better relief from marijuana or cannabinoid drugs. (p.
153).
In 2000, Nevada and Colorado voters also passed medical cannabis initiatives
(MPP, 2013). The same year, Hawaii’s legislature became the first to pass a law to
remove criminal penalties for medical cannabis. In 2001, in the first medical cannabis
case heard by the U.S. Supreme Court, the U.S. government sued the Oakland Cannabis
Buyers’ Cooperative, organised to distribute cannabis for medical purposes to qualified
patients, to cease operating as their activities violated the CSA’s prohibitions on
distributing, manufacturing, and possessing with the intent to distribute or manufacture
cannabis (United States v. Oakland Cannabis Buyers' Cooperative, 2001; MPP, 2013).
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The U.S. Supreme Court ruled that there is no medical necessity exception to the CSA
and that the medical necessity defence cannot be used to avoid federal prosecution by
third parties seeking to manufacture or distribute cannabis for others who need it
(United States v. Oakland Cannabis Buyers' Cooperative, 2001; MPP, 2013). However,
the question of whether individual patients charged with personal possession or
cultivation can use the medical necessity defence was left open. It is notable that the
CSA makes no distinction between medicinal and recreational use of cannabis. The
second and last medical cannabis case to be heard at the federal level was “Gonzales v.
Raich” (Gonzales v. Raich, 2005; MPP, 2013). The case followed DEA raids on two
medical cannabis patients who argued that the federal government’s powers to regulate
interstate commerce did not extend to their personal use and cultivation of medical
cannabis. In 2005, the U.S. Supreme Court ruled that the Congress has the power to ban
the use of medical cannabis even where states approve its use for medicinal purposes
(Gonzales v. Raich, 2005). The court did not question the validity of the state laws and
the patients remained protected under state, but not federal law.
In 2003, during the 108th Congress, in response to DEA raids on medical
cannabis users and providers in states with medical cannabis laws, Representative
(Rep.) Maurice Hinchey and Rep. Dana Rohrabacher introduced a bipartisan bill
seeking to prevent the Department of Justice from using appropriated funds to interfere
with the operations of medical cannabis laws in states with such laws (Departments of
Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act,
2004). Between 2003 and 2007 the bill was debated and rejected five times, the
opponents arguing that smoked cannabis is not safe and effective as medicine and sends
the wrong message to young people (Eddy, 2010).
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A more specific bill, the States’ Rights to Medical Marijuana Act (2005), was
introduced in 2005 and sought to move cannabis from Schedule I to Schedule II of the
CSA. It also sought to provide that in states with medical cannabis laws no provisions
of the CSA or the Federal Food, Drug, and Cosmetic Act could prohibit or restrict
prescription or recommendation of cannabis by a physician for medical use or an
individual from obtaining and using cannabis from a prescription or recommendation of
cannabis by a physician for medical use by such individual. The bill was never referred
to a committee hearing (Eddy, 2010).
In 2004, Montana voters approved a medical cannabis initiative and Vermont’s
legislature passed medical cannabis legislation and in 2006 Rhode Island became the
11th state to legalise medical cannabis after its legislature overrode the governor’s veto
(MPP, 2013). In 2006, the FDA said that they opposed medical cannabis and supported
its listing in the most restrictive CSA Schedule I (FDA, 2006). The FDA stated that
smoked cannabis is harmful, and that no scientific evidence supports its medical use.
They also said that there are FDA-approved medications for treatment of different
conditions that can be used instead of cannabis. The agency also stated that if cannabis
were to be marketed, there would need to be sufficient scientific evidence showing it is
safe and effective to use (FDA, 2006). However, due to federal opposition to medical
cannabis and a difficult research approval process, few controlled studies have been
approved and conducted in the U.S. (Marshall, 2005).
In another first for New Mexico, attempts to legalise medical cannabis were
successful in 2007, when Democratic (D) Governor (Gov.) Bill Richardson became the
first governor in history to enact a medical cannabis law while running for the
presidency (Lynn and Erin Compassionate Use Act, 2007; MPP, 2013). He signed
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Senate Bill 523 into law, making New Mexico the 12th state to allow medical cannabis
use for qualifying patients. The House of Representatives approved the bill by a 36-31
vote, while the Senate approved it 32-3 (MPP, 2013).
Showing how difficult it is to obtain cannabis for research purposes, Lyle
Craker, at the University of Massachusetts, petitioned the DEA for permission to
cultivate cannabis to use in university-approved clinical studies on cannabis’
effectiveness as a medicine (Eddy, 2010; MPP, 2013). In 2007, the DEA Administrative
Law Judge, Mary Ellen Bittner, recommended that Craker’s application be granted and
concluded that “there is currently an inadequate supply of marijuana available for
research purposes, that competition in the provision of marijuana for such purposes is
inadequate…” (U.S. Drug Enforcement Administration, 2007, p. 87). The Judge also
concluded that Craker’s registration to cultivate cannabis would be “in the public
interest”. However, because rulings by administrative law judges are nonbinding, in
2009 the DEA rejected Judge Bittner’s recommendation (Lyle E. Craker; Denial of
Application, 2009). It wasn’t the first time the DEA rejected an administrative law
judge’s recommendation, as it previously happened to Judge Young’s 1998 ruling.
On November 4, 2008, the Michigan Medical Marihuana Act (2008), which
allows the use of medical cannabis for qualifying patients, was approved by Michigan
voters through a ballot initiative. The same year the ACP questioned cannabis’ Schedule
I placement and urged a review of this (ACP, 2008). The ACP said they supported
programs for scientific research into cannabis as a medicine, but also noted that the
research has been limited by a difficult approval process, difficulty in obtaining
research-grade cannabis, and the legalisation debate (Clark, 2000). The American
Medical Association (AMA) (2009) also called for more controlled clinical studies to be
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conducted on cannabis as a medicine and recommended a review of cannabis’ Schedule
I classification in order to enable more research to be conducted on its potential as a
medicine. The association also urged the National Institutes of Health (NIH) to
implement administrative procedures which would assist in developing and conducting
clinical trials into medicinal properties of cannabis (AMA, 2009).
In October 2009, the Obama Administration Deputy Attorney General David
Ogden issued a memorandum to U.S. attorneys saying that in states with medical
cannabis laws federal resources should not focus on individuals whose actions “are in
clear and unambiguous compliance with existing state laws providing for the medical
use of marijuana” (U.S. Office of the Deputy Attorney General, 2009, p.2). The
announcement followed a pledge that was made by then-candidate Obama during the
presidential campaign (Eddy, 2010). In a subsequent memorandum in June 2011,
Deputy Attorney General James Cole reaffirmed that medical cannabis patients should
not be targeted and stated that “it is likely not an efficient use of resources to focus
enforcement efforts on individuals with cancer or other serious illnesses who use
marijuana as part of a recommended treatment regimen consistent with applicable state
law, or their caregivers” (U.S. Office of the Deputy Attorney General, 2011, p.1).
However, he also added that state laws or local ordinances are not a defence to civil or
criminal enforcement of federal law with respect to individuals who are in the business
of cultivating, selling, or distributing cannabis and are in violation of the CSA (U.S.
Office of the Deputy Attorney General, 2011).
In 2010 Arizona voters approved a medical cannabis initiative (MPP, 2013).
This law used the word “certification” instead of “prescription” which made the medical
cannabis law effective, unlike the state’s 1996 measure. The same year, New Jersey
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legislature passed medical cannabis legislation (MPP, 2013). New Jersey became the
first state to enact a medical cannabis law that did not provide for home cultivation but
relied solely on medical cannabis dispensaries.
Medical cannabis since 2010. Since 2010, there has been an increase in medical
cannabis laws being passed through the legislative process; Delaware, Connecticut,
New Hampshire, Illinois, Maryland, Minnesota and New York legislatures passed
medical cannabis legislation. Since Arizona voters approved a medical cannabis
initiative in 2010, all other state laws to date were passed by the legislature. At the time
when the material for this thesis was collected, 17 3 of 50 U.S. states and the District of
Columbia have enacted laws allowing the use of cannabis for medical purposes (MPP,
2013; ProCon.org, 2014). Ten of the state medical cannabis laws were passed by a
ballot initiative and seven were passed by the legislature (ProCon.org, 2014). It is
important to note the role of state legislatures in the medical cannabis movement, as
only 17 U.S. states and the D.C. have an initiative process under which citizens can, by
collecting a specified number of signatures on a petition, place an issue before the
state’s electorate (Birkland, 2005; Britannica Educational Publishing [BEP], 2010;
Howard, 2005; Initiative and Referendum Institute [IRI], 2009; Katz, 2003). This means
that 27 states must rely on their state legislatures to enact medical cannabis laws.
In 2011, a first ever federal cannabis legalisation bill was introduced into the
U.S. House of Representatives (Ending Federal Marijuana Prohibition Act, 2011). The
bill sought to remove cannabis from the CSA schedule and remove prohibition on its

3

Since 2011, when the material for this thesis was collected, six more states enacted medical cannabis
laws, taking the number of states with medical cannabis laws to 23.
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import and export; the language of the bill was similar to the changes enacted by the
Congress to repeal the federal prohibition of alcohol (NORML, 2011). On their website,
the NORML stated that their organisation along with representatives from the Drug
Policy Alliance (DPA), Students for Sensible Drug Policy and the Marijuana Policy
Project (MPP) worked closely with members of Congress in drafting the bill (NORML,
2011). The bill was not enacted and was introduced again during the 113th U.S.
Congress (Ending Federal Marijuana Prohibition Act, 2013).
In 2011, the DEA also rejected a petition to reschedule cannabis in “Americans
for Safe Access v. DEA” (2013) and the rejection of the rescheduling petition was
upheld in federal court in 2013 (MPP, 2013; U.S. Drug Enforcement Administration,
2011). However, in 2013 Deputy Attorney General James Cole again issued a
memorandum to federal attorneys in which he outlined the federal law enforcement
policy in relation to state medical cannabis laws and instructed federal attorneys and law
enforcement to focus their resources and efforts on the enforcement priorities outlined
in the memorandum, while emphasising that “the Department of Justice has not
historically devoted resources to prosecuting individuals whose conduct is limited to
possession of small amounts of marijuana for personal use on private property” (U.S.
Office of the Deputy Attorney General, 2013, p.2). He also wrote that the federal
government has traditionally relied on states and local law enforcement agencies to
address cannabis activity through the enforcement of their own laws. The interplay
between state and federal government will be further discussed in Chapter Two.
Overall, over the years medical cannabis activists have turned to state and local
governments in order to pass medical cannabis laws and enable patients to obtain
cannabis for medical purposes. While the state medical cannabis laws are effective at
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the state level, the laws put the states in violation of federal laws because cannabis is a
Schedule I substance according to the CSA (Eddy, 2010; MPP, 2013). Medical cannabis
patients, their caregivers, and cannabis providers can therefore be arrested and
prosecuted at the federal level, although the federal government has indicated as
recently as 2013 that prosecuting medical cannabis patients would not be their priority.
However, what has also been created by state medical cannabis laws is what Cohen
(2010) referred to as a “regulatory vacuum” creating an absence of appropriate state
regulations to control the distribution and use of medical cannabis. As Cohen put it:
It should be obvious that unless physicians adhere to their ethical and
fiduciary responsibilities to patients, controlling the number of
dispensaries or limiting the areas allowed for cultivation will not suffice
to allow marijuana to be treated as a genuine medication recommended
in good faith as part of the legitimate practice of medicine. (p.659).
There has also been a push to reschedule cannabis from Shedule I of the CSA in
order to permit medical use. However, the federal government has maintained its stance
that cannabis is not safe and that no sound scientific studies supported medical use of
cannabis (Cohen, 2010; Eddy, 2010). This has been made more difficult by restrictions
placed on medical cannabis research, and the fact that the results of research that does
get conducted are not always accessed by those who need to make policy-related
decisions and are not always used as intended by scientists. Clark (2000) suggested that
if cannabis were moved to Schedule II to be used for medical purposes, the federal
government would be able to better regulate its use.
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Medical cannabis advocates note that cannabis will most likely not be
rescheduled until there is sufficient scientific evidence for its effectiveness (Marshall,
2005). However, cannabis research projects are rarely approved (Cohen, 2010;
Marshall, 2005). Under the federal Food, Drug, and Cosmetic Act, the FDA decides
whether a drug is sufficiently safe and effective to enter the marketplace (Federal Food,
Drug, and Cosmetic Act, 2000). The decision is based on clinical trials, where the drug
in question has to be proven safe and effective for human use (Federal Food, Drug, and
Cosmetic Act, 2000; Joy, Watson, & Benson, 1999). The drug in question is first tested
as an IND and, after a series of tests demonstrating its effectiveness and safety, a New
Drug Application is filed with the FDA. If the FDA determines that the benefits of the
drug outweigh its risks, it will allow it to be manufactured for commerce (Federal Food,
Drug, and Cosmetic Act, 2000). The process is made more difficult due to cannabis’
Schedule I classification and the fact that cannabis supply required for research can only
be obtained through the federal government (ACP, 2008; Cohen, 2010; Joy, et al.,
1999).
In spite of the impediments to conducting research on the medical use of
cannabis, several scientific bodies have recommended such studies and have
recommended a review of cannabis’ scheduling. However, the recommendations have
so far been rejected by the federal agencies and the DEA has also rejected the
recommendations of its own administrative law judges. Cohen (2010) stated that the
approval of any drug for medical use should be based on scientific evidence rather than
political considerations and that such evidence should be used to weigh up the risks and
benefits of cannabis use and whether it justifies its FDA approval for medical use.
Cohen (2009) also questioned why legislators rather than experts acted to deny cannabis

Medical Cannabis in the United States

33

being recognised as a medicine at the federal level, and why the use of cannabis for
medical purposes was legitimised through legislation, ballot initiatives and referenda
rather than by experts qualified by scientific training and experience.
As previously mentioned, there are many factors influencing the creation of
public policy, and in terms of medical cannabis, while scientific evidence has played a
part, there are other political and institutional dynamics at work in setting the policy,
such as “presidents seeking public approval, bureaucrats seeking increased funding,
members of Congress seeking re-election” (Bertram et al., 1996, p. 101). Cohen also
argued that instead of being driven by scientific evidence and experts in what should
have been a straightforward process, it has been complicated by “politics, ideology,
prejudice, and unwarranted fear” (2009, p. 131). The understanding of the role of
scientific evidence in the formation of medical cannabis policies will offer those
individuals involved in research an insight into how scientific evidence can be given a
more significant role in informing policy.
The present research sought to (a) Identify the main issues pertaining to the
development and formation of medical marijuana policies in the U.S. and how problems
and issues are recognised and raised; (b) Understand factors leading to different
outcomes in medical cannabis policy; and (c) Examine the role that scientific evidence
plays in passing medical cannabis legislation in the U.S. and the extent to which it
informs the policy.
The current research focused on the following research questions:
1. What role does scientific evidence play in medical cannabis policy making?
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2. What factors and processes have influenced medical cannabis policy
creation?
3. What lead to medical cannabis policy being passed in states with current
medical cannabis laws?
Chapter Two of this thesis describes the political context within which medical
cannabis laws were passed by providing an outline of the U.S. political system. Chapter
Three discusses cannabis as a medicine and provides a review of relevant medical
cannabis literature. Chapter Four describes, chronologically, the passing, attempts to
pass, and failure to pass medical cannabis policies in five U.S. states; two with a current
medical cannabis law; one where attempts to pass a law have been made, but a law has
not yet been passed; and two states where no or few attempts at passing a medical
cannabis law have been made. These states are Michigan, New Mexico, Illinois,
Kentucky, and Louisiana, respectively. Chapters Five and Six discuss the research
design, sampling and data collection procedures, the techniques used for data analysis,
and results for study groups One, Two, and Four. Finally, Chapter Seven will present
the discussion of the research findings, the implications of the study, and directions for
future research.
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Chapter 2- The United States Political System
To understand the policy process, it is important to understand the political
system. The political system of the U.S. is a distinctive and complex democratic system
(Singh, 2003; Watts, 2010). Democracy is defined as government where the supreme
power is vested in the people; exercised through their elected agents (U.S. Department
of State, 2007). This chapter will discuss areas of the U.S. political system relevant to
understanding policy formation, including the interaction between the two levels of
government- federal and state.
The U.S. Constitution
The U.S. government, under its Constitution, is a federal, representative,
democratic republic consisting of 50 states and one federal district (H.R. Doc. No. 10894, 2003). The Declaration of Independence of 1776 and the Constitution of 1787 form
the foundations of the U.S. government (H.R. Doc. No. 108-94, 2003; R. Harris &
Tichenor, 2009). The Constitution assigns specific powers to the national government
and the states, although these powers can often be intertwined (Volden, 2005). State
governments make decisions affecting the daily life of people in their community, while
the federal government makes decisions affecting the whole country. However, the
powers assigned by the Constitution have been and are subject to interpretations by
courts, the highest of which is the Supreme Court. Overall, the Constitution provides the
people in government with enough power to effectively run the nation, but also makes it
difficult to accumulate and abuse power (W. Storey, 2007).
The Constitution specifies three branches of the federal government: the
Executive Branch; the Legislative Branch; and the Judicial Branch (H.R. Doc. No. 108-
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94, 2003; W. Storey, 2007). Each branch has its own distinct responsibilities, but also
limits the authority of others (K. Thomas, 2001). In order to prevent concentration of
power, a series of checks and balances are written into the Constitution, permitting each
branch to participate in and check and balance the powers of other branches. Although
each branch is formally separate from the other two, there is also cooperation among the
branches (Administrative Office of the U.S. Courts, 2003; Kaiser, 2001). The following
section will describe the three levels of government in the U.S.; federal, state, and local
government.
Federal Government
Executive branch. The Executive Branch of government is responsible for
carrying out the political system’s laws or directives (BEP, 2010; H.R. Doc. No. 10894, 2003; Watts, 2010). It consists of the president, vice president, department heads
(Cabinet members), and heads of various independent agencies (Dinan & Krane, 2006;
H.R. Doc. No. 108-94, 2003; R. Harris & Tichenor, 2009). The president is the head of
the executive branch of the federal government (Watts, 2010). The president’s term of
office lasts four years and the president may be re-elected for only two terms (BEP,
2010).
Federal bureaucracy. Bureaucrats, or government employees, play an
influential role in shaping public policy (Birkland, 2005; Kaufman, 2001; Singh, 2003).
Those who act as advisors to a branch of the federal government also have, through the
way they do their job, the potential to directly influence policy-makers (Kaufman,
2001). The bureaucracy’s main functions are executing laws, creating rules, and the
implementation of public policy. It is also responsible for adjudicating disagreements
over laws and their interpretation (Singh, 2003). All three branches of government
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influence the shape and role of federal bureaucrats. For example, Congress has the
authority to establish and instruct agencies; the president has the authority to appoint
department and agency heads; and the federal court has the authority to determine
whether agency actions are constitutional (BEP, 2010; Singh, 2003). Also, federal, state,
and local governments may have bureaucracies working on specific issues such as
education or health (Singh, 2003).
Federal Legislative branch. Congress is the legislative branch of the U.S.
federal government (Watts, 2010). Congress consists of two chambers; the House of
Representatives and the Senate. Between them, the two chambers are responsible for
making federal law in the areas set out in the Constitution. They are responsible for
deciding on taxation and how taxes should be spent, borrowing money on behalf of the
U.S., regulating commerce, coining money, declaring war, raising and supporting
armies, and making all laws necessary for the execution of Congress’ powers (H.R.
Doc. No. 108-94, 2003; W. Storey, 2007). In addition, Congress acts as a watchdog
over other branches of the federal government, the Executive and the Judiciary (H.R.
Doc. No. 108-94, 2003).
House of Representatives. The House of Representatives comprises 435
Members who are elected to two-year terms from among the 50 states. In addition,
nonvoting delegates from the D.C. and the U.S. territories are also elected to a two-year
term. The members are distributed according to population, so that the larger the state’s
population, the more representatives it is allocated (Cushman, 2005; H.R. Doc. No. 10894, 2003; Watts, 2010). Each state must have at least one house seat and each member
has only one vote (Cushman, 2005; H.R. Doc. No. 108-94, 2003). Each chamber can
introduce legislation on any subject, but revenue bills must originate in the House of
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Representatives, and both chambers need to approve a bill in order for it to be passed
(Cushman, 2005; Watts, 2010).
Senate. The Senate is intended to provide for state representation in Congress,
protect the interest of the states, and provide a check upon the House of Representatives
(H.R. Doc. No. 108-94, 2003; Watts, 2010). The Senate comprises 100 members, two
for each of the 50 states. Senators serve for six years, with a third of the membership of
the Senate elected every two years (H.R. Doc. No. 108-94, 2003). Each senator has one
vote (H.R. Doc. No. 108-93, 2003; Watts, 2010).
How a bill becomes law. A member of Congress may introduce a proposal in
one of four forms: the bill, the joint resolution, the concurrent resolution, and the simple
resolution (H.R. Doc. No. 108-93, 2003). The Member’s constituents also have the right
to petition and pass on their proposal to the Member for consideration. Any Member
can introduce a bill at any time, while the Congress is in session (Birkland, 2005). The
following section will describe the bill passing process only, as it is relevant to this
thesis.
The process. Before a bill becomes law it must be approved by both chambers
and signed into law by the president. Bills may originate in either of the chambers,
though the Constitution specifies that all bills concerning the raising of revenue must
originate in the House of Representatives (Birkland, 2005; H.R. Doc. No. 108-94,
2003). Anyone may draft a bill but only members of the Congress can introduce
legislation and therefore become the bill’s sponsor (s). After a proposal is drafted into
bill form, it is introduced into one of the two Chambers. If the author is a Senator, the
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bill is introduced in the Senate; if the author is a Representative, the bill is introduced in
the House of Representatives (Birkland, 2005; H.R. Doc. No. 108-94, 2003).
As soon as a bill is introduced it is assigned, according to the subject area, to the
appropriate committee for its first hearing. The committee seeks the input of the
relevant departments and agencies. During the committee hearing, the author presents
the bill to committee, subcommittees may make reports on the bill, and testimonies in
support or opposition to the bill may be heard. The committee votes whether to pass the
bill on or pass with amendments. A majority vote is needed to pass the bill out of the
committee and onto the floor of the chamber where it originated or to the next
committee. If the bill is passed by the committee it was assigned to, it is read a second
time on the floor of the house where it originated, and a bill analysis is prepared before
the third reading. If the committee does not act on a bill, the bill is “dead” and does not
progress further (Birkland, 2005; H.R. Doc. No. 108-94, 2003).
At the third reading, the bill is read and explained, discussed by members, and
voted on (H.R. Doc. No. 108-94, 2003). A majority vote is required for the bill to be
passed. When the bill is approved by the house of origin, it is passed onto the other
house where the same procedure is repeated. A bill that has been agreed to by both
houses is sent to the president for approval, and becomes law after either presidential
approval, failure by the president to return it with objections to the House of origin
within 10 days, or the overriding of a presidential veto by two thirds of the vote in each
House (Birkland, 2005; H.R. Doc. No. 108-94, 2003).
Judicial branch. The federal Judiciary explains and applies the law and serves
as a check on potential government abuse of power (H.R. Doc. No. 108-94, 2003; W.
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Storey, 2007; U.S. Department of State, 2007). The Supreme Court is the highest court
in the federal judiciary, and is also the final court of appeal. The Constitution does not
stipulate the number of Supreme Court Justices and their number is determined by the
Congress (Administrative Office of the U.S. Courts, 2003; Barker, 2005).
State Government
State and Federal governments are independent, although there is an evolving
relationship between the two and a historical drift of power from states to the federal
government (Babcock, 1965; Grodzins, 1960; Watts, 2010). Although the power of the
federal government has grown significantly since the Constitution was written, states
still have responsibility for most issues within their own borders such as education,
health, transportation, and law enforcement (W. Storey, 2007; K. Thomas, 2001; U.S.
Department of State, 2007). They are limited in their authority regarding regulation of
foreign imports and exports, or the conduct of foreign affairs (K. Thomas, 2001).
The U.S. history is marked by an ongoing debate over states’ rights versus
federal rights and the issue us states’ rights has always been a contentious area (Drake
and Nelson, 1999). States’ rights calls for the limitation of powers of the federal
government, with the belief that states could best resolve pressing issues and protect the
rights of individuals. While decision makers from two or more governments may
cooperate with each other in one policy area, they may be have conflicting views in a
different area (Dinan & Krane 2006; Drake and Nelson, 1999; Williams, 2009). States
can also differ with each other over policy issues and can adopt different approaches to
the same issue.
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It is suggested by Dinan and Krane (2006) that the reason for national policy
making is the lack of action by state governments. Conversely, state governments often
engage in policy initiatives because of inactivity at the federal level in relation to a
particular problem (Dinan & Krane, 2006). Each state has their own Constitution which
outlines the government’s structure and responsibilities (Williams, 2009). State
constitutions differ significantly from the federal one; they are longer, more detailed,
and cover more topics. However, state constitutions do not and cannot contradict the
U.S. Constitution, which can override a state constitution. Both the federal Constitution
and federal statutes can override the state constitutional provisions. States also have to
respect laws and court decisions in other states. Like the national government, the states
have a separation of powers between three branches of government: executive,
legislative, and judicial. Each branch is checked and balanced by each other, and by the
federal government (Williams, 2009).
Executive branch. The executive government is responsible for executing the
laws of the state (U.S. Immigration and Naturalization Service, 1987; Williams, 2009).
The state executive branch of government is headed by the governor. The role and
importance of governors vary according to the individual state. The term of a governor’s
office also varies among states, but today all but two governors serve for four years.
Some states also have restrictions on the number of terms a governor can serve. The
governor is responsible for advising the state legislature on laws concerning the state,
proposing new laws, calling special sessions of the state legislature, and serving as head
of the state’s National Guard. In all but two states, the governor also has the power to
veto bills passed by the legislature, and in all but seven states the governor can also use
a line-item veto which enables them to block specific sections of a bill (Watts, 2010).
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Similar to the federal government, the Executive Branch of state government consists of
a group of advisors who perform special duties, such as the Secretary of State and
Attorney General (U.S. Immigration and Naturalization Service, 1987; Williams, 2009).
The influence of a governor also depends on the extent to which they share executive
power with other elected officials and agencies. In Michigan, for example, there are
many state-wide elected officials and agencies and there is therefore less opportunity for
the governor to coordinate and control the executive branch (Watts, 2010).
Legislative branch. Every state except Nebraska has a legislative branch similar
to that of the federal government, with two separate legislative chambers or houses
(U.S. Immigration and Naturalization Service, 1987; Williams, 2009). Nebraska is an
exception to this as it has a unicameral legislature (Williams, 2009). The term of office
varies amongst the 50 U.S. states; usually the term of office in the Senate is four years,
and two years in the House of Representatives (U.S. Immigration and Naturalization
Service, 1987; Williams, 2009). The number of members in each house also differs,
with each state having their own procedure for deciding the number of members. The
procedure for making laws is seen by some as being very similar to the federal
government, while others believe the state legislative process is more constricted and
subject to a variety of constitutional limitations (Williams, 2009). The Legislature’s
passing of laws can also be affected by direct democracy in the form of the initiative
and referendum, as discussed below (Cushman, 2005; Williams, 2009).
Judicial branch. The state Judicial Branches only hear those cases involving
state or local law (United States Courts, n.d.). The state Judicial Branch is similar to the
federal system and consists of a hierarchy of courts. Courts that handle specific legal
matters (e.g. Family Court, Traffic) along with the Municipal County Magistrates Court
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are the lowest and have a limited jurisdiction. At the next level are the state trial courts
(e.g. District, Superior, Common Pleas). They are followed by an intermediate Court of
Appeals, which is not found in all states. The highest court at the state level is the state
Supreme Court (United States Courts, n.d.).
Local Government
Local governments are created by state governments rather than the U.S.
Constitution and are the most common form of government in the U.S. (U.S.
Immigration and Naturalization Service, 1987; U.S. Department of State, 2007;
Zimmerman, 2012). The state government provides the local government with a
“charter”, which describes its role, structure, and authority.. Local governments are
controlled and checked by the state government, and have the power to perform only
those functions assigned by the state. There are four levels of local governments, with
all U.S. residents living within a local government, whether it is a municipality, a
special district, and/or sub-state jurisdictions such as counties (known as parishes in
Louisiana and boroughs in Alaska) (Katz, 2003; Kincaid & Steytler, 2009). County
governments were initially created as administrative arms of the states, but over time
evolved into fairly autonomous governments with directly elected officials
(Zimmerman, 2012). Connecticut and Rhode Island are the only states that do not have
county governments. Twenty states have townships as local governments (Zimmerman,
2012). In some states townships can assume general government powers while in others
they have limited powers. Municipalities (or cities, owns, boroughs, or villages) are
general-purpose governments with directly elected legislative bodies (Zimmerman,
2012). The functions of municipal governments can vary across the states. Special
districts are limited governments that provide a specific service, such as housing, water-
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supply and transit boards, and school boards. Majority of all special districts only
perform a single function (such as housing). In order to perform their functions, local
governments receive funding from the state and federal governments and also collect
property taxes and fees from their constituency (Sutton, 1974; U.S. Immigration and
Naturalization Service, 1987; Watts, 2010). Local governments also have a court
system, which deals with local issues such as traffic laws (Sutton, 1974; U.S.
Immigration and Naturalization Service, 1987).
Direct Legislation
Some states provide their citizens with direct democracy through the initiative,
referendum, and recall process (Birkland, 2005; BEP, 2010; Cushman, 2005). The
history of direct legislation goes back to the 17th century and was primarily a result of
social change and political reforms during the Progressive Era that span the end of the
19th to the beginning of the 20th century (Arnon, 2008). The reform was a reaction
against the laws and widespread corruption in the representative system, in which the
influence of interest groups and powerful party bosses who controlled their party
members’ voting patterns led to political dissatisfaction of the citizens. Direct
legislation was created to act as a check on representative institutions and allow citizens
to be involved in the legislative process (Arnon, 2008). It also allows the lawmaking
power to be shared between the legislature and the people (Braunstein, 2004; Williams,
2009). Out of the states discussed later in this thesis, Michigan has an initiative,
referendum and legislative process; New Mexico has a referendum and legislative
process; Illinois has an initiative, popular referendum and legislative referendum;
Kentucky has a legislative process; and Louisiana has a legislative referendum
(Cushman, 2005; IRI, 2009). The initiative process is the process by which the people
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introduce a new legislation and vote on it at the ballot (Arnon, 2008). The popular
referendum is the process that allows the people to place acts of their legislature on a
ballot and vote on it (Arnon, 2008). Only the initiative process will be described in this
section because it was the only direct democracy process utilised in relation to the
medical cannabis policy in the states reviewed in this thesis.
Over the past two decades, there has been an increase in initiatives in the U.S.
(Watts, 2010). In total, 24 U.S. states and Washington D.C. have an initiative process
under which citizens can, by collecting a specified number of signatures on a petition,
place an issue before the state’s electorate (Birkland, 2005; BEP, 2010; Howard, 2005;
IRI, 2009; Katz, 2003). Of the 24 states with an initiative process, 18 states allow
initiatives to amend the state constitution and 21 states allow initiatives to propose and
pass laws. The initiative may either be direct or indirect. In most cases, once a required
number of signatures have been collected, the measure is brought directly to the state’s
electorate for a vote of the people (direct initiative). Several states use the indirect
initiative which allows the legislature to vote on the initiative first; if passed by the
legislature, is not voted on by the electorate. However, if the proposal is not passed by
the legislature, it is then put to a popular vote (Howard, 2005; IRI, 2009; Singh, 2003).
The initiative process is useful in cases where law makers are unwilling to enact
or consider a law that the citizens want (Watts, 2010). The initiative process may also
have an indirect effect on policy making by voters approving initiatives that define how
future legislators govern, affecting citizen behaviour, giving legislators more accurate
information about voter preferences, increasing the number of interest groups, and
influencing how legislators behave (Bowler & Donovan, 2004). According to Bowler
and Donovan (2004), the initiative process has a greater impact “where it is easier to get
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a measure on the ballot, where it can more easily circumvent the legislative process,
and, perhaps most important, where it is used the most” (p. 359). Over 60 percent of
initiative activity in the U.S. has occurred in Arizona, California, Colorado, North
Dakota, Oregon and Washington, which generally have lesser signature requirements
than other states (Watts, 2010).
In the U.S., in 1998, $400 million was spent nationally on ballot proposition
campaigns (Matsusaka, 2005). Much of the research on the topic has indicated that
monetary resources and a large interest group membership assist in the success of the
initiative process (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby, 1998). It has
also been estimated that 78 percent of ballot campaigns have been won by the side that
spent the most money (Braunstein, 2004). Due to the money required for initiative,
Magleby (1998) suggested that agenda-setting and campaign management in initiatives
is primarily organised by elites, but must involve mass audiences in order to place an
issue on the ballot and win on election day. As a result, some initiative campaigns are
seen as battles amongst wealthy economic interest groups who are trying to secure more
favourable policy, and use signature gathering firms to quickly and cheaply secure
ballot measures, with little consideration given to voter engagement. This results in a
decrease in voter interest and debate on a particular issue. Boehmke & Alvarez (2014)
found that because the signature collection process reaches some voters and not others,
voter participation on a particular measure can vary across voters and within states.
Research has shown that the initiative process can lead to a greater participation
by organised interest groups by providing them with the ability to propose legislation
directly to voters (Boehmke & Bowen, 2010). Because the interest groups are
traditionally disadvantaged in the legislature, the initiative process provides them with a

Medical Cannabis in the United States

47

way to raise their policy concerns. An initiative process can increase the number of
interest groups lobbying in the state by approximately 25 precent (Boehmke & Bowen,
2010). According to Boehmke and Bowen (2010), interest groups tend to campaign
more publicly during issue campaigns in states with an initiative process than for
debates in the legislature, and try to recruit new members to strengthen their side. As a
result, media coverage of the issue increases, which then increases the scope and
intensity of conflict, leading groups to work harder to win the support of individuals and
increase their membership (Boehmke, 2002). Groups in initiative states tend to have
more members than groups in states with no initiative. Interest groups in states with an
initiative process also rely more on outside lobbying tactics to influence government
action, mobilising members, and organising public displays of support to pass an
initiative (Boehmke & Bowen, 2010).
Interest groups can use the initiative process to propose new legislation and to
shape debate (Boehmke, 2008). It can also be used to influence decisions made by the
legislature in a less direct way, by leading legislatures to choose policies that are close
to the average voter preference to discourage interest groups from challenging policies
by a ballot initiative (Boehmke, 2008; Bowler & Donovan, 2004). Also, the presence of
particular measures on upcoming ballots may also encourage groups to mobilise or
lobby. The interest groups that oppose the particular ballot measure may also start
campaigning against the measure once the proponents show sufficient strength or their
measure qualifies for the ballot (Boehmke, 2008). Boehmke (2008) viewed these groups
as likely to be temporary in nature as they form in direct response to the threat posed by
a particular measure. Once the threat is removed or fails, the opposition group is likely
to dissolve. Therefore, the entry and exit rates of interest groups in states with the
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initiative process are likely to be greater than in the states with no initiatives (Boehmke,
2008).
Initiatives also face legal challenge, as state and federal courts have in the past
overturned the people’s vote on state or federal constitutional grounds (Magleby, 1998;
Theodore, 2013). The judicial process can also delay implementation of an initiative. As
Magleby (1998) puts it, “The willingness of federal courts to overturn state initiatives
on U.S. Constitutional grounds is an important manifestation of federalism” (p. 152).
The constitutional assertion of federal constitutional sovereignty over the people’s vote
has in the past led to overturning of successful initiatives on issues such as the death
penalty, abortion, homosexual rights, term limits, physician-assisted suicide, and illegal
immigration (Magleby, 1998). As illustrated by the medical cannabis movement in the
U.S., some state ballot initiatives can also be seen as trying to alter federal policy by
stressing a state policy role in an area thought to be federal in nature.
One of the more prominent criticisms of the process is that voters lack education and
competence to make policy decisions (Burnett & Parry, 2014; Matsusaka, 2005).
Research has shown that most voters are uninformed about public policy, politics and
government, which raises the concern that damaging policy may be adopted as a result
(Burnett & Parry, 2014; Hastings & Cann, 2014). In the absence of information, an
influence on voters’ choice is the position taken by elites (Burnett & Parry, 2014;
Hastings & Cann, 2014). Burnett and Parry (2014) found that voters rely on other
evidence and that the governor’s endorsement of a ballot measure can have an effect on
voter choice; voters who disapproved of the governor’s performance were significantly
less likely to support the initiative while voters who approved of the governor’s
performance were more likely to support the measure (Burnett & Parry, 2014). It has
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also been suggested that the ballot wording influences voters’ choices. How the issue is
framed also plays a role, and research has shown that even small changes in the
presentation of an issue can produce changes in voter opinion (Druckman, 2001;
Hastings & Cann, 2014). Another criticism is that well organised and wealthy interest
groups may use voters’ lack of knowledge to their own benefit, especially in cases of
well organised, wealthy interest groups.
Informal Structures
Even though the U.S. has a constitution, most of the electoral structure (offices,
branches, levels, procedures) is determined and regulated by federal and state laws
outside the Constitution (Young, 2007). For example, the political party system is not
included in the Constitution, and the Constitution does not encompass everything in the
legal system. Although unofficial actors are not mentioned in the Constitution, they play
an important role in the policy process (Birkland, 2005). In this section, four informal
groupings relevant to the medical cannabis policy process will be discussed. These are
interest groups, political parties and the party system, independent research
organisations, and the media.
Interest groups. The democratic system of government in the U.S. allows for
private associations, through which citizens can express their concerns and advance or
defend their particular interests (Birkland, 2005; R. Harris & Tichenor, 2009; Singh,
2003). Interest groups are independent agencies, free of governmental control; although
they frequently seek to influence it. Interest groups can have political significance when
they try to influence public policy, propose new laws, or persuade government officials
to act in their interest. However, not all interest groups have a political significance or
interests (Birkland, 2005; R. Harris & Tichenor, 2009; Singh, 2003). The approach and
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activities of most interest groups is determined by the group’s mission, strategic goals,
objectives, strategies and tactics (Leiden, 1995).
Five broad types of interest groups active in the U.S. include economic interest
groups, public interest groups, sectional groups, attitude groups, and intergovernmental
groups (Birkland, 2005; R. Harris & Tichenor, 2009; Singh, 2003). Economic interest
groups include a range of corporations, labour unions, agricultural groups, and
professional bodies. Citizen, or public interest groups, are those with open memberships
that represent the interests of the general public (Boehmke, 2002). Sectional groups
represent concerns of a particular group of individuals and include organisations such as
the National Organization for Women. Attitude groups advocate a specific political
position or an ideological orientation. Lastly, intergovernmental groups include public
officials seeking to promote a cause and pressure other government institutions (Singh,
2003).
The main functions of interest groups are representation (express the views of
citizens to government); citizen participation (allow ordinary citizens to become active
in the nation’s political life); public education (influence government and help educate
citizens about government and its actions); agenda building (placing issues on the
agenda and forcing decision-makers to act on specific issues); and programme
monitoring (providing an additional check on government, making sure it is functioning
properly) (R. Harris & Tichenor, 2009; Singh, 2003). Leiden (1995) suggested that
many interest groups rarely make their true objectives public, and may be closely held
by the group’s leadership or advocates.
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Over the years, the activism and influence of interest groups has expanded, and
they now play a significant role in the U.S. political system (Singh, 2003). While some
see them as being a positive influence, others accuse them of compromising the
democratic process. For example, some interest groups provide both presidential and
congressional candidates with a large amount of money for their campaign funding,
which is seen as promoting special interests of the wealthy (Birkland, 2005; R. Harris &
Tichenor, 2009; Singh, 2003).
Research has found that states with an initiative process have more interest
groups (Boehmke, 2002). There is also a bias in the interest groups, with research
showing that business groups and corporations tend to be overrepresented while broadbased membership groups are underrepresented (Boehmke, 2002). Interest groups also
take the political and economic context into account when deciding whether to become
active. The initiative process also increases interest groups’ potential to affect policy
and results in more groups being active in states with the initiative process. There is a
relationship between the interest groups and initiative usage. According to Boehmke
(2005) states with more citizen groups experience greater initiative use and states with
more economic groups experience less initiative usage.
Political parties and the party system. Political parties are not mentioned in
the U.S. Constitution (Singh, 2003). The U.S. currently has a two-party political system,
dominated by the Democratic and Republican parties (English, 2003; Singh, 2003).
While there are more than two parties, the two major parties have been dominant since
the Civil War (Singh, 2003). In the U.S., the parties do not have the power to choose
who represents them in the elections for Congress as this decision is made by the voters
in each state or district in primary elections. Primary elections take the power of
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candidate nomination from the party leaders to the people, in turn allowing the parties to
be made more attentive to what their constituents want, hence allowing the two parties
to keep their dominance of the system (English, 2003; Singh, 2003). As a result, most
elected government officials are either Republicans or Democrats. Third parties can also
have a significant influence and, if they manage to gain sufficient support, may be able
to influence a major party by bargaining for its votes (Birkland, 2005; Singh, 2003).
Which party has control of the Congress can influence the passing of laws and
other legislative functions. Congress is organised along party lines, and committee
assignments are based on party affiliation (Birkland, 2005; English, 2003). However,
political parties in the U.S. are weaker and more fragmented than in many other
countries, and a party government is difficult to achieve. While there are differences
between the ideologies of the two major parties, these differences are not fundamental;
some Republicans have expressed Democratic sentiments, and vice versa (Krause &
Bowman, 2005). In many cases, it is not in the interest of the party for all their members
to vote the same way, and members must give consideration to how the voters will react
to their actions. As party influence is not always very strong, members can often find
that an independent stance on an issue can gain them more support from the voters
(Birkland, 2005; English, 2003).
In order to gain power, a party has to win majority support from all levels and
sections of society (Krause & Bowman, 2005; Singh, 2003). There are regional
differences in voter support for the political parties, with parties known to dominate
certain states. Over the years, however, a decrease has been observed in the strength of
voter-party identification, which makes voters more unpredictable at election time
(Singh, 2003). To win support the political parties have to, amongst other things,

Medical Cannabis in the United States

53

constantly change their stance on issues in order to meet the expectations and changing
views of the electorate. Party candidates also have to be carefully selected, in order to
gain public approval and support. Overall, political parties play a significant role in the
government system, from framing the nature of political debate to influencing decisionmaking, and providing an avenue for everyday citizens to influence the governmental
decision-making process (Birkland, 2005; Singh, 2003).
Independent research organisations. Independent research organisations such
as the Brookings Institution and RAND can play a role in informing and shaping public
policy (Birkland, 2005). The organisations consist of academic scholars and policy
experts, and provide information that policymakers can use when forming policies.
Many of these organisations identify with a particular ideological position, while those
associated with universities are generally more scholarly and less ideological. Federal,
state and local governments often rely upon university research organisations to obtain
expert advice (Birkland, 2005).
However, policymakers do not always have access to scientific research results
and may turn to other sources for information (Ritter, 2009). There appears to be a
discrepancy between the sort of information that policymakers require (simple
summaries, policy-accessible language) and the information provided by many of the
research organisations. Research evidence is therefore not the only factor influencing
policy and other factors such as interest groups, legislative processes, and opportunistic
windows can influence the decision-making process (Kaiser, 2001).
The media. The media is believed to play an important role in the democratic
political system (Birkland, 2005; R. Harris & Tichenor, 2009). It is essential in
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facilitating communication between citizens and their elected officials and providing
information to the public, its role in the political system further enhanced by the
advances in the mass media technologies (internet, blogging). The media can also act as
a government “watchdog”; keeping an eye on politics and policy-making activities of
the government and reporting them to the public (Birkland, 2005; R. Harris & Tichenor,
2009).
While some believe that the mass media has a short-term and limited effect on
the policy process, others believe it has a strong influence in the areas of agenda setting,
priming, and framing (Birkland, 2005; R. Harris & Tichenor, 2009). Arguably, the
media may not have a direct influence on the policy making process, but it can have an
effect on the actions and attitudes of policymakers and the public (R. Harris & Tichenor,
2009). It can help bring public attention to certain issues and can expand issues to
broader audiences, which in turn creates more pressure for change. Interest groups also
recognise the value of media and can gain access to it to further promote their case.
However, it is not a flawless process. There can be biases in the media coverage, such
as taking a particular side in the debate, which can influence policy. A decision on what
stories to cover can also influence public opinion. Individual journalists also play a role
as they are the ones that write the coverage of the news and events (Birkland, 2005; R.
Harris & Tichenor, 2009).
Medical cannabis and the federal-state relations
Over the past decade, state officials and the public have acted on many issues
where they felt that the federal government was not taking action or was making
unacceptable policy decisions, in policy areas such as education, welfare and drug
control (Ferraiolo, 2008; Hall & Degenhardt, 2003; Pickerill & Chen, 2008). In the area
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of medical cannabis, state activism took place in the form of initiatives. State direct
democracy measures have had an impact on federal-state relations, as cannabis is
generally considered to be a policy area of federal concern, and have hence created a
conflict between state and federal governments (Ferraiolo, 2008; Hall & Degenhardt,
2003; McDonough, 2000; Pickerill & Chen, 2008). As a result of the conflict, patients,
doctors, police, prosecutors, and public officials are placed in a difficult position as they
still can be prosecuted at the federal level (Hall & Degenhardt, 2003; McDonough,
2000; MPP, 2013).
The question that this raises is whether states should be able to decide for
themselves whether to legalise cannabis for medical use or if the federal government
should regulate this area of policy (Pickerill & Chen, 2008). In Gonzales v. Raich
(2005), the U.S. Supreme Court upheld the Congress’ authority under the CSA when it
ruled that the Congress has the power to ban the use of medical cannabis even where
states approve its use for medicinal purposes. However, the ruling did not deter states in
passing medical cannabis laws and widening the gap between federal law and voter
preference (Ferraiolo, 2008).
According to Pickerill and Chen (2008), allowing a state to experiment with a
policy allows for any potential harm or failures to be localised to that state, and that if a
policy works other states may learn from it and choose to adopt it. They also suggested
that allowing a state to experiment with a policy may lead to different states trying
different ways to approach the issue and assess which approaches are more or less
effective (Pickerill & Chen, 2008). In the states that currently have medical cannabis
laws, the laws vary in such terms as which debilitating medical conditions cannabis is
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allowed for, whether or not they allow dispensaries and whether patients need registry
cards (MPP, 2013).
Summary
Overall, it is important to examine all levels of government as each has a
significant role to play. The government operates in a complex multi-level system,
based not only on the U.S. Constitution, but laws and statutes outside of it. There are
many individuals and organisations that have not been included in the Constitution
which can influence the political system and how the nation is governed. Most state
agencies were created by legislative enactment, rather than by provisions of the state
constitutions. Because the U.S. is a democratic system where the supreme power is
vested in the people, its aim is to allow all citizens to have an equal say in decisions
affecting them. However, there are other factors and informal structures which can play
a role in the political system, one of them being scientific evidence. The following
chapter will discuss cannabis as a medicine and provide a review of relevant medical
cannabis literature.
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Chapter 3- Cannabis as a Medicine: A Review of the Literature
Cannabis has long been recognised for its medicinal properties and is the third
most commonly used psychoactive substance after tobacco and alcohol in America
(Baker, Pryce, Giovannoni, & Thompson, 2003; Eddy, 2010; Kreit, 2003; Marshall,
2005; Russo, 2007). For the purposes of this thesis, cannabis will be the term applied to
all products derived from the plant Cannabis sativa, which has over 400 compounds
(IOM, 1999; McPartland & Russo, 2001; Ryder et al., 2006). Cannabis is made up of
Phytocannabinoids, Terpenoids, and Flavonoids (McPartland & Russo, 2001).
Phytocannabinoids (cannabinoids) are a group of compounds uniquely produced by
cannabis and over seventy different cannabinoids have been identified (McPartland,
2008; McPartland & Russo, 2001).
THC is the main psychoactive ingredient in the cannabis plant (Baker et al.,
2003; Ben Amar, 2006; IOM, 1999; Russo, 2007; Ryder, et al., 2006). THC was first
isolated, synthesised and stereochemically defined in the 1960s (Baker et al., 2003). It is
estimated that over the past decade the THC content increased from 1-3 percent to 6-13
percent and above, with an average of 7 percent THC content in the U.S. (Baker et al.,
2003; Russo, 2007). Cannabidiol (CBD), a non-psychoactive compound, is cannabis’
major constituent. It is believed to have medicinal properties and reduces THC’s sideeffects (Mather, 2005; McPartland & Russo, 2001). Cannabinoids bind to specific
receptors of which two have been identified, the CB1 and CB2 receptors. CB1 receptors
are mainly found in the brain and both male and female reproductive systems
(American College of Physicians [ACP], 2008; Ben Amar, 2006; McPartland, 2008;
Robson, 2001). These receptors mediate most of the central nervous system responses to
cannabinoids and are believed responsible for cannabis’ euphoric effects. CB2 receptors
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are found mostly in the peripheral nervous system and are believed to be responsible for
cannabis’ anti-inflammatory and immunosuppressive effects (AMA, 2009; McPartland,
2008; Robson, 2001). Several endogenous fatty-acid ligands (atoms or molecules that
bind to another), known as endocannabinoids, have also been found (Baker et al., 2003).
These compounds have cannabinoid receptor binding activity, but their physiological
roles are not yet know.
Marijuana, hashish, charas, bhang, ganja and sinsemilla are the terms used for
different cannabis preparations, the effects of which vary with different delivery
methods (IOM, 1999; Julien, Advokat, & Comarty, 2008; Russo, 2007). Bhang and
marijuana are low-grade preparations taken from the dried mixture of cannabis flowers,
leaves, and stems. Ganja and sinsemilla are the seedless unfertilised female flowering
tops. Charas and hashish are the most potent cannabis preparations and are derived from
cannabis resin (Julien, et al., 2008; Russo, 2007). Studies have shown that there are also
different strains of cannabis which can have various effects (Russo, 2007).
There are different ways of administering cannabis, with each method having
advantages and disadvantages. Route of cannabis administration can affect the
therapeutic benefits experienced by some patients (Clark, 2000; Grotenhermen, 2001).
The following section will discuss different routes of cannabis administration and the
use of synthetic cannabinoids in the U.S.
Synthetic Cannabinoids
What is often forgotten in the debate on medical cannabis is that there are
currently two synthetic cannabinoids approved in the U.S., dronabinol (Marinol) and
nabilone (Cesamet). Dronabinol is approved by the FDA for oral administration as an
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appetite stimulant for HIV/AIDS-related wasting syndrome, along with relief of nausea
and vomiting (Beal et al., 1997; Hazekamp & Grotenhermen, 2010; Werner, 2001).
Nabilone is also approved by the FDA and is used primarily to treat nausea and
vomiting resulting from cancer chemotherapy, when other medications have proven
ineffective (National Library of Medicine, 2012). Evidence has shown that these
compounds have medical use and they have passed the strict requirements of the FDA
for approval as medicines for human consumption (Iversen, 2000). Research is also
being done on other synthetic cannabinoids, such as CT-3, a synthetic derivative of a
non-psychoactive THC metabolite called THC-11-oic acid, to determine their
effectiveness in the treatment of some debilitating medical conditions.
However, despite dronabinol’s positive effects, reports indicate that patients
prefer smoked cannabis to dronabinol (Earleywine, 2002). The drug is reported difficult
to swallow by patients with nausea and vomiting, and due to its oral administration the
effects do not appear rapidly. Many patients claim that dosage is easier to regulate with
smoked cannabis than with dronabinol. Dronabinol (Marinol in the U.S.) is also
expensive, with patients paying up to $1, 000 per bottle of 60 capsules (Earleywine,
2002; Gieringer, Rosenthal, & Carter, 2008).
Route of Administration
Smoking. Smoking is the most popular method of cannabis administration for
recreational use and one of the most direct methods of ingestion (Gieringer et al., 2008;
Iversen, 2000). Smoking cannabis rapidly delivers THC to the brain, making it easier
for patients using the drug for medicinal purposes to control dosage and alleviate
symptoms (Degenhardt, Hall, & Lynskey, 2003; Mack & Joy, 2000). Maximum THC
concentration is reached within approximately five minutes and THC can be detected in
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plasma seconds after first inhalation. Psychoactive effects are felt within seconds to
minutes, reaching their maximum after 30 minutes, and last approximately two to three
hours (Degenhardt, et al., 2003). A major disadvantage of smoked cannabis is that some
chemicals found in cannabis smoke can be toxic and damaging to the respiratory tract
(Gieringer et al., 2008). The frequency and amount of cannabis smoked by an average
individual may differ in comparison to tobacco, but smoked cannabis contains the same
harmful toxins present in tobacco smoke, with greater concentrations of carcinogenic
substances (Clark, 2000; Robson, 2001). While some reports have claimed that smoking
is a relatively ineffective route of administration because it destroys up to 70 percent of
THC, most have found smoking to be a more efficient mode of administration (Mack &
Joy, 2000; Russo, 2007).
Vaporisation. The use of inhalation devices, such as vaporizers, has been
suggested as an alternative to smoking cannabis as they allow inhalation of cannabis
without the negative health effects of smoking (ACP, 2008; Grotenhermen, 2001).
Vaporisation offers the same rapid delivery of THC and other cannabinoids as smoking,
but may require more getting used to than smoking cannabis. Vaporisers may be bought
commercially or the users can make their own (Gieringer et al., 2008). Vaporisers
require the use of a hot plate to heat cannabis to the point where cannabinoids vaporise
and users can then inhale the vapour (Earleywine, 2002). The disadvantage of using a
vaporiser is that the vapour usually contains a low amount of THC and a high amount of
cannabinol (Earleywine, 2002).
Eating/drinking. THC is soluble in fats and alcohol so it can be extracted and
added to various food and drinks and administered in that way (Iversen, 2000).
Absorption occurs through the walls of the stomach and intestines and therefore gives a
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much slower absorption and avoids the irritating effects of inhaled smoke. The effects
of cannabis administered this way take longer to manifest than smoking, usually one to
two hours, and peak more slowly, but the effects can last three up to four hours.
Cannabis can also be mixed with alcohol and the tincture made into tea. This route of
administration is considered unreliable as the dosage is difficult to titrate due to delayed
onset of effects (ACP, 2008; Robson, 2001).
Capsules. Taking THC by mouth in capsule form is not very reliable as a
method of delivering a consistent dose of the drug (Iversen, 2000). While THC is
absorbed reasonably well from the gut, the process is slow and unpredictable and most
of the absorbed drug is rapidly degraded by metabolism in the liver before it even
reaches the general blood circulation. The peak blood levels of THC occur anywhere
between one and four hours after ingestion and the overall delivery of active THC to the
bloodstream averages less than 10 percent. The effects of oral administration can be
affected by the acid in the stomach and gut and the presence or absence of food (ACP,
2008; Grotenhermen, 2001). Orally-administered products have not proved consistently
effective in their medical application as THC may be erratically or slowly absorbed into
the bloodstream and patients suffering from nausea and vomiting have found it difficult
to keep oral cannabinoids in their system long enough for the effects to be felt (Clark,
2000). Difficulty in regulating dosage can result in a possible over-dosage or underdosage (Grotenhermen, 2001; Julien, et al., 2008).
Suppositories. Another way of delivering the drug is in the form of rectal
suppositories, where THC can be converted to a hemisuccinate (Julien, et al., 2008).
Absorption can be good by this mode of administration, as it delivers the drug directly
into the systemic circulation, bypassing the liver, and avoids the problem of liver
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metabolism, which limits oral THC absorption. This mode of administration can deliver
approximately twice as much active drug to the bloodstream as the oral route, although
there can still be variability in drug absorption amongst individuals (Julien, et al., 2008).
Spray. A new spray based on natural cannabis extracts has been developed in
the United Kingdom (Gieringer et al., 2008). The oral spray, known as Sativex, consists
of equal parts THC and CBD extracted from cannabis and is administered under the
tongue, from where it is absorbed into the bloodstream. Sativex differs from Marinol in
that it is a mixture of compounds derived from the Cannabis plant; incorporates CBD
and other plant ingredients as well as THC. Its absorption is not as fast as inhalation as
it takes several minutes for the cannabinoids to be absorbed through the membrane of
the mouth, but it is faster than oral ingestion (Gieringer et al., 2008). The spray delivers
a more consistent dosage because the cannabinoids are absorbed directly into the blood
without having to pass through the digestive system. Sativex is not currently approved
for use in the U.S.
Topical. Topical cannabis preparations have been used as folk medicine in India
and Latin America (Gieringer et al., 2008; Mack & Joy, 2000). Cannabis can be applied
topically to the skin in the form of ointments, lotions, or poultices, for treatment of such
conditions as swollen joints and skin inflammation (Gieringer et al., 2008). However,
research is unclear on whether there is an effective method for transporting THC or
other cannabinoids through the skin. Suppositories are thought to be a better way of
delivering cannabinoids to the system and there is no commercially available topical
cannabis treatment.
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Intravenous. Cannabis is very difficult to administer intravenously as THC is
extremely insoluble in water. Cannabis can be injected by adding an alcoholic solution
of THC to a rapid intravenous infusion of saline solution, but this is rarely used
(Iversen, 2000). The method delivers THC to the blood circulation rapidly. This mode
of administration is very rare (Earleywine, 2002).
Anecdotal and clinical reports have suggested cannabis could potentially be
effective in the treatment of various debilitating medical conditions (Mack & Joy, 2000;
Mather, 2005). The following section will review clinical trials of cannabis and
cannabinoids in the treatment of various medical conditions and compare the results
with conclusions reached in other influential earlier reviews of the literature. It is
important to note that the first section does not follow standards set for systematic
literature reviews, but the findings of systematic reviews and meta-analyses on medical
cannabis will be discussed later in the chapter. Additionally, this review only included
studies of cannabis plant and its natural derivatives and excluded studies that focused on
synthetic cannabinoids such as nabilone and dronabinol. Synthetic cannabinoids
nabilone and dronabinol are already approved by the FDA for use in the treatment of
some debilitating medical conditions, and were excluded because the focus of the
research in this thesis was on laws as they relate to medical cannabis, and research on
synthetic cannabinoids was deemed beyond the remit of this study.
Review Strategy
For the purpose of this review, an electronic search was made in the OneSearch
program of Edith Cowan University (ECU) library system of all literature published
until February 2011. The search included the following keywords: “cannabis”,
“cannabinoids”, “marijuana”, “marihuana”, “THC”, “tetrahydrocannabinol”, “medical”,
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“medicinal”, and “therapeutic”; or a combination of these keywords. Only full-text
articles in peer-reviewed journals, obtained either online or through ECU or other
university libraries, were included in the search. Other reports were identified through a
general internet search of medical and scientific journal websites, pages devoted to
medical cannabis, and Google Scholar. Additional reports were also identified from the
reference lists of retrieved articles and reports. It is important to note that some studies
were not accessed and included in this review because they could not be accessed
through the standard university system. The search only included articles in English or
with an English translation. Data from review articles, case reports, and where abstracts
only were available were not included.
Inclusion criteria. The method for assessing the quality of a clinical trial and
the inclusion criteria were as described by the Jadad Scale (Jadad et al., 1996). The
Jadad Scale assesses the methodological quality of studies by the presence of three key
features: randomization; double-blinding; and accounting for all patients, including
withdrawals and dropouts. Studies were included if they met these three key criteria, or
had a score point of three or more on a five-point scale (Jadad, et al., 1996). One point is
given to a study for each of the following points: randomisation, use of appropriate
randomisation procedures, double-blinding, use of appropriate double-blinding
methods, and a description of reasons for patient withdrawals and dropouts. Some
critics suggest that the scale may be limiting in focusing only on three key criteria, and
may not provide the most comprehensive measure (Armijo Olivo et al., 2008). It also
does not allow for the studies to be divided into “low” and “high” quality. For the
purpose of this research, the Jadad Scale was chosen for its ease of use and its known
reliability and external validity (Armijo Olivo, et al., 2008). The scale was also chosen

Medical Cannabis in the United States

65

because it assesses measures of internal validity and accounts for methodological errors
such as the placebo effect, which can affect the results (Jadad, et al., 1996). It should be
noted that the scale was not used only to exclude studies but to identify common
methodological weaknesses, and raise questions that need to be addressed in medical
cannabis research.
Level of evidence. All of the studies included in this review are considered to be
Level II evidence, according to the National Health and Medical Research Council
guidelines (National Health and Medical Research Council, 1999). The levels evaluate
the degree to which bias has been eliminated by study design; Level II grading
encompasses evidence “obtained from at least one properly designed randomised
controlled trial” (National Health and Medical Research Council, 1999, p. 8).
Review Summary
The following section will discuss the scientific evidence from clinical studies
on the effectiveness of medical cannabis, as determined by the previously mentioned
selection criteria. In total, 38 studies fitting the selection criteria have been identified.
As can be seen in Table 1, this review identified 10 conditions in which studies fitting
the selection criteria were conducted. While no study specifically examined the effect of
medical cannabis on sleep, cannabis’ sleep-inducing properties and effects on quality of
sleep have been mentioned in a number of studies discussed in this review. For each
study reviewed, methodology, route of cannabis administration, treatment and control
groups, the number of participants, drop-out rates, outcome measures, and results will
be described. A summary of the results for each debilitating medical condition will also
be provided.
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Table 1
A Summary of Studies Reviewed
Number of
Medical Condition
Studies

Range of study
participants

Total number of
participants

Pain

16

10-177

794

Nausea and vomiting

7

9-214

474

Spasticity

6

13-630

1, 073

Appetite/Weight

2

67-243

310

Gilles de la Tourette
syndrome

2

12-24

36

Parkinson’s disease

1

19

19

Epilepsy

1

15

15

Glaucoma

1

6

6

Bladder dysfunction

1

135

135

Schizophrenic
psychosis

1

13

13

Sleep*

Mentioned in other studies
TOTAL

38

66

2,875

Pain
A total of 16 randomised controlled clinical trials examining cannabis and its
constituents in the treatment of pain met the inclusion criteria for this review (Abrams et
al., 2007; Berman, Symonds, & Birch, 2004; Blake, Robson, Ho, Jubb, & McCabe,
2006; Conte et al., 2009; Ellis et al., 2008; Johnson, Burnell-Nugent, Lossignol, GanaeMotan, & Fallon, 2010; Notcutt et al., 2004; Noyes, Brunk, Avery, & Canter, 1975;
Nurmikko et al., 2007; Raft, Gregg, Ghia, & Harris, 1977; Rog, Nurmikko, Friede, &
Young, 2005; Selvarajah, Gandhi, Emery, & Tesfaye, 2010; Wade, Robson, House,
Makela, & Aram, 2003; Wallace et al., 2007; Ware et al., 2010; Wilsey et al., 2008).
The four different forms of pain covered include: neuropathic or chronic pain, acute
pain, chronic cancer pain, and rheumatic pain.
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Table 2
(Chronic) Neuropathic Pain
Author

Methodology

Abrams et
al. (2007)

Randomised
placebocontrolled
trial

Route of
Administration
Smoked
cannabis (3.56%
THC)

Number of
participants
54 patients
with HIVassociated
neuropathic
pain.
50 (93%)
patients
completed the
trial.25 in
each group.

Ellis et al.
(2008)

Phase II,
double-blind,
placebocontrolled,
crossover trial

Smoked
cannabis (1-8%
THC)

34 HIVinfected
patients.
28 (82%)

Treatment and
Control Groups
27 randomly
assigned to receive
a cannabis cigarette.
27 to receive an
identical placebo
cigarette, three
times daily for 5
days

Outcome
measures
Ratings of
chronic pain,
percentage
achieving >30%
reduction in
pain intensity,
side effects

Patients were
administered either
smoked cannabis or
an identical looking
placebo cigarette 4x

Measures of
multiple pain
(such as
analgesia) and
side effects

Results

Side Effects

Cannabis
smoking reduced
neuropathic pain
significantly
more than
placebo (34%
reduction to
17%
respectively).
Twelve (48%) of
patients who
smoked cannabis
reported a
reduction in pain
of more than
30% from
baseline to end
of treatment,
compared to 6
(24%) of
placebo
receiving
patients.
Smoked
cannabis
significantly
reduced
neuropathic pain

Cannabis side effects
ratings were
significantly higher
than those of placebo
for anxiety, sedation,
disorientation,
confusion, and
dizziness. No patient
withdrew from the
study due to side
effects.

The frequency of
some side-effects,
including
concentration
difficulties, fatigue,
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Wilsey et
al. (2008)

Randomised,
placebocontrolled,
crossover trial

Smoked
cannabis; highdose (7% THC),
low-dose (3.5%
THC)

patients
completed
treatment (13
placebocannabis, 15
cannabisplacebo)

daily over 5
consecutive days.
34 patients were
randomised (16
received placebo
first followed by
cannabis, 18
received the reverse
order).

38 patients
with
neuropathic
pain.

During three 6-hour
experimental
sessions, 38 patients
were randomised to
receive a high-dose
cannabis cigarette,
low-dose cannabis
cigarette, and a
placebo cigarette
(cannabinoids
extracted) once in
random order.

32 (84%)
patients
completed all
three study
sessions.

Pain intensity,
pain
unpleasantness,
neurocognitive
effects, and
psychoactive
side effects

intensity in HIVinfected patients
compared to
placebo and
when taken in
combination
with an
analgesic
medication. 30%
more patients
achieved pain
reduction from
cannabis (0.46)
than for placebo
(0.18).
Both low and
high THC
concentrations
produced
statistically
significant
analgesic effects
compared with
placebo. The
difference
between high
and low dose
cannabis
cigarettes was
not statistically
significant. Pain
was more
tolerable at
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sleepiness or sedation,
increased duration of
sleep, dry mouth, and
thirst was greater for
cannabis than placebo

Subjects using the
higher THC dose
experienced
significantly greater
side effects than those
using a lower dose or
placebo. Feeling
“high” and feeling
“stoned” scored
significantly greater
for the high-dose
group; both dose
groups significantly
differed from placebo.
Feeling “impaired”,
sedation, and
confusion were
significantly different
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Ware et
al. (2010)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Smoked
cannabis (2.5%,
6%, and 9.4%
THC).

23 patients
with chronic
neuropathic
pain.
21 patients
(91%)
completed all
four treatment
cycles

Patients randomly
assigned to groups
receiving different
cannabis potencies,
over four 14-day
periods.

Daily average
pain intensity,
effects on mood,
sleep and
quality of life,
side effects.

higher
cumulative
doses of
cannabis than
with placebo.
High potency
cannabis (9.4%
THC)
significantly
reduced average
pain intensity
compared with
placebo;
increasing THC
content led to
improvement in
outcomes. At the
end of the trial,
16 (76%)
participants
were able to
correctly identify
the 9.4% THC
treatment, and
13 (62%) were
able to identify
the placebo
period. The 6%
THC period was
identified by 8
(38%)
participants, and
the 2.5% THC
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between the two dose
groups compared with
placebo.

No serious side
effects. Participants
using 9.4% THC
reported significantly
more drowsiness.
Side effects increased
with cannabis
potency. The most
frequent side effects
reported by patients
receiving 9.4% THC
included headache,
dry eyes, burning
sensation, and cough.
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Wade et
al. (2003)

Randomised,
double-blind,
crossover,
placebocontrolled
study

Cannabis based
medicinal
extract
THC (2.5mg):
CBD (2.5mg)

24 patients
with
neurogenic
symptoms
unresponsive
to standard
treatment
20 (83%)
patients
completed the
study (3
withdrew
during openlabel, 1 during
the blinded
phase).

Berman et
al. (2004)

Randomised,
double-blind,
placebocontrolled

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

48 patients
with central
neuropathic
pain

An open label
period during which
patients received a
1:1 combination of
THC (2.5 mg) and
CBD (2.5 mg) was
followed by an 8week double-blind
phase, consisting of
four 2-week stages
during which
patients were
randomised to
receive either
cannabis extract
containing THC
(2.5 mg) only, CBD
only (2.5 mg), a
combination of
both, or matched
placebo. Treatments
were selfadministered by
sublingual spray in
doses of 2.5-120 mg
per day.
Over three 2-week
treatment periods,
patients were
randomised to 6

Symptoms,
well-being, and
intoxication
scores were
recorded on a
Visual Analogue
Scale. Severity
and frequency
of symptoms,
measures of
disability, mood
and cognition,
side effects

Pain severity
score, followed
by pain related
quality of life

period by 7
(33%)
participants.
In comparison
with placebo,
both THC and
CBD alone
significantly
improved pain.
Levels of
intoxication
were highest
with THC

Both THC alone
and Sativex
reached
statistical
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Side effects were
reported by patients in
all groups: 11 (55%)
following THC, 10
(48%) following
placebo, seven (33%)
following CBD, and
six (30%) following
THC:CBD

Dizziness,
somnolence, a bad
taste in the mouth,
nausea and feeling
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trial
45 (94%)
patients
completed the
study

Nurmikko
et al.
(2007)

Randomised,
double-blind,
placebocontrolled
clinical trial

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

125 patients
with
neuropathic
pain of
peripheral
origin
105 (84%)
patients
completed the
study.

sequences of
receiving Sativex
(1:1 ratio of 2.7 mg
THC, 2.5 mg CBD),
a THC extract (2.7
mg), and placebo, in
sublingual spray.
* All patients
remained on their
existing
medications.

and treatment
side effects

In the 5-week study,
patients were
randomised to
receive either
oromucosal Sativex
(63 patients) or a
placebo (62)
identical in
appearance, smell,
and taste. Doses
were self-titrated by
patients in order to
optimise drug
administration.
* Patients remained

Change from
baseline of
mean intensity
of global
neuropathic
pain, allodynia,
sleep
disturbance,
Pain Disability
Index, general
health, cognitive
decline, side
effects

significance in
decreased pain
compared with
placebo, but did
not reach the
pre-determined
level for clinical
significance.
*The
researchers
found it was
difficult to
guarantee full
blinding because
many patients
had previous
experience with
cannabis
Reduction in
pain from
baseline was
statistically
significant for
Sativex (reduced
by 22%)
compared with
placebo (8%).
Improvement in
pain intensity,
allodynia, pain
disability, and
impression of
change, were
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drunk were the most
commonly reported
side effects. They
were generally well
tolerated

Side effects were
reported by 57 (91%)
of patients in the
Sativex group,
compared with 48
(77%) patients in the
placebo group. The
most common sideeffects of Sativex
were dizziness (29%),
nausea (22%), fatigue
(21%), and dry mouth
(17.5%)
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on their existing
analgesic treatment
throughout the
study.
Selvarajah
et al.
(2010)

Randomised,
placebocontrolled,
double-blind,
clinical trial

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

30 patients
with painful
diabetic
neuropathy
24 (80%)
patients
completed the
study.

Rog et al.
(2005)

Randomised,
double-blind,
placebocontrolled,
parallel-group
trial

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

66 patients
with central
pain associated
with multiple
sclerosis
64 (97%)
participants
completed the
study
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also significantly
greater for
Sativex than
placebo.

Patients received
daily doses of
Sativex or placebo
in a sublingual
spray, up to 4 times
a day. Doses were
self-titrated by
patients over 2
weeks, followed by
a 10-week
maintenance phase.
* Patients continued
using their existing
neuropathic pain
treatment.

Change in mean
daily pain
scores, quality
of life, sideeffects

Over the course of 5
weeks, patients
were randomised to
receive either
Sativex (34) or a
placebo (32)
identical in
appearance, smell,
and taste to Sativex.
Treatments were
delivered via

Change in
Neuropathic
Pain Scale and
an 11-point
Numerical
Rating Scale
scores from
baseline to end
of treatment,
side effects

An improvement
in pain scores
was observed in
both groups. The
difference
between groups
was not
statistically
significant. 53%
of Sativextreated patients
responded to
treatment,
compared with
64% of placebotreated
participants.
Reduction in
pain scores on
both Numerical
Rating Scale -11
and Neuropathic
Pain Scale was
statistically
significant for
Sativex in
comparison with
placebo.

Six patients withdrew
from the study due to
side effects, but side
effects were not
outlined by the
authors

30 patients (88.2%)
receiving Sativex
experienced at least 1
side effect; 22
(68.8%) receiving
placebo. Most
common Sativex sideeffects were:
dizziness (56%), dry
mouth (12%),
drowsiness (9%),
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Notcutt et
al. (2004)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

34 patients
with chronic
pain
32 (94%)
patients
completed the
study

oromucosal spray;
doses were titrated.
* Patients continued
using their existing
neuropathic pain
treatment.
Used ‘N of 1’
methodology
(objectively and
systematically
evaluating
participants’
individual responses
to treatment).
Patients randomly
received a different
treatment each week
over two 4-week
sessions: THC,
CBD, a combination
of both (1:1), and a
placebo. Titration
was conducted
under supervision at
the start of each
week.
* Patients continued
using their existing
neuropathic pain
treatment.
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dissociation (9%),
nausea (9%), falls
(9%), and weakness
(9%)

Effects,
tolerability,
safety, and
dosages

Both THC alone
and the THC:
CBD
combination was
significantly
better than
placebo in
providing pain
relief, while
CBD alone was
ineffective. Out
of the 28
patients who
obtained benefit,
most preferred
either THC
alone or the
THC: CBD
combination.
* 7 frequent
cannabis users
were offered
THC: CBD as
rescue
medication

Data on side effects
during the baseline
period was
incomplete due to an
error in data
collection.
Side effects were
common and most
frequently included
dry mouth,
drowsiness,
dysphoria/euphoria,
and dizziness
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Table 3
Acute Pain
Author

Methodology

Wallace
et al.
(2007)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Route of
Administration
Smoked
cannabis
(2%, 4%, and
8% THC)

Number of
participants
19 healthy
volunteers
15 (79%)
participants
completed
the study

Treatment and
Control Groups
Over 4 doserandomised sessions,
participants received
1 of 3 doses of
cannabis or a placebo
identical in
appearance while
being exposed to
capsaicin-induced
pain.

Outcome
measures
Pain,
hyperalgesia,
THC plasma
levels, and side
effects

Results

Side Effects

Cannabis’
effectiveness as an
analgesic was
dose-dependent.
Low dose of
smoked cannabis
(2% THC) had no
analgesic effects; a
medium cannabis
dose (4% THC)
resulted in delayed
pain relief,

Mainly experienced
with high doses of
cannabis and included:
dizziness/faintness,
drowsiness, feeling
cold, cognitive
impairment, shortness
of breath, and dry
mouth. An increase in
heart rate was
experienced at all
cannabis doses.
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Raft et
al.
(1977)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Intravenous
THC (0.022
mg/kg and 0.044
mg/kg)

10 healthy
male
volunteers
undergoing
dental
extractions
9 (90%)
participants
completed
the study

2 intravenous doses
of THC were
compared with
intravenous
diazepam (0.157
mg/kg) and placebo.
Participants were
subjected to both a
surgical experience
and an experimental
noxious stimulus.
Each subject
participated in 4
separate trials where
a single molar (4
molars/patient) was
removed following 1
of the 4 intravenous
treatments
(administered on a
random basis).

Pain, side
effects,
treatment
preference

significantly
inhibiting
capsaicin-induced
pain at 45 minutes
after drug
exposure; high
cannabis dose (8%
THC) produced an
increase in pain at
45 minutes.
Statistically
significant increase
in pain detection
thresholds
observed with
diazepam and both
THC doses (THC’s
effectiveness
attributed to a
disruption of the
normal sensory
signals rather than
an analgesic
effect). No
evidence of
analgesic effects
on pain tolerance
threshold for any
of the treatment
groups. Higher
dose of THC was
least preferred by
participants; it was
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Lower dose THC
reportedly produced
euphoria/dysphoria,
while higher THC dose
produced anxiety
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Conte
et al.
(2009)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Sativex
(sublingual)
(2.7 mg THC:
2.5 mg CBD)

18 patients
with multiple
sclerosis
17 (94%)
patients
completed
the study

Over 8 weeks, the
right tibial nerve was
stimulated with
bipolar electrical
stimuli to measure
whether
cannabinoids can
regulate the
nociceptive system
(which produces
pain). Patients were
randomly assigned to
2 groups of 9 to
receive Sativexplacebo or placeboSativex sequence for
6 weeks, with a 2week washout period
after the 3rd week.
Patients self-titrated
their daily doses up
to a total of 48

Changes in
RIII reflex
variables,
subjective
quality and
intensity of
pain (Visual
Analogue
Scale),
spasticity
(Ashworth
scale), side
effects

associated with
most pain.
Diazepam was
associated with
least pain. Lower
dose of THC was
preferred over
placebo, and
described by
patients as good or
excellent.
A significant effect
was observed on
the pain threshold
and reflex activity
in favour of
Sativex. The pain
rating scores on the
10-point Visual
Analogue Scale
also decreased in
patients using
Sativex, but the
difference between
groups was not
significant. The
authors concluded
that Sativex
showed promise in
modulating pain
processing and
may be useful in
analgesic therapy
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None of the participants
experienced major side
effects. Most frequent
Sativex side effects
were slower thinking
(11 patients), dizziness
and vertigo (8), and
fatigue (6). Most
frequent placeborelated side effects
were fatigue (3) and
headache (3)
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sprays/day.

Table 4
Pain (Other)
Author

Methodology

Chronic Cancer Pain
Noyes et Randomised,
al. (1975) double-blind,
crossover,
placebocontrolled trial

Route of
Administration

Number of
participants

Treatment and
Control
Groups

Outcome
measures

Results

Side Effects

Oral THC

36 patients
with cancer
pain

Placebo, THC
(10 and 20 mg),
and codeine (60
and 120 mg)
were
administered
randomly on
successive days
(single oral
dose), and were
all identical in
appearance. All
patients received

Severity of
pain/pain
ratings, extent
of relief, and
side effects

Significant
differences in pain
reduction and relief
scores were observed
between placebo and
20 mg THC, and
between placebo and
120 mg codeine.
Lower doses of THC
(10 mg) and codeine
(60 mg) did not
achieve statistical
differences when

Heavy sedation
was reported by
patients
receiving high
dose THC, and
drowsiness was
reported by
those on a
lower dose

34 (94%)
patients
completed the
study
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their usual
analgesic
medication, and
varying doses of
oral codeine (60
mg, 120 mg)
and oral THC
(10 mg, 20 mg
capsules)

Johnson
et al.
(2010)

Multicenter,
double-blind,
randomised,
placebocontrolled,
parallel-group
study

Sativex
(sublingual)
(2.7 mg THC: 2.5
mg CBD)
and Tetranabinex
(THC-only extract)

177 patients
with cancer
pain who did
not get
sufficient
relief from
analgesic
medication
144 (81%)
patients
completed the
study

In the 2-week
study, patients
were
randomised to
receive either
Sativex (60
patients),
Tetranabinex
(58), or placebo
(59) using a
pump action
oromucosal
spray. Each
Sativex spray
delivered a dose
containing 2.7
mg THC and 2.5
mg CBD, while
each
Tetranabinex
spray delivered
2.7 mg of THC;

The Numerical
Rating Scale
pain severity
score, use of
opioid
background
medication,
sleep quality,
nausea,
memory,
concentration,
appetite, side
effects

compared to placebo.
6 patients (18%)
reported substantial
pain relief after
placebo; 8 (24%)
after 60 mg codeine;
13 (38%) after 10 mg
THC, 16 (47%) after
120 mg codeine and
16 (47%) after 20 mg
THC
Pain was
significantly reduced
with the THC: CBD
extract compared
with placebo, but not
with the THC
extract.
Approximately twice
the number of
patients achieved a
greater improvement
in pain with the
THC: CBD (43%)
combination, than
those in the THC
(23%) and placebo
(21%) groups.

106 patients
(60%) reported
experiencing
side effects.
Most
commonly
reported side
effects of
Sativex
included
drowsiness
(13%),
dizziness
(12%), and
nausea (10%).
Most
commonly
reported side
effects of the
THC extract
were
drowsiness
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patients selftitrated to their
optimal dose.

Rheumatic Pain
Randomised,
Blake et
al. (2006) double-blind,
placebocontrolled,
parallel-group
study

Sativex
(sublingual)
(2.7 mg THC: 2.5
mg CBD)

58 patients
with arthritis
not adequately
controlled by
other
medication
54 (93%)
patients
completed the
study

In the 5-week
study, 31
participants
were randomly
assigned to
receive Sativex
by an
oromucosal
spray (each
spray delivered
2.7 mg THC and
2.5 mg CBD)
and 27 to
receive placebo.
Dosing was
titrated to a
maximum of 6
sprays per day

(14%),
dizziness (12%)
and raised
gamma GT (a
measure of
liver
dysfunction)
(9%)
Pain on
movement,
pain at rest,
morning
stiffness, sleep
quality, and
disease
activity

Sativex produced a
statistically
significant
improvement in pain
on movement, pain at
rest, and pain at
present, compared to
placebo.

Most frequently
reported side
effects of
Sativex
included
dizziness
(26%), dry
mouth (13%),
lightheadedness
(10%), nausea
(6%), and fall
(6%).
Palpitations
(7%) and
vomiting (7%)
were the most
commonly
reported side
effects of
placebo.
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The largest number of studies included in this review examined cannabis’
analgesic properties; 10 studies addressed chronic neuropathic pain, three focused on
acute pain, and three on other pain types. The number of participants in the studies
ranged from 10-177, with a total of 794 participants. All included studies had a
participant retention rate greater than 75 percent. Most of the studies examined the
effects of Sativex (cannabinoid oromucosal mouth spray) and smoked cannabis. Other
variations of what here is termed cannabis included cannabis based extract, tetranabinex
(THC-only extract), intravenous THC and oral THC.
In terms of chronic neuropathic pain, nine out of 10 studies found significant
results favouring cannabis and its components: smoked cannabis (4 out of 4 studies
(4/4)), cannabis-based medicinal extract (1/1), and Sativex (4/5) (Abrams, et al., 2007;
Berman, et al., 2004; Ellis, et al., 2008; Notcutt, et al., 2004; Nurmikko, et al., 2007;
Rog, et al., 2005; Wade, et al., 2003; Ware, et al., 2010; Wilsey, et al., 2008).
All three studies on cannabis’ effects on acute pain produced results indicating
positive effects of the drug and its different components: smoked cannabis (1/1),
intravenous THC (1/1), and Sativex (1/1) (Conte, et al., 2009; Raft, et al., 1977;
Wallace, et al., 2007). However, Conte et al. (2009) noted that the difference between
groups in pain rating scores on the 10-point Visual Analogue Scale was not significant,
Raft et al. (1977) found no evidence of analgesic effects on pain tolerance threshold for
any of the treatment groups, and Wallace et al. (2007) found that smoked cannabis’
effectiveness as an analgesic was dose-dependent. Lastly, all three studies looking at
other types of pain (chronic cancer and rheumatic) yielded significant results in favour
of oral THC (1/1, dose dependent) and Sativex (2//2) (Blake, et al., 2006; Johnson, et
al., 2010; Noyes, et al., 1975).
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A major caveat in the studies of cannabis’ therapeutic potential in the treatment
of pain is that the data have mainly been collected on small sample sizes of healthy,
regular cannabis users, and usually with more male than female participants.
Psychoactive effects of cannabis also make blinding difficult; in some studies, such as
Ware et al. (2010) subjects were able to correctly identify the treatment they were
receiving due to feeling “high”. Durability of analgesia is also difficult to access in
short-term studies. Therefore, more randomised controlled studies are needed to
determine the therapeutic application of cannabis and its constituents, and an optimal
delivery system.
Overall, cannabis and its constituents have shown considerable potential in
decreasing chronic pain. However, less research has been conducted on its effects in the
treatment of acute pain. Generally, studies on cannabis’ analgesic properties have had
low sample sizes, making them difficult to generalise. They have, however, shown that
cannabis has short-term analgesic potential. Cannabis’ therapeutic potential in some
pain management was no more effective than other drugs. On the other hand, studies
such as Blake et al. (2006) have shown that cannabis may reduce pain in patients whose
pain was not adequately controlled by other medication. Its effects might also be dosedependent, especially if used in smoked form.
In acute types of pain cannabis-based medicines did not show significant results.
However, the three studies included in this review used different routes of cannabis
administration, so it is difficult to reach a conclusion on cannabis’ effectiveness in the
treatment of acute pain based on the limited number of studies. Larger numbers and a
higher degree of homogeneity are necessary in order to be able to comment on the true
size of the analgesic effect of cannabis.
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Relief of Nausea and Vomiting
Seven randomised, controlled clinical trials examining the effects of cannabis
and its constituents on nausea and vomiting met the inclusion criteria for this review
(Chang et al., 1981; Chang et al., 1979; Duran et al., 2010; Frytak et al., 1979; Sallan,
Cronin, & Zelen, 1980; Sallan, Zinberg, & Frei, 1975; Ungerleider et al., 1982). The
studies were grouped by different routes of cannabis administration, and are discussed
below.
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Table 5
Nausea and Vomiting
Author

Methodology

Sallan et al.
(1975)

Randomised,
double-blind,
crossover,
placebocontrolled trial

Sallan et al.
(1980)

Randomised,
double-blind,
cross-over trial

Route of
Administration
Oral THC
(capsules)
15 or 10mg/m²

Number of
participants
20 patients
receiving
chemotherapy
11(55%)
patients
completed all 3
courses of
treatment

Oral THC
(capsules)
15 or 10mg/m²

84 patients
receiving
chemotherapy
57(68%)
patients
completed the
study

Treatment and
Control Groups
Patients received
either THC capsule
or identical placebo
capsule 3 times per
day during three 1day courses; each
patient served as
their own control.
* The study was
limited in scope
because it did not
include a control
group treated with
a standard
antiemetic
Patients received a
combination of 2
one-day treatments
with oral THC and
one with 10 mg
prochlorperazine
(PCP) (standard
antiemetic
treatment), OR 2
prochlorperazine
and one THC
treatment.

Outcome
measures
Nausea,
vomiting,
appetite, and
side effects

Results

Side Effects

A significant
difference between
THC and placebo in
treating nausea and
vomiting was
observed; 14 out of
20 (70%) patients
reported an
antiemetic effect from
the THC, while no
effect was observed
in the placebo group.

13 (81%) patients
receiving THC
reported feeling
“high”; 2 (13%)
reported
experiencing THC
toxicity (e.g.
paranoia, fear,
panic).

Nausea,
vomiting,
food intake,
and feelings
of being
“high”.

The rate of complete
response (no nausea
or vomiting) to THC
treatment (6 complete
responses) was
significantly higher
than the rate for PCP
(1 complete
response). 9 patients
receiving THC had no
response to treatment,
and 11 had no
response with PCP.

All 6 patients who
had a complete
response to THC
experienced feeling
“high”, whereas 2/9
who had no
response reported
feeling “high”.
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Frytak et al.
(1979)

Ungerleider
et al. (1982)

Randomised,
double-blind,
placebocontrolled,
parallel groups
trial

Oral THC
(capsules) 15mg

Randomised,
double-blind,
crossover

Oral THC
(capsules)
(7.5-12.5 mg)

116 patients
receiving
chemotherapy
98 (84%)
patients
completed the
study

214 patients
receiving
chemotherapy

Patients were
randomised to
receive oral THC
(38 patients), oral
prochlorperazine
(10mg) (41
patients) or placebo
(37 patients).
Placebo and PCP
were prepared in
the same gelatine
capsules as THC.
First dose was
administered 24
hours before
chemotherapy, and
subsequent doses
were given 2 and 8
hours after
chemotherapy. On
the remaining 3
study days,
treatments were
given 3x a day.
Patients were
grouped by two
standard

Nausea,
vomiting,
appetite,
sedation,
feelings of
“high”, and
side effects

Appetite,
food intake,
mood,

20/25 patients, who
were treated with
both drugs and who
expressed a
preference, preferred
THC to PCP
On Day 1, a
significantly higher
percentage of placebo
patients experienced
nausea and vomiting
than patients in other
two study groups.
The antiemetic effects
of oral THC were
equivalent to those of
PCP, and were more
significant than
placebo. Seventeen
(45%) THC, 18
(44%) PCP and 20
(54%) placebo group
participants reported
experiencing repeated
vomiting. 12 patients
considered THC
therapy intolerable.

No significant
differences between
THC and PCP were
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Side effects such as
ataxia, hypotension,
and visual
hallucinations were
more frequent and
severe with THC
(12, 32%) than PCP
(1, 2%) and placebo
(1, 3%)
*18 patients
(15.5%) dropped
out after Day 1 due
to side effects (10
out of THC, 5 PCP,
and 3 placebo
group)

Side effects were
reported by 75
(45%) of patients

Medical Cannabis in the United States
design trial

chemotherapy
regimens (98 were
randomly assigned
to a single-day
regimen, 41 to a
multiple-day
regimen).
Prochlorperazine
was administered in
a fixed dose of 10
mg, while THC was
administered in
proportion to the
body surface area.
Both treatments
were administered
orally 1h before
chemotherapy and
every 4 hours
thereafter, for a
total of 4 doses/ day
for each day of
chemotherapy.
15 patients with During 6
chemotherapy- subsequent
related nausea
chemotherapy
and vomiting
treatments (3 THC,
3 placebo) each
15 (100%)
patient served as
patients
their own control.
completed the
Placebo capsules
study
were identical to
THC capsules, and
139 (65%)
patients
completed the
study

Chang et al.
(1979)

Randomised,
double-blind,
crossover,
placebocontrolled trial

Oral THC (10
mg/m²)
Smoked cannabis
(1.93 % THC)*
only used as a
substitute for oral
THC in case of its
failure/inadequacy
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activity,
relaxation,
interaction,
and
concentration

observed in
antiemetic response
and effectiveness; 54
(41%) of evaluable
patients experienced
less nausea when
using THC, compared
with 41 (31%) of
those using PCP.
* 2/3 of patients who
completed the study
were able to correctly
identify the drug they
received, and this
group did
significantly better on
THC.

receiving THC,
compared to 56
(31%) of those
receiving PCP.
Frequency of side
effects was
significantly greater
for patients
receiving THC than
PCP. There were
significant drug
effects with THC:
less ability to
concentrate, less
social interaction,
and less activity.

Number of
nausea and
vomiting
episodes,
appetite, sideeffects, and
THC plasma
concentration
s

THC treatment
produced a
statistically
significant reduction
in the number of
vomiting and retching
episodes, degree of
nausea, duration of
nausea, and volume
of emesis compared

Sedation was
reported by 12
(80%) patients, but
no participant
withdrew from the
study
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placebo cigarettes
had an identical
odour and taste to
cannabis cigarettes

Chang et al.
(1981)

Randomised,
double-blind,
crossover,
placebocontrolled trial

Oral THC (10
mg/m²)
Smoked cannabis
(1.93 % THC)*
only used as a
substitute for oral
THC in case of its
failure/inadequacy

9 patients
receiving
chemotherapy
8 (89%) were
evaluable

Each patient served
as his or her control
and completed 3
paired trials of
either the THCplacebo or placeboTHC
sequence.THC or
an identical looking
placebo were
administered 5
times/day. The
order of THC and
placebo
administration was
randomised. In case
of vomiting, the
patient was given a

Number of
vomiting and
retching
episodes,
volume of
emesis,
degree and
duration of
nausea,
feelings of
being “high”;
and other side
effects

to placebo. 14/15
(93%) patients
reported a reduction
of nausea and
vomiting with THC.
Nausea and vomiting
decreased with
elevation of THC
plasma concentration.
Smoked cannabis was
more effective and
reliable than oral
THC in reaching a
higher, therapeutic
plasma concentration.
Oral or smoked THC
did not significantly
reduce the number of
vomiting or retching
episodes, volume of
emesis, degree of
nausea, or duration of
nausea compared to
placebo. 3 (38%)
patients had a “fair”
response to THC in
reducing nausea and
vomiting; 5(62%) had
no response. Drug
absorption was
observed to be poor
and highly variable
for all scheduled
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Apart from
euphoria (75% of
patients) and short
episodes of
tachycardia, no side
effects were
reported
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Duran et al.
(2010)

Pilot,
randomised,
double-blind,
placebocontrolled,
phase II
clinical trial

Whole-plant
cannabis-based
medicine (CBM)
(oromucosal
spray)
THC (2.7 mg),
cannabidiol (2.5
mg)

16 patients
receiving
chemotherapy
15 (94%)
patients
completed the
study

cannabis cigarette
for the remainder of
that trial.
The CBM was
taken in
conjunction with
standard antiemetic
therapies. 7 patients
were randomised to
receive the CBM in
a 120 hour postchemotherapy
period, and nine to
receive a placebo.
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doses.

Response to
treatment,
frequency and
duration of
nausea and
vomiting, side
effects,
impact on
daily life,
satisfaction
with
treatment

Six (86%) patients in
the CBM group and
all the patients in the
placebo group
tolerated dose
titration. Complete
response to treatment
(no nausea) was
significantly higher in
the CBM group
compared with
placebo (5, 71%
patients in CBM and
2, 22% in placebo
group). 4 patients
(57%) of patients
receiving CBM and 8
(88%) receiving
placebo were satisfied
with their treatment.

At least one side
effect was reported
by six (86%) CBM
and 6 (67%)
placebo receiving
participants;
somnolence was the
most reported
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In the seven studies of cannabis’ antiemetic properties reviewed here, the
number of participants ranged from 9-214, with a total of 586 participants. Four (57%)
studies had a participant retention rate greater than 75 percent. The studies examined the
effects of oral THC and CBM (cannabis-based medicine). Five out of seven studies
produced results indicating positive effects of the drug and its components: oral THC
(4/6) and CBM (1/1) (Chang, et al., 1979; Duran, et al., 2010; Frytak, et al., 1979;
Sallan, et al., 1980; Sallan, et al., 1975).
Only one study comparing cannabis to other antiemetic drugs found its
antiemetic effects to be superior (Sallan, et al., 1980). Two studies found that the
antiemetic effects of cannabis and its constituents were similar or equal to those of other
antiemetic drugs (Frytak, et al., 1979; Ungerleider, et al., 1982). Side effects occurred
more often with cannabinoids than with other antiemetics, but these usually occurred in
a small number of patients and disappeared after a short period of time.
It should be noted that only one study reviewed here has been conducted
recently, and all others were conducted in the 1970s and 1980s, bringing into question
their generalisability and applicability, as it is known that the THC content of cannabis
plants has increased in past decades. None of the studies evaluated the effects of
smoked cannabis. Comparison of the studies is also made difficult due to variability in a
number of areas including participants, dosage, types of chemotherapy and antiemetic
drugs administered, and number of patients who withdrew or dropped out. One of the
potential explanations for a large number of drop outs is disease progression. Cancer
can be a terminal illness, and patients terminating the study early may be attributable to
the disease itself. Performing a double-blind trial may also be difficult when using
cannabis, due to patients experiencing psychoactive drug effects. Feeling these effects
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may enable patients to correctly identify the drug received and perform better on a
particular treatment, as was the case with Ungerleider et al. (1982).
Based on the number of studies reviewed here, it is difficult to reach a
conclusion on cannabis’ anti-emetic properties, especially in terms of smoked cannabis.
The overall consensus is that cannabis and its constituents (cannabinoids) are superior to
placebo in the treatment of nausea and vomiting in individuals receiving cancer
chemotherapy, especially when used together with other antiemetic drugs (Sallan, et al.,
1980). However, cannabis and its constituents did not adequately control nausea and
vomiting in some patients due to issues with oral administration and the side-effects
associated with orally administered drugs, such as difficulty in swallowing and titrating
dosage. Smoking is suggested as a better route of administration for individuals
experiencing nausea and vomiting or those that have difficulty swallowing or keeping a
pill down, but no study included in this review examined the antiemetic effects of
smoked cannabis.
Further clinical trials are recommended in order for an effective dosage to be
established as well as the most effective route of administration. As studies on the
antiemetic properties of cannabis have often been criticised for their sample size, further
large-sample human clinical trials comparing the action of cannabinoids with modern
antiemetic medication are recommended.

Spasticity
A total of six randomised controlled clinical trials evaluating the effectiveness of
cannabis and its constituents in the treatment of spasticity met the inclusion criteria for
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this review (Collin, Davies, Mutiboko, Ratcliffe, & Group, 2007; Ungerleider,
Andrysiak, Fairbanks, Ellison, & Myers, 1988; Vaney et al., 2004; Wade, Makela,
Robson, Houre, & Bateman, 2004; Wade, et al., 2003; Zajicek et al., 2003). Spasticity is
a chronic disorder characterised by an abnormal increase in muscle tone and resistance
to passive movement (Collin, et al., 2007; Zajicek, et al., 2003). It is a symptom of
conditions such as multiple sclerosis (MS) and spinal cord injury.
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Table 6
Spasticity
Author

Methodology

Ungerleider
et al. (1988)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Zajicek et
al. (2003)

Randomised,
double-blind,

Route of
Administration
Oral THC
(2.5-15mg/day)

Cannabis extract
(capsules) (2.5mg

Number of
Treatment and
participants
Control Groups
13 patients with Patients were
MS
divided into 2
dosing groups
(depending of the
12 (92%)
time of their most
patients
severe spasticity).
completed at
One group (2
least two
patients) received
paired trials
their treatment at
5 (38%)
bedtime and the
completed
other group (11
three paired
patients) received
trials
their treatment
2x/day. Each group
was randomised to
receive 5 days of
oral THC (2.5-15
mg per day)
followed by 5 days
of placebo, or the
reverse sequence.
Patients were
initiated at varying
doses of THC
which were later
adjusted.
630 patients
In the 15-week
with MS
study, patients were

Outcome
measures
Motor
function, limb
spasticity, and
limb
weakness
(assessed by
physician
rating scales);
spasticity and
side effects
(patient rating
scales)

Results

Side Effects

Patient rating scales
indicated a significant
reduction in spasticity
for 7.5 mg THC dose
compared with
placebo; 2.5 and 5 mg
doses were deemed
ineffective. The
results indicated that
a reduction is
spasticity began at 7.5
mg and continued for
most participants at
10 and 15 mg doses.
The 7.5 mg THC dose
was selected as the
highest tolerable dose
because 75% of
participants who
received the 10 mg
dose of THC
complained of
intolerable side
effects.

Side effects were
frequent with the
7.5 mg THC dose
and included dry
mouth, weakness,
dizziness,
relaxation, mental
clouding, shortterm memory
impairment, and
spatial-time
distortions.
* Authors suggested
that side effects
might have
interfered with
patient blinding

Change in
MS-related

Treatment with
cannabinoids was not

A total of 50 (8%)
participants (12
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parallel groups,
placebo
controlled trial

THC: 1.25mg
CBD, and less
than 5% of other
cannabinoids per
capsule)
Synthetic THC
(Marinol,
capsules)

Vaney et al.
(2004)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Cannabis extract
(oral) (2.5 mg
THC: 0.9 mg
CBD per capsule)

randomised to
receive: Marinol
capsules 206
patients), cannabis
extract capsules
(211 patients), or
placebo (213
patients). Doses
were administered
according to
bodyweight, with a
maximum 25 mg
daily. As the
researchers were
unable to make the
active treatments
identical, each had
its own matched
placebo identical in
appearance.
57 patients with 28 patients were
MS
randomised to
receive cannabis
extract capsules for
37 (65%)
14 days followed
patients
by a placebo
completed the
identical in shape,
study pertaste, and colour; 29
protocol
received the reverse
sequence.
Treatments were
administered in 12
capsules daily, with
611 (97%)
participants
completed the
study
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spasticity (
using the
Ashworth
scale),
mobility,
symptoms,
disability
scale, side
effects

found effective in
improving MS
associated spasticity,
as measured by the
Ashworth scale.
However, a
significant reduction
in spasticity was
reported by patients
receiving both
synthetic THC (60%)
and the cannabis
extract (61%). 46% of
patients receiving
placebo reported an
improvement in
spasticity.

receiving cannabis
extract, 18
receiving Marinol,
20 receiving
placebo) reported
serious side effects
and 558 (89%)
patients reported
minor side effects;
these were
generally found to
be well tolerated

Change in
MS-related
spasticity (
using the
Ashworth
scale), spasm
frequency and
symptoms,
Rivermead
Mobility
index, ninehole peg test,
side effects

While not statistically
significant, the active
treatment produced
favourable results for
spasm frequency,
mobility, and
patients’ general
condition. Evaluation
by the Ashworth scale
found no beneficial
effects on spasticity
unless the analysis
was restricted to 37

Cannabis extract
was well tolerated
and no serious
adverse events were
reported. However,
significantly higher
toxicity levels were
reported during
active treatment
compared with
placebo. Most
frequently reported
side effects
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Wade et al.
(2003)

Randomised,
double-blind,
placebocontrolled,
crossover trial

Cannabis extract
containing THC
(2.5mg)
Cannabis extract
containing CBD
(2.5mg)
Combination of
both THC
(2.5mg): CBD
(2.5mg)

24 participants
(18 with MS, 4
with spinal
cord injury, 1
with brachial
plexus damage)
20 (83%)
patients
completed the
study

(sublingual spray)

Wade et al.
(2004)

Randomised,
double-blind,
placebocontrolled trial

Sativex
(sublingual)
(2.7 mg THC; 2.5
mg CBD)

160 patients
with MS
154 (96%)
participants
completed the

varying proportions
of active treatment
(15-30 mg of THC
per day) and
placebo. Patients
continued using
their current
medication.
Patients were
randomly assigned
to receive either
cannabis extract
containing THC
CBD, a
combination of
THC: CBD, or
matching placebo in
a sublingual spray
four times/day
(maximum 120
mg/24 hours) over
four 2-week study
periods.

Eighty patients
were randomised to
receive Sativex
administered in
sublingual spray at
2.5-120 mg doses

Visual
Analogue
Scale score
for target
symptoms,
wellbeing,
and
intoxication.
Severity and
frequency of
symptoms
(numerical
rating scales
and standard
measures of
disability
(Barthel
Index)).
Visual
Analogue
Scale score
for target
symptoms,
measures of
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(65%) patients who
took 90% or more of
the prescribed dose;
then significant
improvements in the
frequency of spasms
were observed.

included dizziness,
feeling “high”, and
difficulty
concentrating

In comparison with
placebo, both CBD
and THC extract
significantly
improved pain. THC
extract also
significantly
improved muscle
spasm, spasticity and
appetite. THC: CBD
significantly
improved muscle
spasm and sleep.
While rescue
medication was
offered, 12 (50%)
patients used zero or
negligible amounts of
it.
Primary symptom
Visual Analogue
Scale scores were
compared between
groups and indicated
that Sativex

Levels of
intoxication were
highest with THC.
Side effects were
reported by patients
in all groups: 11
(55%) following
THC, 10 (48%)
following placebo,
7 (33%) following
CBD, and 6 (30%)
following
THC:CBD

Side effects were
generally mild and
well tolerated. Most
frequent side effects
experienced by the
Sativex group
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Collin et al.
(2007)

Randomised,
double-blind,
placebocontrolled,
parallel-group
trial

Sativex
(sublingual)
(2.7 mg THC; 2.5
mg CBD)

study

for a period of six
weeks; 80 received
placebo. The first
dose was supervisor
and the rest were
titrated by patients
at home.

disability,
cognition,
mood, sleep
and fatigue,
side effects

significantly
decreased spasticity
compared to placebo.
There was also a
significant
improvement in
patients’ assessment
of the quality of sleep
with Sativex.

189 patients
with MS

In the 6-week
study, participants
were randomised
in a 2:1 ratio; 124
to oromucosal
Sativex (2.7 mg
THC, 2.5 mg
CBD), and 65 to an
identically
flavoured placebo.
Titration was
performed as
required, up to a
maximum of 48
sprays per day.

Numerical
Rating Scale
for the
severity of
spasticity, the
Ashworth
scale score of
spasticity, and
a subjective
measure of
spasm, sideeffects

A statistically
significant decrease
in spasticity score as
evaluated by the
Numerical Rating
Scale was reported in
the Sativex group
compared with
placebo. Sixty six
(57%) participants in
the Sativex group
reported that their
condition improved,
compared with 31
(48%) participants
receiving placebo.

174 (92%)
participants
completed the
study
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included dizziness
(26, 33%),
application site
discomfort (21,
26%), and fatigue
(12, 15%). Patients
receiving placebo
most frequently
reported application
site discomfort (18,
23%), headache
(13, 16%), and
dizziness (10, 13%)
Side effects were
reported by 102
(82%) participants
receiving Sativex
and 46 (71%)
receiving placebo;
majority were mild
to moderate.
Only 6 (4.8%)
participants from
the Sativex and 2
(3.1%) from the
placebo group
withdrew due to
side effects.
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Six studies included in this review examined cannabis’ effectiveness in treating
spasticity, with a focus on patients with MS. The number of participants in the studies
ranged from 13-630, with a total of 1,073 participants. Five (83%) studies had a
participant retention rate greater than 75 percent; one of the studies included in the
count reported 92% completing at least two paired trials, with 38% completing three.
The studies examined the effects of Sativex, THC, CBD, cannabis extract, and oral
THC.
Five out of six studies found significant results favouring cannabis and its
components: oral THC (1/1), cannabis extract (1/2), THC and combination of
THC:CBD (1/1), Sativex (2/2) (Collin, et al., 2007; Ungerleider, et al., 1988; Wade, et
al., 2004; Wade, et al., 2003; Zajicek, et al., 2003). The effects of THC were dose
dependant, with higher doses producing better results. Conversely, higher THC doses
resulted in frequent side effects which led to difficulties in performing patient blinding
(Ungerleider, et al., 1988). The side effects, however, were generally well tolerated.
Overall, results from clinical trials are mixed but show that cannabis and its
derivatives have the potential to reduce spasticity and objective ratings of spasticity in
patients with MS. Results have also indicated that it might be an effective long-term
treatment. However, more research is needed to establish the most effective mode of
cannabis administration, and whether the therapeutic benefits outweigh the negative
side effects associated with the drug. As no comparisons with other anti-spastic drugs
have been made in the studies reviewed here, it is not possible to determine whether
cannabis and its components are the most effective method of decreasing spasticity and
for whom they might be appropriate. Also, most reports in favour of cannabis came
from subjective scores rather than objective measurements, therefore future research
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should look at determining the most appropriate measurement of the effects of cannabis
and its components on spasticity.
Appetite Stimulation/Weight Gain
Two randomised, controlled trials examining the effectiveness of cannabis and
its constituents on appetite stimulation met the inclusion criteria for this review (Abrams
et al., 2003; Strasser et al., 2006). The studies are described below.
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Table 7
Appetite Stimulation/Weight Gain
Author

Methodology

Strasser et
al. (2006)

Multicentre,
phase III,
randomised,
double-blind,
placebocontrolled,
parallel trial

Abrams et
al. (2003)

Randomised,
placebocontrolled, 21day
intervention
trial

Route of
Administration
Oral THC (2.5
mg)
Cannador (an oral
whole plant
cannabis extract
with 2.5 mg THC
and 1 mg CBD)

Number of
participants
243 patients
with cancerrelated
anorexiacachexia
syndrome
164 (67%)
patients
completed the
study

Cannabis
(smoked) (3.95%
THC)

67 HIVinfected
patients

Dronabinol (oral)
(2.5mg)

62 (93%)
patients
completed the
study

Treatment and
Control Groups
In the 6-week
study, patients were
assigned to receive
either THC (100
participants),
Cannador (95
participants), or
placebo (48
participants) twice
daily.

Outcome
measures
Appetite,
mood, nausea
(monitored
with a visual
analogue
scale), quality
of life,
cannabinoidrelated
toxicity

Rolled cannabis
cigarettes were
administered to 21
patients (1 to 3 a
day); 25 patients
received oral THC;
and 21 patients
were assigned to the
placebo group.

HIV RNA
levels, CD4+
and CD8+
cell subsets,
pharmacokine
tics, change
in weight

Results

Side Effects

No significant
differences were
observed between the
three study arms for
appetite or
cannabinoid-related
toxicity. Increased
appetite was reported
by 58%, 73%, and
69% of participants
receiving THC,
Cannador, or placebo,
respectively. No
differences between
treatment arms in
body weight at
baseline or week 6
(end of treatment)
were reported
The primary aim of
the study was to
assess the effects of
cannabinoids on the
severity of HIV
infection progression,
but the results showed
that participants in the
cannabis and

No significant
differences between
side effects were
observed. The most
common side
effects include
nausea, fatigue,
pain, anemia,
dizziness, dyspnea,
diarrhoea, and
obstipation

Side effects were
generally well
tolerated
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Both oral THC and
placebo were
administered in a
capsule; smoked
and oral cannabis
were administered
on the same
schedule. There was
no smoked placebo
group- the authors
did not think they
could successfully
blind study
participants to
cannabis given their
previous cannabis
experience.

dronabinol groups
gained significantly
more weight than
those in the placebo
group (an average of
3.0 kg; 3.2 kg; and
1.1 kg respectively).
The short-term use of
cannabinoids did not
adversely affect viral
load in individuals
with HIV infection
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While dronabinol (Marinol) is prescribed in the U.S. for the treatment of AIDSrelated wasting syndrome, a relatively small number of clinical, randomised, doubleblind trials have been conducted to assess its effectiveness. In the two studies included
in this review, there were 67 participants in one study and 243 in another, with a total of
310 participants. Only one study had a participant retention rate greater than 75 percent.
The studies evaluated the effectiveness of smoked cannabis, oral THC, and Cannador
(oral whole plant cannabis extract).
Abrams et al. (2003) compared the effects of dronabinol and smoked cannabis,
and found that participants receiving both smoked cannabis and dronabinol gained
significantly more weight than those in the placebo group. Treatment related side effects
were reported in all studies, but were well tolerated. No long-term study fitting the
selection criteria has been identified, possibly due to disease progression and difficulty
retaining participants. Strasser et al. (2006) examined the effects of oral THC and
Cannador and found no significant differences between oral THC, Cannador and
placebo for appetite and no differences between treatment arms in body weight at
baseline compared to week 6 (end of treatment) were reported.
Overall, cannabis and its derivatives have shown some potential in stimulating
appetite and increasing weight in patients with AIDS or cancer related wasting
syndrome. However, the side effects of cannabis constituents need to be considered in
comparison to other appetite stimulants, which may prove more or equally beneficial
but with less side effects. Cannabis may be useful for individuals for whom other
appetite stimulants have proven ineffective, or for those who cannot take other
treatments orally. However, limited research prevents any firm conclusions being drawn
on the effectiveness of cannabinoids on appetite and more research is needed to evaluate
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the long-term effects of cannabis and the effectiveness of different routes of cannabis
administration, especially in comparison with other already available treatments.
Other Conditions
Seven studies met the selection criteria for inclusion in this review (Carroll et
al., 2004; Cunha et al., 1980; D'Souza et al., 2005; Kavia, DeRidder, Constantinescu,
Storr, & Fowler, 2010; M¨uller-Vahl et al., 2002; M¨uller-Vahl et al., 2003; Tomida et
al., 2006). The conditions covered by the studies were Gilles de la Tourette syndrome,
Parkinson’s disease, epilepsy, glaucoma, bladder dysfunction and Schizophrenic
psychosis.
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Table 8
Other Conditions
Author

Methodology

Route of
Administration
Gilles de la Tourette Syndrome
Randomised,
Oral THC
M¨ullerdouble-blind, (5.0, 7.5, and
Vahl et al.
placebo10.0 mg)
(2002)
controlled,
crossover trial

Number of
participants

Treatment and
Control Groups

Outcome
measures

Results

Side Effects

12 patients
with
Tourette’s
syndrome

Patients received
different doses of
oral THC based on
their age, sex, and
prior use of
cannabis. 6
patients were
randomly assigned
to receive a single
dose of THC
capsule followed
by an identical
placebo over 2
days; 6 received
treatment in the
reverse sequence.
After a 4-week
washout phase,
patients were
crossed over to the
other treatment
sequence

Tic severity
(assessed by
the Tourette
Syndrome
Symptom
List (selfrating scale)
and Shapiro
TouretteSyndrome
Scale
(examiner
ratings)).

Side effects were
mild and reported
by five (58%)
patients receiving
THC and two (17%)
patients receiving
placebo. Higher
THC doses of 7.5
and 10.0 mg
produced more
significant side
effects including
headache, nausea,
ataxia, and anxiety.
Researchers
suggested that the
side-effects were
likely to decrease
after long-term
treatment.

In the 6 week
study, patients
were randomly
assigned to receive
THC capsules or
identical placebo.

Tourette
Syndrome
CGIS
(Clinical
Global
Impression

Using a self-rating
scale, the results
showed a significant
reduction of motor
and vocal tics, and
obsessive
compulsive
behaviour.
Examiner ratings
showed a significant
improvement in
subscores in favour
of THC; the
differences between
groups in overall
global tic severity
scores did not reach
statistical
significance.
9/12 patients (75%)
indicated that THC
was a more
successful treatment
than placebo
A statistically
significant
difference was
observed in favour
of THC based on the
CGIS scores. Using

All patients
(100%)
completed the
study

M¨ullerVahl et al.
(2003)

Randomised,
double-blind,
placebocontrolled
trial

Oral THC (2.5
and 5.0 mg
capsules)

24 patients
with
Tourette’s
syndrome
17 (71%)

Side effects were
generally mild and
well tolerated; five
(42%) patients
receiving THC and
three (25%)
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Parkinson’s disease
Randomised,
Carroll et
double-blind,
al. (2004)
placebocontrolled,
crossover trial

Epilepsy
Cunha et al.
(1980)

Randomised,
double-blind,
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participants
completed the
study

Treatment dosage
was titrated to the
target of 10.0 mg
THC, starting at
2.5 mg per day.

Scale),
examiner
ratings, selfratings, and a
video-based
rating scale

a self-rating scale at
10 treatment days,
there was a
significant
difference between
both groups. THC
reached efficacy
after approximately
three weeks of
treatment; this
efficacy persisted or
increased after more
than four weeks up
to the end of the
study

receiving placebo
reported mild side
effects.

Cannador
(ethanolic
cannabis extract)
(2.5 mg THC:
1.25 mg CBD per
capsule)

19 patients
with
Parkinson’s
disease

Ten patients were
randomised to
receive Cannador
followed by
placebo; nine the
reverse sequence.
The treatment dose
was administered
based on weight
(maximum 0.25
mg/kg of THC).
Each treatment
phase lasted 4
weeks, with a 2week washout
period.

Effects on
Parkinson’s
disease
severity and
duration of
dyskinesia,
adverse
effects, and
dosing
schedules

Results indicated
that Cannador had
no significant effect
on dyskinesia and
had no pro- or antiparkinsonian effects.
However, 11
patients (65%) did
not attain the target
dose on Cannador
and 9 (53%) on
placebo.

No serious adverse
effects were
reported. Mild side
effects were
reported by both
groups, but were
more common with
Cannador (37
reported adverse
events) than placebo
(15). Main side
effects included
drowsiness/lethargy,
dry mouth, and
detachment

Cannabidiol
(CBD) (oral)

15 epileptic
patients who

Participants
continued using

Absence of
convulsive

3 patients receiving
CBD showed an

4 patients receiving
CBD and 1

17 (89%) of
patients
completed the
study
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parallel
groups,
placebocontrolled
trial

did not obtain
satisfactory
results with
their
prescribed
anticonvulsant
medication
12 (80%)
patients
completed the
study

Glaucoma
Tomida et
al. (2006)

Randomised,
double-blind,
placebocontrolled, 4

Oral THC (5 mg)
Oral CBD (20 mg
or 40 mg)

6 patients with
ocular
hypertension
or early
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their prescribed
anticonvulsant
medication and
were randomly
assigned to two
groups; one group
(7 patients) was
administered CBD
(200-300 mg
daily) and the
other (8) placebo
in capsule form for
up to 4 ½ months.
The patients were
instructed to take 2
or 3 capsules daily
*One patient
receiving placebo
was transferred to
the CBD group
after one month

crises,
neurological
examination
and EEG,
clinical and
laboratory
examinations,
clinical
evaluation of
treatment

improvement in the
EEG pattern. 2
patients receiving
placebo had an
improved EEG
pattern on one
occasion only.
Improvements in
clinical evaluation
scores were
observed in both
groups in the 1st
week; from the 2nd
week all but one
placebo patient
returned to their
previous clinical
state. 4 patients
receiving CBD
remained convulsion
free throughout the
treatment; 3 showed
partial
improvement. 1
patient receiving
placebo showed an
improvement in
their condition; 7
showed no
improvement.

receiving placebo
reported
somnolence. 1 CBD
patients complained
of painful gastric
sensations after
taking the drug;
symptoms
disappeared after
taking antacid.

Patients received a
single dose of 5
mg THC, 20 mg
CBD, 40 mg CBD,

Intraocular
pressure,
visual acuity,
vital signs,

Results indicated
that two hours after
administration of 5
mg THC the

Side effects were
generally mild and
well tolerated. Only
one patients
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way crossover
trial

primary angle
glaucoma

or placebo.

psychotropic
effects

intraocular pressure
was significantly
lower than after
placebo, returning to
baseline levels after
four hours. No
significant
therapeutic effects
were observed with
either of the CBD
doses. In contrast,
the 40 mg dose of
CBD led to an
increase of
intraocular pressure
at four hours after
administration.

experienced a panic
like reaction after
receiving THC

In the 10-week
trial, 67 patients
were randomised
to receive
oromucosal
Sativex and 68 to
receive placebo.
Patients selftitrated to their
optimal dose
(maximum 48
sprays per day).

Daily number
of urinary
incontinence
episodes,
incidence and
urgency of
nocturia,
bladder
condition,
quality of
life, and
patient’s
impression of
change

Sativex marginally
reduced the daily
number of urinary
incontinence
episodes compared
to placebo, but
statistical
significance was not
reached. A statistical
difference was
reached in the
decrease of number
of episodes of
nocturia, number of
voids per day,
patient impression
of change, and

Sativex-related side
effects were
generally mild or
moderate. Main
Sativex side effects
were dizziness
(12%), headache
(6%), vomiting
(6%), disorientation
(6%), and
dissociation (6%).
Dizziness (6%) and
urinary tract
infection (6%) were
the main placeborelated side effects

All patients
(100%)
completed the
study

Bladder dysfunction
Kavia et al. Randomised,
double-blind,
(2010)
placebo
controlled,
parallel-group
trial

Sativex
(sublingual) (2.7
mg THC: 2.5 mg
CBD)

135 patients
with MS
118 (87%)
patients
completed the
study
*86 (64%)
patients were
included in
per-protocol
analysis of
efficacy
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overall bladder
condition.
Schizophrenic psychosis
Randomised,
D’Souza et
double-blind,
al. (2005)
placebocontrolled
trial

Intravenous THC
(2.5 mg or 5 mg)

13 stable,
antipsychotic
drug treated
schizophrenia
patients
9 (69%)
participants
completed all
three test days

Over 3 test days,
patients were
randomised to
receive 2.5 mg or
5 mg THC, or
placebo in a
counterbalanced
order. Tests days
were separated by
at least one week.

Safety and
cognitive,
behavioural,
motor, and
neurochemical
effects

THC transiently
increased a range
of positive and
negative
schizophrenia
symptoms,
learning and recall
deficits, perceptual
alterations, and
medication side
effects associated
with
schizophrenia. It
failed to produce
any obvious
“beneficial
effects”.

No serious long or
short term side
effects were
reported, but a
comparison found
patients with
schizophrenia were
more vulnerable to
THC effects on
learning and
memory than
healthy subject
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Two studies, comprising a total of 36 participants, evaluated the effects of oral
THC on Gilles de la Tourette syndrome (M¨uller-Vahl, et al., 2002; M¨uller-Vahl, et al.,
2003). Gilles de la Tourette syndrome is a neurological condition characterised by rapid
movements and sounds (called tics), and a range of behavioural and cognitive features
(M¨uller-Vahl, et al., 2003). Both studies produced results indicating positive effects of
oral THC; a significant reduction of motor and vocal tics, obsessive compulsive
behaviour, and an improvement in the Tourette Syndrome Clinical Global Impression
Scale (CGIS) scores was reported. However, it is difficult to draw a conclusion on the
effectiveness of cannabis constituents from the results of two trials with relatively small
samples, one of which used only single-dose THC. While preliminary, the results are
promising and suggest that oral THC has the potential to reduce tics associated with
Tourette’s syndrome without serious side effects. Further research is needed to establish
the optimal dosage and compare oral THC to other routes of administration in order to
determine the most effective one. Larger-scale and longer studies are also necessary to
determine the long term effects of cannabis and its constituents and evaluate their
potential in treatment of tics in Tourette’s syndrome.
One study of 19 participants examined the effects of Cannador on patients with
Parkinson’s disease (Carroll, et al., 2004). The cannabis derivatives did not demonstrate
an anti-Parkinsonian effect in a controlled clinical setting (Carroll, et al., 2004). Lack of
significant effect in the Carroll et al. (2004) study could be attributed to failure in most
patients to attain a recommended treatment dose, although this conclusion is difficult to
make due to low number of participants, route of administration, and the complexity of
the disease. The results so far have not been promising and indicate that cannabinoids
are not very effective in the treatment of dyskinesia nor do they have anti-Parkinsonian
effects.
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One study of 15 epileptic patients who did not obtain satisfactory results with
their prescribed anticonvulsant medication found that cannabidiol treatment led to
improvement in the EEG pattern (Cunha, et al., 1980). While the results were
encouraging, a major caveat of the study is that no tests of significance were conducted.
Since 1980, no further clinical trials that fit the inclusion criteria for this review have
been conducted in order to confirm the results reported by Cunha et al. (1980). While
cannabis may have anticonvulsant properties, one study is insufficient to draw firm
conclusions. In the study described here, patients continued using their prescribed
anticonvulsant medication, which makes it difficult to determine whether CBD
potentiated the effects of anticonvulsant treatments or worked independently. Further
studies are therefore required in order to explore the therapeutic potential of cannabis
and its derivatives on epilepsy.
While anecdotal evidence has suggested that cannabis is effective in the
treatment of glaucoma, the number of randomised controlled studies which have
assessed the effectiveness of cannabis and its extracts on treatment of intraocular
pressure is very limited. One study assessed the efficacy of THC and CBD in the
treatment of glaucoma in six patients with ocular hypertension or early primary angle
glaucoma (Tomida, et al., 2006). Results indicated that THC could be beneficial in the
treatment of intraocular pressure, but effects were dose-dependent; two hours after
administration of 5 mg THC the intraocular pressure was significantly lower than after
placebo. However, valid conclusions cannot be drawn from one small-scale study and
more research into the appropriate dosage benefits and risks of cannabis use in
treatment of glaucoma is needed before conclusions can be made.
One study assessed the efficacy of Sativex as an add-on treatment for bladder
dysfunction in 135 patients with MS (Kavia, et al., 2010). Sativex marginally reduced
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the daily number of urinary episodes, but statistical significance was not reached. A
statistical difference was reached in the decrease of number of episodes of nocturia,
number of voids per day, patient impression of change, and overall bladder condition.
Due to the limited number of studies, a valid conclusion on the effectiveness of Sativex
or other cannabis derivatives in treating bladder dysfunction cannot be reached. The
results reported here, however, are promising and warrant further research into the
effects of cannabis and its constituents in treatment of bladder dysfunction.
One study examining the effects of cannabis constituents in patients with
schizophrenic psychosis met the inclusion criteria for this review. A 3-day study by
D’Souza et al. (2005) examined the effect of intravenous THC administration on 13
stable, antipsychotic drug treated schizophrenia patients. The data from the study were
compared with effects in healthy subjects reported by other studies, but the results failed
to produce any obvious beneficial effects. Due to the limited number of studies, low
number of participants, and a low retention rate, it can be concluded that THC did not
show promise in the treatment or management of schizophrenia symptoms.
Sleep. While no study of cannabis and its constituents has been identified in
which sleep was the primary disorder, cannabis’ sleep-inducing properties and effects
on quality of sleep have been mentioned in a number of studies discussed in this review
(Berman, et al., 2004; Blake, et al., 2006; Notcutt, et al., 2004; Wade, et al., 2004;
Wade, et al., 2003; Zajicek et al., 2005). In a study of 48 patients with neuropathic pain,
Berman et al. (2004) found that both THC (2.7 mg in sublingual spray) and a
combination of THC and CBD produced statistically significant improvements in sleep
quality. Similar results were reported by Notcutt et al. (2004) who found that sleep
quality was significantly better in a subjective assessment of 34 patients receiving THC
alone, CBD alone, and a THC/ CBD combination compared with placebo.
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Zajicek et al. (2005) found that synthetic oral THC (Marinol) capsules and
cannabis extract (2.5 mg THC and 1.25 mg CBD) produced a statistically significant
improvement in subjective ratings of sleep quality in a study of 630 patients with MS.
In another study of 18 patients with MS, Wade et al. (2003) reported a statistically
significant improvement in sleep quality with a combination of THC (2.5 mg) and CBD
(2.5 mg) compared with placebo. Wade et al. (2004) conducted a study of 160 patients
with MS and found a statistically significant subjective improvement in sleep quality
with a cannabis extract (2.7 mg THC and 2.5 mg CBD) compared to placebo. Lastly,
Blake et al. (2006) reported that Sativex use led to a statistically significant
improvement in sleep quality in a study of 58 patients with arthritis.
The secondary outcome measures from the studies discussed in this review
indicate that cannabis has sleep-inducing properties and can potentially improve sleep
quality. However, a study primarily on cannabis’ sleep-inducing properties has not been
identified by this review. While encouraging, the current results are limited and further
research is needed in this area. Future studies should aim to specifically focus on
cannabis’ potential to improve the quality of sleep, its effectiveness in the treatment of
sleep disorders, and the viability of such use.
Systematic Reviews and Meta-analyses
This literature review also identified nine systematic reviews and three metaanalyses on cannabis and cannabinoids in the treatment of some debilitating medical
conditions (Campbell et al., 2001; Cotter, 2009; Iskedjian, 2007; Lakhan & Rowland,
2009; Lynch & Campbell, 2011; Machado Rocha, Dos Santos Júnior, Stefano, & Da
Silveira, 2014; Machado Rocha, Stéfano, De Cássia Haiek, Rosa Oliveira, & Da
Silveira, 2008; Martín-Sánchez, Furukawa, Taylor, & Martin, 2009; Tramer et al.,
2001). A systematic review by Tramer et al. (2001) and a systematic review and meta-
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analysis by Machado Rocha et al. (2008) were excluded as they only reviewed studies
of synthetic cannabinoids and as such were beyond the scope of this thesis.
Campbell et al. (2001) completed a systematic review of nine studies of
cannabis given by any route of administration with any analgesic or placebo in patients
with acute, chronic, non-malignant, or cancer pain. However, no studies of smoked
cannabis were included in the review. Campbell et al. (2001) evaluated nine studies;
five related to cancer pain, two to chronic and non-malignant pain, and two to acute
postoperative pain. Campbell et al. (2001) found that cannabinoids had a moderate
effect on pain, but were no more effective than codeine in controlling pain. The study
concluded that due to their adverse effects, cannabinoids were unlikely to be useful in
acute pain.
Martín-Sánchez et al. (2009) completed a systematic review and meta-analysis
of 18 double-blind, randomised controlled trials to assess the efficacy and harms of
cannabis preparations in the treatment of chronic pain. Five of the reviewed studies
examined Sativex, four examined TCH capsules and oromucosal spray, and eight
examined synthetic cannabinoids. Similarly to the review completed in this thesis, the
systematic review conducted by Martín-Sánchez et al. (2009) found evidence of
efficacy in the use of cannabis therapy for patients with chronic pain. The meta-analysis
found that cannabinoids reduced visual analogue scale scores of pain by -0.61 (-0.84 to
-0.37), but the authors concluded that effects may be offset by potentially serious harm.
In terms of efficacy, the results indicated a positive and moderate short-term trend
toward a reduction in the intensity of pain in chronic patients, but the authors questioned
the long-term effectiveness of cannabis due to a high number of adverse effects reported
by patients.
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More recently, Lynch and Campbell (2011) conducted a systematic review of 18
randomised controlled trials of cannabinoids in management of chronic pain; four trials
examined smoked cannabis, seven examined oromucosal extracts of cannabis based
medicine, and eight studies examined synthetic cannabinoids. The review found modest
analgesic effects in non-chronic non-cancer patients. Similarly to this literature review,
several trials reviewed by Lynch and Campbell (2011) reported significant
improvements in sleep. There were no serious adverse events reported, with most
common adverse effects being sedation, dizziness, dry mouth, nausea and disturbances
in concentration. Adverse effects were generally described as being well tolerated,
transient, and mild to moderate. The main limitations to findings by Lynch and
Campbell were short trial duration, small sample sizes, and modest effect sizes. As a
result, Lynch and Campbell (2011) called for larger trials of longer duration so that
efficacy and safety of cannabinoids can be examined over the long term and in greater
numbers of patients.
A meta-analysis by Iskedjian (2007) examined the efficacy and safety data of
cannabinoid-based drugs for neuropathic and MS related pain. Data were extracted from
four studies looked at Sativex, five at cannabidiol, and three dronabinol. Iskedjian found
statistically significant lowering of pain scores; some patients did not obtain relief while
others responded very well. However, the analysis was limited by a small number of
trials and patients, and assumption that pain in MS and any neuropathic pain would be
affected in the same manner (Iskedjian, 2007).
Cotter (2009) reviewed 10 clinical trials of smoked and oral synthetic THC in
order to ascertain whether they are effective in the treatment of chemotherapy-induced
nausea and vomiting. Cotter found that cannabis and synthetic oral THC were more
effective than placebo in treating nausea and vomiting. Smoked cannabis and oral
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synthetic THC were found to be equally effective in controlling symptoms of nausea
and vomiting when compared to traditional antiemetics. However, side effects of both
were greater when compared to placebo and other antiemetics. The review also found
that patients did not have significant preference for oral THC capsules as opposed to
traditional antiemetics. Some patients were unable to tolerate cannabis smoke and it was
deemed unacceptable to many patients. As such, Cotter (2009) suggested the addition of
cannabinoids to existing antiemetic regimens may provide increased relief of
chemotherapy-induced nausea and vomiting.
Similarly to the review completed for this thesis, Lakhan and Rowland (2009)
conducted a systematic review of six studies of whole plant cannabis extract in the
treatment of spasticity in MS. The studies were reviewed for treatment dosage and
duration, objective and subjective measures of spasticity, and reports of adverse effects.
The review found evidence that combined extracts of THC and CBD may reduce
symptoms of spasticity in patients with MS. However, subjective measures of spasticity
were found to be significant while objective measures failed to show significant
changes. Adverse health effects were reported in each trial in which patients received
active treatment, and varied greatly depending on dosage. The review found some
evidence that combined extracts of THC and CBD may reduce the side effects of THC
alone.
Lastly, Machado Rocha et al. (2014) completed a systematic review of literature
on clinical and experimental trials of antitumor effects of cannabinoids on gliomas
(primary tumours originating in the glial cells). Machado Rocha et al. (2014) reviewed
35 studies; one study was a pilot phase I/II clinical trial done on human participants, and
the remaining were experimental studies of patients with gliomas, laboratory animals,
and glioma cells in in vitro experiments. In all experimental studies reviewed,
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cannabinoids showed antitumoral activity in vitro and/or antitumoral evidence in vivo in
several models of tumour cells and tumours. The review concluded that cannabinoids
show promise in the treatment of gliomas, especially on account of present scarcity of
effective resources to treat some types of cancers (Machado Rocha et al., 2014).
Because the review completed for this thesis only included randomised controlled trials,
it is difficult to compare the findings of the two reviews, but Machado Rocha et al.
(2014) review results appear encouraging and indicate that there are perhaps conditions
which cannabis can be used for that research has not yet explored.
Reports
As well as controlled trials and reviews, the medical uses of cannabis and its
derivatives have been reviewed and recommendations made by various bodies including
the U.S. IOM, the British House of Lords Select Committee on Science and
Technology, the AMA, the American College of Physicians, and the New South Wales
Working Party on the Use of Cannabis for Medical Purposes (Working Party) (ACP,
2008; AMA, 2009; Center for Medicinal Cannabis Research, 2010; House of Lords,
1998; IOM, 1999; Working Party on the Use of Cannabis for Medical Purposes
[WPUCMP], 2000). The 1999 IOM report recognised that cannabis has therapeutic
properties and recommended that the drug be made available to individuals requiring it
(IOM, 1999). The report also found evidence to show that cannabis can be effective for
the treatment of pain, nausea and vomiting, and weight loss associated with HIV/AIDS.
It found no significant data showing that cannabis was a “gateway” drug, leading to
other drug use. Similarly to the findings of the review in this thesis, the IOM report
inferred that there were no significant benefits of cannabis use in the treatment of
glaucoma compared to other already available medicines. The report concluded that:
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The critical issue is not whether marijuana or cannabinoid drugs might
be superior to the new drugs, but whether some group of patients might
obtain added or better relief from marijuana or cannabinoid drugs. (p.
153).
The Working Party (WPUCMP, 2000) report concluded that there was evidence
for cannabis’ use for the treatment and management of the wasting syndrome; pain
unrelieved by conventional treatments; neurological disorders, including but not limited
to, multiple sclerosis, Tourette’s syndrome, and motor neurone disease; and
chemotherapy-related nausea and vomiting. The Working Party report, however, called
for further controlled trials in order to examine the benefits of cannabis and its
constituents and their effectiveness in the treatment of the abovementioned medical
conditions. Smoking was also not the preferred method of administering the drug, and
further research into other routes of cannabis administration was recommended
(WPUCMP, 2000).
Britain’s House of Lords concluded that cannabis had potential medical benefits
and could assist patients for whom other conventional medicines have proven
ineffective (House of Lords, 1998). The report found that there was sufficient evidence
to suggest that cannabis has potential to relieve pain or the symptoms of MS; enough to
justify legalising cannabis’ medical use. The House of Lords recommended research
into effective modes of cannabis administration other than smoking, and encouraged
further clinical trials evaluating the drug’s medicinal properties.
The AMA (2009) also called for more controlled clinical studies to be conducted
on cannabis as a medicine and recommended a review of cannabis’ Schedule I
classification in order to enable more research to be conducted on its potential as a
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medicine. The association also urged the NIH to implement administrative procedures
which would assist in developing and conducting clinical trials into medicinal properties
of cannabis (AMA, 2009).
Overall, the conclusions made by these reports were not uniform. For example,
in terms of debilitating medical conditions, three reports concluded that there were
adequate data from controlled trials to support cannabis’ anti-nausea effects (House of
Lords, 1998; IOM, 1999; WPUCMP, 2000). Similarly, three reviews concluded that
there was reasonable scientific evidence supporting the effectiveness of cannabis and its
constituents in appetite stimulation, while the House of Lords report concluded that the
evidence was unclear (AMA, 2009; House of Lords, 1998; IOM, 1999; WPUCMP,
2000). The House of Lords (1998) report raised concern for use of cannabis in AIDS,
due to the drug’s immunosuppressive effects. However, the other side to this argument
is whether patients with terminal illnesses should be prevented from using cannabis if it
helps them and in the absence of other effective medication, even with its long-term
effects being unclear. Evidence also suggests that cannabis can be an effective
antiemetic, even superior to some antiemetic drugs, but the issue of its side effects in
comparison to other antiemetics needs to be further explored. While the review
undertaken for this thesis concluded that cannabis may have anti-emetic properties,
further studies were recommended. Similarly to the reports, the review undertaken for
this thesis indicated that cannabis does have therapeutic potential as an analgesic.
The House of Lords (1998) report concluded that there was strong anecdotal
evidence for cannabis’ therapeutic potential in the treatment of MS-related symptoms,
and recommended urgent clinical trials of cannabis’ effectiveness for the treatment of
MS. In comparison to the review presented in this thesis, these results seem generous.
While the House of Lords referenced anecdotal reports, the review completed in this
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thesis covered only randomised, double-blind human trials which indicated that the
clinical evidence on the use of cannabis in multiple sclerosis and chronic conditions
involving spasticity was promising but required further study. In terms of Tourette’s
syndrome and motor neurone disease, the number of studies identified and included in
this review was deemed too low to make valid conclusions.
The overall consensus appears to be that cannabis and its derivatives do have
therapeutic benefits, with the evidence being the strongest for chronic pain, appetite
stimulation and weight gain, and MS. However, there are issues with some of the
evidence such as low numbers of participants, different routes of administration and
dosages used, as well as differences between conditions and patient demographics.
While this review only focused on clinical trials, both anecdotal and clinical reports
have suggested cannabis could potentially be effective in the treatment of various
debilitating medical conditions (Mack & Joy, 2000; Mather, 2005). In terms of this
review, the strongest evidence came from studies on cannabis’ effect on pain, nausea
and vomiting, and spasticity. The review completed for this thesis excluded synthetic
cannabinoids and focused on the cannabis plant and its natural derivatives, which may
explain the contrast in some of the findings. The following table summarises the
findings for the review undertaken for this thesis, per debilitating medical condition, in
comparison to the five reports on medical cannabis discussed here.
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Table 9
A Summary of Findings per Medical Condition
Medical
Condition

This
Review

IOM

House
of
Lords

AMA

American
College of
Physicians

Working
Party

Campbell
et al.
(2001)

Martín
Sánchez
et al.

Lynch
and
Campbell
(2011)

Iskedjian
(2007)

Pain

××××
Chronic
×× Acute

××××
Chronic

××××
Chronic

××××

××× Chronic
×× Pain
management

x

xxx

xx

xxxx
Neuropathic
and MS
related

Nausea and
vomiting

×××

××××
Chron
ic
××
Acute
××

N/A

×

××××

××××

Spasticity

×××

××

××××
MS

×××

×××

××

Appetite/
Weight

××

××××

N/A

××××

××××

×××

Gilles de la
Tourette
syndrome

××

×××

N/A

N/A

N/A

×××

Movement
disorders
Parkinson’s
disease
Dystonia
Epilepsy

×

×

N/A

N/A

×××

××

×

×

×

N/A

×

×

Glaucoma

××

×

×

×

×

×

Bladder
dysfunction

××

N/A

N/A

N/A

N/A

N/A

Cotter
(2009)

Lakhan
and
Rowland
(2009)

xxxx
xxx

Machado
Rocha et
al. (2014)
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××

N/A

N/A

N/A

N/A

N/A
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xx
xx
Gliomas

Other

××××
×××
××
×
N/A

Recommended- strong supporting evidence
Encouraging- some supporting evidence, might have a role, further research needed
Promising, but further research is needed
Not recommended- very limited or no supporting evidence
Not available
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When evaluating cannabis’ effectiveness in the treatment of some debilitating
medical conditions, it is important to consider the side effects of cannabis use and
determine whether the benefits outweigh the risks for patients. The adverse effects are
discussed next.
Adverse Effects of Cannabis Use
Generally, THC is considered a very safe drug, both acutely and on long-term
exposure (Iversen, 2000). It is estimated that a fatal human dose of THC is between 15g
and 70g, which is much higher than that smoked by a heavy user (Hall & Degenhardt,
2009). However, it is cannabis’ psychoactive effects that give the greatest concern in
considering it for medical use. Patients who have not had any prior experience with
cannabis often find the intoxicant effects disturbing, while others do not like
experiencing the feeling of “high”. The drug also affects short-term memory and other
aspects of cognition, and can impair psychomotor skills. Although cannabis is generally
safe for moderate use, the likelihood of adverse effects increases with long-term, heavy
use (Gieringer et al., 2008). There is also growing recognition that both tolerance and
dependence can occur in some chronic users of the drug (Iversen, 2000). Research has
also raised concerns about cannabis and psychosis, although there are currently no data
on the extent of risk for psychotic symptoms among medical cannabis users
(Degenhardt & Hall, 2008). The epidemiological data on the long-term effects of
cannabis is still scarce and long-term studies are encouraged.
More specifically, there are also concerns over the use of the drug by smoking.
While smoking can be an efficient way of titrating dosage and delivering an appropriate
dose of THC to the patient, the method of delivery is not considered to be safe.
Cannabis smoke is very similar in chemical composition to tobacco smoke, which
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contains more than 6000 chemical constituents, with thousands more present in trace
amounts. Cannabis joints have also been shown to deliver at least four times as much tar
to the lungs as tobacco cigarettes of equivalent weight (Mack & Joy, 2001). Due to its
similarity to tobacco smoke, cannabis can have possible links to chronic respiratory
disease and cancer. Because of its potential for harm, it is unlikely that smoked cannabis
will ever be approved by the FDA for the long-term treatment of any illness where its
use needs to be regular. On the other hand, it could be argued that in patients with
terminal illness or with reduced life expectancy because of illness, the long-term health
effects of cannabis are irrelevant and smoked cannabis could be a viable option for them
if their illness does not respond to conventional medicine.
In terms of medical cannabis, this literature review identified one systematic
review of 31 studies with published adverse effects of medical cannabinoid use (23
randomised controlled trials and eight observational studies) (Wang, Collet, Shapiro, &
Ware, 2008). No randomised controlled trials of medical cannabis administered by
smoking were included in the review. Wang et al. (2008) excluded studies that focused
on adverse effects of cannabis occurring in combination with other agents and those that
involved synthetic cannabinoids. Respiratory (16.5%), gastrointestinal (16.5%), and
nervous system disorders (15.2%) were the most frequently reported categories of
serious adverse events among those patients assigned to receive cannabinoids, while
nervous system disorders (30%) was the most frequently reported adverse event among
controls. There was no evidence of a higher incidence of serious adverse events
following medical cannabis use compared with controls. In 23 controlled clinical trials
reviewed, nervous system disorders were the most frequently reported non-serious
adverse event for both groups. In the eight observational studies, nervous system
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disorders were the most frequently reported category for both serious and non-serious
adverse events. Psychiatric disorders were the second most frequently reported
category. Overall, incidence rate of non-serious adverse events was significantly higher
among subjects assigned to cannabinoid therapy than among those assigned to control
groups (Wang et al., 2008).
Long-term adverse effects were not well defined in clinical trials and
observational studies reviewed by Wang et al. (2008), therefore more high-quality trials
of long-term exposure were deemed necessary. Wang et al. (2008) cautioned against
assuming that the adverse effects commonly reported in recreational cannabis use can
be expected to occur with medical use of cannabis, as “the amounts used, the existence
of comorbidities and the methods of drug delivery are different in the two populations,
which should therefore be evaluated separately” (p. 1676).
While much of what is known about the long-term effects of cannabis use comes
from recreational users, the long-term effects of medical use of cannabis are unclear
(Degenhardt & Hall, 2008). According to Degenhardt and Hall (2008), we “know
nothing of the risks of incident cannabis dependence in the context of long-term
supervised medical use” (p. 1686). While short-term use of cannabinoids for medical
purposes has an acceptable safety profile, more research is needed on the adverse effects
of long-term use of cannabinoids for medical purposes, especially in those patients who
smoke cannabis for medical purposes (Degenhardt & Hall, 2008). Because the effects of
cannabis depend on the dose received, the route of administration, the users previous
experience with the drug and the setting in which it is used, future research will need to
take these factors into consideration if we are to get a clearer picture of the long-term
effects of medical cannabis use.
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Discussion
Overall, the research evidence reviewed here has shown that cannabis and its
constituents have therapeutic potential for a number of conditions, some for which the
evidence is mixed and unclear. Most of the research evidence supports the use of
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an
appetite simulant for AIDS-related wasting syndrome.
Although the research on nausea and vomiting is relatively old, a substantial
amount of research has been conducted on the topic to suggest cannabis may have
therapeutic potential. However, this review excluded studies on synthetic cannabinoids
such as the already available dronabinol and nabilone, which have already been
approved by the FDA for this purpose. The studies reviewed here showed encouraging
results in terms of the antiemetic effects of oral THC and CBM, but no study focused on
smoked cannabis which has now been legalised in 17 U.S. states. The question that this
raises is whether any more anti-emetic cannabis derivatives are needed with two already
legally available? The other issue is that some patients, especially those with nausea and
vomiting, struggle with taking oral tablets, and therefore may benefit from other modes
of administration. However, with no studies completed on smoked cannabis in the
treatment of nausea and vomiting included in the review undertaken for this thesis, it is
impossible to draw a conclusion on its effects based on scientific evidence.
While conclusions on cannabis’ analgesic effectiveness are somewhat mixed, its
effectiveness in the treatment of chronic neuropathic pain is well documented. The
same, however, cannot be said for acute pain. Systematic reviews on cannabis’
analgesic properties found that cannabis had a moderate to significant effect on pain,
depending on dosage and patient, but there were concerns over its adverse effects
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(Campbell et al., 2001; Iskedjian, 2007; Lynch & Campbell, 2011; Martín-Sánchez et
al., 2009). Overall, research included in this review has indicated that cannabis does
have therapeutic potential as an analgesic medication, but further research is needed to
evaluate the extent of cannabis’ therapeutic potential and the effects of its long-term
therapeutic use.
Cannabis’ therapeutic role in the treatment of spasticity is also relatively well
documented but is mainly based on subjective ratings by the participants, which makes
it difficult to draw valid conclusions regarding its clinical efficacy. A systematic review
by Lakhan and Rowland (2009) found evidence that combined extracts of THC and
CBD may reduce symptoms of spasticity in patients with MS, but similarly to this
review significant findings were obtained from subjective measures of spasticity while
objective measures were not. However, cannabis in the treatment of spasticity does
show potential in both long and short term treatment and further research in the field is
warranted.
Only one randomised, double-blind study on glaucoma fitted the inclusion
criteria for this review. While THC did show some short-term potential in the treatment
of intraocular pressure, further research exploring different methods of cannabis
administration and long-term studies are needed before valid conclusions can be drawn.
Results for other less researched conditions such as insomnia, epilepsy, and Tourette’s
syndrome warrant further research.
While cannabis and its derivatives have been found to have therapeutic potential,
they also produce some unwanted side-effects. Some of the possible side-effects of
cannabis include an increase in heart rate; decrease in blood pressure; impairment of
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short-term memory, attention, motor skills, reaction times; fatigue; vertigo; euphoria;
dysphoria; hallucinations; and the organisation and integration of complex information.
Smoked cannabis also contains many of the same compounds of tobacco smoke, and
can lead to cancer and lung damage (ACP, 2008).
Short term effects such as feeling the psychoactive effect of the drug, anxiety,
panic, paranoia, and feelings of impending doom, are not considered as a serious
limitation to cannabis’ medical use because they can be controlled by dosage, and can
also be experienced with other conventional medication. Long term effects are difficult
to assess and may include effects on cognitive performance, respiratory disorders, and
lung cancer due to smoking. Possible tolerance may make medical use of the drug
difficult, although this can be experienced with other conventional medication and is not
considered a major problem in the medical use of cannabis. While the research so far
has identified the potential side effects of cannabis use, it should be acknowledged that
other conventional medicines also have recognised side effects, which need to be
weighed against their benefits. For conditions such as multiple sclerosis, which aren’t
always successfully treated by other medicines, medical cannabis may be a beneficial
addition to treatment or management of the condition (Zajicek, et al., 2003).
Optimal doses and routes of cannabis administration have not yet been
established through scientific research (Robson, 2001). Different routes of
administration appear to be appropriate for different medical conditions and an accurate
titration of effects and reliability is necessary. Smoking is generally not the
recommended route of administration, and further research is therefore necessary in
order to establish an alternative route of administration, with both short and long term
safety and efficacy (House of Lords, 1998; Robson, 2001; WPUCMP, 2000). However,
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it may take years to develop effective alternative methods or devices for delivering THC
(WPUCMP, 2000).
As suggested by this review, there is evidence supporting cannabis’ therapeutic
use for some medical conditions. In the U.S., at the time when the material for this
thesis was collected, 17 states and the District of Columbia had enacted laws allowing
smoked cannabis to be used for medicinal purposes (NORML, 2010). While there are
promising results in terms of cannabis’ potential in treating some debilitating medical
conditions, more studies are urgently needed to test the effectiveness of different routes
of administration. In this literature review of 38 studies, only six studies (16%)
evaluated smoked cannabis; four in the treatment of chronic pain, one in treatment of
acute pain, and one in appetite stimulation. The long-term effects of medical cannabis
use also remain relatively unknown and urgently need to be researched. However, Wang
et al. (2008) cautioned against comparing the adverse effects of recreational and
medical cannabis users as the way in which they use the drug differs, therefore longterm studies of medical smoked cannabis use are required.
While there is undoubtedly evidence for cannabis’ potential as a medicine, the
question arises of how much of a role scientific evidence played in influencing
policymakers and leading to change in state laws to allow for medical cannabis use?
While many would disagree on the interpretation of the medical cannabis literature, one
would assume that reasoned scientific debate would play an important part in public
health policy development. Why did laws in the 17 states focus on smoking as the mode
of administering medical cannabis as opposed to other modes of administration? What
factors played a role in the 17 states that led to the medical cannabis laws being passed?
In order to understand what happened in this policy process it is important to determine
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the role scientific evidence plays in public health policy making and identify factors it
contends with in the sometimes arduous policy making process (Birkland, 2005; Ritter,
2009).
It is also important to understand how the context in which these policy changes
took place and the process that occurred before medical cannabis laws came to be
enacted in 17 of 50 U.S. states and the District of Columbia. For the purpose of this
thesis, two representative states were chosen as examples of how medical cannabis laws
came to be passed. Michigan was chosen as a representative state for medical cannabis
laws passed by ballot initiative, while New Mexico was chosen as a representative state
for medical cannabis laws passed by the legislative process. The states were chosen
because they were the most recent states to pass a medical cannabis law at the time of
writing this thesis.
Three other representative states (Illinois, Kentucky, and Louisiana) were
chosen. Illinois was chosen as a state which is considering medical cannabis laws, but
has not passed one to date 4. Kentucky was chosen as a state which has no medical
cannabis laws and has not considered one, while Louisiana is a state which has not
considered passing a medical cannabis law, but has an ineffective, symbolic, medical
cannabis law on its books.
The chronological accounts in the following chapter will outline what happened
in each of the representative states in terms of medical cannabis and the use of media

4

Illinois became the 20th state in the U.S. to legalise medical cannabis in July 2013, after this thesis was
submitted.
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available to the general public will allow the reader to see how the issue was framed in
those particular states.
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Chapter 4- Medical Cannabis in Five Representative States
For the purpose of this thesis, two representative states were chosen as examples
of how medical cannabis laws came to be passed. Michigan was chosen as a
representative state for medical cannabis laws passed by ballot initiative, while New
Mexico was chosen as a representative state for medical cannabis laws passed by the
legislative process. The states were chosen because they were the most recent states to
pass a medical cannabis law at the time of writing this thesis. 5
Three other representative states (Illinois, Kentucky, and Louisiana) were
chosen. Illinois was chosen as a state which is considering medical cannabis laws, but
has not passed one to date. 6 Kentucky was chosen as a state which has no medical
cannabis laws and has not considered one, while Louisiana is a state which has not
considered passing a medical cannabis law, but has an ineffective, symbolic, medical
cannabis law on its books. 7
The chronological accounts in the following five chapters were generated
through a review of publicly available literature including government publications,
newspaper articles, parliamentary proceedings, court documents, and press releases. A
general internet search using Google as a search engine was also made with the use of
the keywords including the name of the state in question and “cannabis”, “marijuana”,
“marihuana”, “medical”, “medicinal”, and “therapeutic”, “law”; and/or a combination

5

The study was completed in 2011 and thesis submitted for examination in 2012.
At the time of writing this thesis, Illinois did not pass a medical cannabis law. Illinois subsequently
passed a medical cannabis law on August 1, 2013.
7
At the time of writing this thesis Kentucky and Louisiana did not consider medical cannabis law. Since
then, there have been activities in both states in relation to medical cannabis.
6
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of these keywords. Additional newspaper reports were also identified through the Media
Awareness Project website, http://www.mapinc.org/.
Michigan
On November 4, 2008, the Michigan Medical Marihuana Act, which allows the
use of medical cannabis for qualifying patients, was approved by Michigan voters
through a ballot initiative (Michigan Medical Marihuana Act, 2008). The act took effect
on December 4, 2008, and allows patients with specific debilitating medical conditions
to acquire, possess, cultivate, manufacture, use, deliver, transfer or transport medical
marijuana and paraphernalia relating to marijuana administration, in order to treat or
alleviate a debilitating medical condition (Michigan Medical Marihuana Act, 2008). A
qualifying patient is only allowed to have one caregiver, while a caregiver can care for a
maximum of five patients. Specifically, a debilitating medical condition is defined by
the act as one or more of the following: cancer, glaucoma, positive status for human
immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C,
amyotrophic lateral sclerosis, Crohn’s disease, agitation of Alzheimer’s disease, nail
patella, or symptoms of conditions such as cachexia or wasting syndrome. The patient
or their carer can legally possess up to 2.5 ounces (70.9g) of usable marijuana, and
grow, in an enclosed, locked facility, up to 12 plants. The law does not specify how the
seedlings or plants are to be obtained by the patient or their caregiver in order for them
to be grown (Michigan Medical Marihuana Act, 2008).
In order to qualify for the program, individuals meeting the specific criteria are
required to obtain an identification card from the Michigan Department of Community
Health (MDCH) in which the act vested responsibility for medical cannabis program
implementation and administration (Michigan Medical Marihuana Act, 2008). In order
to qualify, patients must also have a recommendation from their physician saying that
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they will benefit from the use of medical marijuana. According to the act, the physician
will be exempt from arrest, prosecution or penalty in Michigan.
At the state level, qualifying individuals and their carers can also assert medical
reasons for using cannabis as a defence to any prosecution involving their cannabis use
and/or possession. The defence is not limited to registered patients only, and, while it
does not protect a patient from arrest, it requires the charges to be dropped if the patient
can prove that a doctor has stated they will benefit from marijuana use, they did not
possess more than the necessary amount, and that the possession, manufacture or
delivery of the drug was done for the purpose of treating the patient (Michigan Medical
Marihuana Act, 2008).
In the following section, Figure 2 will chronologically review the history of
medical cannabis in Michigan, followed by a chronological description of the process
by which the act was passed.
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• Michigan Liutenant Governor signs legislation authorising a therapeutic cannabis program
for cancer and glaucoma patients

• Reports of shortage of federally grown cannabis
• Physicians start reporting patient complaints regarding quality of federally-supplied
cannabis

• Michigan's Public Health Code section allowing cannabis use for therapeutic research
expires and is not renewed

• Peter McWilliams, a cancer and AIDS patient, announces he is attempting to set legal
precedent in Michigan by using medical necessity as a defence on a posession charge
• Judge denies McWilliams' medical necessity defence
• Suggestions that some anti-drug groups are softening their anti-medical cannabis stance

• Michigan newspapers publish a summary of the IOM report
• Executive vice president of the Partnership for a Drug Free America says the organisation
supports the report's recommendations
• Activists propose a "Personal Responsibility Amendment" allowing individuals with
debilitating medical conditions "personal amount" of cannabis

• Libertarian party petitions to prevent Ann Arbor Police from charging individuals who use
cannabis for medical reasons

• Second petition drive to place the "Personal Responsibility Amendment" on the 2002 ballot
occured
• Michigan NORML joins "Adopt-A-Highway" program to counter negative perceptions of
NORML
• Michigan senators speak against medical cannabis legislation

• Detroit Coalition for Compassionate Care starts city-based petition to amend city charter in
relation to allow medical cannabis use

• Ann Arbor activists place medical cannabis ordinance change proposal on city ballot
• Governor Granholm reported as the biggest opposition to Ann Arbor ordinance change
initiative
• Ann Arbor voters pass medical cannabis ordinance amendment; Police Chief instructs
officers to continue enforcement of all cannabis-related offences
• Detroit voters pass medical cannabis ordinance amendment
• "Love. The Anti-Drug" launched in Detroit by director of the ONDCP
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• Ferndale and Traverse City pass medical cannabis ordinance amendment
• Activist group "Win-The-War" starts circulating petitions to amend state constitution to
legalise cannabis use and regulate it like alcohol
• Bruce Mirken from the MPP says U.S. Supreme Court ruling would not deter medical
cannabis efforts in Michigan and other states
• Medical cannabis bill HB 5470 introduced in the Michigan House of Representatives;
Deputy Director of the ONDCP asks for the bill to be rejected
• HB 5470 dies at the end of the legislative session
• "Medical and Recreational Peace" (MRP) group proposes making cannabis legal for those
over 18 years of age
• Michigan NORML announce they will try to get a bill similar to HB 5470 on the 2008
ballot but not in conjunction with MRP proposal
• Flint city voters pass change to the city ordinance legalising use of medical cannabis
• Medical cannabis bill HB 4038 introduced to the House of Representatives
• Spokesperson for the ONDCP says medical cannabis laws would not help sick individuals
• Michigan Coalition for Compassionate Care (MCCC) announce they will launch a
Michigan Medical Marihuana Act initiative
• MCCC publish a poll on their website indicating 67% of Michigan voters support
legalising cannabis for medical use
• Michigan State Medical Society announce they oppose medical cannabis, except for use in
controlled studies
• Detroit News article revealed that MCCC spent over $1.1 million on campaigning, with
most money coming from MPP
• Citizens Protecting Michigan's Kids is formed, opposing medical cannabis law
• Chair of Workplace Law Practice Group issues a memorandum opposing medical
cannabis proposal
• Director of the ONDCP goes to Detroit to speak against medical cannabis proposal
• A group of local law enforcement agencies issue a statement opposing the medical
cannabis initiative
• Proposal 1 passed by 62.7% of votes on November 4, 2008.
• The first draft of rules for the medical cannabis program resulted in protests from patients
and advocates
• The debate on whether the law should or should not have been passed still active
• Judge Robert Turner says the medical cannabis law was ambiguous

• Ongoing debates over the medical cannabis law’s ambiguity
• Confusion regarding the law resulted in local governments passing their own ordinances

• Calls for the legislature to make the medical cannabis law workable
• Six bills passed during the 2011-2012 legislative session to tighten regulations on medical
cannabis
• Reports that, in the first two years of the medical cannabis law, over 100,000 Michiganders
registered to use medical cannabis and the Michigan government made a profit of $8
million profit

Figure 2. Time chart of medical cannabis history in Michigan.
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2008 Michigan Medical Marijuana Act: Chronological account. In the
1970s, Michigan was one of the first states to authorise cannabis use for therapeutic
purposes (Drug Enforcement Administration [DEA], n.d.; MPP, 2013). In 1978 Roger
D. Winthrop, who organised the Michigan chapter of the NORML and lobbied the
Michigan legislature on issues including Michigan drug policy reforms, asked Senator
Jerry Hart (Democrat [D]) to sponsor cannabis-related legislation (DEA, n.d.). The
legislation sought to make cannabis available for glaucoma and cancer patients, and
those undergoing neurological therapies. Hart agreed, and the legislation was introduced
at the start of the 1979/1980 legislative session. Senator Hart had previously introduced
a bill aimed toward decriminalising general cannabis use, which was defeated at the end
of the 1977/1978 legislative session. He intended to reintroduce the bill with an added
section for medical cannabis use (DEA, n.d.).
At the same time, Senator Steve Monsma (D) wanted to introduce medical
cannabis legislation separately from Senator Hart’s (DEA, n.d.). Senator Monsma was
concerned that being linked with general cannabis decriminalisation would jeopardise
the medical initiative (DEA, n.d.). According to Winthrop, when Senator Hart’s bill was
heard before the Senate Judiciary committee, there was vigorous debate regarding the
part of the bill aimed at cannabis decriminalisation, while there was significant public
and political support for the drug’s medical use. Subsequently, Senator Monsma’s bill
was introduced, and was modelled on New Mexico’s 1978 medical cannabis legislation
(DEA, n.d.).
As patients were called upon to share their medical cannabis experiences with
the legislature, press coverage also grew (DEA, n.d.). According to Winthrop, it was
clear that the issue of medical cannabis and general cannabis decriminalisation had to be
separated, which resulted in Senator Hart agreeing to let Senator Monsma’s bill take
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priority. At the same time, the FDA threatened to block the medical cannabis program
implementation by withholding cannabis supplies. Afterward, Senator Monsma
proposed an amendment to the bill, which, if passed would have allowed the use of
confiscated cannabis for treatment of patients if the necessary supply was not received
from federal sources. A spokesperson for the FDA also said that, if Michigan
conformed to regulations, the federal government would supply the cannabis (DEA,
n.d.).
On June 25, 1979, the Michigan senate passed Senator Monsma’s bill by a 29-5
vote. The bill was then moved on, and on October 3, 1979, the House Public Health
Committee unanimously passed it (DEA, n.d.). On October 10, the bill went for a House
hearing, and was passed by a 100-0 vote of the House. On October 22, 1979, Lieutenant
Gov. James Brickley signed the legislation requiring the Michigan Department of Public
Health to operate a therapeutic cannabis program for physician-recommended cancer
and glaucoma patients, as Public Act 125 of 1979 (Public Health Code Act, 1978).
In 1980, it was advised that there was a shortage of federally grown cannabis
(DEA, n.d.). Physicians also started reporting patient complaints regarding federal
cannabis quality. According to Winthrop, cannabis supplied to the Michigan therapeutic
research program was lower in quality than the mandatory standards. It was suspected
that the federal government had cannabis of better quality, but did not provide it for
Michigan (DEA, n.d.). The Michigan Public Health Code’s section, allowing cannabis
use for therapeutic research expired on November 1, 1982, and has not been renewed
since. This took away the health department’s responsibility for establishing a
therapeutic cannabis research program (Public Health Code Act, 1978).
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Following the expiration of the medical cannabis legislation in 1982, no media
reports focusing on medical cannabis were reported in Michigan until October of 1997
when PR Newswire, issued a press release announcing that a cancer and AIDS patient,
Peter McWilliams, was attempting to set a legal precedent in Michigan by using
medical necessity as a defence on a cannabis possession charge (“McWilliams Hopes”,
1997). The following day, the judge in the case, Tina Green, allowed Mr McWilliams’
lawyer to base his defence on the use of cannabis for medical purposes. However, Judge
Green then changed her mind after reviewing the law and advised that McWilliams did
not meet the criteria for such a defence because McWilliams not using cannabis would
not result in death or serious bodily harm (Cain, 1997; “Judge Denies Author's Medical
Defense”, 1997). His attempt was unsuccessful, but there followed an increase in media
reports on medical cannabis (“McWilliams Hopes”, 1997). McWilliams’s house was
raided by DEA in December 1997, on apparent suspicion that McWilliams was
cultivating or dealing drugs (Farmanfarmaian, 1998). McWilliams alleged that the DEA
was interested in the material he was collecting for a book he was writing on medical
cannabis (Farmanfarmaian, 1998).
The year 1999 saw the publication of the IOM report (IOM, 1999). The Detroit
Free Press published a summary of the report, which found that cannabis has medical
benefits (McFarling, 1999). The article also reported that some anti-drug groups
appeared to be softening their anti-medical cannabis stance, and quoted Steve Dnistrian,
of the Partnership for a Drug Free America, as saying that the organisation supported
the report’s recommendations as they did not want to contradict what doctors and
scientists said (McFarling, 1999).
After the IOM report was published, a “Personal Responsibility Amendment”
was proposed to the Michigan constitution to allow individuals with debilitating
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medical conditions to grow a “personal amount” of cannabis (“Activists Promote
Legalized Marijuana”, 1999). This was specified as being no more than three mature
plants, seedlings, and 3 ounces (85g) of dried cannabis. The initiative, started by
Gregory Schmid from the Michigan branch of the NORML, required 302,711 signatures
in order to be put on the November 2000 ballot (“Legalized Marijuana”, 1999).
However, the organisation encountered difficulties in organising a petition drive and did
not manage to collect enough signatures (Trahan, 2001). This was the first attempt at
passing medical cannabis legislation in Michigan since the 1980s.
A second petition drive to place the “Personal Responsibility Amendment” on
the 2002 ballot occurred at the annual Ann Arbor ‘Hash Bash’, where people gather to
protest cannabis prohibition (Restivo, 2001; Trahan, 2001). Gregory Smith, who
organised the previous year’s petition, said he was confident enough signatures would
be gathered despite having limited funding (Trahan, 2001). Articles were published in
support of medical cannabis and encouraged people to vote for it (“Just Say Yes”, 2001;
“Marijuana- Leave Room”, 2001). The Michigan NORML chapter also joined
Michigan’s Adopt-A-Highway program, committing to pick up litter on a 2-mile stretch
of road, in order to counter negative perceptions people might have of the NORML
(“Pro-Marijuana Group Sponsors”, 2003).
Despite the “Personal Responsibility Amendment” failing, the issue of medical
cannabis continued to be discussed in the media and both opponents and proponents of
medical cannabis were making their opinions heard. Michigan Senator Bill Bullard Jr.
(Republican [R]) spoke out against medical cannabis legislation in the state, arguing
that it promoted recreational use of the drug and said that the legislature would not
approve such legislation, which would leave petitioning as the only way to get medical
cannabis on the ballot and this required money and organisation (Crimmins,
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2001).Another senator, John Schwarz (R), said he opposed the legislation because
cannabis was already available in tablet form (Marinol) (Crimmins, 2001). Robert
Sharpe, the program officer for the Lindesmith Centre Drug Policy Foundation,
responded to the senator’s comments by stating that cannabis has been used as a
medicine for thousands of years, and should be legalised and regulated (Sharpe, 2001).
Movements towards medical cannabis legislation at the state level also coincided with
attempts at city-level changes.
Changes at the city level. Although largely symbolic, local medical cannabis
laws have the potential to influence priorities of local law enforcement officers and
prosecutors (Eddy, 2010). Ann Arbor led the way at the local level, with a petition
initiated by the Libertarian party aiming to prevent Ann Arbor Police from charging
people who used cannabis for medical reasons (Wahlberg, 2000). However, some of the
movement was not solely to do with medical cannabis and James Tudler of the
Libertarian party said that the organisation aimed for the legalisation of all drugs,
starting with medical cannabis (“Activists Promote Legalized Marijuana”, 1999;
Wahlberg, 2000). The Libertarian party failed to submit their petition on time and the
amendment was not put on the city ballot (Hoffman, 2000; Meehan, 2000).
However, in 2004, activists from the Washtenaw Coalition for Compassionate
Care managed to collect 7,000 signatures on a petition seeking support for amendments
to the Ann Arbor ordinance (Charter for the City of Ann Arbor, 1956; Tomkie, 2004).
The amendments were designed to decrease the fines for cannabis use and prohibit the
local police from fining medical cannabis patients for its possession (Charter for the
City of Ann Arbor, 1956; Tomkie, 2004). There was a suggestion that, if passed, Ann
Arbor’s ordinance amendment would set the trend towards decriminalisation of
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cannabis (“Medicinal Marijuana Could Lead”, 2004; “A Possible Model for Medical
Marijuana”, 2004).
The press reported that Scio Township Trustee Charles Ream, who led the Ann
Arbor drive by collecting 7,000 petition signatures, paid $1 for each voter signature
using $5,000 of his own money, while the MPP donated $4,000 (Tee, 2004). According
to the Michigan Daily, Ream decided to rely on newspaper articles and editorials to
make people aware of the initiative (Tee, 2004). As was also the case in Detroit, the
media reports indicated that the biggest opposition to the initiative came from Gov.
Jennifer Granholm (D), who publicly said she did not approve of medical cannabis use
(Tee, 2004). Despite opposition, on November 2, 2004, approximately 75 percent of
Ann Arbor voters passed the ballot proposal (Rott, 2004). The following day, Ann
Arbor Police Chief Dan Oates released a written statement saying he had instructed his
officers to continue enforcement of all cannabis-related offences (Davis, 2004).
At the same time as Ann Arbor, there was also activity in Detroit. The Detroit
Coalition for Compassionate Care (DCCC) started a city-based petition in order to
amend the city charter to make medical cannabis possession the lowest law enforcement
priority (O'Brien, 2002). According to Tim O’Brien, the advertising and media
consultant for the DCCC, even though a city charter is superseded by state and federal
laws, changing Detroit’s charter could still make an impact. He believed a change could
be possible as the responsibility for enforcement of cannabis possession offences fell to
the local police. The proposal came under scrutiny in part because, according to the
opposition, it did not specify the conditions and symptoms for which the drug could be
used (O'Brien, 2002).
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While the support for the initiative was strong and supporters raised $30,000 in
campaign funds, there was strong opposition from the Partnership for a Drug-Free
Detroit (Angel, 2004). It was alleged in the media that the opposition was receiving
funds from the federal government in order to fight against the amendment to the city
code (P. Smith, 2004). Partnership for a Drug-Free Detroit stated in a published
memorandum that the medical cannabis initiative should be opposed because (a) the
drug was dangerous and hurt AIDS patients; (b) safer evidence-based treatments could
be used instead of cannabis; and (c) the initiative was deceptive and based on politics,
rather than facts (P. Smith, 2004). Despite the opposition from Gov. Granholm and
suggestions that the ordinance change was only symbolic and would not guarantee that
patients would not be prosecuted, the DCCC initiative appeared on the August 3 ballot
and was passed (“Detroit Okays Medical Use”, 2004; Gantert, 2004; “Medical Pot
Victory”, 2004).
Ferndale and Traverse City joined the medical cannabis movement, and both
passed a medical cannabis ordinance amendment in November 2005 (Flesher, 2005;
McConnell, 2005; McCray, 2005). The Traverse City amendment did not make medical
cannabis use legal, but made it the lowest law enforcement priority (Flesher, 2005). In
February 2007, Flint Coalition for Compassionate Care, which received a $7,500 grant
from the MPP, succeeded in their aim to change the city ordinance, with Flint voters
supporting measures legalising the use of medical cannabis with doctor’s approval
(“Flint Legalizes”, 2007; Rook, 2006; “State Should Allow”, 2006).
Increase in medical cannabis debate. Changes at the local level were followed
by an increase in the medical cannabis debate across the state. In the same year the
Detroit ordinance was changed, a national ad campaign, “Love. The Anti-Drug”, which
urged parents to take a stand against youth drug use, was launched in the city by John
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Walters, director of the ONDCP (“A Talk With Drug Czar”, 2004). In May of 2005, the
Detroit Free Press reported that there was again movement towards amending the state
constitution to legalise the use of medical cannabis. A group called Win-The-War,
headed by Bruce Ritchie, started circulating petitions for a proposal seeking to legalise
general cannabis use and regulate it in the same way as alcohol (“Marijuana Petition
Drive for 2006”, 2005; Range, 2005). According to news reports, the group was
working on limited funds and had $3,000 to $4,000 available to fund the campaign.
Ritchie said he hoped that they would get more funding from the MPP (Range, 2005).
The group’s efforts were unsuccessful.
In 2005, Bruce Mirken from the MPP said that the U.S. Supreme Court ruling
which found that federal agents could arrest medical cannabis users in the states that
have legalised medical cannabis would not deter medical marijuana efforts, but would
instead strengthen the movement in Michigan and other states (“Buzz Over Medical
Marijuana”, 2005). The same year, House Bill HB 5470 was introduced by Rep. LaMar
Lemmons III (D) in the Michigan House of Representatives. The bill sought to allow
licensed physicians to prescribe small cannabis amounts to patients with debilitating
medical conditions, such as cancer and glaucoma (Bell, 2006; H.R. Rep. No. 5470,
2005). The introduction of the bill saw both sides of the debate speaking out. Scott
Burns, Deputy Director of the ONDCP urged the House Government Operations
Committee to reject the legislation, because smoked marijuana was not safe or effective
and legalising it would be bad for patients and society (Bell, 2006). Prominent medical
cannabis users testified in support of the bill, but the committee took no action, letting
the bill die at the end of the 2006 legislative session (Andrews, 2006; Cain, 2006). The
following year, another medical cannabis bill, HB 4038, was unsuccessfully introduced
to the House of Representatives. It sought to allow use of medical cannabis for
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individuals with specific medical conditions, with a referral from their physician (H.R.
4038, 2007).
This was followed by a new petition by Medical and Recreational Peace (MRP)
that proposed making cannabis legal for those older than 18 years, as long as they were
using or growing cannabis on private property (“Marijuana Petition Drive for 2008”,
2006). Tim Beck, then the Executive Director for Michigan NORML, distanced his
organisation from the MRP and said that the NORML would also try to get a proposal
similar to HB 5470 on the 2008 ballot, but not in conjunction with the MRP proposal.
He said the MRP proposal sought to legalise marijuana for general use and came out of
nowhere (Aisner, 2006; Rook, 2006). The medical cannabis movement drew opposition
from Raphael Lematrie, spokesperson for the ONDCP, who said that medical cannabis
laws would not help sick individuals (D. Storey, 2007). Both proposals were
unsuccessful.
Proposal 1. The opposition did not deter the newly established Michigan
Coalition for Compassionate Care (MCCC), founded by Tim Beck. In May 2007 they
announced the launch of the Michigan Medical Marihuana Act initiative to legalise
medical cannabis in the state. Using both volunteers and paid signature collectors, the
organisers planned to collect 550,000 signatures within 6 months to get the petition on
the 2008 ballot (Guyette, 2007; Kozlowski, 2007). The initiative received opposition
from law enforcement figures such as Ingham County Sheriff Gene Wrigglesworth, who
said it was a mistake and would be difficult to enforce and regulate (Andrews, 2007a).
Meanwhile, Dianne Byrum, a former state legislator, worked with the MCCC to get the
measure on the ballot and discussed the benefits of medical cannabis in the media.
Michigan NORML’s Executive Director Rev. Steven Thompson declined to discuss the
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specifics of the MCCC initiative, but expressed his support (Andrews, 2007a; Czarnik,
2007).
Some of those using cannabis for medicinal purposes were active in sharing their
stories and experiences, appearing in articles across different newspapers (Andrews,
2007a; Czarnik, 2007; Guyette, 2007). Support was also received from the former U.S.
Surgeon General Joycelyn Elders and Howard J. Wooldridge, a retired police detective
campaigning against prohibition. Wooldridge said that the reluctance to adopt new drug
laws came mainly from the pharmaceutical industry’s concern that they would suffer
significant monetary loss should cannabis be legalised (Andrews, 2007a; R. E. Martin,
2007).
By November 2007, the necessary signatures were collected by the coalition
(McVicar, 2007). The opposition spoke out, with Ingham County Sheriff Wriggelsworth
indicating he did not support the proposal because it would require an increased police
presence and open the door for general cannabis use (McVicar, 2007). State Senator
Tom George (R) said that legalising smokeable cannabis would have no benefits and
would make determining the right dose difficult (Killian, 2008a). Senate majority Floor
Leader Alan Cropsey (R) also spoke out against the proposal. The senator believed that
the legislature was unlikely to enact the law and would let the initiative go to ballot
instead (Andrews, 2007b). The legislature did not enact the law and the initiative,
known as Proposal 1, was set to go before voters on November 4, 2008 (Bell, 2008a).
The MCCC published on their website a March 2008 poll, which found that 67 percent
of Michigan voters supported removing criminal penalties for the medical use of
cannabis (Michigan Coalition for Compassionate Care [MCCC], 2008).
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One of the issues raised by opponents was that patients would have to obtain
cannabis from someone, who would be committing a felony by selling it to them,
because the proposal did not provide for a legal supply network (Citizens Research
Council of Michigan, 2008; Killian, 2008b). The Michigan State Medical Society also
announced that they opposed medical cannabis, except for use in controlled studies
(Doty, 2008). The MDCH representative James McCurtis said that they could not
legally take a stand on the proposal, but saw both sides of the argument (Roltsch, 2008).
While there were individuals speaking out in opposition of medical cannabis in
the state, until September 2008 there was no specific organised group opposed to
medical cannabis laws. Then, according to the State of Michigan (2008) on September
23, Citizens Protecting Michigan’s Kids (CPMK) was formed. CPMK consisted of
medical, law enforcement and anti-drug organisations (Leubsdorf, 2008). They were set
to launch their campaign in five cities: Southfield, Lansing, Grand Rapids, Traverse
City and Saginaw (Citizens Protecting Michigan's Kids [CPMK], 2008). On their
webpage, CPMK declared that they were formed in order to urge voters to vote against
Proposal 1 (CPMK, 2008). Michigan Court of Appeals Judge Bill Schuette spoke on
behalf of the CPMK in opposition to the proposal and was supported by the Howell
Chief of Police George Basar (Leubsdorf, 2008). Ron Schafer, Ionia County
Prosecuting Attorney, also joined in the opposition, reasoning that the proposal had a
gap which would allow people to drive under the influence of cannabis and increase
danger on the roads (CPMK, 2008).
The debate intensified in October 2008 when the CPMK started airing a
television advertisement showing a storefront called “Cannabis Company” and talking
about the hundreds of pot-smoking clubs which opened in California after voters
approved the use of medical cannabis in 1996 (Van Dussen, 2011). The announcer says
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that “They grow pot there. They smoke it there in every neighbourhood just blocks from
schools”. At this point, MCCC staff posted a blog on their website responding to the
television advertisement which they believed was misleading, lied to the public and was
just using scare tactics (MCCC, 2008a). The MCCC also started running advertisements
featuring Dr George Wagoner who helped his wife by obtaining cannabis to ease her
symptoms of chemotherapy (YesOnProp1, 2008). It was also reported that through to
October 20 that year, the MCCC raised more than 10 times the amount Proposal 1
opponents raised, $1.5 million to $125, 500 (Oosting, 2008).
A memorandum was also issued to Michigan employers by Steven J. Fishman, a
chair of the Workplace Law Practice Group, opposing the proposal and claiming that
there was no scientific evidence that smoking cannabis was safe or effective, and that
because it is not FDA approved, employers would not be able to monitor its use
(Fishman, 2008). Fishman reasoned that, as Michigan was a state with a high
unemployment rate and among the least attractive for business, it could not afford to
have cannabis in the workplace (Fishman, 2008). MCCC spokeswoman Dianne Byrum,
together with Bruce Mirken, responded to Fishman’s claims saying that the MCCC did
not believe that Proposal 1 would affect workplaces (Bell, 2008b). Byrum said she was
not aware of any cases of workplace problems with medical cannabis in states that have
already adopted such laws. Fishman’s memorandum, however, had an impact on the
Chamber of Commerce, who previously adopted a neutral position on the proposal but
said Fishman’s memorandum raised significant and previously unconsidered points
(Bell, 2008b; CPMK, 2008).
Less than a month before the election, Judge Bill Schuette and Michigan State
Medical Society’s House of Delegates speaker Daniel Michael wrote a number of
articles against Proposal 1 (Schuette & Michael, 2008a, 2008b). Similarly to the CPMK
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advertisements, they suggested that California’s medical cannabis law resulted in chaos
and that the same would happen in Michigan should Proposal 1 be passed (Schuette &
Michael, 2008a, 2008b). While claiming the proposal was bad because it did not require
a prescription for cannabis, they strongly urged voters to vote no on the proposal
(Schuette & Michael, 2008a). Judge Schuette and members of the Michigan Sheriff’s
Association also joined the deputy drug czar Scott Burns in Grand Rapids to campaign
against Proposal 1, while Oakland County Sheriff Michael Bouchard, prosecutor David
Gorcyca and Southfield Police Chief Joe Thomas held a press conference and spoke
against the proposal (CPMK, 2008; “Deputy Drug Czar Will”, 2008).
One of the more high-profile opponents, John Walters, Director of the ONDCP,
went to Detroit to speak against the proposal he called the first step towards legalising
drugs (“Drug Czar Visits”, 2008). He said that its proponents did not have any facts but
relied on the sympathy of the voting public. Following Walters’s arrival, a joint
statement opposing the initiative was released by a group of local law enforcement
agencies (Kloosterman, 2008). The statement said that medical cannabis (a) was a
Trojan horse for legalising the drug itself and making it available with disregard for
scientific evidence; (b) had no scientific base; (c) was dangerous; and (d) could have a
staggering effects on families and children (Kloosterman, 2008). Afterwards, Howell
Police Chief George Baser encouraged voters to vote no on the proposal which he
believed would lead to more people, including children, using cannabis (Totten, 2008).
He said that, if the drug were truly for medical use, the proposal would include a
requirement for physicians’ prescription (Totten, 2008). Donald Allen, Director of the
Michigan Office of Drug Control Policy, was also quoted as saying that medical
cannabis was not in the public health interest (Satyanarayana, 2008a).
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In response to the opposition’s comments, Dianne Byrum presented the
argument that cannabis legalisation was not the goal of Proposal 1 but providing options
for patients in pain (Totten, 2008). Campaigners such as Dr. George F. Wagoner and
Reverend Steve Thompson of Benzie County NORML wrote to different newspapers
relating experiences with medical cannabis and voicing support for the initiative
(Wagoner, 2008a, 2008b). Thompson alleged that CPMK only posted half-truths and
said it was not clear who stood behind them. In response to claims that legalising
medical cannabis was just a step towards legalising cannabis in general, Thompson said
that the NORML wanted the drug completely legalised, for both recreational and
medical use, and that was why they took a back seat to the MCCC, whose goal was
legalisation for medical purposes only (Coates, 2008).
In October, CPMK spokespersons stopped in Battle Creek to speak against
Proposal 1, calling the initiative preposterous and a con (“Medical Marijuana a Hot
Issue”, 2008). Following the group’s visit to Battle Creek, David Headings from the
Battle Creek Police Department and Al Byam, Sheriff of Calhoun County, wrote a letter
to the Battle Creek Enquirer, strongly opposing medical cannabis (Headings & Byam,
2008). They said that the initiative could make drugs available to children under the
guise of medical use and that advocates of cannabis legalisation played on people’s
emotions by presenting cases of sick patients who have benefited from the use of the
drug (Headings & Byam, 2008).
While the MDCH previously took no stance on the medical cannabis issue, at
the end of October, Janet Olszewski, the department’s director, stated in the Detroit Free
Press that legalising cannabis for medical purposes was not the right answer for treating
pain (Olszewski, 2008). She said that major public health organisations did not support
medical cannabis and that there was no need for it, as Marinol (dronabinol) was
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available and had medical value. According to Olszewski, the proposal had loopholes
that could cause legal confusion and drug enforcement problems (Olszewski, 2008).
On October 30, prominent figures, including Macomb County Sheriff Mark
Hackel and prosecutor Eric Smith, joined Bill Schuette at Macomb County to urge
voters to vote against Proposal 1 (Wilczynski, 2008). Schuette said that wealthy
millionaires from New York, Washington D.C., and California were spending millions
to promote the medical cannabis initiative, with the aim ultimately being general
cannabis legalisation (Wilczynski, 2008). Matt Resch, spokesman for the CPMK, said
the opposition was slow to start their campaign, but were busy in October airing
television commercials (Bell, 2008c).
At the start of November, the Detroit Free Press indicated the polls showed
strong support for the proposal (Bell, 2008c). Debates over the issue were evident
across newspapers leading up to the election, with both supporters and opponents
presenting their views (Panian, 2008; Satyanarayana, 2008b). Then, on November 4,
2008, voters passed the proposal (Michigan Department of State, 2008a). The
information from the Department of State showed that Proposal 1 received majority
‘yes’ votes in every one of the 83 Michigan counties; 3,006,820 (62.7%) voted in favour
of the proposal and 1,790,889 (37.3%) voted against (Michigan Department of State,
2008a).
Funding. On Tuesday, November 4, 2008, the co-chairs of CPMK Judge Bill
Schuette and Jim Barrett released a statement on CPMK’s website following the passing
of Proposal 1, stating that the organisation campaigned on a limited budget (CPMK,
2008). This section will outline the funds and expenditures for both MCCC and CPMK
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during 2008 and the election cycle, as reported in the Michigan Department of State
documents.
The documents indicated that, in 2008, MCCC processed 99 separate donations,
yielding a total of $69,563.48 (Michigan Department of State, 2008b). The MPP made
12 separate donations, totalling $67,475.84 for 2008, and a cumulated total of
$1,240,460.07 worth of donations for the election cycle. In 2008, MCCC spent a total of
$36,159.35; a large proportion of which was spent on political consultations and legal
fees. Examples of other expenses included printing, signature verification, federal taxes,
state taxes, and classified advertisements in the Flint Journal and the Kalamazoo
Gazette. Total MCCC expenditures for the election cycle cumulated to $1,105,927.04.
According to the Michigan State documents, CPMK was officially formed on
September 23, 2008 (Michigan Department of State, 2008c). From October 21, 2008 to
November 24, 2008, the CPMK received $184,030.71 worth of donations and a
cumulative total of $309,520.71 for the election period. Major donators to CPMK
included the presidents of Alticor and R.D.V. Sports; Richard M. DeVos, a
businessman; Save Our Society from Drugs; Robert Thompson, a retiree; the Dow
Chemical Corporation; and DTE Political Action committee. On October 7, 2008,
Michigan Health and Hospital Association donated $100,000. Total expenditures from
October 21, 2008 to November 24, 2008 were $215,288.69, with a cumulative total of
$276,632.11 for the election period. In total, CPMK spent $198,596.58 for media and
television advertising and approximately $5,265 on consulting services (Michigan
Department of State, 2008c).
Post-Proposal 1. After the law was passed, the Bureau of Health Professionals,
under the MDCH, had 120 days to draft and finalise rules for the medical cannabis
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program (Kinstle, 2008). The registry program was to be completed by April 14, 2009.
However, questions were raised regarding the new law’s so called vague language and
how cannabis was to be obtained by patients (Merion, 2008). Dianne Byrum attempted
to dispute the concerns regarding the law and stated it was well structured, well written
and very limited (Merion, 2008).
In January of 2009, the first draft of rules for the medical cannabis program,
created by the MDCH, resulted in protests from patients and medical cannabis
advocates (McNamara, 2009). They argued that the MDCH was, in some instances,
contradicting the law passed by voters by seeking to restrict access to medical cannabis.
Karen O’Keefe, a lawyer for the MPP, said the MDCH was overstepping its boundaries
and took the draft rules further than it was assigned to do. According to O’Keefe, the
department was only given the duty of setting up a patient registry and overseeing the
list of diseases that would allow patients to register for the medical cannabis program
(McNamara, 2009).
The Michigan medical cannabis law received criticism from Judge Robert
Turner who said it was the worst legislation he had seen, after he dismissed felony
charges against a couple who were charged with intent to manufacture cannabis
("People v. Redden," 2010). The couple had their physician’s letter of recommendation
but did not possess the MDCH issued ID cards, which were due to be issued five days
after the couple’s arrest. Their lawyers argued that physician recommendation was
sufficient grounds for cannabis use while the prosecution contended that defendants
were required to abstain from cannabis use until they were able to obtain an
identification card and that they did not have a bona fide physician-patient relationship
with their doctor. Defendants argued that the plain language of the medical cannabis act
did not require possession of a card ("People v. Redden," 2010). Judge Turner said the
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medical cannabis law was ambiguous, as it did not specify the exact amount of cannabis
a registered patient was allowed to possess, leaving judges to determine what a
reasonable amount was. In 2010, the Michigan Court of Appeals affirmed the circuit
court’s decision to reinstate the charges against the defendants, but Judge Peter D.
O’Connell also wrote:
No system of regulation can succeed without a clear set of rules. Those wishing
to use marijuana need to know when, how, and under what conditions they can
legally do so. Providers need to know under what conditions they can legally
grow, harvest, and distribute their product, and the operators of the new medicalmarijuana clinics that appear to be springing up on every corner need to know if
they are in fact set up to dispense marijuana to the public legally (para.223).
The confusion regarding the law resulted in local governments passing their own
ordinances, to accommodate or restrict medical cannabis dispensaries (Bukowski, 2010;
Householder & Martin, 2010; Steber, 2013). However, this resulted in inconsistencies in
local laws, some of which also conflicted with the interpretations of the medical
cannabis act (Steber, 2013). Steber (2013) suggested that political preferences of the
municipalities also played a role in influencing local laws regarding medical cannabis,
as it appears that the more liberal cities were permitting medical cannabis dispensaries
and were more likely to facilitate patients’ access to medical cannabis.
During the 2011-2012 legislative session, the Michigan legislature passed six
bills amending the state’s medical cannabis act (MPP, 2014). House Bill 4856 (2012)
was passed to amend the medical cannabis act for medical cannabis patients and
caregivers to keep cannabis in a case in the trunk of their vehicle or enclosed in a case
that is not readily accessible if the vehicle does not have a trunk, when transporting
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cannabis. House Bill 4834 (2011) provided that patients and caregivers will need to
renew their registry cards every two years. House Bill 4851 (2011) requires doctors who
recommend cannabis to patients to first establish a “bona fide physician-patient
relationship” by the doctor reviewing the patient’s medical records and completing a
full assessment of the patient’s medical history, creating and maintaining records of the
patient’s condition, having an expectation that they will provide follow-up care, and
notifying the patient’s primary care physician of the patient’s condition and use of
medical cannabis. The bill also changes the definition of “enclosed, locked facility”
where patients can grow cannabis to say that it must be “stationary” and “fully
enclosed”. The bill also permits outdoor cultivation as long as the plants are not visible
from adjacent property and are grown in a stationary and enclosed structure. The other
House Bill 4853 (2011) applied the state’s criminal sentencing guidelines to the crime
prohibited by the original act. The two senate bills passed during the 2011-2012
legislative session specified that medical cannabis or related expenses are not required
to be covered by insurance companies and that employers are not required to reimburse
their employees for medical cannabis treatment (MPP, 2014). There are currently 30
pending bills related to medical cannabis in the state’s legislature (MPP, 2014).
New Mexico
New Mexico’s attempts to legalise medical cannabis were successful in 2007,
when, on March 13, Gov. Bill Richardson, a Democrat, became the first governor in
history to enact a medical cannabis law while running for the presidency (Lynn and Erin
Compassionate Use Act, 2007; MPP, 2013). He signed SB 523, known as the “Lynn
and Erin Compassionate Use Act”, into law, making New Mexico the 12th state to allow
medical cannabis use for qualifying patients. The House of Representatives approved
the bill by a 36-31 vote, while the Senate approved it 32-3. The bill took effect on July
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1, 2007. The New Mexico Department of Health (NMDH) finalised the rules for the
medical cannabis program in January 2009. The New Mexico legislature also passed a
non-binding resolution which urged the federal government to allow doctors to
prescribe cannabis to patients. The resolution did not change the state policy, but was
significant because it officially stated the legislature’s position on the issue (MPP,
2013).
Not all of the currently included debilitating medical conditions were included in
the original bill. Following amendments in January and April of 2009, the following
conditions were specified as enabling patients to qualify for the New Mexico medical
cannabis program: severe chronic pain; painful peripheral neuropathy, intractable
nausea/vomiting; severe anorexia/cachexia; hepatitis C infection currently receiving
antiviral treatment; Crohn’s disease; Post-traumatic Stress Disorder; Amyotrophic
Lateral Sclerosis (Lou Gehrig’s disease); cancer; glaucoma; multiple sclerosis; damage
to the nervous tissue of the spinal cord with intractable spasticity; epilepsy; HIV/AIDS;
inflammatory autoimmune-mediated arthritis; hospice patients; and any other condition
subject to approval by the NMDH (Lynn and Erin Compassionate Use Act, 2007; MPP,
2013). In order to qualify, patients have to be residents of New Mexico, and be
diagnosed by a medical practitioner as having one or more of the specified debilitating
medical conditions, including a statement from their practitioner that, in their opinion,
the potential health benefits of using medical cannabis would outweigh the health risks
for the patient. The length of New Mexico residency before a patient can apply for
participation in the program is not specified. The practitioners are exempt from arrest or
prosecution for recommending medical cannabis to a patient with specified medical
conditions (Lynn and Erin Compassionate Use Act, 2007).
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The NMDH is responsible for issuing identification cards to eligible patients and
caregivers (Lynn and Erin Compassionate Use Act, 2007). Patients may legally possess
six ounces of usable medical cannabis, four mature plants and 12 seedlings. However, if
they have their physician’s approval, patients can apply to the Medical Advisory Board
to possess more than 6 ounces of useable cannabis. State regulations also authorised
non-profit facilities to apply to produce and dispense medical cannabis, with state
licensed producers permitted to grow up to 95 mature plants at one time (Lynn and Erin
Compassionate Use Act, 2007; New Mexico Register, 2008). At the state level, patients
are also able to use a medical necessity defence, should they be prosecuted for an
offence involving cannabis, as long as they are in possession of no more than the
necessary amount of cannabis needed to relieve their pain and ensure an uninterrupted
supply of the drug. The defence is not limited to registered patients only, and while it
does not protect a patient from arrest, it requires the charges to be dropped if the
specified conditions are met (Lynn and Erin Compassionate Use Act, 2007).
New Mexico’s law was the first in the country to specifically instruct the state to
develop and implement a cannabis production and distribution system, in order to assist
patients in obtaining the drug (Lynn and Erin Compassionate Use Act, 2007; MPP,
2013). This meant that patients could register to grow their own cannabis, or non-profit
businesses wanting to produce and distribute the drug could apply for their licence
through the NMDH. A Medical Advisory Committee consisting of eight medical
professionals was also created, to assist the NMDH with program development and give
advice on rules governing the Medical Cannabis Program (“Local Doctors”, 2007; New
Mexico Department of Health [NMDH], 2007b). The committee is required to meet at
least twice a year to hold public hearings and evaluate patients’ petitions to add
conditions to the list of qualifying medical conditions.
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In the following section, Figure 3 will chronologically outline the history of
medical cannabis in New Mexico, followed by a chronological description of the
process that took place before the Lynn and Erin Compassionate Use Act was passed.
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• New Mexico becomes the first U.S. state allowing therapeutic cannabis research program
• As a result of the act, the Controlled Substances Act was amended to allow cannabis
possession to qualifying patients participating in the program

• By 1983, 180 patients had participated in the program
• A report by the Behavioral Health Services Division found that 75% of the patients showed
a positive response to the treatment they received as part of the program

• Program ends in 1986 after the Legislature decided not to renew its annual funding of the
program
• Medical cannabis remained legal for therapeutic research purposes in New Mexico

• New Mexicans for Compassionate Use is created

• Bryan Krumm, founder of New Mexicans for Compassionate Use , spoke in front of New
Mexico Board of Pharmacy to gain support to reschedule cannabis

• 1999 Gov. Johnson suggests that the federal government should consider
decriminalisation of drugs
• U.S. drug czar Barry McCaffrey visited New Mexico in order to counter Gov. Johnson’s
statements on drug legalisation
• Activists announce potential lawsuit to reinstate the 1978 therapeutic program
• Alex Valdez, Secretary of the New Mexico Department of Health told medical cannabis
activists he would move to reinstate the medical cannabis law
• Alex Valdez, acting on Gov. Johnson's instructions, drafts a measure aimed at reviving
the the medical cannabis law

• Gov. Johnson successfully uses his power of line-item veto to remove a provision banning
the use of budget money on promotion of drug legalisation and decriminalisation
• Gov. Johnson said that cannabis should be legalised
• Alex Valdez suggests replacing the old medical cannabis law with one modelled on
Hawaii's medical cannabis program
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• The Drug Policy Advisory Group, created by Gov. Johnson, recommends the reform of
the Lynn Pierson Act to allow for patient access to medical cannabis
• The group recommends New Mexico's medical cannabis law should be modelled on
Oregon and Hawaii's program
• Reports that the advisory group was created by Gov. Johnson using private money
• Reports that Gov. Johnson plans to propose eight drug-reform bills to the state
Legislature, including decriminalisation of possession of small cannabis amounts, and
legalising cannabis use for medical purposes
• Opposition vocal in the media, saying Gov. Johnson is sending a bad message to people
• NORML begins airing radio advertisements supporting drug law changes
• Two medical cannabis bills introduced, one in the House of representatives and one in
the Senate
• Opposition lobbying lawmakers to reject some of Gov. Johnson's drug reform bills
• Poll finds that 61% of participants support medical cannabis

• Following Supreme Court ruling, Gov. Johnson waters down a medical cannabis bill from
previous versions
• New medical cannabis bill introduced in the Senate by Sen. Maes
• The bill's proposition that patients should grow and dispense cannabis draws criticism
• NMDH spokesperson supports cannabis as a medicine

• Compassionate Use Medical Cannabis bill introduced again and defeated in the House of
Representatives
• Gov. Johnson replaced by Gov. Richardson

• Sen. McSorley announces that he would sponsor a medical cannabis bill
• Media reports that the pharmaceutical industry contributed more than $97,000 to New
Mexico political campaigns
• Legislative support for medical cannabis decreased since Gov. Johnson was replaced by
Gov. Richardson
• Senate passes three medical cannabis bills
• Gov. Richardson says that if the House passes a medical cannabis bill he would sign it

• Gov. Richardson announces he would include a medical cannabis bill on his agenda
• House Speaker asks the governor not to include the bill on his agenda as there is not
enough time for it to be heard
• Another medical cannabis bill introduced in Senate by Sen. McSorley; legislative session
ended before the bill could get a house floor vote
• Patients speak in support of the medical cannabis bill
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• Lynn and Erin Compassionate Use Act introduced in the Senate by Sen. Ortiz y Pino
• Opponents say the bill runs contrary to federal law
• Erin Armstrong, a cancer patients, speaks in support of the bill
• Lynn and Erin Compassionate Use Act defeated and replaced by the Compassionate Use
Medical Marijuana Act
• Gov. Richardson says that signing the bill would be the right thing to do
• Gov. Richardson signs SB 523 known as the "Lynn and Erin Compassionate Use Act" into
law on April 2, 2007
• Allegations that Gov. Richardson used medical cannabis issue to gain support for his
presidential campaign
• Gov. Richardson received monetary contributions from medical cannabis activists
• NMDH starts accepting applications from medical cannabis patients on July 1, 2007
• Eight medical professionals appointed to a Medical Advisory Committee
• Gov. Richardson sends a letter to President Bush asking him to end the priority placed on
arresting and prosecuting state workers involved in the medical cannabis program
• Reports that there are approximately 200 medical cannabis users in the state
• NMDH Medical Advisory Board holds a public hearing to discuss adding new debilitating
medical conditions to the program's list

• NMDH finalises regulations for the registry identification cards and a production/distribution
system

• By October 2011 there were 5, 495 enrolments in the state's medical cannabis program
• The state's medical cannabis program used as a model for other states

Figure 3. Time chart of medical cannabis history in New Mexico.
2007 Lynn and Erin Compassionate Use Act: Chronological account. In
1978, New Mexico was the first U.S. state to pass a law allowing a therapeutic cannabis
research program, which involved receiving cannabis supplies from the federal
government (Behavioral Health Services Division [BHSD], 1983). The act was passed
by the Legislature, and was renamed in 1979 the Lynn Pierson Therapeutic Research
Program (LPTRP), in honour of Lynn Pierson, a cancer patient, who lobbied for
medical cannabis in New Mexico. It was administered by the then Health and
Environment Department, run through the University of New Mexico, and sought to
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provide cannabis and delta-9-THC to cancer chemotherapy patients suffering from
nausea and vomiting caused by their therapy (BHSD, 1983). As a result of the act, the
Controlled Substances Act was amended to allow cannabis possession to qualifying
patients participating in the LPTRP. However, due to federal law superseding state law,
starting the LPTRP required approval from the FDA, the DEA, and the NIDA. After
these agencies approved the program, the first shipment of the required drugs arrived
and the program began in January 1979 (BHSD, 1983).
By 1983, 180 patients had participated in the program, and another 51 applied
but did not enter it (BHSD, 1983). Half of the patients were administered cannabis,
which was inhaled; the other half received delta-9-THC, which was ingested in capsule
form. A report by the Behavioral Health Services Division found that 75 percent of the
patients showed a positive response to the treatment they received as part of the
program, with inhalation found to be superior to ingestion. The report noted that the
LPTRP implementation was successful, with no recorded misuse or abuse of the drug,
and no problems with approving patients for participation (BHSD, 1983).
Despite its reported success in treating patients, the LPTRP ended in 1986 after
the Legislature decided not to renew its annual funding of the program (Jadrnak, 1999;
T. Smith, 1997). Even though the program became defunct, medical cannabis remained
legal for therapeutic research purposes in New Mexico, although this was largely
symbolic and no therapeutic research program has been run since 1986. Since it ended,
medical cannabis advocates have attempted to revive the LPTRP, first through the
Board of Pharmacy, and then, as of 2001, in the State Legislature (Baker, 2006).
After the LPTRP became defunct in 1986, no significant efforts to revive it were
noted until, in 1997, Bryan Krumm, founder of New Mexicans for Compassionate Use,
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was set to address the New Mexico Board of Pharmacy at their monthly public meeting
seeking assistance to re-assign cannabis to Schedule II (T. Smith, 1997). New Mexicans
for Compassionate Use was created in 1996, with the aim of make changes to cannabis’
status at the state level, making it more accessible to people who need it. Krumm said
that he was hoping to get Gov. Gary Johnson (R) to introduce law changes at the next
legislative session, in order to reclassify cannabis. However, Richard W. Thompson, the
board’s executive director, said that there was little chance medical cannabis would
become legal in New Mexico in the near future (T. Smith, 1997). Thompson said that
legalising cannabis was unnecessary as Marinol was already available although Krumm
said that he did not think Marinol worked as well as cannabis. Krumm also suggested
that it was the pharmaceutical companies who stood in the way of legalising medical
use of cannabis, for fear of profit loss. Jerry Montoya, chief drug inspector for the Board
of Pharmacy, disagreed with this statement and claimed that pharmaceutical companies
make most of their money on anti-depressants (T. Smith, 1997).
In 1999 Gov. Johnson admitted to using cannabis and cocaine while in college,
and suggested the Federal Government should consider decriminalisation of drugs
(Janofsky, 1999). He said that the campaign against drugs had left courts and prisons
overwhelmed. Gov. Johnson’s statements were considered controversial and drew
criticism from both sides, including the ONDCP. In October of 1999, U.S. drug Czar
Barry McCaffrey visited New Mexico in order to counter Gov. Johnson’s statements on
drug legalisation and Gov. Johnson said that he did not expect much support from law
enforcement organisations (“Drug Debate Fizzled”, 1999; Janofsky, 1999). While his
views got him national attention, it was suggested in the media that Gov. Johnson’s past
office record countered his drug legalisation views, as he had previously consistently
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vetoed such programs when they were presented to him by the legislature (“Drug
Debate Fizzled”, 1999).
The same year, Bryan Krumm and Ed McWilliams were announced in the media
as potential plaintiffs in a class-action lawsuit, requesting that the 1978 medical
cannabis program be reinstated (Jadrnak, 1999). In October of 1999, Alex Valdez,
secretary of the NMDH, told the medical cannabis activists he would move to reinstate
the program, and they delayed filing the lawsuit. He said that the program was not his
priority for the fiscal year budget, but he was informed by the DEA about what federal
requirements he must fulfil to reinstate the program. According to Jadrnak (1999),
Valdez stated he wanted to make it clear that his interest in the medical cannabis
program was not related to Gov. Johnson’s discussion on cannabis legalisation, as he
did not want people to think medical cannabis was the first step to general legalisation
of the drug.
In November of the same year, Alex Valdez, acting on Gov. Johnson’s
instructions, drafted a measure aimed at reviving the 1978 medical cannabis law
(“Legislature to Study”, 1999). Allegedly, Valdez started studying the law after threats
of a class-action lawsuit. Earlier in the month, Valdez was sued by attorney Charlie
Knoblauch on behalf of Tony Cognetto, for not providing his sick client with cannabis.
Bryan Krumm and Ed McWilliams also threatened to sue. It was alleged that it was the
governor who pushed Valdez towards reviving the medical cannabis program, after he
said it was not going to be his priority (“Legislature to Study”, 1999).
The following year, Gov. Johnson successfully used his power of line-item veto
(deleting a particular provision of a bill enacted by legislature) to remove a provision
banning the use of budget money on promotion of drug legalisation and
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decriminalisation (Fecteau, 2000a; Watts, 2010). He said that removing criminal
penalties from drugs such as cannabis and heroin would reduce drug use because it
would allow for the substance to be controlled, regulated and taxed. The governor also
pledged to continue to push for a public debate on drug-related issues until the end of
his time as a governor, despite the fact he was aware his popularity would decline as a
result (“60 Minutes to Air”, 2000; Fecteau, 2000a). He was also to discuss drug reform
and legalisation of some drugs on CBS’s “60 Minutes” program (“60 Minutes to Air”,
2000).
Following the airing of the “60 Minutes” program with Gov. Johnson, in which
he advocated legalisation of both cannabis and heroin, the governor said that he thought
cannabis should be legalised, and that he intended to support general cannabis
legalisation even after he left office (Fecteau, 2000b). The governor said his opinion had
changed since he filmed the “60 Minutes” program in December of 1999 and said that
talking about heroin scared people, which led him to decide to separate the two drugs
and only focus on cannabis legalisation (Fecteau, 2000b). Alex Valdez also spoke in
support of medical cannabis and suggested the state replace its old medical cannabis law
with one modelled on Hawaii’s medical cannabis program (Fecteau, 2000c).
In 2001, the Drug Policy Advisory Group, created by Gov. Johnson,
recommended the reform of the Lynn Pierson Act to allow for patient access to medical
cannabis for people with serious medical conditions for which it has been shown to
decrease pain and suffering (New Mexico Governor's Drug Policy Advisory Group,
2001). The report stated that since the act was enacted in 1979 the medical
appropriateness of cannabis has been established for a variety of medical conditions and
that many states have enacted medical cannabis laws. The group recommended that
New Mexico’s program be modelled on Oregon and Hawaii’s programs. The group also
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recommended amendment of existing criminal statutes to remove the criminal penalty
for personal possession of cannabis and to allow for civil penalties, rather than criminal
penalties, for use of cannabis in public places (New Mexico Governor's Drug Policy
Advisory Group, 2001). According to a newspaper article, the advisory group was
created by Gov. Johnson using private money (Mahesh, 2001a).
In January of 2001 it was reported that, after recommendations from the Drug
Policy Advisory Group, Gov. Johnson planned to propose eight drug-reform bills to the
state Legislature, including decriminalisation of possession of small cannabis amounts,
and legalising cannabis use for medical purposes (McClannahan, 2001). State Rep. Ron
Godbey (R) spoke in opposition and said that he thought Gov. Johnson would send a
bad message to people and that he was appalled at what the governor was trying to do.
Rep. Godbrey said he was especially concerned with the push to legalise cannabis for
medical purposes, as other medicines that could be used in its place were already
available. He also expressed his belief that the push for medical cannabis legalisation
did not come from the medical community, but from the “druggies” (McClannahan,
2001). Rep. Ted Hobbs (R) also opposed medical cannabis and said that it was a step
towards general legalisation. Matt Sandoval, president of the New Mexico District
Attorneys Association, said that the proposal amounted to legalisation and would lead to
higher drug use (Mahesh, 2001a).
Senator (Sen.) Cisco McSorley (D) and Rep. Joseph Thompson (R) agreed to
sponsor two cannabis-related bills proposed by Gov. Johnson (Mahesh, 2001b). Sen.
McSorley, together with Sen. Roman Maes (D), were to introduce Senate Bill 315, a
medical cannabis bill allowing cannabis use for people with specific medical conditions,
while Rep. Thompson was to introduce House Bill 431 in the House of Representatives
(H.R. 431, 2001; Mahesh, 2001b; S.B. 315, 2001). Thompson said he did not find a
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House co-sponsor for his medical cannabis bill, but that, at that point, a lot of
representatives indicated they would vote for it. McSorley also agreed to sponsor a bill
which aimed to decriminalise possession of up to an ounce of cannabis for personal use
(Mahesh, 2001c). Around the same time, the NORML began airing radio
advertisements in support of the drug law changes (NORML, 2014b). The two week
campaign of radio spots was intended to help build support for Gov. Johnson’s call to
legalise cannabis and ran approximately 150 times on two Albuquerque stations and one
Santa Fe station (NORML, 2014b).
Two medical cannabis bills, part of Gov. Johnson’s drug-reform package, were
approved by Senate Committees in February of 2001, despite some law enforcement
groups voicing their disapproval (Terrell, 2001). Senate Bill 315 (2001) then cleared the
Senate on a 29-12 vote, and was due to be considered by the House. In March, House
Bill 431 (2001), sponsored by Rep. Joe Thompson, cleared the house by a 35-32 vote.
While the bill proposed to make cannabis available to those suffering from cancer,
HIV/AIDs, glaucoma, neuro-muscular conditions, and other severely debilitating
illnesses, it also included a sunset provision, which meant that, if passed, it would
expire on July 1, 2005, when the legislature would have had the option of extending it
(Mahesh, 2001d).
Thirteenth Judicial District Attorney, Lemuel Martinez, said members of the
New Mexico District Attorneys Association were lobbying lawmakers and testifying
before the Legislature to reject some of Gov. Johnson’s drug reform bills (Pawloski,
2001). Reasons Martinez gave for opposing Gov. Johnson’s proposals included sending
a negative message to children, an increase in cannabis-impaired drivers on the streets,
and disadvantaging those trying to complete drug rehabilitation programs by
“undermining incarceration” (i.e. removing the threat of incarceration which the drug
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courts often use as a threat to those wo do not comply with the “rehabilitation”
program). Katherine Huffman, director of the New Mexico Drug Policy Project of the
Lindesmith Center (now the Drug Policy Alliance), disagreed with Martinez’s claims,
and said the bill would not legalise cannabis for everyone (Pawloski, 2001).
In March 2001, a study was commissioned by the Lindesmith Center, and was
conducted by Research and Polling, Inc. (Research and Polling, 2001). As part of the
study, 504 registered voters in New Mexico were randomly selected and interviewed
over the telephone about their attitudes and opinions on issues relating to drug use and
drug laws in New Mexico. The study found that 61 percent of participants strongly
supported making cannabis available to seriously ill or terminal patients, while 17
percent somewhat supported the idea (Research and Polling, 2001).
Meanwhile, Gov. Johnson continued to promote his proposals, and spoke at the
annual NORML convention, where he vowed to keep fighting for drug law reform in
New Mexico (Coleman, 2001). He also spoke at the Lindesmith Center’s international
conference at Albuquerque about cannabis legalisation (Jojola, 2001). Governor
Johnson said cannabis legalisation was needed, as well as a move from a criminal model
to a medical model approach to drug-related issues. Ethan Nadelmann, the Lindesmith
Center’s executive director, praised the governor and his commitment to the drug
reform issue (Jojola, 2001).
When three out of his eight drug-reform bills died during 2001, Gov. Johnson
said he would not give up and would introduce more drug-reform legislation in 2002 (B.
Smith, 2001). His views continued to cause controversy and raised questions over why
Gov. Johnson did not make his position on drug use clear until his second term as a
governor (Zeleny, 2001). However, when Gov. Johnson made his position on drug use
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clear his approval rating dropped by 11 points and three members of his
administration’s anti-drug task force resigned. There was also a political aspect to the
debate and a newspaper article quoted a professor of political science at the University
of New Mexico who said the Democrats used the controversy Gov. Johnson’s views
created to paint the Republicans as being pro-vice and pro-sin (Zeleny, 2001). In
October of 2001, Gov. Johnson spoke at a forum along with former Gov. Toney Anaya
(D), who was paid by the Lindesmith Center to lobby for Gov. Johnson’s drug reform
package before the legislature (B. Smith, 2001). According to Anaya, some Democrats
in the Legislature did not support Gov. Johnson’s bills because they were proposed by a
Republican governor (B. Smith, 2001).
After the 2001 medical cannabis bills failed to clear both houses, and following
the Supreme Court decision which ruled that patients can still be arrested under federal
law even if their state allows the use of medical cannabis, Gov. Johnson watered down a
medical cannabis bill from previous versions (B. Smith, 2002). The 2001 bill proposed
that the NMDH should grow and distribute cannabis for qualifying patients
(Compassionate Use Medical Cannabis Act, 2002) . This provision was removed in the
2002 bill, and introduced in the Senate by Sen. Roman Maes (D) as the Compassionate
Use Medical Cannabis Act (2002). Lawmakers on the Senate committee considered the
bill, but disagreed about who should grow and dispense cannabis. The bill’s proposition
that patients should grow their own cannabis drew criticism from lawmakers who feared
some patients may abuse this (Mahesh, 2002). Some senators, such as Sen. Mary Jane
Garcia (D), said they would prefer physicians to prescribe cannabis to patients, instead
of patients growing their own. The committee members therefore voted 6-2 to amend
the bill to remove the provision allowing patients to grow cannabis, while Sen. Rod

Medical Cannabis in the United States

166

Adair (R) recommended having a state agency or a university grow and distribute the
drug (Mahesh, 2002).
After the bill was introduced, Steve Jenison, from the NMDH, suggested
cannabis could effectively be used as a medicine in certain cases, in place of other
medications that people do not find beneficial (Jenison, 2002). Jenison stated that he
supported cannabis use for certain debilitating medical conditions, and therefore
supported the Compassionate Use Medical Cannabis bill which was introduced by Sen.
Roman Maes (D). He also responded to claims that medical cannabis is unnecessary as
Marinol was already available by saying that Marinol did not help some individuals,
while smoking small amounts of cannabis did. Jenison encouraged people to support the
bill and said a distinction had to be made between cannabis as a medicine and as a
recreational drug (Jenison, 2002). The bill was not successful and was introduced again
in 2003 and defeated in the House of Representatives by a 46-20 vote (“Medical
Marijuana Bill Fails in New Mexico”, 2003). District attorneys and law enforcement
groups opposed the medical cannabis proposal and Lemuel Martinez, president of the
New Mexico District Attorneys Association, said he expected the group to continue
opposing medical cannabis use (Massey, 2005).
In 2005, Sen. Cisco McSorley (D) sponsored the Lynn Pierson Compassionate
Use Act (2005), which included a provision whereby the NMDH would oversee a
program providing cannabis to qualifying patients. Senator McSorley said that no
lawmaker ever lost their seat because of the medical cannabis issue, and they should
therefore not fear to vote for it (Massey, 2005). In March 2005, the Senate passed Sen.
McSorley’s bill and two other medical cannabis bills, each of them establishing a
program run by the state NDMH (Compassionate Use Medical Marijuana Act, 2005;
Lynn Pierson Compassionate Use Act, 2005; Medical Therapeutic Use of Cannabis Act,
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2005). Senator Steve Komadina (R) sponsored the Medical Therapeutic Use of
Cannabis Act (2005) which required cannabis to be of pharmaceutical grade in order to
obtain a consistent and regulated dosage. However, smoking of the drug was to be ruled
out. The Compassionate Use Medical Marijuana Act (2005) was sponsored by Sen.
Shannon Robinson (D) and sought to allow people with specific medical conditions to
use cannabis topically, such as in patches and creams. Senator Robinson and Sen.
Komadina’s bills did not contain a medical necessity provision and did not provide for
patients to grow their own cannabis (Compassionate Use Medical Marijuana Act, 2005;
Medical Therapeutic Use of Cannabis Act, 2005). The opposition raised questions over
the sort of message that would be sent out to children if any of the bills were passed
(Baker, 2005).
Governor Richardson, who succeeded Gov. Johnson in 2003, said that if the
House passed a medical cannabis bill, he would sign it. While the pharmaceutical
industry had not been visible active in opposing medical cannabis legislation, the New
Mexican newspaper reported that in 2002 the pharmaceutical industry contributed more
than $97,000 to New Mexico political campaigns, including $40,000 to new Governor
Bill Richardson (Terrell, 2005a). The more visible opposition came from law
enforcement, with Mike Bowen, a lobbyist for police organisations, saying his
organisation would most likely oppose the 2005 medical cannabis bills, mainly because
they were against federal law, and there were not enough controls in them (Terrell,
2005a). It was also noted that the legislative support for medical cannabis appeared to
have decreased since Gov. Johnson was no longer the governor (Terrell, 2005a).
All three medical cannabis bills passed through the Senate with bipartisan
approval, and were sent to the House of Representatives (Terrell, 2005b). Sen.
McSorley’s (D) bill passed on a 27-11 vote; Sen. Komadina’s (R) bill passed on a 29-11
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vote; and Sen. Robinson’s (D) bill was passed on a 31-9 vote (Terrell, 2005b). Two
patients with debilitating medical conditions, Essie Debonet and Erin Armstrong were
constantly present at the House session in order to hear the medical cannabis bills being
discussed (Andersen, 2005). Erin Armstrong, a cancer survivor and the daughter of state
Aging and Long-Term Services secretary, Debbie Armstrong, also spoke in support of
medical cannabis, and described her struggle with cancer and the cost of her treatments
(Massey, 2005; Terrell, 2005a).
The bill introduced by Sen. McSorley, the chairman of the Judicial Committee,
was due to be heard, but was stalled due to a dispute involving an unrelated bill. It was
alleged that Rep. Dan Silva (D) experienced difficulties getting his bill heard in the
Senate Judiciary Committee, and therefore tried to delay the medical cannabis bill
(Terrell, 2005c). McSorley said Silva believed his bill was more important than others,
and said he would not give special consideration to legislation in order to have his own
bill passed. Representative Henry Saavedra (D) carried the bill for McSorley in the
House, but was also a co-sponsor of Silva’s bill (Terrell, 2005c).
This resulted in some controversy, and the bill did not end up passing the House
(Polly, 2005). It was sitting for days on the House calendar, until its supporters
attempted to pass it in the last minutes of the House session (Terrell, 2005d). The bill
was stopped by House Speaker Ben Lujan (D), who said the bill was too controversial,
would need a three-hour debate, and there was not enough time to discuss it before the
session’s end (Polly, 2005; Terrell, 2005d). It was also alleged that Rep. Henry
Saavedra, who carried the bill in the House, asked for it to be passed over (Terrell,
2005d). Reena Szczepanski, director of New Mexico’s DPA, said it was not due to lack
of votes that the bill did not pass, but because it was trapped in the middle of a game.
Szczepanski had been lobbying for the bill during the legislative session and said that
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the legislators were sending a bad message to sick individuals by holding up the bill and
not passing it, and held Rep. Silva responsible for the hold-up (Polly, 2005).
The following year, a new medical cannabis bill was due to be introduced and,
according to Reena Szczepanski, Gov. Richardson received hundreds of letters from
medical cannabis supporters, which the DPA believed made him consider the
importance of the issue (Terrell, 2006a). Governor Richardson also announced that he
would include a medical cannabis bill on his agenda for the 2006 legislative session
(Terrell, 2006a). The governor said that he decided to put the bill on the agenda after
speaking with many sick New Mexican patients. However, before the session started,
House Speaker Rep. Ben Lujan (D) said he asked the governor not to include the bill on
his agenda, as there was not enough time for it to be heard (Terrell, 2006a).
Democratic Sen. Cisco McSorley, who sponsored a failed medical cannabis bill
in 2005, was sponsoring it again in 2006, making it the fifth time the legislature was
considering a medical cannabis bill in six years (Tiffin, 2006). Cancer, glaucoma,
multiple sclerosis, spinal cord injuries, epilepsy and HIV were included in the bill as
debilitating conditions for which qualifying patients may use cannabis (Lynn Pierson
Compassionate Use Act, 2006). The bill also included a provision for licensed growers
certified by the state, who would provide patients with the required cannabis (Lynn
Pierson Compassionate Use Act, 2006). The bill was unanimously passed by the Senate
Public Affairs Committee who heard from patients with debilitating medical conditions
in support of medical cannabis (Baker, 2006; Rubel, 2006; Terrell, 2006b). Erin
Armstrong was also at the hearing and asked the committee to recommend the bill. The
opponents who testified at the hearing were from law-enforcement. Law enforcement
groups voiced their disapproval of the bill, saying it clashed with the federal law and,
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according to some, passing of the bill would have led to an increase in criminal activity
in the state (Tiffin, 2006).
After the bill passed the Senate on a 34-6 vote, it was sent to the House
Agriculture and Water Resources Committee, which had never heard such a bill before,
and was known to be generally disapproving of medical cannabis (Drug Policy Alliance
[DPA], 2007; “New Mexico Medical Marijuana”, 2006). It was alleged by Rep. Joseph
Cervantes (D) that the bill was sent to that specific committee in order to be killed.
According to the media, one of the testimonials that the members of the committee were
reportedly swayed by was that of Errol Chavez, director of the New Mexico High
Intensity Drug Trafficking Area, who opposed the bill and testified that cannabis use
and growth increased in California after its medical cannabis law was passed (“New
Mexico Medical Marijuana”, 2006). After the bill was rejected on a 4-3 vote, the
supporters successfully prompted the House Speaker Lujan (D) to pull it out of the
Agriculture Committee and into the House Judiciary Committee, which subsequently
passed it (DPA, 2007). However, the legislative session ended before the bill could get a
house floor vote (DPA, 2007).
After many failed attempts at passing a medical cannabis bill, attempts were
made again in 2007, the first of which was the Lynn and Erin Compassionate Use Act
(2007a), introduced by Sen. Gerald P. Ortiz y Pino (D). The bill sought to enact and
amend provisions of the Controlled Substances Act, in order to allow medical cannabis
use for alleviating symptoms caused by certain debilitating medical conditions.
Debilitating medical conditions included were cancer; glaucoma; multiple sclerosis;
damage to the nervous tissue of the spinal cord with intractable spasticity; epilepsy;
positive HIV/AIDS status; and any other medical condition as approved by the NMDH.
It also provided for cannabis producers, licensed by the NMDH to produce, possess,
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distribute and dispense cannabis to qualifying patients (Lynn and Erin Compassionate
Use Act, 2007a).
The bill was approved by the Senate, and then sat on the House calendar for six
days before it was heard (Nash, 2007). Opponents said the bill ran contrary to federal
law, with several Republican representatives proposing amendments to it. At first, the
vote on the bill resulted in a tie (Alba, 2007a). However, as three members were absent
from the House chamber, Majority Floor Leader Ken Martinez (D) brought the measure
back for a second vote. In the second round of votes, some of the members changed
their original votes, and the three previously absent lawmakers cast theirs (Alba, 2007a).
Reportedly, the original House vote tied at 33-33, over protests by Rep. Al Park (D) that
his yes vote was not recorded (Baker, 2007a). When the measure was considered again,
it lost when 33 lawmakers voted for it and 36 against (Baker, 2007a).
Representative Larry Larranga (R) spoke in opposition of the bill and said it was
a way for people to obtain illegal drugs and would result in the state losing federal
crime-fighting money. In response, Rep. Antonio Maestas (D), who carried the bill in
the House for Ortiz y Pino (D), said none of the other states with a medical cannabis law
had experienced issues with federal funding (Nash, 2007). Erin Armstrong also spoke to
lawmakers and reporters in support of medical cannabis (Nash, 2007). Despite Ortiz y
Pino’s bill failing to pass the House, Armstrong and other advocates said they would
continue working on medical cannabis measures until one was approved by the
legislature (Nash, 2007). The governor said that he was also meeting with lawmakers in
an effort to bring back the medical cannabis bill, which he believed it was important to
pass (Baker, 2007a).
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After the Senate Bill 238 Lynn and Erin Compassionate Use Act (2007a) was
defeated by a 36-33 margin, it was substituted by Senate Bill 523 (2007). Originally,
Senate Bill 523 was known as the Compassionate Use Medical Marijuana Act and only
focused on topical use of cannabis, such as in ointments and patches. However, after
Senate Bill 238 died on the House floor, Sen. Robinson (D), who sponsored the bill,
agreed for his bill to become a substitute for the Lynn and Erin Compassionate Use Act
(Peacock, 2007). The Senate Bill 523 was now to be known as the Lynn and Erin
Compassionate Use Act. The bill proposed that, due to research showing that cannabis
is effectively used in the treatment of a range of conditions, state law should make a
distinction between the drug’s medical and non-medical use. The medical conditions
specified by the proposed act included one or more of the following: cancer; glaucoma;
multiple sclerosis; damage to the nervous tissue of the spinal cord, with objective
neurological indication of intractable spasticity; epilepsy; positive HIV/AIDS status;
admittance into hospice care; and any other medical condition as approved by the
NMDH (Lynn and Erin Compassionate Use Act, 2007b). In order to qualify for the
program, patients had to be residents of New Mexico and be diagnosed by a medical
practitioner to have one or more of the specified debilitating medical conditions,
including a statement from their practitioner that, in their opinion, the potential health
benefits of using medical cannabis would outweigh the health risks for the patient. The
bill also proposed that a medical board, consisting of seven medical professionals, be
appointed to assist with the program. It also included provisions for a medical necessity
defence, should patients or their caregivers be prosecuted for an offence involving
cannabis (Lynn and Erin Compassionate Use Act, 2007b).
The bill passed the Senate on a 32-3 vote, and cleared the House Judiciary
Committee with a 10-3 vote. Once the bill went to the House, Gov. Richardson said that
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he had spoken to some representatives who had previously voted against medical
cannabis bills, in order to persuade them to change their minds (Peacock, 2007; Terrell,
2007a). According to media reports, Sen. Carol Leavell (R) and Sen. Rod Adair (R)
voiced their disapproval of the bill, suggesting it was hard to understand and sent the
wrong message. District Attorney Matthew Chandler also opposed the bill, and
questioned the necessity of using cannabis as a medicine while, according to him, there
was no research suggesting it was effective for terminally ill patients (Peacock, 2007).
On the other hand, Rep. Keith J. Gardner (R) supported the bill as it was written, and
believed it to be very controlled, with a low margin of error (Peacock, 2007).
After rejecting a medical cannabis bill a week earlier, the House passed the Lynn
and Erin Compassionate Use Act with a 36-31 vote, with the bill set to return to the
Senate for approval of minor amendments (Alba, 2007b; Miles, 2007). The House made
an amendment to the bill to state that medical cannabis cannot be distributed within 300
feet of churches, schools, or day care centres. According to media reports, legislators
raised the same arguments as they did with the previous medical cannabis bill, arguing
that passing of the measure would suggest to children that lawmakers support illegal
drug use (Alba, 2007b). Three representatives, John Heaton (D), James Strickler (R) and
Manuel Herrera (D) questioned the bill’s effectiveness, and suggested it sent the wrong
message to children. In response, Rep. Antonio Maestas, who carried the bill to the
House, said cannabis’ effectiveness has been proven, and patients should have the right
to try it (Miles, 2007). The governor said that he was busy lobbying House members to
vote for the bill, as it provided much needed relief to patients with specific medical
conditions (Alba, 2007b; Miles, 2007).
According to the media, as Gov. Richardson was due to sign the medical
cannabis bill, he said he knew that if he was to run for president his actions could
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become an issue (Baker, 2007b). However, Gov. Richardson stated that signing the bill
would be the right thing to do, as it assisted people in great pain. The article suggested
the White House urged Gov. Richardson not to sign the bill. Thomas Mann, a policy
analyst at the Brooking Institution in Washington, said that signing the bill was not
something that is done to earn great political support, as it was a very controversial issue
(Baker, 2007b). Lonna Atkeson, professor of political science at the University of New
Mexico agreed, and added that she was surprised at the governor’s support of medical
cannabis, as it was a risky move. If he were to sign the bill, Gov. Richardson would be
the first ever presidential candidate to publicly support and sign medical cannabis
legislation (Baker, 2007b).
On April 2, 2007, Gov. Bill Richardson signed the Lynn and Erin
Compassionate Use Act into law, making New Mexico the 12th state to legalise the
medical use of cannabis (Baker, 2007c; Lynn and Erin Compassionate Use Act, 2007).
The law, named in part after Lynn Pierson, a medical cannabis lobbyist who lobbied for
the 1978 medical cannabis research program, took effect on July 1, 2007, and included a
mandate for the NMDH to set up a system to license medical cannabis providers, and
distribute the cannabis to qualified patients itself (Baker, 2007c; Del Mauro, 2007a;
Lynn and Erin Compassionate Use Act, 2007). Its passing was set to make New Mexico
the first state in which the state NMDH distributed cannabis to qualified patients (Del
Mauro, 2007a; MPP, 2013).
Before the bill was passed, Attorney General Gary King voiced his concerns and
suggested that, even with the passing of the state law, cannabis would still be illegal
under federal law, which would leave the state employees involved in the medical
cannabis program with no protection from federal prosecution (Bacon, 2007; Del
Mauro, 2007a). John Walters, the White House drug czar, had reportedly asked Gov.
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Richardson not to sign the medical cannabis bill, and criticised him after he had done
so, as Walters believed the law would worsen New Mexico’s illegal drug use and would
result in the same problems as California had been experiencing. Walters also suggested
Richardson was only trying to get donations from wealthy medical cannabis advocates
for his presidential campaign (Baker, 2007c).
Reena Szczepanski, from the DPA of New Mexico, who worked on getting the
medical cannabis bill passed, said that she believed that Americans would stand behind
Gov. Richardson as he sought the 2008 Democratic nomination, as, according to her,
Americans would stand behind those who believe in providing sick patients with relief
(Baker, 2007c; Parker, 2007). According to the New Mexican newspaper, in 2006 the
DPA contributed $50,000 to Gov. Richardson’s campaign (Del Mauro, 2007a).
Governor Richardson’s campaign reporting documents, which were later brought up by
those opposing medical cannabis, indicated that he received $25, 000 from the DPA
Network on the 20th of July 2006, and on 24th of July 2006 received another $25,000
from George Soros, who has been linked to the DPA (New Mexico Secretary of State,
2007).
The NMDH started accepting applications from medical cannabis patients on
July 1, 2007, in order for them to take part in the medical cannabis program (NMDH,
2007a; Parker, 2007). The law specified medical cannabis required for registered
patients was to be solely obtained from an intrastate source (Lynn and Erin
Compassionate Use Act, 2007). However, despite what was originally believed, Debra
Busmeyer, a spokesperson for the NMDH said patients would have to obtain cannabis
on their own, as the department would not be distributing the drug. The lawenforcement community disagreed with this move, as they believed there would be a
problem due to lack of quality control, and the move was contrary to what was
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originally discussed at the legislative session when the medical cannabis measure was
passed (Del Mauro, 2007b). Reena Szczepanski said the legislation was very specific in
who could obtain medical cannabis, but as the legislation did not specify where the drug
would come from, patients would have to obtain it on their own. Szczepanski also said
that selling the drug from shops would only confuse the issue (Parker, 2007). The
legislation originally established an October 1st deadline for NMDH to form a plan for
distributing medical cannabis to patients (Baker, 2007d; Parker, 2007).
As different legal implications were considered, the NMDH also consulted the
New Mexico Attorney General’s Office to determine the best way to proceed with
medical cannabis distribution and to determine whether its employees could be federally
prosecuted if the program went ahead (Baker, 2007d; NMDH, 2007a). When the bill
was passed, the Attorney General did not support the plan to distribute cannabis (Bacon,
2007). In response to the department’s inquiry as to the best way to proceed with
implementing the second phase of the state law, the Attorney General cautioned that the
NMDH and its employees involved in the medical cannabis program could be
prosecuted under federal law (Baker, 2007e). He also said he would not be authorised to
defend the NMDH or its employees, should prosecution occur (Baker, 2007e).
After receiving the Attorney General’s advice, the NMDH decided they would
not pursue the second part of the law, concerning the dispensing of medical cannabis, as
they did not want to subject the department’s employees to federal prosecution (Del
Mauro, 2007c). It was said that King warned lawmakers during the 2007 legislative
session about putting the NMDH in charge of overseeing cannabis growers and
distributors. Reena Szczepanski said there were other options for production and
distribution entities other than the department, such as private companies or volunteer
groups, but this depended on King’s further legal advice (Del Mauro, 2007c).
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Meanwhile, Gov. Richardson, who was running for the Democratic presidential
nomination, instructed the NMDH to continue planning for the production and
distribution of cannabis by the department, as was originally planned by lawmakers
(“Medical Marijuana: Drug Bust”, 2007).
Before the NMDH decided to allow patients to grow their own cannabis, the
department invited various law-enforcement associations to come to a meeting
discussing how to implement the new law. Reportedly, most law-enforcement
associations refused to participate. Director of the State Sheriffs’ and Police
Association, Jim Burelson, said that, like most other law enforcement associations, they
refused to participate in the NMDH initiated meetings to discuss how to implement the
new law for fear they would be legally implicated in distribution of a controlled
substance (Del Mauro, 2007b). In response to criticism, Dr. Steve Jenison, medical
director of New Mexico’s Medical Cannabis Program, said that even if the measure
allowing state-licensed production and distribution centres was put in place, patients
would still be allowed to grow their own cannabis plants (Del Mauro, 2007b).
On August 17, 2007, Gov. Richardson sent a letter to President Bush asking him
to end the priority placed on arresting and prosecuting state workers involved in medical
cannabis programs, as well as patients using the drug (Gallegos, 2007). He said the
federal government should be trying to deal with “real criminals” and not people in pain
and those trying to help them. The press release alleged that the Bush administration
earlier in the year threatened to target New Mexico state officials with federal
prosecution, if the proposed medical cannabis bill was passed by the legislature.
According to reports, Gov. Richardson promised to defy the federal government and use
available state resources to fully implement the state medical cannabis law (Gallegos,
2007). It was reported in the media that, in the states with medical cannabis laws, eight
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Democratic presidential candidates pledged to stop federal raids on patients (Terrell,
2007b). Santa Fe County Commissioner Harry Montoya, a Democrat, said he was
breaking party lines by opposing the medical law, which he had publicly opposed since
1997. He also mentioned it was not a secret that Gov. Richardson received $50, 000
from the DPA (Haywood, 2007).
In July 2007, eight medical professionals were appointed to a Medical Advisory
Committee, whose purpose was to help guide the new Medical Cannabis Program by
advising the NMDH on rules governing the program (“Local Doctors”, 2007; NMDH,
2007b). The committee was also responsible for holding public hearings twice a year,
where they evaluate patients’ petitions to add conditions to the list of qualifying medical
conditions (NMDH, 2007b). However, by September 2007, it was still unclear how
registered medical cannabis patients were going to obtain the drug, which they could
now legally use (Vorenberg, 2007). The legislature told the NMDH to find a way to
produce and distribute medical cannabis; however, as they were later advised by the
Attorney General Gary King, doing so would subject the department’s employees to
federal prosecution. According to reports, the legislature wanted patients to not have to
grow their own cannabis or have to go to drug dealers in order to obtain the drug.
Despite some of the obstacles, Alfredo Vigil, secretary of the NMDH, said the
department would continue the patient certification process for as long as possible. He
also said the distributions system idea was originally a way to break new ground for
medical cannabis, but turned out to be impossible to put into place. According to Vigil,
the only way for the department to distribute cannabis would be for the Congress to
consider changing the federal law to allow for medical cannabis production (Vorenberg,
2007).
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After the law took effect on July 1, 2007, by the end of September 2007, 50
patients with debilitating medical conditions had qualified for the program (Del Mauro,
2007d). New rules for the program were proposed, and the public had a chance to
express their views at a hearing organised by the NMDH (Del Mauro, 2007d). The first
rule concerned the patient identification card system. Under a temporary provision,
expiring in October, qualifying patients and their caregivers were allowed to possess up
to six ounces of cannabis, four hemp plants and three seedlings. The proposed rules
aimed to change that amount to six ounces of cannabis, four hemp plants and four
seedlings. The other rule concerned the Medical Advisory Board, and aimed to allow
the board to approve other medical conditions to be included in the qualifying
guidelines, with the health secretary having the final say (Del Mauro, 2007d).
The NMDH’s Medical Advisory Board held a public hearing in Albuquerque to
discuss adding new debilitating medical conditions to the medical cannabis program’s
list (“State to Hold Medical”, 2008). The department had already started receiving
petitions to add medical conditions such as Crohn’s disease and hepatitis C to the list
(“State to Hold Medical”, 2008). It took until January 2009 for the NMDH to finalise
regulations for the registry identification cards and a production/distribution system for
its medical cannabis program (New Mexico Register, 2008; “State Finalizes Medical”,
2009). After the amendments in January 2009 passed and more were added in February
of the same year, the following are the debilitating medical conditions qualified for the
NM medical cannabis program: severe chronic pain; painful peripheral neuropathy;
intractable nausea/vomiting; severe anorexia/cachexia; Hepatitis C infection; Crohn’s
disease; Post-traumatic Stress Disorder; Amyotrophic Lateral Sclerosis (Lou Gehrig’s
disease); cancer; glaucoma; multiple sclerosis; damage to the nervous tissue of the

Medical Cannabis in the United States

180

spinal cord with intractable spasticity; epilepsy; HIV/AIDS; and hospice patients
(NMDH, 2009).
By November 2008, there were approximately 200 medical cannabis users in
New Mexico (Riley, 2008). Reena Szczepanski said it had been difficult to make
medical cannabis legal and accessible to patients. However, she said the NMDH was
discussing a proposal to license patients and non-profit organisations for cannabis
production and distribution. Szczepanski said the DPA was in support of the
regulations but wanted to add another provision to the law (Riley, 2008). This would
ensure that patients living in apartment buildings in a town with no non-profit medical
cannabis distributors could have their carer grow the drug for them (Riley, 2008).
When demand for medical cannabis outpaced the supply, patients complained
that the NMDH wasn’t approving producers fast enough (Hamming-Green, 2010;
Haywood, 2011). Patients also complained that they had trouble renewing their
identification cards, issued yearly. As a result, it was reported that some patients were
buying cannabis from unregulated sources (Hamming-Green, 2010; Major Holmes,
2010). Deborah Busemeyer, communications director for the NMDH, said the problems
were arising due to the NMDH’s rigorous screening of applicants and a long list of
regulations (Hamming-Green, 2010; Korte, 2009). She also said that the process was
slow because cannabis is illegal under federal law and therefore needed more
consideration (Hamming-Green, 2010).
Despite the issues, by October 2011 there were 5,495 enrolments in the medical
cannabis program, out of which 4,310 patients were active at that point (NMDH, 2011).
There were also 25 non-profit producers licensed to sell cannabis as part of the program.
The top five conditions of patient enrolment in the program, as reported by the NMDH,
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were post-traumatic stress disorder, chronic pain, cancer, painful peripheral neuropathy,
and HIV/AIDS. The July-September 2011 quarterly data also showed that $80,887.59 in
taxes was collected during that period (NMDH, 2011).
A 2011 newspaper article suggested that the state’s medical cannabis program
was used as a model for other states (Haywood, 2011). Tamar Todd, a staff attorney for
the DPA, said the combination of patient-grown and state-regulated dispensaries was
ideal for patients. Todd said that state-approved dispensaries provided more assurance
for patients than buying the drug from unregulated sources. Additionally, Catherine
Torres, secretary of the NMDH, stated that the department planned to issue a request for
proposals for a system testing the quality of cannabis supplied to patients (Haywood,
2011).
Illinois
Illinois is one of the states that has considered but not passed a medical cannabis
law (MPP, 2013). 8 It is also a state with a ballot initiative process in its constitution, but
initiatives rarely appear on the state ballot due to a limited and difficult to implement
process (IRI, 2009). Further, questions related to medical cannabis cannot be placed on
the ballot in Illinois, as the constitution only allows for ballot initiatives changing the
function or structure of the government (MPP, 2013). While there have been attempts to
pass a medical cannabis law in Illinois, at the time of writing this thesis, no such bills
were passed in the state. The following section will chronologically review the history
of medical cannabis in Illinois (see Figure 4) and discuss the attempts made at passing
medical cannabis legislation.

8

Illinois passed a medical cannabis law on August 1, 2013, after this thesis was submitted.

Medical Cannabis in the United States

1978

2001

2004

2005

2006

182

• Illinois passes a medical cannabis therapeutic research law
• Bill's sponsor says that there is evidence cannabis is effective in reducing eye pressure for
glaucoma patients and relieving negative chemotherapy side-effects
• Bill's co-sponsor is Sen. Sangmeister, a cancer patient
• The law becomes ineffective due to heated political debate and restrictions placed on the
law

• Brenda Kratovil seeks to use a medical necessity defence at her trial, drawing upon the 1978
law

• Court finds that Kratovil had other alternatives to cannabis and was not entitled to a
medical necessity defence
• First attempt at passing medical cannabis legislation with Medical Cannabis Act
• Medical cannabis bill draws media attention and opponents and proponents start speaking
out
• Representative McKeon, who sponsored the bill, who suffered from HIV and nausea for 20
years, sees cannabis as a cure for his pain
• City activity- Chicago Mayor supports issuing fines to individuals found to be in posession
of small amounts of cannabis instead of filing criminal charges
• Dr Barthwell from the ONDCP tours the state speaking against medical cannabis

• The Medical Cannabis Act dies at the Health Care Availability and Access committee
without being voted on
• Medical Cannabis Act again filed by Rep. McKeon
• Dr Bartwell holds seminars speaking against medical cannabis
• Medical cannabis patients testify in favour of the medical cannabis bill
• ONDCP director John Walters arrives in Illinois to testify against medical cannabis
legislation
• Law enforcement groups oppose the medical cannabis bill
• The bill gets rejected by the Human Services committee

• Michael Steelman of NORML says that medical cannabis legislation may be more than a
decade away in the state
• New Medical Cannabis Act introduced in the Senate
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• Increase in media reports on medical cannabis
• Medical cannabis bill introduced in Senate by Sen. Cullerton
• Medical Marijuana Policy Advocacy Project (MMPAP) speak in support of medical
cannabis
• Reports that church leaders were speaking out in support of medical cannabis
• Small step towards change- passing of an ordinance change in Peoria Heights to give police
officers an option of treating posession of small amounts of cannabis as a violation and
issuing a fine
• Medical cannabis documentary by Jed Riffe screened in the Southern Illinois University
Carbondale Student Center
• Dan Linn from NORML active in responding to opposition
• Two medical cannabis bills introduced, one in the House of Representatives and one in the
Senate
• Survey shows that 68% of surveyed Illinois voters support legalising medical cannabis use

• Barack Obama assuming office as the new U.S. President sparks optimism in medical
cannabis supporters
• City activity- Springfield changes its ordinance to allow cannabis posession of less than
2.5g to be prosecuted as an ordinance violation rather than criminal penalty
• Compassionate Use of Medical Cannabis Pilot Program bill introduced in Senate, a
companion bill introduced in the House of Representatives
• Cook County Board votes in favour of passing a change in the city ordinance which allows
police officers to issue fines to those in possession of small amounts of cannabis

• Politicians from both parties indicate that they would consider allowing cannabis for
medical purposes
• Suggestions that some lawmakers did not want to make politically risky votes and were
worried about how they were portrayed
• Compassionate Use of Medical Cannabis Pilot Program bill dies at House of
Representatives

• Compassionate Use of Medical Cannabis Pilot Program re-filed, subsequently died on the
House floor in 2013

Figure 4. Time chart of medical cannabis history in Illinois.
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In 1978, along with 34 other states, Illinois passed a medical cannabis
therapeutic research law which allowed physicians to administer cannabis to glaucoma
and cancer chemotherapy patients (Lichtenberg, 2009). According to the Alliance for
Cannabis Therapeutics (1999), the Illinois medical cannabis therapeutic research bill
was passed in September 1978, on a 140-16 House vote, and a 45-4 Senate vote. Prior
to the bill, Illinois law only had provisions allowing limited use of cannabis for persons
conducting research (Lichtenberg, 2009). The bill’s sponsor was Rep. Joseph B.
Ebbesen (R), who said there was evidence that cannabis was effective in reducing eye
pressure for glaucoma patients, and in relieving negative chemotherapy side-effects
(“Medicinal Pot Use Legal”, 1978). Senator George Sangmeister (D), the bill’s cosponsor who was diagnosed with cancer prior to his involvement with the bill and used
cannabis to help with his treatment, played a key role in passing the bill (Ciccone,
1978). Governor James R. Thompson (R) showed his support for the bill as he signed it
into law, calling it a “step forward in the practice of medicine”. He also asserted that the
bill was not a step towards general cannabis legalisation, and said that he did not want
children to experiment with the drug (“Marijuana Approved for Glaucoma”, 1978). The
bill was due to take effect on January 1, 1979 (“Marijuana Approved for Glaucoma”,
1978). According to a statement made by Sen. Cullerton (D) in 2007, the 1978 Illinois
medical cannabis law became ineffective due to heated political debate at the time and
restrictions placed on the law itself (Huffstutter, 2007).
The Illinois Cannabis Control Act (2005) still contains a provision allowing the
Department of Alcohol and Substance Abuse to authorise (a) possession, (b) production,
(c) manufacture, and (d) delivery of cannabis-containing substances by individuals
taking part in a research program. Under the act, if an individual’s doctor authorised
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them to participate in the research program by certifying such participation was
medically necessary for the treatment of glaucoma or side effects of chemotherapy or
radiation, that patient was then exempt from state-level prosecution. Registered medical
professionals were allowed to apply for federal registration to conduct a medical
cannabis research program in a treatment setting, with written permission from State
Police (Cannabis Control Act, 2005). However, the program is ineffective as the law
requires the participants to be registered with the federal government in order for the
government to supply medical cannabis, and the drug is illegal at the federal level, with
the exception of patients receiving it through the NIDA as part of medicinal research
(Lichtenberg, 2009; Werner, 2001).
Since the law was passed, no person had participated in using cannabis as a
medicine under its provisions, nor was any cannabis obtained from the federal
government for therapeutic research purposes (Lichtenberg, 2009). According to Bryan
Brickner from Illinois NORML, the “War on Drugs” was responsible for the failure of
the Illinois program by allocating authority for the program to the Illinois Department of
Alcohol and Substance Abuse (M. Harris, 2003). Brickner thought that the move
resulted in medical cannabis research falling under “substance abuse”, and therefore
being illegal (M. Harris, 2003).
The issue of medical cannabis drew public attention in 2001, when the house of
Brenda Kratovil in Waukegan, Illinois was searched by the Metropolitan Enforcement
Group, after a neighbour reported seeing cannabis plants in her backyard (M. Harris,
2003). The search was allegedly conducted without a warrant and three months later
resulted in Kratovil being charged with cannabis possession. Kratovil claimed that
cannabis helped her with glaucoma, which she had suffered for over 20 years. She was
also legally blind and diagnosed with multiple sclerosis. Kratovil’s lawyer, David
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Stepanich, sought to use a medical necessity defence at her trial, drawing upon the 1978
Illinois medical cannabis research law (Cannabis Control Act, 2005; M. Harris, 2003;
People v. Kratovil, 2004).
On June 4, 2003 Kratovil’s doctor Michael Savitt testified that Kratovil’s
glaucoma case was severe and that the best treatment option for her would be laser
surgery (People v. Kratovil, 2004). He also testified that the benefits of cannabis in
glaucoma treatment are only temporary and that there was not significant evidence for
its effectiveness in relation to glaucoma (People v. Kratovil, 2004). The court found that
Kratovil had other alternatives to cannabis for treating her condition, and was therefore
not justified in breaking the law or in using the defence (People v. Kratovil, 2004).
Kratovil claimed that under section 11 of the Cannabis Control Act, she had the right to
possess cannabis (Cannabis Control Act, 2005; People v. Kratovil, 2004). The court,
however, found that she was not entitled to a medical necessity defence under the act as
(a) she did not participate in medical research; (b) her doctor was not involved in
medical research, and (c) no authorisation was obtained from the Illinois Department of
Health (IDOH). Kratovil was found guilty of unlawful cannabis possession and
sentenced to 12 months’ conditional discharge and 30 hours of community service
(People v. Kratovil, 2004).
Following Kratovil’s trial, the first attempt at passing medical cannabis
legislation in Illinois was the Medical Cannabis Act (2004a). It was introduced in the
House of Representatives in February of 2004 by Rep. Angelo Saviano (R), was
sponsored by Rep. Larry McKeon (D), and co-sponsored by Rep. Susana Mendoza (D)
(Medical Cannabis Act, 2004a). The bill sought to amend the Cannabis Control Act in
order to allow individuals diagnosed with a debilitating medical condition to use
cannabis for medical purposes. Debilitating medical conditions specified by the bill
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included cancer, glaucoma, HIV/AIDS, cachexia or wasting syndrome, severe pain,
severe nausea, seizures including epilepsy, severe and persistent muscle spasms
including those characteristic of multiple sclerosis or Crohn’s disease, and any other
condition approved by the IDOH. The bill would have allowed patients and their
primary caregiver to possess up to six cannabis plants and one ounce of dried, useable
cannabis, without state-level prosecution (Medical Cannabis Act, 2004a).
The first medical cannabis bill received media attention, and both opponents and
proponents spoke out. While critics said there were other drugs available in place of
cannabis, Bruce Mirken from the MPP maintained cannabis was effective in assisting
some patients with specific debilitating medical conditions, such as the side effects of
cancer therapy or AIDS medication (McKinney, 2004). Opponents also claimed the bill
would be hard to enforce and would increase drug use (Griffy, 2004). Representative
Patricia Bellock (R) spoke against the bill and stated that it was not up to the electorate
or the General Assembly to decide what is considered medicine, but up to professionals
(S. Miller, 2004). Deputy Director of the White House’s ONDCP, Dr. Andrea
Barthwell, also spoke in Springfield against the proposed medical cannabis legislation
(McKinney, 2004). On her tour of Illinois Dr. Barthwell said there were no proven
medical benefits for cannabis, only short and long term risks. She also said that medical
cannabis would (a) affect the whole society; (b) would make the drug available to
children; and (c) would result in an increase in drug addiction (Griffy, 2004).
Support for medical cannabis legislation came from Richard J. Rawlings from
the Illinois Marijuana Party (IMP) who said he believed doctors should not be
criminally prosecuted for prescribing cannabis to their patients if they believe it to be
necessary (Rawlings, 2004). Rawlings said that prohibition, not cannabis, was a
gateway to use as it resulted in a rise in all illegal drug use. However, Greg Sullivan,
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executive director of the Illinois Sheriff’s Association, thought that such a law would
increase the illegal flow of cannabis (Rawlings, 2004).
The bill was assigned to the Health Care Availability and Access committee,
where it died in January of 2005 without being voted on (Illinois General Assembly,
n.d.-d). An identical bill was introduced in the Senate in February 2004 by Sen. Carol
Ronen, but it also failed to pass (Medical Cannabis Act, 2004b). It was expected that the
medical cannabis bill would be introduced again in the next legislative session (A. L.
Smith, 2004). The bill’s sponsor Rep. Larry McKeon (D) said he would not give up on
the bill despite opposition in the legislature (S. Miller, 2004). Representative McKeon
suffered from HIV and nausea for 20 years and saw cannabis as a cure for his pain (S.
Miller, 2004). He said that the legislation was not about expanding the drug’s
availability on the street, but helping sick individuals (S. Miller, 2004).
In January 2005 a Medical Cannabis Act was again filed by Rep. Larry McKeon
(D), this time with changes in the amount of cannabis an individual was allowed to
possess (Illinois General Assembly, n.d.-b). The bill also sought to allow non-profit
organisations to grow limited amounts of cannabis for registered patients (Illinois
General Assembly, n.d.-b). When the bill was introduced, Dr. Barthwell was touring 18
Illinois cities holding seminars opposing cannabis legalisation, including medical
cannabis (Bowen, 2005). Representative McKeon said that he believed Barthwell’s
seminars were a smear campaign against his medical cannabis proposal and challenged
Dr. Barthwell to a public debate on the issue (Massingale, 2005). McKeon’s debate
challenge was refused by Dr. Barthwell, who said she did not engage in “street theatre”
(Massingale, 2005). At the same time it was reported in the media that Dr. Barthwell
was considering a run for the U.S. Senate, representing Illinois (Hahn, 2005).
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Richard Rawlings from the IMP suggested that Dr. Barthwell was spreading
drug war propaganda (Rawlings, 2005). He said that drug prohibition did not work and
that the government had to focus on “harder” drugs rather than cannabis, while
organisations such as the MPP and the NORML were trying to change unfair laws
(Rawlings, 2005). Barthwell denied that her Illinois tour was related to the introduction
of a medical cannabis bill in the state but said that there was no “compelling” scientific
or medical evidence for cannabis’ effectiveness. Barthwell also said that while she was
compassionate to sick individuals, she believed cannabis did more harm than good
(Bowen, 2005). Bruce Mirken from the MPP disagreed with Barthwell and said many
things she was stating were not true. He opposed her claims and expressed his support
for Rep. McKeon’s bill, while adding that the FDA had no role in regulating personal
use of a drug (Bowen, 2005).
The start of 2006 saw a new medical cannabis bill introduced in the Senate by
Sen. John Cullerton (D) (Medical Cannabis Act, 2006). The bill sought to allow
individuals diagnosed by their doctor as having a debilitating medical condition and
their caregivers to legally possess up to 12 cannabis plants and two and a half ounces of
dried, useable cannabis (Medical Cannabis Act, 2006). The bill was assigned to the
Health & Human Services Committee, where it died in January of 2007 (Illinois
General Assembly, n.d.-h). A newspaper article suggested that the medical cannabis
debate was only getting started in Southern Illinois (Morelli, 2006). However, Michael
Steelman of the NORML said that medical cannabis legislation may be more than a
decade away in the state. Steelman said that while there was some support in the
legislature, people were generally unwilling to talk about the medical cannabis issue and
were not progressive (Morelli, 2006).
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The year 2007 saw an increase of media articles on medical cannabis and
suggestions that the federal government should not waste tax dollars on failed policies
and should allow more research into medical cannabis if they claim not enough
scientific evidence on the drug’s medicinal effectiveness was available (Sharpe, 2007;
“Truth and Medical Marijuana”, 2007). In February of 2007, a new medical cannabis
bill was introduced by Sen. John Cullerton (D) (S.B. 0650, 2007). It sought to allow
individuals diagnosed with a specific debilitating medical condition and their caregivers
to legally possess no more than twelve cannabis plants and two and a half ounces of
useable cannabis (S.B. 0650, 2007). The bill was assigned to the Public Health
Committee where it passed on a 6-4 vote in March 2007 (Illinois General Assembly,
n.d.-f). However, the bill died on the Senate floor on a 29-22 vote in May of the same
year (Illinois General Assembly, n.d.-f). Senator Cullerton (D) said that he was
disappointed the bill was not passed as it was overwhelmingly supported in the
community (Potter, 2007).
In March of 2007, Dr. David Ostrow, co-founder of the Howard Brown Health
Research Center of Chicago and founder of the Medical Marijuana Policy Advocacy
Project (MMPAP) said that there was significant evidence for the effectiveness of
cannabis in the treatment of a number of debilitating medical conditions, including
HIV/AIDS (Ostrow, 2007). An increase in religious denominations speaking out in
favour of medical cannabis was also observed in 2007. It was reported that dozens of
pastors and church leaders in Illinois spoke out in support of medical cannabis,
suggesting that lawmakers had a moral responsibility to allow seriously ill patients to
use medical cannabis (Huffstutter, 2007). They sent an email to Illinois senators in
March asking them to remove criminal sanctions from doctors recommending cannabis
to patients and from patients using cannabis for debilitating medical conditions. They
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also questioned whether it should be up to the government to decide on medical issues
or up to those in research and medical fields (Huffstutter, 2007). Meanwhile, Calvina L.
Fay, Executive Director of the Drug Free America Foundation (DFAF), a national drug
policy group, disagreed with the medical cannabis legislation and said that religious
leaders could not necessarily judge an issue such as medical cannabis (Huffstutter,
2007).
In November of 2007, a documentary on medical cannabis by Jed Riffe screened
in the Southern Illinois University Carbondale Student Center (Rodriguez, 2007). The
documentary followed patients who used cannabis to help with their medical conditions
as well as parents who had lost their children to addiction, as Riffe said he believed in
showing both sides of the argument. Dan Bernath, assistant director of communications
for the MPP, supported the documentary and said it was a good way to start a discussion
on the topic (Rodriguez, 2007).
In February 2008 one medical cannabis bill was introduced in the House of
Representatives and one in the Senate (Alternative Treatment Act, 2008; Medical
Marijuana Pilot Program, 2008). A Medical Marijuana Pilot Program (2008) bill was
introduced in the Senate by Sen. John J. Cullerton (D) and it sought to allow patients
diagnosed by their doctor as having a debilitating medical condition to obtain an IDOHissued identification card. The card would then allow the patients and their caregivers to
possess no more than 12 cannabis plants and two and a half ounces of dried, useable
cannabis. The bill was referred to the Public Health Committee which amended it to
include a provision stating that qualified patients in possession of allowed amounts of
cannabis, their caregivers and physicians would not be subject to prosecution (Illinois
General Assembly, n.d.-i). The bill passed the committee and was sent to the senate
floor. The second amendment came in the Senate in November 2008, and added a
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sunset clause to the bill which meant it would expire three years after taking effect. The
amendment also changed the maximum number of plants allowed to be in patient’s
possession to seven. However, the bill died in the Public Health Committee in January
of 2009 (Illinois General Assembly, n.d.-i). The second bill was introduced in the House
by Rep. Angelo Saviano (R) and was the same as the bill introduced in the Senate
(Alternative Treatment Act, 2008). It was assigned to the Health Care Availability and
Access Committee on 11th March of 2008 where it was amended (Illinois General
Assembly, n.d.-e). However the bill failed to pass as amended on a 9-3 vote and
subsequently died in committee (Illinois General Assembly, n.d.-e).
Prior to the bills’ failure, Sen. Cullerton said his bill was about preventing
patients from suffering and not about the law being abused to obtain cannabis
(Mehrotra, 2008). However, Sen. Dale Righter (R) disagreed and said medical cannabis
legalisation was a bad idea (Mehrotra, 2008). Laimutis Nargelenas, director of the
Illinois Association of Chiefs of Police, said there were better ways of legalising
cannabis than using sick people as a cover up for the drug’s legalisation (Mehrotra,
2008). Nargelenas said he had no objections to medical cannabis but believed those
attempting to legalise the drug for general use were hiding behind sick people and
medical cannabis (Radosevic II, 2008). He also mentioned that the measure sent a
mixed message to children. According to reports, the Illinois State Police opposed the
bill as it believed its wording would create a loophole allowing motorists to drive while
under the influence of cannabis (Radosevic II, 2008).
Dan Linn, from the NORML, was very vocal throughout 2007, writing
numerous articles to the state newspapers in favour of legalising cannabis, as well as
responding to opposition arguments. He also spoke in favour of general cannabis
legalisation and suggested taxation and regulation of the drug (Linn, 2008a; Linn,
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2008b; Linn, 2008c; Linn, 2008d; Linn, 2008e). Linn said the move would raise
revenue for the government and would regulate the market (Linn, 2008b). He also
maintained that it was cruel to keep sick people away from something that could help
them ease their suffering and that studies had shown cannabis was not a ‘gateway drug’
(Linn, 2008c). In November of 2008, Linn said that Illinois made a lot of progress
during the 2008 legislative session (Linn, 2008f). He said that Illinois needed a medical
cannabis law and that the decision of what medicine is the best for an illness should be
left to the patient and their doctors, not law enforcement personnel (Linn, 2008f). He
urged the lawmakers to pass Sen. Cullerton’s bill as cannabis was a safe, natural
medicine, which doctors should be able to recommend to their patients (Linn, 2008g).
With an increase in individuals and organisations voicing their support for
medical cannabis legislation, a survey was conducted by Mason-Dixon Polling and
Research Inc. in 2008 (Radosevic II, 2008). It found that 68 percent of 625 registered
Illinois voters surveyed favoured legalising medical cannabis use by seriously or
terminally ill patients (Radosevic II, 2008). The results also showed that 49 percent of
respondents would be more likely to vote for their state legislators if they supported and
voted for a medical cannabis measure (MPP, 2008). The MPP initiated the survey and
its spokesman, Dan Bernath, said the results were not surprising as the issue of medical
cannabis was becoming more of a health issue rather than a political one (Radosevic II,
2008). Also sparking optimism in medical cannabis supporters was seeing Barack
Obama assume office in 2009 as the new U.S. President. Medical cannabis advocates
such as Dan Linn hoped this would lead to a change in medical cannabis laws (Linn,
2009a).
New attempts. On 11th February 2009, Sen. William R. Haine (D) introduced
the Compassionate Use of Medical Cannabis Pilot Program Act (2009a) which sought
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to enable those diagnosed by their doctors as having a debilitating medical condition to
obtain an identification card from the IDOH. The card was to enable the holder and their
caregiver to possess no more than seven cannabis plants and two ounces of useable
dried cannabis without prosecution at the state level. The bill specified that a distinction
would be made between the medical and non-medical use of cannabis by the State in
order to protect patients with debilitating medical conditions. Some of the debilitating
conditions specified by the bill included glaucoma, HIV/AIDS, epilepsy and other
ailments. Consistent with the amendment made to the 2008 bill, Sen. Haine’s bill
included a sunset clause stating the act would expire after three years from the day it
took effect (Compassionate Use of Medical Cannabis Pilot Program Act, 2009a).
Senator Haine was a former state’s attorney and it was believed by some that he could
better address the issues raised by law enforcement regarding medical cannabis
(Colindres, 2009). The media also speculated that because Sen. John Cullerton (D), who
had sponsored a medical cannabis bill previously, became the Senate president, the
medical cannabis bills might pass through the Senate more easily as a result of Sen.
Cullerton’s role (Colindres, 2009).
The bill’s supporters claimed its purpose was to help the seriously ill (Colindres,
2009). Dan Linn said that it was trying to protect those using cannabis with their
doctor’s recommendation and for medical purposes (Colindres, 2009; Nave, 2009).
Speaking in opposition, Laimutis Nargelenas said the law enforcement community had
compassion towards very sick individuals, but that those who were trying to get high
and were not seriously ill could abuse the medical cannabis law. Nargelenas said that
calling cannabis a medicine was sending a bad message to children (Colindres, 2009).
On 20th February 2009, a companion bill to Sen. Haine’s (D) Compassionate
Use of Medical Cannabis Pilot Program Act, sponsored by Reps. Lou Lang (D) and
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Angelo Saviano (R), was introduced in the House (Compassionate Use of Medical
Cannabis Pilot Program Act, 2009b). The bill sought to allow patients diagnosed by
their doctor as having a debilitating medical condition to obtain an identification card
from the IDOH, entitling them to possess medical cannabis without state-level
prosecution. The bill would allow patients and their primary caregivers to possess up to
seven cannabis plants and two ounces of dried, useable cannabis. It also included a
provisional clause which specified the act would end after three years of taking effect
(Compassionate Use of Medical Cannabis Pilot Program Act, 2009b). The bill’s
sponsor, Rep. Lou Lang (D), said people were suffering needlessly while cannabis had
the potential to ease their pain (Wills & Schott, 2009). He stated that a medical cannabis
bill was a difficult one to pass, even with a three year sunset clause (Wills & Schott,
2009). The bill was assigned to the Human Services Committee in February where it
was passed on a 4-3 vote (Illinois General Assembly, n.d.-c). It was then sent to the
House floor, from which it was re-referred to the Rules Committee. The bill died in
House in 2011, without ever being called for a vote (Illinois General Assembly, n.d.-c).
Speaking in opposition to medical cannabis, Rep. Patricia Bellock (R) said that
the bill could be misused by those who did not have a debilitating medical condition
(Wills & Schott, 2009). She also wondered whether the bill would open the door for
general cannabis legalisation in Illinois (Wills & Schott, 2009). Representative Robert
Pritchard (R) said he voted against the legislation, as he believed it was not a pilot
program but an experiment which could result in places selling cannabis without
regulation (Wills & Schott, 2009). Senator Chris Lauzen (R) spoke against the bill, but
said that as he aged he was more conflicted about it (Bonner, 2009). In his opinion,
Marinol was effective and already available in place of cannabis. Raising a common
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issue, Rep. Kay Hatcher (R) said the Illinois bill was loosely written and would send a
wrong message to children (Bonner, 2009; Griffith, 2009b).
Opponents of the medical cannabis legislation were also speaking out against
several pro-medical cannabis advertisements produced by the MPP (Griffith, 2009b;
MPP, 2013). Dr. Andrea Barthwell, by now chief executive officer of the Human
Resource Development Institute (HRDI), said the advertisements were spreading
misinformation and that the health and welfare of children as well as community safety
would be affected as a result. Judy Kreamer, president of Educating Voices, said her
organisation’s efforts to oppose medical cannabis could not match those of the MPP.
The television commercials were introduced in April and ran in Chicago, Peoria, and
the Decatur/Springfield/Champaign areas. They featured testimonials from two Illinois
medical cannabis patients, Lisa Lange Van Camp and Lucie Macfarlane (MPP, 2013).
Senator Haine said he hoped the lawmakers would realise there were many patients who
would benefit from medical cannabis legislation. He also said the introduced legislation
included many safeguards and differed from California’s in order to avoid problems
experienced by that state. In response to opponents’ claims that cannabis was a gateway
drug, Sen. Haine said they should read his bill, as most of those who would be using
medical cannabis were people who were dying (Griffith, 2009b).
Senator Haine’s bill was assigned to the Public Health Committee in February of
2009 where it was passed on a 6-2 vote (Illinois General Assembly, n.d.-g; M. Thomas,
2009). In May of 2009, the Senate passed the Compassionate Use of Medical Cannabis
Pilot Program Act by a vote of 30-28. The bill was then sent to the House and assigned
to the Human Services Committee, which passed it on a 4-3 vote in May of 2009.
Senator Haine (D) said it was an important step for those who were suffering, and who
relied on medical cannabis (Griffith, 2009a). In October 2009 the bill was waiting for its
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final reading and a vote on the House floor, and was given a final action deadline of 30th
November 2009 (Illinois General Assembly, n.d.-g). Discouragingly for the supporters,
Rep. Lou Lang (D), who previously sponsored a medical cannabis bill which died in the
House, said he was unsure how far any medical cannabis measure would go in the
House of Representatives (“Senate Approves Medical Marijuana”, 2009).
The law enforcement agencies maintained their opposition to medical cannabis
(Griffith, 2009c). Madison County Sheriff Robert Hertz said he could not speak on
behalf of all law enforcement but was personally against the bill. Hertz said he worried
cannabis would be hard to control once it was legalised for medical purposes. He
questioned whether, if cannabis was legalised, cocaine and methamphetamine would be
next. Sen. Haine (D), however, said he believed in the bill and the positive impact it
could have on people, and that received more letters for the bill than against it.
However, he admitted that, overall, he did not receive a lot of mail on the subject, and
interpreted this as people not caring about the issue (Griffith, 2009c). Reportedly, Haine
also stated that he worried that the legislation would send a wrong message to children,
which is why most people would not be supportive of it. Despite this, he said no one
should live in pain (Griffith, 2009c).
While the Compassionate Use of Medical Cannabis Pilot Program Act passed
two House committees, in April 2010 it had still not been brought up for a House vote
(Illinois General Assembly, n.d.-c). Representative Lang (D) said that some officials
chose to vote against it and their own beliefs for political reasons (Thompson, 2010). He
said that he had to be careful when to put the bill to a vote because he could not afford it
to fail, as many legislators would only vote for such a bill once. Because he believed
people were scared of problems resulting from a medical cannabis law, Lang said that
he made the bill controlled and restrictive. Senator Linda Holmes (D) said that she
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voted against the 2008 medical cannabis bill because she was up for re-election and did
not want to be seen as a supporter of drugs. In May 2009, however, she voted “yes” on
the medical cannabis bill and said the reaction of her constituents was more positive
than negative (Thompson, 2010).
In 2010, news reports indicated that politicians from both parties said that they
would consider allowing cannabis for medical purposes (Frick Carlman, 2010;
O'Connor, 2010). Some, like Sen. Linda Holmes (D), had personal reasons for
supporting the bill. Senator Holmes, one of 12 sponsors of the medical cannabis bill and
an MS sufferer, said she supported medical cannabis legislation because it could help
bring MS sufferers relief from pain and spasticity and stimulate appetite (O'Connor,
2010). However, there were also those who believed that medical cannabis legalisation
would lead to general legalisation of the drug (Frick Carlman, 2010; O'Connor, 2010).
Overall, 2010 saw the debate continue, with opponents claiming that cannabis is a cover
for other illegal activity and proponents suggesting that, apart from medical benefits,
cannabis was a safe drug, especially when compared to other drugs it replaced. There
were also suggestions made by the proponents that medical cannabis legislation would
generate tax revenue for the state (D. Miller, 2010).
In April 2010, Rep. Lang (D) announced to the media that he was short of the 60
votes needed for the bill’s approval in the House of Representatives (Patterson, 2010).
He said he was told by some members that they hoped the bill would pass, but they did
not plan on voting for it. It was suggested that some lawmakers did not want to make
politically risky votes and were worried about how they were portrayed (Patterson,
2010). As a result, Lang said he would not call for a vote until he knew that the measure
would pass (Olsen, 2010). He was considering bringing the bill up for discussion in the
House of Representatives in January, before the new legislators took their seats at the
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General Assembly (Huchel, 2010). A late year session would have required 71 votes for
the bill to pass, while in January session it would take only 60 votes (Huchel, 2010).
Medical cannabis advocates said that they would continue to push for the
legislation (Olsen, 2010). However, despite efforts, the 2010 medical cannabis failed to
pass the House (Hess, 2011; Lester & Riopell, 2010). The bill received 56 votes in its
favour, but needed 60. In response, Dan Linn said there were a lot of politics involved
(Lester & Riopell, 2010). The bill’s sponsor, Rep. Lang (D) said he would continue to
push for medical cannabis legislation (Hess, 2011). The bill known as the
Compassionate Use of Medical Cannabis Pilot Program Act was filed again as House
Bill 30 (Illinois General Assembly, n.d.-a).
In 2011, Rep. Tom Cross (R) changed sides to support medical cannabis
legislation (Brownfield, 2011a; Wilson, 2011). He said that he had a change of heart
after being approached by several constituents. Representative Lang indicated that he
thought that this time, with the support of Rep. Cross, he could pass the bill which the
sponsors were trying to make the most restrictive law out of all the states (Wilson,
2011). Rep. Lang hoped that putting more restrictions into this bill would get additional
votes (Brownfield, 2011a). The proposed legislation would not allow patients to grow
their own cannabis, but would have to buy it from a state-licensed dispensary. The bill
would also legalise cannabis for medical purposes for three years, after which the law
would have to be renewed (Wilson, 2011).
The bill was placed on postponed consideration after failing to get enough votes
to be passed by the House of Representatives (Morse, 2011). The bill received 56 votes
in its favour out of the 60 required for it to be passed, but this was enough for it to be
placed on postponed consideration so that it can be voted on again in the future
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(Brownfield, 2011b; Morse, 2011). Representative Lang said he would seek another
vote on the bill if he could find more votes in favour of it. He pointed out that the bill
was about health care and not about drugs, including cannabis. However, Rep. Jim
Watson (R), who voted against the bill, said that every local law enforcement official
called on him to oppose it (Brownfield, 2011b). It was also said by the opposition that
the bill was a very bad piece of legislation, which opposed the federal law (Morse,
2011).
Changes at the city level. The same year the Medical Cannabis Act was
introduced, there was also some activity reported at the city level when Chicago Mayor,
Richard Daley, said that he embraced an idea to issue fines to individuals found to be in
possession of small amounts of cannabis instead of filing criminal charges (“Daley: Just
Ticket Marijuana”, 2004). Bryan Brickner, a chairman of the Illinois chapter of the
NORML, said the plan was a turning point (Goze, 2004). However, his concern was that
Chicago was focusing on generating revenue with fines of between $250-$1,000, which
Brickner predicted could significantly affect poor and minority residents (Goze, 2004).
Amongst reports that Mayor Daley was considering such a plan it was reported that
most North Shore (Chicago) police agencies had already been doing something similar
for nearly 25 years (Goze, 2004). Wilmette Police Chief George Carpenter said the
village had an ordinance by which officers had the option to issue fines of $100 to
individuals in possession of ten grams or less of cannabis. It was created in August 1978
as a way of dealing with high rates of cannabis use and an overloaded court. He said the
ordinance was a more sensible approach to minor violations and did not mean cannabis
was decriminalised. Kenilworth, a village in Cook County, also had a similar ordinance
(Goze, 2004).
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In May 2007 an ordinance change was due to take effect in the village of Peoria
Heights (Haney, 2007). It was set to give police officers an option of treating possession
of small amounts of cannabis as a violation and issuing a fine rather than criminally
charging individuals (Haney, 2007). Possession of less than 2.5 grams of cannabis
would result in a $200 fine; between 2.5 and 10 grams, a $300 fine; and between 10 and
30 grams, a $400 fine (Haney, 2007). At the same time Dan Linn, Executive Director of
the Illinois NORML, suggested changes should be made to the Illinois cannabis law and
said that lawmakers should legalise and tax cannabis as a form of revenue raising (Linn,
2007). Linn said it made more sense than arresting people and advised that Illinois
should stop wasting tax dollars and start making money by taxing cannabis use by
adults (Linn, 2007).
In February of 2009, a small change in relation to cannabis occurred in
Springfield (Poole, 2009). The city changed its ordinance to allow cannabis possession
of less than two and a half grams to be prosecuted as an ordinance violation resulting in
a fine, rather than a criminal penalty (Poole, 2009). Cities with similar ordinances
included Joliet, Aurora, Bloomington, Champaign and Urbana. It was reported that
Springfield’s ordinance change was a way of raising revenue for the city, which
reportedly faced a $12.5 million budget deficit (Poole, 2009). Dan Linn suggested that
cannabis could be a good way of tax and revenue raising and said government could
make even more money if cannabis was made legal (Linn, 2009b).
In July of 2009, the Cook County Board voted in favour of passing a change in
the city ordinance which allows police officers to issue fines to those in possession of
small amounts of cannabis. This then results in a misdemeanour charge instead of
criminal prosecution (Kadner, 2009). The ordinance change gave police officers an
option of issuing a $200 fine to those caught with 10 grams of cannabis or less. At that
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point, however, Cook County Sheriff Tom Dart said he was not sure what he thought of
the change (Kadner, 2009).
Dan Linn, of Illinois NORML, said the organisation supported Cook County
changing their ordinance (Linn, 2009c). However, he said the problem was the potential
for discriminatory arrests, as it would be up to police officers to decide whether to fine
or arrest individuals (Linn, 2009c). His suggestion was that cannabis should generally
be legalised and regulated like alcohol and tobacco (Linn, 2009c). Reverend Alexander
Sharp, executive director of Protestants for the Common Good, said he also supported
the ordinance change (Sharp, 2009). He said the local government needed all the money
it could get and fining those possessing small amounts of cannabis would raise revenue.
Reverend Sharp also said he was not advocating cannabis use, but believed people
needed to change their way of thinking in regards to drugs (Sharp, 2009).
Kentucky
Unlike the 36 states that have had some form of medical cannabis law since
1978, Kentucky has never had such a law or consideration of such laws on its political
agenda (MPP, 2013) 9. As Kentucky does not have a ballot initiative process, passing a
medical cannabis law remains an issue dependent on the state legislature or the
executive which had, at the time of writing this thesis, not shown significant interest in
the topic (IRI, 2009). According to the 2002 Kentucky Drug Threat Assessment report,
cannabis was rated as the most widely available illicit drug in the state and the leading
crop grown for sale (National Drug Intelligence Center, 2002).The report suggested that

9

Since the writing of this thesis, there has been consideration of a medical cannabis law in the state of
Kentucky.
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the central and eastern parts of Kentucky were the areas of largest cannabis cultivation.
Kentucky was also named as one of top five cannabis producing states in the nation.
In accordance with state laws, cannabis possession, cultivation, sale, or use, are
criminal offences in Kentucky while research on industrial hemp is authorised (Ky. Rev.
Stat. § 218A.010, 1992; Ky. Rev. Stat. § 260.853, 2001). Hemp refers to a fibre derived
from certain species of cannabis that contains minimal amounts of THC (Hollister,
2001). Hemp fibre can be used in the making of rope, clothes, paper, and other products.
As Kentucky has no medical cannabis law, the following section will chronologically
review (see Figure 5) the history of the brief but unsuccessful attempts made at passing
such legislation.
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• Focus on hemp- separating hemp from general cannabis use
• Movement to separate cannabis use from other drugs

• Governor Paul Patton signs into law a bill allowing research on hemp

• Supporters of cannabis legalisation organise a rally

• Supreme Court's ruling on medical cannabis restarts debate
• Reports from law enforcement that cannabis trade is a big problem in Kentucky
• Kentucky a leading state in cannabis cultivation

• Student action- dozens of students gather for a rally held by the University of Kentucky (UK)
chapter of NORML
• UK NORML say they were established in 2005 but didn't have funds to organise big events
• Western Kentucky University's president of the Campus Activities Board organises a debate
on cannabis legalisation
• Approximately 30 students advocating cannabis legalisation gathered at UK to promote the
university’s NORML chapter
• Dispute over medical cannabis on religious grounds
• Students at University of Louisville host a debate on cannabis legalisation
• Religious leaders join the medical cannabis debate

• Cannabis debate reignites
• Student Activities Board of UK organises a debate on cannabis legalisation
• Gatewood Galbraith, medical cannabis advocate, holds lectures describing how smoking
cannabis helped cure his asthma
• Galbraith said that he predicts that President Obama would decriminalise cannabis use and
that Kentucky could make money by making cannabis legal
• Newspaper article suggests that the Kentucky state government should consider legalising the
use of cannabis for medical purposes as a way of raising state revenue
• Republican gubernatorial candidate Phil Moffett says he supports legalising industrial hemp
production, but is not in favour of cannabis legalisation
• Galbraith to run for governor as an independent
• NORML says they are not advocating smoking cannabis but its medicinal and industrial use

• Galbraith dies

2012

• Jonathan Miller, Kentucky politician, says it is time for the state to legalise cannabis use
• A bill to legalise cannabis' use for medical purposes introduced in the Kentucky State Senate
and is known as the Gatewood Galbraith Memorial Medical Marijuana Act

Figure 5. Time chart of medical cannabis history in Kentucky.
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In the late 1990s, the focus in Kentucky was on separating hemp from general
cannabis use rather than medical cannabis (“Victory for Hemp?”, 1997). In Kentucky,
supporters of general cannabis legalisation attempted to make the legalisation
movement stronger by separating cannabis use from other drugs such as heroin
(“Victory for Hemp?”, 1997). In March of 2001, Kentucky Governor Paul Patton (D)
signed into law a bill allowing research on hemp to be conducted at Kentucky
universities (“Kentucky Governor Signs”, 2001; Ky. Rev. Stat. § 260.853, 2001). Joe
Hickey, head of a Hemp Growers Cooperative, said that hemp was a way of
compensating for the loss of revenue Kentucky tobacco farmers were facing, and was
not an attempt at cannabis legalisation (“Kentucky Governor Signs”, 2001).
Following the passage of hemp research legislation, cannabis and its medical use
did not get a significant mention until May 2004, when supporters of cannabis
legalisation organised a rally through downtown Lexington (“Cures, Not Wars”, 2004).
The rally was organised by Gatewood Galbraith, a Kentucky politician and lawyer
(“Cures, Not Wars”, 2004; Galbraith, 2004). Galbraith ran for governor of Kentucky in
1999 as a member of the Reform Party; for Congress in 2000 as a Reform Party
candidate and again as an independent in 2002; and for Commissioner of Agriculture in
1983 as well as Attorney General in 2003 (B. Thomas, 2006). Galbraith said cannabis’
use as a medicine spanned over thousands of years and was the basis for over 50
medicines (Galbraith, 2004). At the rally, some speeches discussed the benefits of
cannabis as a medicine in the treatment of some medical conditions, while others
suggested that legalising the medical use of the drug would help Kentucky’s budget and
health-care crises (“Cures, Not Wars”, 2004).
Following the rally, there was some mention of medical cannabis and its benefits
for some individuals with debilitating medical conditions, but this occurred mainly in
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student newspapers (Adkins, 2004). However, after brief mentions of it in 2004, there
was no movement on the medical cannabis front until mid-2005, when the Supreme
Court’s ruling on medical use of cannabis re-started the debate (Slider, 2005).
Supporters started writing to newspapers in support of medical cannabis and in
disagreement with the war on drugs (Rector, 2005; Slider, 2005). While some tried to
discuss cannabis’ medical benefits, Capt. Lisa Rudzinski, spokeswoman for the
Kentucky State Police, discussed the number of cannabis plants seized in the state
(Covington, 2005). Cheyenne Albro, director of the Pennyrile Narcotics Task Force,
said cannabis trade was a big problem in Kentucky and one the police tried to get under
control. According to police reports, in the period between 2000 and 2005, an average
of more than 450,000 cannabis plants were found and destroyed annually by Kentucky
law enforcement agencies. Despite this, Kentucky remains one of the leading states in
cannabis cultivation (Covington, 2005).
Student action. The following year, in April of 2006, dozens of students
gathered for a rally held by the University of Kentucky (UK) chapter of the NORML
(B. Thomas, 2006). The university’s NORML president, Drew Duncan, said the
organisation had been around since 2005 but did not have enough financial support to
organise big events. Gatewood Galbraith was invited by the UK NORML to speak to
students in an attempt to increase NORML membership (B. Thomas, 2006). He spoke
to students about cannabis legalisation and their rights in relation to possession of the
drug. Opinions on Galbraith were mixed, with some believing he would increase
NORML membership, while others believed his presence was an attempt to get votes
for his next attempt at public office (B. Thomas, 2006).
A week after the NORML event at the UK, Daniel Trujillo, president of the
Campus Activities Board at Western Kentucky University organised a “Heads vs. Feds”

Medical Cannabis in the United States

207

debate on cannabis legalisation (Keene, 2006). Steven Hager, editor-in-chief of High
Times magazine, represented supporters of cannabis legalisation while Bob Stutman, a
retired DEA agent, represented the side advocating the continued criminalisation of the
drug. Event organisers said its purpose was to inform students about cannabis and give
them both sides of the cannabis legalisation debate (Keene, 2006).
In November of 2006, approximately 30 students advocating cannabis
legalisation gathered at UK to promote the university’s NORML chapter (Troutman,
2006). Gatewood Galbraith was once again the guest speaker at the gathering, during
which he voiced his support for medical cannabis and the hemp industry (Troutman,
2006). Following on the same topic, it was reported in a newspaper article that groups
advocating cannabis legalisation such as the DPA and the NORML argue that cannabis
eradication programs such as the one operating in Kentucky are “a waste of money,
doing little to cut the supply of pot while helping keep prices artificially high on the
black market” (Estep, 2006). It was also claimed that the potency of cannabis grown in
Kentucky has increased over the years, making it a prized drug outside of the state
(Estep, 2006).
March of 2007 again saw student involvement when the University of Louisville
Properties (ULP), which offer student housing for University of Louisville on campus
students, hosted a debate on cannabis legalisation (Shastry, 2007). Sergeant Steve
Salyers from the Louisville Police Narcotics/Vice Department moderated the debates.
The debates were co-ordinated by Lamont Johnson, assistant community manager for
ULP, and were aimed at presenting students with both sides of the cannabis legalisation
debate. Medicinal and economic benefits gained from cannabis legalisation were
emphasised by the pro-legalisation side, while the opposing side argued that cannabis
was a gateway to “harder” and more dangerous drugs (Shastry, 2007).
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In 2009, the Student Activities Board of UK organised a debate on cannabis
legalisation on campus (Coovert, 2009; Hurt, 2009). As in earlier years, the debate
called “Heads vs. Feds” occurred between Steve Hager and Bob Stutman. When
questioned, Hager said his magazine, High Times, promoted cannabis legalisation but
was not involved in any illegal activities. Despite disagreements on the topic, Stutman
said that he and Hager were personal friends and that he hoped students would hear a
rational and intelligent presentation from both sides. During the debate, Hager spoke
about the medical benefits of cannabis and suggested it should be legalised because it is
a cheap medication (Coovert, 2009; Hurt, 2009). Meanwhile, Stutman claimed cannabis
was bad for people’s health and was not the benign drug people thought it was (Coovert,
2009; Hurt, 2009). However, both sides seemed to agree that cannabis use was about
responsibility (Hurt, 2009).
Religious stance. September of 2006 saw religion become involved in the
cannabis debate, with Dr. Ted Beam, Senior Pastor of the United Methodist Church,
writing against cannabis legalisation (Beam, 2006). He said that removing illegal drugs
from the community would have a positive effect and disagreed with statements which
suggested God intended for people to use cannabis (Beam, 2006). In response, Rev.
Meril Draper said he disagreed with Dr. Beam’s sentiments as he was not interpreting
scripture correctly (Draper, 2006). Reverend Draper said he spoke on the topic of
medical cannabis from personal experience, as his grandfather used the drug while
suffering from cancer. He questioned whether or not Dr. Beam would go out and start
smoking cannabis if it were legalised, to which he believed the answer was no.
Reverend Draper then asked why Dr. Beam believed everyone else would do so
(Draper, 2006). Dr. Beam’s letter proved somewhat controversial and caused more
individuals to write to newspapers to dispute his claims on religious grounds, question
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the war on drugs, but also suggest that cannabis is a gateway drug and that its
legalisation wold lead to legalisation of other drugs such as cocaine (Givens, 2006;
McLaurine, 2008; N. Miller, 2008a; N. Miller, 2008b; Ryan, 2007).
Debates. In 2009, the cannabis debate was again reignited when UK organised a
debate on cannabis, which was followed by Gatewood Galbraith holding lectures in
Kentucky in which he described how smoking cannabis helped cure his asthma (Reed,
2009). He said that earlier in history, America learnt that cannabis was the number one
plant for all uses, but that the forming of chemical industries led to the criminalisation
of the drug. Galbraith argued that cannabis had a variety of uses and was not bad for
people’s health. Galbraith predicted that President Obama would decriminalise cannabis
use and that Kentucky could make money by making cannabis legal (Reed, 2009).
Galbraith wasn’t the only one to suggest that money could be made from
cannabis legalisation, with a 2010 newspaper article suggesting that the Kentucky state
government should consider legalising the use of cannabis for medical purposes as a
way of raising state revenue (“Why Not Medical Marijuana”, 2010). The article stated
that a medical cannabis bill would create jobs, generate revenue, and provide relief for
tens of thousands of individuals suffering from a debilitating medical condition. The
article suggested that the Federal government was forbidden from saying anything
positive about cannabis by the Controlled Substances Act of 1970, and that the only
good thing the federal government did was to decide not to interfere with medical
cannabis users, doctors and providers as long as they abide by the state law. The article
concluded that proposing a medical cannabis bill would be beneficial to legislators, as it
would make the voters think the legislators were prepared to make a change (“Why Not
Medical Marijuana”, 2010).
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Kentucky Republican gubernatorial candidate Phil Moffett said he supported
legalising industrial hemp production, but was not in favour of cannabis legalisation (P.
Smith, 2010). He said he opposed medical cannabis use on an “official level”, but
would personally not “get in the way” of someone dying of cancer and smoking the
drug for comfort. Moffett believed there was a humanitarian aspect to allowing cannabis
use for seriously ill individuals such as terminally ill cancer patients (P. Smith, 2010).
Despite mentions of the medicinal properties of cannabis and its possibility of
increasing Kentucky’s revenue, no medical cannabis bill was introduced in the
legislature at the time of writing, nor was any such law passed.
In 2011 Gatewood Galbraith was set to run for governor as an independent
(Brockman, 2011). In February of the same year, he spoke to students at the Eastern
Kentucky University, in a meeting organised by the NORML. Ashley Sharp, the
executive director of NORML, said that they wanted Galbraith to speak to students in
order to raise awareness of what the organisation’s mission is. Sharp also mentioned
that the NORML was not advocating smoking cannabis, but its medical and industrial
use (Brockman, 2011).
Follow-up. In January 2012 it was announced that Galbraith had died, five
months after running his campaign for governor (Blackford, 2012; Gerth, 2012).
Following his death, Jonathan Miller, a Kentucky politician, declared that it was time
for the state to legalise cannabis use (J. Miller, 2012). Miller expressed his belief that
cannabis was not as addictive as alcohol, tobacco, and some other drugs, as well as that
there was evidence for its medical use. He also said that cannabis was Kentucky’s
“number one cash crop” and would have economic benefits if it was legalised (J. Miller,
2012).
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At the start of February 2012, a bill that would legalise cannabis’ use for
medical purposes was introduced in the Kentucky State Senate (“Medical Marijuana
Comes”, 2012). The bill known as the Gatewood Galbraith Memorial Medical
Marijuana Act was introduced by Sen. Barry Clark (D) and sought to make cannabis a
Schedule II drug. It also sought to give doctors the ability to prescribe up to five ounces
of cannabis per month to their patients, or allow them to cultivate up to five cannabis
plants (S.B. 129, 2010). However, by March 2012, the bill was stalled in the Senate
Judicial Committee when its chair Sen. Tom Jensen (R) refused to call the measure
before the committee, which meant that the bill could be dead for the 2012 legislative
year (Clarke, 2012).
Louisiana
Like Kentucky, Louisiana is a state that has no effective medical cannabis law
and is not in the process of considering such a law (MPP, 2013). 10 The difference
between these two states is that Louisiana has an existing medical cannabis law, enacted
in 1978 and amended in 1991, which has remained ineffective and purely symbolic (La.
Rev. Stat. § 40:1046, 1991; Loh-Harrist, 2002; MPP, 2013). The 1978 Therapeutic Use
of Marijuana law allowed cancer and glaucoma sufferers to receive a cannabis
prescription from their doctor. The law was amended in 1991 to include patients with
spastic quadriplegia (La. Rev. Stat. § 40:1046, 1991). The law, however, remains
ineffective as it does not include a way for doctors or patients to obtain cannabis, and
federal drug laws made it available only for research programs (MPP, 2013).

10

Since this thesis was submitted, there has been consideration of a medical cannabis law in the state of
Louisiana.
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Cannabis possession, cultivation, sale, or trafficking, are a criminal offence in
Louisiana (La. Rev. Stat. § 40:966, 1972). Penalties for possession of any amount of
cannabis, even for a first offence, include a fine and possibly a term in prison. Despite
the ineffective medical cannabis law, the state has not legalised cannabis use for
medical purposes, and such use remains a criminal offence (La. Rev. Stat. § 40:966,
1972). As Louisiana does not have a ballot initiative process, the legislature is
responsible for proposing law changes in the state (IRI, 2009). However, at the time of
writing this thesis, the state’s legislature had not attempted to pass a medical cannabis
law since 1991 (Brumble, 2009). As Louisiana does not have an effective medical
cannabis law, the following section will chronologically review the history of attempts
made to pass medical cannabis legislation in the state.
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• Louisiana Governor Edwin Edwards signs a bill to let doctors prescribe cannabis to assist
glaucoma and cancer patients
• The word "prescribe" made the law ineffective as doctors cannot legally prescribe an
illegal substance

• Amended version of the 1978 bill signed into law but remained ineffective

• A law similar to that passed in 1978 is signed by Goveror Roemer but no action was taken
and law remained ineffective

• Arrest sparks debate- Wesley Sarradet arrested for cultivating and using cannabis he
alleged was for medical problems
• NORML says the reason there were no good clinical trials on the effectiveness of cannabis
is the fact that the federal government kept tight control over cannabis

• Dr Robert Goidel from the Public Policy Research Lab says that there is little interest in
medical cannabis in the Southern states
• Gubernatorial candidates Kathleen Bloanco and Bobby Jindal both oppose legalising
cannabis for general use
• Bruce Mirken, of the MPP, says that if a Louisiana governor was to consider a medical
cannabis law, recommendations should be made to ensure the law was passed on a model
that had proven workable in other states with an active medical cannabis law

• City-level action- Cannabis Action Network (CAN) collects enough signatures to get a
cannabis initiative onto parish-level ballot
• Louisiana State University chapter of CAN holds parties to promote cannabis legalisation
• DPA announce the organisation would begin a lobbying initiative in Louisiana

• Media frenzy follows the arrrest of country music star Willie Nelson for cannabis
posession

• Matthew Zugsberger, California medical cannabis patient, arrested in Louisiana on a
cannabis posession charge
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• Reports that cannabis arrests on university campuses had increased
• Announcement made by President Obama’s attorney general, who said that the federal
government would not prosecute medical cannabis clinics that comply with state laws,
discussed in the media
• Zugsberger makes headlines when appearing in a Louisiana court to face cannabis
posession charges
• Louisiana newspaper reports that cannabis research was conducted by LSU Health
Sciences Centre in New Orleans
• Supporters say that that it would take a lot of advocacy to pass medical cannabis
legislation in Louisiana
• NORML becomes more active in Louisiana and states that it will only focus on medical
cannabis
• By the end of the year it is reported that Louisiana NORML is not very active due to
conflict among the executive board
• Protests against cannabis legalisation continue to be held across Louisiana
• New Orleans city cuncil reclassifies cannabis posession to municipal offence

Figure 6. Time chart of medical cannabis history in Louisiana.
In 1978, Louisiana Governor Edwin Edwards signed a bill to let doctors
prescribe cannabis to assist glaucoma and cancer patients (Loh-Harrist, 2002). It should
be noted that using the word “prescribe” made the law ineffective, as doctors cannot
legally prescribe an illegal substance to their patients (Delaney, 2010a). The law
required a Marijuana Prescription Review Board to be formed to determine who would
be eligible to legally receive cannabis. However, the board was never formed and the
law remained ineffective. Then, in 1981 an amended version of the 1978 bill was
introduced and signed into law by Gov. David Treen, but again remained ineffective. A
similar medical cannabis bill was signed into law by Gov. Buddy Roemer in 1991 (LohHarrist, 2002). Gov. Roemer again appointed a board to oversee the implementation of
the law, but no action was taken and the board was dismissed in 1992 (Delaney, 2010a).
Bobby Delaney, from the Louisiana chapter of the NORML, attributed the law’s failure
to its conflict with federal cannabis laws (Delaney, 2010a). In Delaney’s opinion, it was
unclear why Louisiana’s legislature passed such legislation, which ultimately proved to
be useless (Delaney, 2010a). Since 1991, there has been very little political discussion
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on the topic of medical cannabis (Brumble, 2009). In 2002, Wesley Sarradet, who
suffered from spastic cerebral palsy and cultivated and used cannabis to help ease his
condition, was arrested by agents from the River West Narcotics Task Force (RWNTF)
(Loh-Harrist, 2002). He was charged with two drug felonies and a misdemeanour.
While Sarradet maintained he had cultivated and used cannabis solely for medical
purposes, RWNTF director Maj. Jerome Fontenot said he did not believe Sarradet’s
claims. James Johnson, one of the arresting officers, said Sarradet most likely did have
medical problems. However, Johnson said he had a duty to uphold the law. In his
defence, Sarradet said he had tried using medication such as Vicodin and morphine
patches to help ease his pain and various other drugs to assist with other symptoms, but
found cannabis to be cheaper, more effective, and to have fewer side effects than other
drugs. Sarradet also believed he would not have been convicted had he been allowed to
use his medical records and use medical necessity as his defence (Loh-Harrist, 2002).
A brief discussion of medical cannabis in the media followed Sarradet’s arrest
and sentencing. Dr. John Cole, an oncologist at the Ochsner Cancer Institute, said there
were no good clinical trials which looked at the effectiveness of cannabis in treating
medical conditions (Loh-Harrist, 2002). He also added that it could not be said with
certainty that cannabis was better than other medications. However, Dr. Cole agreed
that Marinol was not an effective anti-nausea medication and said he generally avoided
prescribing it. If it were legal do so, Dr. Cole said he would probably prescribe cannabis
to his patients. He also did not object to his patients using cannabis to help treat their
medical conditions (Loh-Harrist, 2002).
In response to Dr. Cole’s statement, the NORML spokesman, Paul Armentano,
said the reason there were no good clinical trials on the effectiveness of cannabis was
the fact that the federal government kept tight control over the drug (Loh-Harrist, 2002).
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Armentano was of the opinion that the federally produced cannabis, grown for research
purposes, was of poor quality and would most likely skew tests conducted on the drug’s
effectiveness. He also pointed out that the pharmaceutical industry appeared to oppose
legalisation of any medicine that could be grown by patients for themselves (LohHarrist, 2002). Robert Sharpe, a program officer for the DPA, agreed with Armentano
and added that there was a need for state-level medical cannabis distribution programs
the federal government would not intrude upon (Sharpe, 2002).
Media articles on the issue decreased until November 2003, when gubernatorial
candidates Kathleen Blanco (D) and Bobby Jindal (R) were both said to oppose
legalising cannabis for general use (Alford, 2003). Jindal also firmly opposed medical
cannabis and said he would not sign such legislation. He attributed his stance to his
experience at the state Department of Health and Hospitals, where he said experts
believed cannabis was a gateway drug. Meanwhile Blanco, who was later elected
governor, said she was always taught that cannabis was a gateway drug and did not
believe in legalising it for general use. However, she believed that cannabis should not
be denied to patients with some debilitating medical conditions if the drug could help
alleviate their pain. Commenting on the issue, Bruce Mirken, of the MPP said that if a
Louisiana governor was to consider a medical cannabis law, recommendations should
be made to ensure the law was passed on a model that had proven workable in other
states with an active medical cannabis law (Alford, 2003). In 2003, Dr. Robert Goidel,
co-director of the Public Policy Research Laboratory in Baton Rouge said he was
surprised medical cannabis was not a more popular topic in Louisiana (Alford, 2003).
He said that he came to the conclusion that there was little interest in medical cannabis
in the Southern states.
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A city-level attempt. Following the gubernatorial election, no significant
discussion on the topic of medical cannabis was noted in the media until April of 2005
when Daniel Williams, a member of the Cannabis Action Network (CAN), discussed
his organisation in an article published by the Advocate, the primary newspaper of
Baton Rouge (Ventura, 2005). The CAN aimed to collect enough signatures to get a
cannabis initiative on the East Baton Rouge parish-level ballot. Williams said the
organisation opted for a parish-level ballot initiative as they did not have a lot of
funding or political influence. The initiative’s aim was to change the city’s ordinance to
decrease cannabis possession penalties, so that a person caught in possession of the
drug, no matter what offense, would only receive a fine (Ventura, 2005). The city’s
assistant chief administrative officer, Alfred Williams, said he would oppose any such
initiative as he believed it would only make cannabis more available to youth (Ventura,
2005).
A representative of Louisiana’s Partnership for a Drug Free America chapter,
Janice Williams, disagreed with CAN’s initiative as she believed cannabis was a
gateway drug which led to more harmful and deadly substances (Ventura, 2005). Mary
Roper, a special assistant in the Parish Attorney’s office, looked at the proposed
initiative and concluded that even if an ordinance change were passed, the local police
would still be able to choose whether or not to follow the local or the state law. She
believed passing such an ordinance change would lead to the city government losing
money. While the CAN attempted to collect enough signatures for their initiative,
Michael Blain, a spokesman for the DPA, announced the organisation would begin a
lobbying initiative in Louisiana (Ventura, 2005). Blain said that Louisiana’s cannabis
sentencing was overcrowding the state’s prisons and the state therefore needed to look
at decreasing sentences for cannabis offenses (Ventura, 2005). First movement at the
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city level came when the New Orleans city council reclassified cannabis possession to a
municipal offense, allowing police the option to issue a summons rather than make an
arrest (Eggler, 2010).
In April of 2006, the Louisiana State University (LSU) chapter of CAN was
publicising its efforts to legalise cannabis (Alexander & Broussard, 2006). The
organisation held yearly parties to promote its cause and set up information tables at
various venues such as nightclubs and taverns in order to recruit new members and sign
petitions (Alexander & Broussard, 2006; Ventura, 2005). However, by the end of 2006,
CAN was no longer an official student organisation but the issue continued to be
discussed in student newspapers (Alexander & Broussard, 2006; “Anti-Marijuana
Laws”, 2008; Blake, 2006; Ruchalski, 2006).
Arrests draw attention to the issue. Media frenzy followed the arrest of
country music star Willie Nelson, who was charged with misdemeanour drug possession
(Brown, 2006; “Willie Nelson”, 2006). The musician was an active advocate for
cannabis legalisation and was in possession of the drug at the time of his arrest in Saint
Martin Parish, Louisiana. In 2007, he made news headlines again, when a Louisiana
court sentenced him to six months of probation after he pleaded guilty to a cannabis
possession charge (Burges, 2007).
In 2008, Matthew Zugsberger, a California resident, was arrested in Louisiana
on a cannabis possession charge (Campo, 2008; Legendre, 2008). Zugsberger had a
doctor’s letter and a California-issued medical cannabis patient card. He said it was not
his intent to break the state law as he only used cannabis to ease severe nausea caused
by a spinal cord injury (Campo, 2008; Legendre, 2008). He decided to fight the charges
but said he did not want to fight the system, only help refine it. Zugsberger’s aim was to
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prove that his California licence for using cannabis as a medicine should be recognised
in Louisiana and the rest of the U.S. states (Legendre, 2008). If deemed necessary, he
planned to take the matter to the Supreme Court, but held hope that a Louisiana judge
would change the state’s stance on medical cannabis (Campo, 2008).
In April of 2009, it was reported that cannabis arrests on university campuses
had increased (Bove, 2009). According to one article, the LSU Police Department
spokesman, Maj. Lawrence Rabalais, said the department’s goal was preventing
students and other citizens from using the drug again. Rabalais, who was personally
against cannabis legalisation, wondered what drug would be next if cannabis were
legalised and where drug legalisation would stop (Bove, 2009). The topic of cannabis
legalisation continued to be debated, but largely at the student level, with both
proponents and opponents writing to the student newspapers to voice their opinions on
the issue (Albright, 2009; Bove, 2009; Freeman, 2009; Macmurdo, 2009).
In May of 2009, Ronald Fraser, who writes for a civil liberties organisation, the
DKT Liberty Project, discussed an announcement made by President Obama’s attorney
general, who said that the federal government would not prosecute medical cannabis
clinics that comply with state laws (Fraser, 2009). As a result of the announcement,
Fraser suggested that lawmakers were free to decide whether or not cannabis use for
medical purposes would become legalised. The author said that thousands of ill
individuals could testify that cannabis assisted them with their medical condition, while
the federal government maintained that the drug had no medical properties. He therefore
said it was up to the state legislature to decide whether or not medical cannabis would
be legalised in Louisiana (Fraser, 2009).
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Matthew Zugsberger continued to make headlines when he was scheduled to
appear in a Louisiana court to face cannabis possession charges (Legendre, 2009).
Zugsberger argued that cannabis helped ease his pain better than other medication did.
The prosecution disputed this argument and stated Zugsberger’s prescription was
invalid in Louisiana. His court case was the first such case ruled upon in Louisiana.
Zugsberger alleged that the Lafourche District Attorney’s Office was stalling the case,
as it did not want to be responsible for legalising medical cannabis in Louisiana. In
response, Lafourche District Attorney Cam Morvant II said Zugsberger’s claims were
not true. When asked to comment on the case, NORML’s executive director, Allen St.
Pierre, said that illnesses did not change due to geographic location (Legendre, 2009). In
August 2011, Matthew Zugsberger pled guilty to felony charges after three years of
prosecution and received a suspended jail sentence (Gorman, 2011).
The week of Zugsberger’s trial, an article in a Louisiana newspaper reported that
cannabis research was conducted by LSU Health Sciences Centre in New Orleans
(Brumble, 2009). The research was funded by the NIDA and looked into the effects of
cannabis on people affected by HIV and AIDS. However, Rep. Richard Burford (R)
said there appeared to be no interest in passing medical cannabis legislation, and if there
were, he would not be in favour of it. Malone thought the same, and said it would take a
lot of advocacy from reputable and knowledgeable medical cannabis users and
supporters in order to pass medical cannabis legislation in Louisiana (Brumble, 2009).
The year 2010 saw NORML become more active in Louisiana, when the
organisation’s state chapter held its second Medical Cannabis Rally in Monroe (Kelly,
2010). The organisation was also set to have a booth at the Bluegoose Music Festival in
August of 2010, where people could obtain NORML merchandise and sign up to
become members of the organisation (Delaney, 2010f). The event’s organisers and
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guest speakers, including Bobby Delaney, declared the Monroe event a success and
were impressed by the support the cause was receiving (Delaney, 2010d). Delaney said
a number of people wanted to share their personal experiences with medical cannabis
and stories about loved ones who suffered from debilitating medical conditions. He said
most of the sick patients refused to use cannabis, even with doctors’ recommendations,
as they did not want to break the law. Delaney said that stories like these were the
reason NORML Louisiana was formed (Delaney, 2010d). In his NORML Louisiana
blog, Delaney encouraged medical cannabis supporters to write letters to newspaper
editors in support of medical cannabis and provided a step-by-step guide on how to do
so most effectively (Delaney, 2010b).
Louisiana NORML’s website stated that their mission is to obtain “safe and
legal access to medical cannabis for suffering patients” (Delaney, 2010e). Unlike
national-level NORML, the organisation’s Louisiana chapter said that they solely focus
on medical cannabis. Delaney maintained that separating medical cannabis from general
cannabis legalisation was important and a moral obligation they had to patients.
Delaney also said that religious leaders were the organisation’s valuable allies (Delaney,
2010c).
By the end of 2010, it was reported that the Louisiana NORML chapter wasn’t
very active due to conflict among the executive board (John, 2010). However, protests
against cannabis prohibition, organised by Legalize Louisiana, continued to be held in
various cities across Louisiana (Doughty, 2012; Duvernay, 2011). Legalize Louisiana
was founded by Donnie Griffith, who was of the belief that cannabis should be used for
medical purposes to help those suffering from medical conditions (Doughty, 2012).
Discussion
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Following the federal government’s establishment of the NIDA and the IND
Compassionate Use Program for medical cannabis, several states including Michigan,
New Mexico, Illinois and Louisiana passed laws that addressed the use of medical
cannabis. Illinois and Louisiana laws became ineffective the same year they were
passed, due to political debate and the threat by the federal government to remove a
doctor’s power to prescribe controlled substances if they prescribed cannabis. This
restricted the doctors in prescribing cannabis for medical purposes, making the laws
referring to a prescription by a doctor ineffective. Before the IND program ended, there
were reports of shortage of federally grown cannabis and patients complaining about its
quality. Subsequently, some states tried to revive medical cannabis laws, while others
opted for new ones. It was an important change in drug control policy, with states
choosing to take the lead and enact medical cannabis laws, against the federal
government’s wishes. Following the early research in the 1980s, the medicinal effects of
cannabis were more widely discussed and in 1996 California took the lead and passed a
medical cannabis law. In relation to the representative states discussed in this chapter, a
number of issues emerged. The following section will discuss the factors that led to
passing of medical cannabis legislation and will provide a chronological outline of
major events that occurred at the federal level and the five representative states (Table
10).
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Table 10
Chronological Account of Medical Cannabis Related Events at the Federal and State Level
Year Federal-level
1978 Federal government
IND Compassionate
use program starts
supplying patients
with medical
cannabis

Michigan

1979

Michigan passes
medical cannabis law
and therapeutic
research law
Reports of shortage of
federally grown
cannabis
Patients complaining
about quality of
federally-supplied
cannabis

1980

New Mexico
New Mexico passes first
state law recognising
medical value of
cannabis and allowing for
therapeutic research into
medical cannabis

Kentucky

Louisiana
Gov. Edwin Edwards
signs bill to let
doctors prescribe
cannabis to assist
glaucoma and cancer
patients

Amended version of
the 1978 bill signed
into law but remained
ineffective

1981

1988

Illinois
Illinois passes a
medical cannabis
therapeutic research
law
The law becomes
ineffective due to
heated political
debate and
restrictions placed
on it

DEA
Administrative Law
Judge rules in
favour of NORML
to make cannabis a
medicine

Medical cannabis
therapeutic research
program ends
Cannabis remains legal
for therapeutic research
purposes
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Federal government
suspends IND
Compassionate Use
Medical Marijuana
Program

A law similar to that
of 1978 is signed but
remained ineffective

1996

1997

1999

IOM study findings
published
Marinol moved to
Schedule III of the
CSA

2000
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Peter McWilliams
attempts using medical
necessity defence and
is denied
Suggestions that antidrug groups are
softening their antimedical cannabis
stance
Summary of the IOM
report published in
Michigan newspapers
Partnership for a Drug
Free America supports
the report’s
recommendations
Activists propose
“Personal
Responsibility
Amendment” allowing
individuals with
debilitating medical
conditions “personal
amount of cannabis”

Libertarian party starts

New Mexicans for
Compassionate Use is
created
Bryan Krumm from New
Mexicans for
Compassionate Use
speaks in front of New
Mexico Board of
Pharmacy to gain support
to reschedule cannabis

Gov. Johnson suggests
that federal government
should decriminalise
drugs
Drug czar visits New
Mexico to counter Gov.
Johnson’s statements
Activists announce
potential lawsuit to
reinstate the 1978
therapeutic program,
Alex Valdez of New
Mexico Department of
Health says he will move
to reinstate the law, based
on Gov. Johnson’s
instructions
Gov. Johnson uses line-
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petition in Ann Arbor
to stop police charging
individuals using
medical cannabis

2001

Supreme Court rules
there is no medical
necessity exception
to the CSA in U.S.
v. Oakland
Cannabis Buyers’
Cooperative

Second petition drive
to place “Personal
Responsibility
Amendment” on ballot
Michigan NORML
organises activity to
counter negative
perceptions of the
organisation
Michigan senators
speak against medical
cannabis legislation

item veto to remove a
provision banning the use
of budget money on
promotion of drug
legalisation and
decriminalisation
Gov. Johnsons says
cannabis should be
legalised
Alex Valdez suggests
modelling medical
cannabis program on
Hawaii’s program
Drug Policy Advisory
Group recommends
reform of the Lynn
Pierson Act and that the
state’s medical cannabis
law should be modelled
on Oregon and Hawaii’s
program
Gov. Johnson supports
medical cannabis law
Opposition vocal in the
media, saying Gov.
Johnson is sending a bad
message and lobbying
lawmakers to reject some
of Gov. Johnson’s drug
reform bills
NORML begins airing
radio advertisements
Two medical cannabis
bills introduced
Poll finds majority

Brenda Kratovil
seeks to use a
medical necessity
defence at her trial,
drawing upon the
1978 law

Gov. Patton signs
into law a bill
allowing research
on hemp
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Detroit Coalition for
Compassionate Care
starts city-based
medical cannabis
petition

2002

2003

U.S. House of
Representatives
rejects amendment
to stop federal raids
on medical cannabis
patients

support for medical
cannabis
Gov. Johnson waters
down a medical cannabis
bill following a Supreme
Court ruling
New medical cannabis
bills introduced in the
Senate
NMDH spokesperson
supports cannabis as a
medicine
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Arrest sparks debateWesley Sarradet
arrested for
cultivating and using
cannabis, alleges it
was for medical
problems
NORML says the
reason behind o good
medical cannabis
clinical trials is
federal government’s
tight control over
cannabis
Dr Robert Goidel
from Public Policy
Research Lab says
there is little interest
in medical cannabis
in the Southern states

Compassionate Use
Medical Cannabis bill
introduced in the House
of Representatives and
defeated
Gov. Johnson replaced by
Gov. Richardson

Gubernatorial
candidates oppose
legalising cannabis
for general use
MPP say Louisiana
cannabis laws should
be modelled on a law
proven workable in
other states
2004

Ann Arbor medical
cannabis ordinance
change placed on city

Court finds that
Kratovil had other
alternatives to

Supporters of
medical cannabis
legislation
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ballot
Governor Granholm
opposes Ann Arbor
Ordinance change
Detroit voters pass
medical cannabis
ordinance amendment
“Love. The Anti-Drug”
launched in Detroit by
director of the ONDCP

cannabis and was
not entitled to a
medical necessity
defence
First attempt at
passing medical
cannabis legislation
with Medical
Cannabis Act
Medical cannabis
bill draws media
attention and
proponents and
opponents start
speaking out
Representative
McKeon say that he
sees cannabis as a
cure for his HIV
related pain
City activityChicago Mayor
supports issuing
fines to individuals
found to be in
possession of small
amounts of cannabis
Dr Barthwell of the
ONDCP tours the
state and speaks

organise a rally
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2005

The U.S. Supreme
Court upholds the
power of Congress
to prohibit and
prosecute medical
cannabis

Ferndale and Traverse
City pass medical
cannabis ordinance
amendments
Activists start
circulating petitions to
legalise cannabis and
regulate it like alcohol

Media reports that the
pharmaceutical industry
contributed money to
New Mexico political
campaigns
Legislative support for
medical cannabis
decreased since Gov.
Johnson was replaced by
Gov. Richardson

MPP say the Supreme
Court ruling will not
deter medical cannabis Senate passes three
efforts in Michigan and medical cannabis bills
other states
Gov. Richardson says
Medical cannabis bill
that if the House passes a
introduced in the
medical cannabis bill he
House of
would sign it
Representatives, the
ONDCP ask for it to be
rejected

2006

FDA confirms
Medical cannabis bill
opposition to
dies
smoked cannabis for Activist group

Patients speak in support
of medical cannabis

against medical
cannabis
Medical cannabis
bill dies at a
committee without
being voted on, bill
filed again
Dr Barthwell holds
seminars speaking
against medical
cannabis, the
ONDCP director
arrives in Illinois to
testify against
medical cannabis
legislation

Supreme Court
ruling on medical
cannabis restarts
debate
Reports from law
enforcement that
cannabis trade is a
big problem in
Kentucky, a
leading state in
cannabis
cultivation
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CAN gather enough
signatures to put
cannabis initiative
onto parish-level
ballot
CAN hold parties at
Louisiana State
University to
promote cannabis
legalisation
DPA announce they
wold begin a
lobbying initiative in
Louisiana

Medical cannabis
patients testify in
favour of medical
cannabis
Law enforcement
groups oppose
medical cannabis
legislation
Medical cannabis
bill rejected by the
Human Services
committee
NORML say that
medical cannabis
legislation in Illinois

Students gather at
a medical cannabis
rally organised by

Media frenzy follows
the arrest of country
music star Willie

Medical Cannabis in the United States
medical purposes

proposes making
cannabis legal for
those over 18 years of
age
NORML announce
they will try to get a
medical cannabis bill
on the 2008 ballot but
distance themselves
from the cannabis
legalisation proposal

2007

DEA
Administrative Law
Judge recommends
allowing new source
of cannabis for
research

Flint City voters pass
medical cannabis
ordinance change
Medical cannabis bill
introduced in the
House of
Representatives
ONDCP say medical
cannabis laws would
not help sick
individuals
MCCC announce they
will launch a Michigan
Medical Marihuana

Gov. Richardson
announces he will
include a medical
cannabis bill on his
agenda, House Speaker
asks the governor not to
include the bill on his
agenda

may be a decade
away

Kentucky chapter
of NORML

New medical
cannabis bill
introduced in the
Senate

Medical cannabis
debate organised at
Western Kentucky
University
Students gather to
promote
University of
Kentucky’s
NORML chapter

Medical cannabis bill
dies on Senate floor

Lynn and Erin
Compassionate Use Act
introduced in the Senate
Opponents say medical
cannabis bill contradicts
federal law

Increase in media
reports on medical
cannabis
Medical cannabis
bill introduced in
Senate

Lynn and Erin
Compassionate Use Act
defeated and replaced by
another ac

MMPAP speak in
support of medical
cannabis

Gov. Richards says that
signing the bill would be
the right thing to do

Church leaders
speak in support of
medical cannabis

Allegations that Gov.

Ordinance change in

Dispute over
medical cannabis
on religious
grounds
Students at
University of
Louisville debate
medical cannabis
legislation
Religious leaders
join the medical
cannabis debate
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Nelson for cannabis
possession
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initiative

Richardson used medical
cannabis to gain support
for his presidential
campaign
Gov. Richardson signs
the Lynn and Erin
Compassionate Use Act
into law

2008

American College
of Physicians calls
for cannabis
reclassification and
supports nonsmoked forms of
medical cannabis

Peoria Heights for
possession of small
amounts of cannabis
Medical cannabis
documentary
screened in Southern
Illinois University

MCCC poll reveals
67% of Michigan
Voters support medical
cannabis

NORML active in
the media,
responding to
opposition

Michigan State
Medical Society
oppose medical
cannabis, except for
use in controlled
studies

Two medical
cannabis bills
introduced

Newspaper reports
MCCC spent over $1.1
million on
campaigning, with
most money coming
from MPP
Citizens Protecting
Michigan’s Kids is
formed, opposing
medical cannabis law
Director of the
ONDCP speaks against
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Survey shows that
majority of Illinois
voters support
medical cannabis

Medical cannabis
patient from
California arrested in
Louisiana on a
cannabis possession
charge
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medical cannabis in
Detroit
A group of local law
enforcement agencies
issue a statement
opposing medical
cannabis proposal
Michigan voters
approve medical
cannabis initiative
2009

DEA rejects ruling
to allow new source
of cannabis for
research
AMA calls on the
federal government
to reconsider
cannabis’
classification under
federal law
Deputy Attorney
General says raids
on medical cannabis
clinics will not
continue

2010

President Obama
assuming office
sparks optimism in
medical cannabis
supporters
City activitySpringfield and
Cook County
change ordinance in
relation to cannabis
possession
Two medical
cannabis bills
introduced

Politicians from

Cannabis debate
reignites

Reports that cannabis
arrests on university
campuses increased

Cannabis
legalisation debate
organised at
University of
Kentucky

Deputy Attorney
General’s statement
discussed in the
media

Gatewood
Galbraith holds
lectures on
medical cannabis

Medical cannabis
research conducted
by LSU Health
Science Centre

Galbrait says he
predicts that
President Obama
will decriminalise
cannabis use and
that Kentucky
could make money
by making
cannabis legal
Suggestions that

Supporters say it
would take a lot of
advocacy to pass
medical cannabis
legislation in
Louisiana

NORML becomes

Medical Cannabis in the United States
both parties indicate
they would consider
medical cannabis
bills
Suggestions that
some lawmakers
were worried about
making politically
risky voters
Medical cannabis
bill dies

2011

Medical cannabis
bill re-introduced

Kentucky should
consider legalising
cannabis for
medical cannabis
as a way of raising
state revenue
Republican
gubernatorial
candidate says he
supports legalising
industrial hemp,
but is not in favour
of cannabis
legalisation

Galbraith set to run
for governor as an
independent.
NORML say they
are not advocating
smoked cannabis
but its medicinal
and industrial use
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more active in
Louisiana and state
they will only focus
on medical cannabis,
however NORML
less active by the end
of the year due to
conflict among the
executive board
Protests against
cannabis legalisation
held across Louisiana
New Orleans city
council reclassifies
cannabis possession
to municipal offence
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The role of scientific evidence. A 2010 report on medical cannabis concluded
that “it is widely believed that science should rule when it comes to medical issues”
(Eddy, 2010, p.46). However, based on the reviews of representative states in this
chapter, this is often not the case, there being a discrepancy between what the evidence
tells us and how this is reflected in current medical cannabis laws. The research
evidence reviewed has shown that cannabis and its constituents have therapeutic
potential for a number of conditions including chronic pain, spasticity, nausea and
vomiting, and as an appetite simulant for AIDS-related wasting syndrome. The laws in
New Mexico and Michigan cover these and other conditions. Use of smoked cannabis is
generally not the recommended route of administration, but all the medical cannabis
state laws provide for the use of smoked cannabis (House of Lords, 1998; Robson,
2001; WPUCMP, 2000).
Ideally, scientific evidence should always be incorporated in selecting and
implementing programs, developing policies, and evaluating progress but the review of
the medical cannabis laws has shown the situation to be otherwise (Brownson, Baker,
Left, Gillespie, & True, 2011). The policy process is primarily a political rather than
scientific process which does not rely solely on research evidence (Anderson, 2003;
Brownson et al., 2009; Brownson et al., 2011; Pentz, Marers, Schinke, & Rohrbach,
2004; Ritter, 2011).
It can also be seen that scientific evidence was presented to the general public,
but mostly filtered through the media. While proponents and opponents were active in
putting forward their opinions, researchers were not featured prominently in the medical
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cannabis debates. According to Weiss’ (1979) “enlightenment model”, the impact of
research on policy is not direct, but research is instead seen as one of several sources of
information available to policymakers; a gradual shift in thinking over time and
accumulation of research will influence policy by educating the policymakers. While
those involved in the field have called for more research into medical cannabis, based
on the evidence reviewed in this thesis it cannot be said that further research will play a
bigger role in influencing medical cannabis laws.
“Cherry-picking”: the selective use of evidence. Weiss identified ways in which
the results of policy research enter the policy field and suggested that research can be
used to support positons already adopted. That is, policymakers and/or interest groups
use research to support their position (Weiss, 1991). While scientific evidence may not
directly inform medical cannabis policy development, the findings of the research
presented in this thesis suggest that it still plays a role in the process, just not a direct
one. However, scientific evidence, regardless of its quality, appears to rarely enter the
debate except when it is used as ammunition. Both opponents and proponents of
medical cannabis tend to use research findings as a means of attacking or defending
their arguments, rather than as the key to deciding whether cannabis should be available
as a medicine for specific conditions or not. For example, the IOM (1999) review
outlined both positives and negatives of cannabis use and provided ammunition for both
proponents and opponents to use in the medical cannabis debate. Medical cannabis
supporters focused on the report’s findings that cannabis has medicinal properties and
that there was no convincing evidence for the “gateway” theory. Opposition,
meanwhile, mainly focused on the report’s findings that cannabis smoke can be toxic.
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As Weiss (1991) suggested, research being used to argue a position is more
likely to be influential when conflict is high and different sides are seeking justification
to strengthen their own case and in legislatures where argumentation is the prevailing
mode (Weiss, 1991). In Michigan and New Mexico, for example, once the findings of
the IOM report were published they were used by both sides to support their arguments.
Most debate in Michigan occurred in the months prior to the medical cannabis bill going
on the ballot, and in New Mexico the debate intensified following the IOM report and
the 2001 Supreme Court ruling that there is no medical necessity exception to the CSA.
Public opinion. Public opinion is particularly influential in states passing a law
through a ballot initiative. For example, Michigan’s law was passed through a ballot
initiative and there was much focus on getting public support, convincing the public,
and portraying the issue as being ether detrimental to the public or in its best interest. In
Michigan particularly, medical cannabis opponents frequently appealed to the public
and portrayed their cause as being about preventing “wrong messages” from getting to
the public or to certain groups. It can be difficult to argue against a vague concept such
as “sending the wrong message”; in Michigan there was little questioning of what these
wrong messages were and what sort of an effect they would have. In Michigan, medical
cannabis opponents also accused the proponents of relying on the sympathy of the
voting public, creating policies which were not in the public’s best interest, and called
shutting down of medical cannabis dispensaries “a matter of public safety”. New
Mexico did not experience the same amount of public debate or attempts at influencing
public opinion as Michigan did. Illinois did experience significant public response
regarding the medical cannabis issue, but since questions related to medical cannabis

Medical Cannabis in the United States

236

cannot be placed on a ballot initiative in this state, the attempts at influencing public
opinion were somewhat futile (IRI, 2009; MPP, 2013).
That is not to say that public opinion does not influence policy in states
attempting to pass a law through the legislative process, as public opinion has been
identified as one of the major factors politicians take into account when making policyrelated decisions. Public opinion can be of importance to politicians as it is the public
who determines whether the politician stays in power or not. Amongst other things,
politicians are therefore concerned with what they think the public wants. This raises the
question of how much of a role public opinion plays when a politician is not up for reelection.
Local governments. Over the years, local governments have become more
representative of the communities they serve; this has made it easier for the electorate to
raise issues and voice their opinions; and sometimes act more quickly at the local level
than the state and federal governments do (Katz, 2003; U.S. Immigration and
Naturalization Service, 1987). In Michigan, cities led the movement towards medical
cannabis legislation. The first movement occurred in 2004, when Detroit voters passed
an initiative to legalise medical cannabis in the city, despite opposition from Gov.
Granholm. Ann Arbor followed, with approximately 75 percent of voters supporting
amendments to the ordinance to decrease fines for cannabis use and prohibit local police
from fining medical cannabis patients for possession. Ann Arbor has a history of
passing cannabis ordinances dating back to 1972 (Cannabis laws in Ann Arbor,
Michigan, n.d.). Despite opposition, in 2005 both Ferndale and Traverse Cities passed
medical cannabis related ordinance changes. There was also city-level activity in Illinois
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and Louisiana and movements towards medical cannabis legislation at the state level
also coincided with attempts at city-level changes.
The people as legislators: Influence of direct democracy. Initiatives give the
electorate a more direct input to the enactment of laws that were originally created as
means of directly enacting public policy (Kousser & McCubbins, 2005). However,
Kousser and McCubbins (2005) claimed that in the recent years the initiative process
has been used as a check on the legislature and a way of pressuring it into adopting
certain policies. The findings in this study indicate that using the initiative process
helped pass medical cannabis laws initially in some states and helped them gain
momentum in other states, eventually leading to legislatures passing such laws. Starting
with California, the first seven state medical cannabis laws were passed by a ballot
initiative. To date, 10 of the state medical cannabis laws were passed by a ballot
initiative and 7 were passed by the legislature (ProCon.org, 2014).
Michigan’s medical cannabis law was passed through the initiative process.
While there were attempts to pass medical cannabis laws via the legislature, those
attempts proved unsuccessful. The findings also indicate that there may be some
differences between the factors which play a role in passing medical cannabis laws in
states with the initiative process and those without. For example, two key factors, both
external to the state legislative and executive branches, were important in moving
Michigan towards its medical cannabis law. These were the actions of several cities to
enact their own policies and the use of the ballot initiative. The medical cannabis cause
in Michigan received more attention from national organisations such as the MPP and
NORML, and also received more funding for the cause. There was also more activity in
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Michigan, in terms of promoting the issue, media attention, and the number of organised
state-based support groups.
The initiative process can be a powerful agenda-setting tool which can be used
by interest groups, politicians and occasionally political parties to drive an issue onto
the national agenda because of the widespread media attention given to some initiatives
(Magleby, 1998). Even when defeated at the polls, attention can still be drawn to a
particular issue, leading decision makers to discuss and comment on it. Magelby (1998)
highlighted that because proponents need to meet the signature requirements to place
their issue on a ballot, which requires either a large number of volunteers or funds to
hire signature collectors, the initiative process is becoming less a “grass-roots
phenomenon” and more dominated by large and well organised interest groups. He also
highlighted the importance of campaigns in defining what the issue means for voters
and said that initiative campaigns are “largely fought in thirty- and sixty-second
commercials using attention-getting advertisements” that motivate citizens to either care
about the issue or create doubts about the initiative (Magleby, 1998, p. 149).
Interest groups prefer to use direct initiatives to indirect and often propose and
finance initiatives in multiple states to attract national attention to their issue and
advance their interests (Hastings & Cann, 2014; Magleby, 1998). Getting a proposition
on the ballot is a costly and time-consuming process (Cushman, 2005). Requirements
for putting a proposal on the ballot vary among states, but in some states more than 500,
000 signatures in support of the initiative are required. It has been argued that this
process can put well-funded special interest groups at an advantage because of their
access to campaign professionals, access to donor lists, and media strategies (Birkland,
2005; Braunstein, 2004; Cushman, 2005; Magleby, 1998).
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Organised interest groups. While organised interest groups are more likely to
have a greater access to resources and make campaign contributions in order to advance
their desired outcomes, money is very important as it enables the groups to do so
(Birkland, 2005; Boehmke & Bowen, 2010). Much of the research on the topic has
indicated that monetary resources and a large interest group membership assist in the
success of the initiative process (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby,
1998). There has been a growth in the “initiative industry” that specialises in services
such as petition circulation and polling. As can be seen by the Michigan reports, interest
groups paid money for voter signature collection in order to place medical cannabis on
the ballot. It has been estimated that 78 percent of ballot campaigns have been won by
the side that spent the most money (Braunstein, 2004).
Interest groups are very important in the policy process and are an effective way
for people to express their desires for policy (Birkland, 2005). Advocacy groups have
been very active in states such as Michigan, where they had a persistent and prominent
involvement. Michigan also experienced significant involvement from national
organisations such as the MPP, the Open Society Foundation (founded by George
Soros), and NORML, who played a major role in raising public awareness of the issue.
Not only were advocacy groups influential in passing legislation, they also influenced
what sort of legislation was passed. In his assessment of interest group influence on
U.S. policy change, Grossman (2012) found that since 1945, policy historians credited
385 out of 790 significant policy enactments to factors related to interest groups, mainly
general support and lobbying by advocacy organisations.
The extent to which advocates for both sides of the debate are organised may
have contributed to the successful enactment of medical cannabis laws. For example, in

Medical Cannabis in the United States

240

Michigan, MCCC successfully lobbied for medical cannabis over a period of time,
while there was no specific organised opposition group until 2008, shortly before the
issue was due to be voted upon. This could have given medical cannabis supporters the
advantage, as the opposition only had months to prepare their stance and get actively
engaged in lobbying against the initiative. The supporters also had a chance to carefully
set out a strategy, and through the use of media spread their message to a wider
population. But this is not the case in New Mexico, where no specific group was
formed. Whether or not this was due to the process taking place predominantly within
the political system, there being no ballot initiative, is a point worthy of further
consideration.
Allocation of money. Another issue which can affect the policy process is the
allocation of money to support either side of the argument. As New Mexico does not
have a ballot initiative process, the medical cannabis debate occurred within the
political system, and little external money was spent there (IRI, 2009). Michigan,
meanwhile, has a ballot initiative process, which resulted in the debate occurring in the
public as well as the political arena. In Michigan, in 2008 alone, the MCCC processed
99 separate donations and a large proportion of external money was spent on the media
and increasing public awareness of the issue. However, money is not always used to
support an issue, but can also be used to oppose it, or prevent a law from being passed.
Because New Mexico does not have an initiative process, instead of money being
donated to the medical cannabis cause, it was found that, in 2002, the pharmaceutical
industry contributed money to new Governor Bill Richardson, which he stood to lose if
cannabis became a legal treatment.
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Politicians and political parties. Politicians play an important role in the
enactment or non-enactment of medical cannabis policy. In states with no ballot
initiative process, medical cannabis laws were passed by the legislature. While it is
important to have support from politicians, the support does not come easily as there are
many factors politicians need to take into account when making policy-related
decisions. If the aim is to make policy making more evidence-based and educate
politicians, then scientists should be aware of the political process and the factors, apart
from scientific evidence, that are important to politicians and that politicians need to
take into account.
A very important factor is getting re-elected. As previously mentioned,
politicians need to carefully consider the timing of their decisions to support or oppose
particular legislation. Politicians also need to consider the impact and benefit of their
decisions, and what happens in the future. Other factors include, but are not limited to
campaign funding (who provides support for their re-election and how the decision to
support or oppose particular legislation will impact fund raising); how they are
perceived; international standing; lobby, pressure, and interest groups; political
ideology; what happened and is happening in other states; public opinion; scientific
evidence; and the policy advice they receive. Scientists interested in informing policy
need to consider these factors and create the sort of evidence that fits in with what
politicians need and are looking for.
Politicians also need to take into account their party ideology. The two major
parties have, over the years, become distinct in their ideologies and positions they
assume on a range of issues (Birkland, 2005; Singh, 2003). Generally, the Democrats
have typically preferred to centralise policymaking, seek to promote equality, and
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support government intervention to deal with important problems. The Republicans
generally wish to decentralise policymaking authority, and tend to support fiscal
prudence and limiting government intervention. The Democrats are generally seen as
being more liberal while the Republicans are seen as conservative. In terms of medical
cannabis, the general notion is that the dominant Democrat position is to support
medical cannabis, while the dominant Republican position is to oppose it (Pickerill &
Chen, 2008). However, some of the states, such as New Mexico, neither support for nor
opposition to medical cannabis were clearly defined amongst political parties. What the
parties attempted to do was use the opponents’ positions as campaign issues, while not
taking a clearly defined stance themselves. The state’s two last governors, one of whom
was a Republican, were supporters of medical cannabis, with Gov. Johnson being very
vocal on not only medical cannabis legalisation, but general cannabis legalisation as
well. This was in opposition to most medical cannabis activists attempting to separate
medical cannabis from general cannabis legalisation.
High-profile politicians. While there were high-profile organisations
supporting medical cannabis, the issue also drew opposition from some sections of the
public and some politicians, including the White House. While the ONDCP and the
DEA were also active in voicing their anti-medical cannabis stance, their influence was
counteracted by high-profile state politicians who supported medical cannabis. In New
Mexico, two governors supported medical cannabis laws, even though they came from
opposite sides of the political fence. The influence that support from high-profile
politicians can have on passing legislation should not be underestimated, especially in
states such as New Mexico, where there is no ballot initiative. There was also no
significant support from high-profile individuals in Kentucky and Louisiana, where
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public support was lower than in other states and there was no significant involvement
from high-profile organisations.
Decoupling. Making a clear distinction between medical cannabis and the
broader aim of decriminalisation or legalisation of cannabis for recreational as well as
medical use has played a major role in the medical cannabis debate. In both Michigan
and New Mexico, medical cannabis advocates made it clear that their main, limited aim
was legalising cannabis for medical use only. In Kentucky and Louisiana, however, the
distinction was not as clear. Decoupling has political importance, as one of the main
arguments used by the opposition is that medical cannabis is a step towards legalising
cannabis use in general. Making a clear distinction between these counteracts the
opponent’s arguments and makes medical cannabis legalisation more generally
acceptable.
However, it is not always as straightforward in terms of who supports what.
Some medical cannabis advocates have made it clear that their only aim is to make
cannabis legal for medical purposes. Other organisations, however, have failed to make
a clear distinction and sometimes tend to fluctuate between being medical cannabis
supporters only and supporting general cannabis legalisation. For example, while
Michigan NORML campaigned for medical cannabis legislation, one NORML
representative said that the organisation wanted the drug legalised for both recreational
and medical use. The MPP, on the other hand, have consistently maintained that their
efforts were aimed towards making cannabis legal for medical purposes only, and that
medical cannabis was not a step towards general cannabis legalisation.
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Having no uniform stance on the issue has the tendency to confuse the public
and raises a question of what the real goal of such organisations is. It can also influence
how the public perceives medical cannabis advocates and whether or not the issue
garners enough support. The advocate organisation may therefore need to compromise
in order for an issue to be passed. In Michigan, for example, because the two
organisations had conflicting messages, NORML took a back seat to the MCCC to
counter the claims that legalising medical cannabis was a step towards legalising
cannabis in general, because MCCC made it clear that their sole goal was legalisation
for medical purposes only.
Use of anecdotal evidence and personal experience. While scientific evidence
plays some role in the policy process, it can also be argued that the process is influenced
more by anecdotal reports than by scientific evidence. The majority of evidence on
cannabis as a medicine comes from personal and historical accounts (Mack & Joy,
2000). Throughout the medical cannabis debate in the states reviewed in this thesis,
patient accounts and personal experience have frequently been mentioned. Patient
testimonies were most prominent in New Mexico, where the medical cannabis law was
passed by the legislature. Michigan also saw its share of patient testimonies, but most
were presented in the media, either as accounts of their experience with the drug, or as
letters written to the media. The opposition also used individuals and their personal
experience to testify against medical cannabis bills.
There have also been a number of anecdotal reports published, especially in the
case of cannabis’ use in the treatment of glaucoma. This may have influenced the
inclusion of glaucoma in the list of debilitating medical conditions cannabis can be used
for in the states with a medical cannabis law, despite limited scientific evidence
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supporting the use of cannabis in the treatment in intraocular pressure (ProCon.org,
2014). Only two states do not specifically include glaucoma in the list of the conditions,
these being Delaware and Vermont. Interestingly, both states passed their laws through
the legislature.
Anecdotal reports also have the potential to inspire further research, as was the
case with the House of Lords (1998) report, which found that there was strong anecdotal
evidence for cannabis in the treatment of MS and recommended urgent clinical trials. In
their examination of the role of anecdotal evidence in public scientific controversies,
Moore and Stilgoe (2009) found that anecdotal evidence can be used as a guide towards
further investigation of an issue. Findings from this thesis indicate that politicians listen
to anecdotal evidence and can sometimes base their decisions on it, more so than on
scientific evidence. This could be due to the fact that anecdotal evidence is considered
by some as a representation of public concerns. Anecdotal evidence also admits public
involvement in development of research programs. Anecdotal evidence is also a more
localised form of understanding, based on individual experience and knowledge of
specific, local conditions that are not necessarily “typical” circumstances (Moore &
Stilgoe, 2009).
Media. How an issue is framed in the media, or how facts and ideas are
assembled into messages, can also shape how individuals interpret and evaluate the
issue (Lee, McLeod, & Shah, 2008). Research also suggests that the way an issue is
framed can not only direct the kind of knowledge that is activated in the person reading
but also how individuals then weigh such issues as relevant attitudes and beliefs, based
on what they were exposed to (Lee et al., 2008). Geographical location also plays a role
in terms of the media attention given to a particular issue. In terms of medical cannabis,
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one study found that in both the Southeast and the Midwest of the U.S., the news
sources paid the least amount of attention to medical cannabis, comparing to the
Northeast (Pickerill & Chen, 2008).
Policy research has not been clear whether media is a just a channel used to
convey information or a major contributor to the policy process (Gerstl-Pepin, 2007;
Shanahan, Mcbeth, Hathaway, & Arnell, 2008; Speck, 2010). In terms of medical
cannabis policy, media acted as a sort of battle arena where the debate occurred, and
both sides got to present their opinions. There was a tendency for two different sets of
views to be presented. On one side, cannabis was presented as a harmless drug with
medicinal properties, while, on the other, it was portrayed as a harmful drug which
should continue to be prohibited for both recreational and medical use (Strang, Witton,
& Hall, 2000). Media can also serve as a link between the people and the government
and can help determine which issues are discussed and which issues the public and
advocacy organisations get involved in. As a result, the media kept the public actively
involved in the issue, especially in states such as Michigan, which has a ballot initiative
process.
Organisations such as MPP and NORML have used media to draw attention to
the issue, and have encouraged medical cannabis supporters to contact media and write
letters of support. Medical cannabis opponents have been less active in using the media
to promote their stance, but this could also be attributed to the funds available to them.
Interestingly, the number of media reports on medical cannabis was very high in
Michigan and New Mexico, but they were fewer in Louisiana, and even more scarce in
Kentucky. The “hot topic”, or the topic media focused on the most, was different
amongst the states too. For example, in Kentucky the focus was on hemp over medical
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cannabis, in New Mexico it was general cannabis legalisation, while in Michigan the
main focus was on medical cannabis. Speck (2010) argued that the media had the power
to decide what they want to portray and how, and what they think is newsworthy,
influencing what the general public sees.
Findings also indicate that media can filter scientific evidence, and can be
selective as to what is or is not put forward to the public. As is the case in the review of
the media articles in the five representative states in this chapter, Shanahan et al. (2008)
found that there is limited use of science in media articles, and that the information
presented is mostly based on “interest groups, elected officials, judges, governmental
agencies, and business/individual citizens” (p. 131).
Overall, it can be said that the media is an integral part of politics, acting as a
watchdog and an important check and balance on the political system (Gerstl-Pepin,
2007). It is the main way the public receives information on political issues and can
influence how an issue is portrayed and what the focus is on. Media can also be used as
a tool, enabling supporters and opponents to be persistent and active in promoting their
cause. However, care needs to be taken as to how media is used, as it can be either
detrimental or beneficial to a particular issue. In terms of the goal of creating evidencebased policies, scientists need to consider ways to disseminate the evidence in a way
that it is picked up by the media, or go directly to the public and those who make policy
decisions if there are misinterpretations and misrepresentations in the media.
The findings from the state by state review conducted in this chapter indicate
that a number of factors influenced the passing and failure to pass medical cannabis
laws in the five states under review. Scientific evidence is one factor, but this is often
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not used in the manner scientists would prefer but rather as ammunition to support an
already adopted position by those involved in the debate. Anecdotal reports of those
who have or could potentially benefit from medical cannabis are important, as is the
role of organised and well-funded advocacy groups. While the support of powerful
politicians can be important, as in the case of New Mexico, lack of such support does
not prevent laws being enacted, as the case of Michigan illustrates. It should also be
noted that the decoupling of medical cannabis from wider moves to decriminalise or
legalise cannabis use is important. The findings also indicate that the allocation of funds
(how they are allocated, where, and by whom) can influence whether or not a law is
passed, as can the level of public support for the issue in a particular state. Lastly, it is
important to consider the state political system and ways of passing legislation.
The second part of the thesis (see Figure 7), as discussed in the following two
chapters, used questionnaires to elicit the factors influencing policies as perceived by
four groups of participants. The questions asked were derived from the literature review
presented in Chapter Three and the review of five representative states presented in
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Chapter Four.

Identifying themes
MULTI METHOD
PHASE

Literature Review
State by State
Review

Qualtrics
Questionnaire
(Groups 1-3)

QUALITATIVE
PHASE
Telephone
Interviews

Thematic analysis
Data Analysis
Qualtrics,
Descriptive
statistics

Integration of
Findings
Implications for
Drug Policy
Conclusion

Thematic Analysis
QSR NVivo

(Group 4)

Figure 7. Explanatory study design.
Chapters Five and Six will describe the four study groups and will discuss the
research design, sampling and data collection procedures, and the techniques used for
data analysis for each group. Group One comprised individuals directly involved in the
medical cannabis policy process in at least one of the five states referred to in the state
by state review. Group Two comprised individuals participating in research in the
alcohol and other drug field; Group Three comprised individuals currently participating
in the political field in one of the five U.S. states; and Group Four comprised selected
members of the International Society for the Study of Drug Policy (ISSDP).
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Chapter 5- Group One and Group Two Study
This chapter will outline in detail how the Group One and Group Two studies
was undertaken, provide details of the study design, and present findings. Group One
participants were active participants in the medical cannabis debate described in
Chapter Four of this thesis. Group Two participants were individuals participating in
research in the alcohol and other drug field in one of the five U.S. states under review in
this thesis.
A multimethod approach was employed, combining both closed-ended and
open-ended questions. The multimethod approach was used in order to obtain relevant
demographic information and basis statistics, while gaining an understanding of the
participants’ opinions, attitudes, and involvement in the medical cannabis process (Ellett
& Beausang, 2002). While priority was given to the qualitative component to allow the
exploration of participants’ opinions on what they perceived to be the main factors that
played a role in the passing or failure to pass medical cannabis laws in the states
reviewed in this thesis, each method was used for a specific purpose in order to achieve
an overall comprehensive understanding of the complex medical cannabis policy
process.
Sample
Group One participants were selected through a non-random sampling method.
They were identified as active participants of the medical cannabis movement in at least
one of the five representative states, as described in Chapter Four. Any one individual
who participated in the debate was invited to be a participant in the research and their
opinions on what happened in the representative states they were active in were sought
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to further explore the medical cannabis movement in those states and the main factors
that played a role. As such, selection bias might have resulted, and will be addressed in
more detail later.
Group One participants were all from the U.S. and were actively or previously
involved in the medical cannabis debate. Their backgrounds included government
officials, lobbyists, medical professionals, and other individuals. A total of 172
participants identified by the review were invited to participate; 147 were contacted via
email and invited to complete an online Qualtrics (www.qualtrics.com) survey, and 25
were contacted by mail and sent a printed questionnaire. Of those, approximately 12
emails were undeliverable, and four participants advised that they would be unable to
participate. Overall, 31 (18%) of the identified participants responded to and completed
the survey. Of those, 24 completed both quantitative and qualitative portions, while five
completed only the first (quantitative) portion. The results of the five participants were
included in the analysis of quantitative data only.
Group Two participants were also selected through a non-random sampling
method. Group Two participants were researchers who were currently conducting
research funded by either the National Institute on Alcohol Abuse and Alcoholism
(NIAAA), the NIDA, or the Substance Abuse and Mental Health Service
Administration (SAMHSA) in one of the five states under review in this thesis. The
participants were selected as it was expected that they would provide a more objective
perspective on the medical cannabis movement.
Group Two participants were identified using the National Institutes of Health’s
reporter website (http://projectreporter.nih.gov/reporter.cfm), which provides names and
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contact details of researchers receiving funding in specific states. The list of potential
participants was created by narrowing the numbers down to those working with or
funded by organisations relevant to the alcohol and other drug field (i.e. NIDA,
NIAAA, and SAMHSA). A total of 209 participants fitting the selection criteria were
identified and were contacted via email and invited to complete the online Qualtrics
survey. Of those, 23 (11%) responded to the survey and 22 completed both quantitative
and qualitative portions of the questionnaire. The results of the one participant who
completed only the quantitative section were included in the quantitative only. Four
individuals declined to participate because they felt that they could not be of any
assistance.
Procedure
Approval for the study was obtained from the ECU Human Research Ethics
Committee prior to commencing the research. The following section will describe the
procedures used in the development of questions and questionnaire design and how the
questionnaires were distributed. The data collection period for Group One spanned from
11th October 2010 to 14th January 2011, and involved two data collection methods: an
online questionnaire and a mailed/printed questionnaire. It was anticipated that
utilisation of different collection methods would increase the number of respondents
and produce a rich source of data. The data collection period for Group Two spanned
from 16th November 2010 to 16th January 2011, and utilised an online questionnaire as a
data collection method.
Data collection methods. Online questionnaires have been increasingly used for
a wide range of research topics (Van Selm & Jankowski, 2006). The use of primarily
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online questionnaire surveys was deemed the most appropriate method of addressing the
research questions, as it was in most cases the only form of contacting the participants.
Online questionnaires allow access to a wide range of participants, especially when they
are distributed across a large geographic region (Van Selm & Jankowski, 2006). Due to
participants residing in the U.S., this form of data collection was deemed suitable. Using
online questionnaires also allowed the participants enough time to complete the
questionnaire at a time suitable to them, therefore minimising inconvenience (Van Selm
& Jankowski, 2006). No identifying information apart from the respondents’ IP address
was recorded from the questionnaire in order to offer participants anonymity (O'Leary,
2004). A self-administered online questionnaire also avoids potential errors of data
entry, as the data were automatically transferred into an Excel database.
Mailed questionnaires were deemed appropriate for those participants without an
email address, or whose email address could not be found. Mailed questionnaires also
allowed access to participants from different states and allowed the participants enough
time to complete the questionnaire at their own leisure (O'Leary, 2004).
Questionnaire design. Group One. In the state by state review part of this
study, journal articles, newspaper articles, parliamentary proceedings, and court
documents relating to medical cannabis policies were analysed for emerging themes.
These themes were then used to develop a questionnaire which was sent to Group One
participants (see Appendix A). The questionnaire was divided into two sections.
Participants were provided with an introduction to each section, as well as instructions
on how to answer specific questions. The first section requested demographic
information from the respondents, and asked questions related to participants’ opinions
on the medical cannabis debate in their state of residence. The questions covered
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participants’ opinions on medical cannabis, scientific evidence, and the importance of
factors such as advocacy groups, politicians, and money in determining whether
medical cannabis legislation is enacted or not. Participants were also asked to rate
factors identified through the state by state review in terms of their level of influence on
medical cannabis legislation. A Likert five-point scaling was used in the first part of the
questionnaire. Likert scales offer a range of responses in a sequence and allowed
respondents to indicate their level of agreement with a specific statement. It was
implemented in order to assess participants’ opinions in relation to medical cannabis
and factors affecting medical cannabis policy (O'Leary, 2004).
The second section contained open-ended questions and provided respondents
with an opportunity to address any other issues not covered in the first section, and
voice more of their own opinions (Van Selm & Jankowski, 2006). No limit was set on
the length of answers in section two. Section two contained general questions relating to
the medical cannabis debate and the factors influencing medical cannabis legislation, as
well as specific questions relating to factors influencing the medical cannabis debate in
the five representative states.
The questionnaire was kept as short as possible and divided into sections, as
research has generally found that participants are less likely to respond to large
questionnaires (Van Selm & Jankowski, 2006). All participants were allowed up to
three months to answer the questionnaire. Two emails were sent to participants who
opted for the online questionnaire, reminding them of the questionnaire closing date;
one a month after the questionnaire was emailed, and one two weeks before the
questionnaire closed. The message was sent to everyone in the selected sample
population and no personal data were retained. The participants were therefore advised
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that the researcher was unable to identify whether or not they had already completed the
questionnaire, resulting in everyone receiving a reminder email.
Group Two. The Group One questionnaire was replicated for Group Two
participants. However, because Group Two participants were not identified through the
state by state review as directly participating in the medical cannabis policy process,
they were asked additional questions relating to their involvement or lack of
involvement in the process, the form and amount of involvement, and their awareness of
the issue (see Appendix B).
Questionnaire administration. Group One. Once they were identified and their
contact details obtained, each Group One participant (n= 172) was sent an email or a
mailed letter inviting them to voluntarily complete an online or paper-based survey
regarding medical cannabis policy being passed or not passed in the U.S. The
participants were provided with an information email outlining the nature of the study,
and were advised that they were free to withdraw their consent and cease their
involvement in the study at any time (Appendix C). One of the limitations of
questionnaires is the fact participants cannot seek clarification (O'Leary, 2004). In turn,
participants were provided with contact details of the researcher, two supervisors, and
an independent contact (ECU Research Ethics Officer) in case they had any questions
about the study. Participants contacted by mail were sent a printed questionnaire along
with the information letter, and were asked to mail back their written consent along with
the questionnaire if they agreed to participate (Appendix D). A coupon was included in
the envelope to cover the cost of a stamp and envelope, so that participants could return
the questionnaire without incurring a charge. Participants contacted by email were asked
to indicate their willingness to participate in the research by sending an email to the
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researcher stating their agreement. After the email confirming their willingness to
participate in the research was received, participants were advised that they were free to
access the online questionnaire. The hyperlink to the online questionnaire was included
in the information email sent to participants.
The questionnaire was available online for three months, and participants did not
have to answer the questionnaire all at once (i.e. they were able to save the
questionnaire and continue at another time). A progress indicator was also used in order
to indicate the length of the questionnaire and encourage participants to persist in their
attempt to complete it (Van Selm & Jankowski, 2006). After the questionnaires were
closed for access, the data were downloaded and stored in a password locked computer
in the researcher’s office at ECU. The mailed questionnaires received were manually
entered into the online questionnaire and combined with those completed online. Hard
copies of mailed questionnaires were kept in a locked cabinet located in the researcher’s
office. Only the researcher had access to mailed questionnaires and raw data stored in
the computer. All participants were assigned numerical codes based on the group they
belonged to and the order that they completed their interview in. For example, a Group
One participant who was the fifth to complete the questionnaire was assigned the code
“G1-5”.
Group Two. The Group One questionnaire administration procedure was
replicated for Group Two participants. Once they were identified and their contact
details obtained, each Group Two participant (n= 209) was sent an email inviting them
to voluntarily complete an online questionnaire regarding medical cannabis policy being
passed or not passed in the U.S. The questionnaire was available online for two months.
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Analysis
Data were analysed using basic descriptive statistics. The use of descriptive
statistics assists with organising and summarising data and establishing a background
for later findings and interpretations (Given, 2008; McHugh & Villarruel, 2003). In
terms of Group One data, descriptive statistics were used to summarise demographic
information and participants’ opinions on medical cannabis policy and factors
influencing it. The analyses were performed manually.
For the qualitative part of the questionnaire, thematic data analysis was
implemented. Thematic analysis is a widely used qualitative analytic method for
“identifying, analysing and reporting patterns (themes) within data” (Braun & Clarke,
2006, p. 79). It involves the identification of themes through reading and re-reading of
the data and coding of recurring themes appearing throughout (Liamputtong & Ezzy,
2005). According to Braun and Clarke (2006), “a theme captures something important
about the data in relation to the research question, and represents some level of
patterned response or meaning within the data set” (p. 82). Thematic analysis was
chosen due to its flexibility, allowing the researcher to play an active role in identifying
patterns within the data and selecting those which capture something important in
relation to the research questions (Braun & Clarke, 2006). It also allows the researcher
to describe and present data in rich detail. Group One thematic analysis was driven by
the open-ended questions asked in the survey as well as the research questions, and the
prevalent issues and themes are reported here.
The analysis was conducted in six phases, as described by Braun and Clarke
(2006). The first phase involved getting to know the data through reading and re-reading
of the survey responses, and noting down initial thoughts and ideas. Phase two involved
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generating initial codes and allocating data to a particular code. Phase three involved
searching for themes and assigning or grouping codes into potential themes. Phase four
involved reviewing themes, and checking whether or not they work or are of relevance.
Phase five involved defining and refining themes. The last phase involved pulling
everything together, relating the analysis back to the research question, and producing a
report of the analysis (Braun & Clarke, 2006).
An audit trail consisting of how codes and themes were developed was kept to
enhance the credibility of the research (Liamputtong & Ezzy, 2005). All themes and
sub-themes were reviewed and discussed with the supervisors of the project. Providing
an audit trail ensures the rigour of the study, which clearly and accurately documents
how the data were collected and analysed and how interpretations were made.
Results
The quantitative data from Groups One and Two are summarised in both
narrative and tabular form. Findings from the qualitative data are examined, and themes
derived from the content analysis are outlined and discussed.
A total of 31 (18%) out of 172 Group One participants approached answered the
survey. Four (13%) respondents actively participated in the medical cannabis debate in
Michigan; eight (26%) in New Mexico; 10 (32%) in Illinois; one (3%) in Kentucky; six
(19%) in Louisiana. Two (7%) respondents resided or participated in the medical
cannabis debate in more than one state. A total of nine (31%) Group One participants
personally used cannabis for medical purposes, 22 (76%) knew someone who did, and
eight (28%) indicated that they had used cannabis for recreational purposes. Overall, 14
(48%) of participants described their political affiliation as Democrat, seven (24%) as
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Republican, and eight (28%) as “other” (Independent, Green Party, Libertarian, nonaffiliated).
A total of 23 (11%) of 209 Group Two participants answered the questionnaire.
In total, five (22%) respondents indicated that they currently conducted alcohol and
other drug related research in Michigan; one (4%) in New Mexico; 11 (48%) in Illinois;
five (22%) in Kentucky; and one (4%) in Louisiana. Four (17%) participants stated that
they were very aware of the medical cannabis debate in their state and 14 (61%) that
they were somewhat aware. Four (17%) participants were somewhat unaware of the
debate; one (4%) was very unaware. In terms of their level of involvement in the
medical cannabis debate no participant classified themselves as very involved; one (4%)
as somewhat involved; eight (35%) classified themselves as neither involved nor
uninvolved; two (9%) as somewhat uninvolved, and 12 (52%) as very uninvolved.
No (0%) Group Two participant personally used cannabis for medical purposes,
seven (30%) knew someone who did, and 11 (48%) indicated that they had used
cannabis for recreational purposes. Overall, 19 (83%) of participants described their
political affiliation as Democrat, none (0%) as Republican, and four (17%) as “other”
(Independent, Libertarian, and no voting rights).
Opinions on medical cannabis laws. Respondents were asked to indicate
whether or not they “strongly agree”, “agree”, “disagree”, “strongly disagree”, or “don’t
know” (Table 11) with statements relating to cannabis and medical cannabis. Upon
analysis, the items were combined so that “agreement” represented both “strongly
agree” or “agree” responses, and “disagreement” represented both “strongly disagree”
and “disagree”. Due to the low number of responses, tests of significance were not
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performed. Participant responses, concerning cannabis and medical cannabis, are
grouped according to the statements used in the questionnaire.
A large majority of participants in both groups indicated that they supported
legislation to make cannabis legally available for medicinal purposes; 22 (71%) Group
One and 16 (69%) Group Two respondents. Twenty three (75%) Group One and 20
(87%) Group Two participants indicated that they believed that cannabis can be used
effectively as a medicine. Despite believing that cannabis can be used as a medicine, 28
(90%) Group One and all Group Two participants indicated that they believed that more
research is needed on cannabis as a medicine. However, more Group One (71%) than
Group Two (61%) participants believed that scientific evidence plays an important role
in the passing of medical cannabis legislation.
While the most common argument used by medical cannabis opponents is that
cannabis is a gateway to the use of other illicit drugs, only ten (33%) of Group One and
seven (31%) of Group Two participants agreed with this statement. A larger percentage
of Group One (71%) than Group Two (65%) participants believed that laws to allow the
use of cannabis as a medicine should be implemented in all U.S. states. More
participants in both groups believed that the laws to allow the use of cannabis as a
medicine should be implemented at the federal level. Lastly, 68% of Group One and
78% Group Two participants indicated that they believed that it is important to separate
medical cannabis legalisation from the broader drug legalisation agenda.
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Table 11
Group One and Group Two Opinions on Cannabis and Medical Cannabis Laws
Agree
%

Disagree
%

Don’t know
%

71

26

3

69

27

4

Cannabis can be used effectively as a
medicine

75

22

3

87

9

4

Cannabis is a gateway drug

33

64

3

31

65

4

90

7

3

100

0

0

71

23

6

61

39

0

71

26

3

65

26

9

81

16

3

69

22

9

68

29

3

78

22

0

Statement
Support medical cannabis legislation

More research is needed on medical cannabis

Scientific evidence is important

Medical cannabis laws in all states

Medical cannabis laws at the federal level

Important to separate medical cannabis
from legalisation

Group One

Group Two
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Factors influencing medical cannabis legislation. Participants were also
presented with a number of factors influencing medical cannabis policy, as described in
Chapter Four. They were asked to consider how important each factor was in
determining whether medical cannabis legislation is enacted or not. Participants were
asked to indicate whether or not a factor mentioned was “very important”, “somewhat
important”, “somewhat unimportant”, “very unimportant”, or “don’t know” (Table 12).
The items were combined so that “importance” represented both “very important” and
“somewhat important” responses, and “unimportance” represented both “very
unimportant” and “somewhat unimportant”.
The largest percentage (97%) of Group One participants, who participated in the
medical cannabis debate, indicated that media and the support of the legislative branch
of the state government play an important role in determining whether media cannabis
legislation is enacted or not. Meanwhile, all (100%) Group Two participants thought
that public support plays a very important or somewhat important role in determining
the success or failure of medical cannabis legislation, while 28 (90%) Group One
participants also indicated that public support plays a very important or somewhat
important role. Twenty nine (93%) Group One participants thought that the support of
the executive branch of the state government was important in determining whether
medical cannabis legislation is passed or not, while 20 (87%) of Group Two participants
thought the support of the executive branch was important. However, 23 (74%) Group
One participants indicated that politicians were important in determining whether
medical cannabis legislation is enacted or not, while more (96%) Group Two
participants thought that politicians played an important role.
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Twenty seven (87%) Group One participants believed that advocacy groups
were important in passing medical cannabis legislation, and 26 (84%) of the participants
believed that the extent to which advocacy groups are well organised was of
importance. Most (92%) Group Two participants believed that advocacy groups were
important and 20 (87%) believed that the extent to which advocacy groups are well
organised was of importance. The amount of money available to both advocates and
opponents was reported as being of importance by 22 (96%) Group Two respondents,
but a lesser number of Group One respondents (71%) thought money was important.
Testimonies from people who have used cannabis as a medicine were considered
important by 25 (81%) of Group One and 17 (74%) of Group Two participants. Media
and the support of the legislative branch were considered important by 21 (91%) of
Group Two participants.
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Table 12
Level of Importance of Factors Influencing Medical Cannabis Legislation
Important
Unimportant
Don’t Know
Factor
%
%
%
Advocacy groups

How well organised advocacy
groups are

Politicians

Money available to advocacy
groups

Testimonies from medical
cannabis users

Support of the executive branch

Support of the legislative branch

Public support

Media

Group One
Group Two

87

7

6

92

4

4

84

10

6

87

4

9

74

20

6

96

4

0

71

19

10

96

0

4

81

16

3

74

26

0

93

3

3

87

4

9

97

0

3

91

0

9

90

6

3

100

0

0

97

0

3

91

4

4
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Participants were also asked to rate factors in terms of the level of influence they
believed the factor has on medical cannabis legislation (Table 13). The 10-point rating
scale was used with 0 representing no influence, 5 representing some influence, and 10
representing very high influence. A total of 29 Group One and all (23) Group Two
participants completed this section. Group One participants rated support in the
legislature (8.28 average score) as having the highest level of influence, followed by
advocacy groups (7.97) and public support (7.97). Other factors, in order of influence,
included money, lobbyists, patient testimonies, media support, high-profile individuals,
and opposition groups. Group Two participants rated money (8.35 average score) as
having the highest level of influence, followed by support in the legislature (8.22),
public support (7.87), media support (7.70), and lobbyists (7.65). Other factors, in order
of influence, included opposition groups, high-profile individuals, advocacy groups, and
patient testimonies.
Table 13
The Average Rating of Factors Influencing Policy on a 0-10 Scale of Influence
Factor
Group 1
Group 2
Rating
Rating
st
8.28 (1 )
8.22 (2nd)
Support in the legislature
7.97 (2nd)
6.35 (8th)
Advocacy groups
7.97 (2nd )
7.87 (3rd)
Public support
7.76 (3rd)
8.35 (1st)
Money
rd
7.76 (3 )
7.65 (5th)
Lobbyists
7.66 (4th)
6.22 (9th)
Patient testimonies
7.59 (5th)
7.70 (4th)
Media support
th
7.48 (6 )
7.09 (7th)
High-profile individuals
6.86 (7th)
7.35 (6th)
Opposition groups

The following section will present themes derived from the qualitative part of
the questionnaire.
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The role of scientific evidence. While it is widely believed that science should
play a major role in public health policy, as discussed in Chapter Four, this is not
always the case. The state by state review concluded that while scientific evidence was
presented in the medical cannabis debate, it was mostly filtered through the media and
was selectively used by the proponents and opponents of medical cannabis. The impact
of scientific evidence tends to be diluted and a number of other factors play a role in
influencing policy. When asked if scientific evidence played a role in the medical
cannabis debate in their state, Group One’s responses could be divided into two themes:
1) strength and recognition of the scientific evidence, and 2) how the scientific evidence
is used. A consensus was hard to reach as the respondents’ opinions were divided on the
role scientific evidence played and continues to play in the medical cannabis debate, but
12 out of 24 Group One respondents who answered the question believed that the
scientific evidence plays no role (or does not play a significant enough role) in the
medical cannabis policy process. Respondents indicated that when scientific evidence
does play a role, it is in informing the public and gaining support for the cause. As some
of the participants stated:
“I think it plays an important role in the process, even here [U.S.], where
many people are fond of hearing horror stories about gateway drugs, the
medical and scientific community are given great weight, which is as it
should be” (G1-24, Illinois).
“Yes. If there is no evidence, I would not support any efforts” (G1-10,
Louisiana).
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Group Two participants were slightly more optimistic when discussing the role
of scientific evidence, with nine out of 15 participants believing it plays a role,
especially in informing the public.
“Scientific evidence plays the largest role. The public needs to be
confident that the benefits outweigh the risks and this can only be
provided through scientific research” (G2-9, Illinois).
“The public needs to be confident that the benefits outweigh the risks
and this can only be provided through scientific research” (G2-7,
Illinois).
However, some respondents believed that anecdotal evidence usually takes
precedence over scientific evidence, and that as a result scientific evidence rarely enters
the debate, despite the fact that it is generally expected that it should play a role.
“No, it was completely ignored. They listened to anecdotal evidence to
make their decisions” (G1-4, New Mexico).
“Very little- it is mainly predicated on the sick patient scenarios
expounded to the legislature” (G1-27, Illinois).
“I wish it did, but unfortunately the science rarely comes into the
debate” (G2-1, New Mexico).
Group Two participants also indicated that the public sometimes does not
understand the available scientific evidence and that the merits of scientific evidence
can often be lost on politicians and the public.
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It is critical that there be sound evidence but the relative merits of
evidence is [sic] often lost with politicians and the public” (G2-6,
Kentucky).
“I don’t think scientific evidence plays much of a role in any debate.
People don’t understand statistics and how that supports evidence” (G220, Kentucky).
The results also indicated that the respondents believed that scientific evidence
should play more of a role than it does, and attributed its insufficient use to a number of
causes such as money, education, and lack of recognition of the available scientific
evidence by politicians, health professionals, and the media.
“Not enough. As long as government spends billions of dollars per year
disseminating lies and refusing to recognize the growing scientific
evidence, and medical schools refuse to train their students in
Cannabinoid Medicine, and big Pharma [sic] keeps promoting addictive
opiate analgesics, the debate will not be influenced adequately by the
mounting and irrefutable scientific evidence” (G1-1, Illinois).
“The single biggest influence, either way, is a scientific ignorance,
public and health care professional, of cannabis and the
endocannabinoid system” (G1-17, Louisiana).
As the literature review conducted for this thesis indicated, the available
evidence on medical cannabis is not as clear as it may first appear, especially when
considering the smoked route of medical cannabis administration. Further to this, some
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participants believed that even if the evidence was available, the policymakers may not
necessarily respond to it and it may not play as much of a role as may be expected.
“Scientific evidence is valuable, but the necessary research is often
lacking. Even in the face of evidence the social and political forces may
not respond to this” (G2-2, Illinois).
“I am not fully informed on this topic. However, I would have to say it
[scientific evidence] plays a role, but it is difficult to get ideologues to
listen to science” (G2-5, Illinois).
Mixed and inconclusive research evidence. Based on the literature review
presented in Chapter Three, the research evidence shows that cannabis and its
constituents have therapeutic potential for a number of conditions, some for which the
evidence is mixed and unclear. Most of the research evidence supports the use of
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an
appetite simulant for AIDS-related wasting syndrome. A substantial amount of research
has also been conducted on cannabis in the treatment of nausea and vomiting to suggest
cannabis may have therapeutic potential. All other conditions, the literature review
concluded, would require further research to be conducted before the use of cannabis as
a medicine could be recommended.
The general consensus between research participants was that cannabis can be
used effectively as a medicine, but the evidence can be contradictory. An overwhelming
majority of participants also agreed that further research on cannabis as a medicine was
needed, particularly research addressing different routes of administration, appropriate
dosage, side effects, and long-term effects. Participants also believed that the scientific
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evidence available at the present time was contradictory or insufficient, and as such did
not influence the medical cannabis debate or policy making. It was also argued that if
the scientific evidence, especially for smoked cannabis, was stronger, it would be easier
to pass medical cannabis legislation.
“If we can get some comprehensive research studies, by independent
researchers, that can conduct a longitudinal meta analysis, the debate
would be led more by facts rather than opinion” (G1-10, Louisiana).
“The scientific evidence for smoking cannabis as an effective medicine is
contradictory. If it were stronger, it would be easier to pass the
legislation...I support legalization for many reasons, but the evidence is
that smoked cannabis is not an effective medication (the side effects
including lung damage and addiction potential far outweigh the
benefits)” (G2-3, Illinois).
“I still think that there is insufficient scientific evidence to convince
people outside of science which stems from problems funding this type of
research” (G2-12, Kentucky).
Need for a change in federal cannabis laws. While there has been a push to
reschedule cannabis from Shedule I of the CSA in order to permit medical use, the
federal government has maintained its stance that cannabis is not safe and that no sound
scientific studies supported medical use of cannabis (Cohen, 2010; Eddy, 2010).
Medical cannabis advocates note that cannabis will most likely not be rescheduled until
there is sufficient scientific evidence for its effectiveness (Marshall, 2005). Three
respondents also believed that the issue of medical cannabis will only come to
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prominence with changes to federal laws, and that there was need to reschedule
cannabis.
“I do know that keeping cannabis as a Schedule I narcotic is WRONG
and should be changed a.s.a.p. by the FDA and the DEA...” (G1-13,
Kentucky).
How the scientific evidence is used. How the scientific evidence is used in the
medical cannabis debate was also a common theme amongst respondents. As discussed
in the state by state review in Chapter Four of this thesis, while the scientific evidence is
not directly used in the medical cannabis debate, it mostly enters the debate as
“ammunition”. Both opponents and proponents of medical cannabis tend to use the
research findings as a means of attacking or defending their arguments, rather than as
the key to deciding whether a policy should be adopted or not. The respondents in both
groups indicated that individuals participating in the medical cannabis debate may not
necessarily always use scientific evidence, or may use it for a specific purpose. Also,
the evidence is not necessarily always used in its purest form (as published) but can be
changed to suit a particular purpose.
“It provides a platform for proponents but opponents essentially ignore
the information and argue other points such as that it is a slippery slope
that will lead to legalization of all drugs” (G2-21, Illinois).
“...it is skewed in the direction of whichever lobby is trying to use it to
support their case” (G2-1, New Mexico).
The respondents agreed that the way in which the available evidence (or lack
of) is used in the process can have an influence on the outcome. One way the scientific
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evidence could be used is as a way of refuting the opposition’s claims and in supporting
an argument.
“Primarily as something advocates can use to rebut opposition” (G1-22,
New Mexico).
“...it allowed us to refute many of the oppositions’ claims” (G1-6, New
Mexico).
“It plays a role in that it makes the argument possible, and enables the
support of many medical and public health organizations” (G1-9,
Illinois).
Decoupling. Separation of medical cannabis from the issue of general cannabis
decriminalisation or legalization for recreational purposes, or decoupling, was another
major theme identified in the state by state review. Twenty one Group One and 11
Group Two participants discussed the separation of medical cannabis from general
cannabis legalisation. Fourteen Group one and four Group Two participants felt that
separating the two was beneficial to passing medical cannabis legislation and played a
role in helping the medical cannabis issue move forward. The participants believed that
legislation legalising cannabis for general use is more difficult to pass than medical
cannabis, and had less public support. As such, keeping medical cannabis separate from
cannabis legislation helped make medical cannabis more generally acceptable.
“Full legalization is a non-starter among legislators and less supported
by the public. Keeping them separate is the only way to get medical
cannabis passed” (G1-9, Illinois).
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“I think it is more palatable if sold as an effort to improve medical
options” (G1-24, Illinois).
“The U.S. is not ready for drug legalization of any sort. It is too
conservative. With cannabis, it is crucial that the medicalization [sic] be
separated from its abuse potential for it to have viability in any state (or
the county) as acceptable policy” (G2-6, Kentucky).
“If they are separated medical cannabis will have a better chance of
passing” (G2-10, Louisiana).
However, some respondents were not so sure of the impact of separation, and
believed that the impact of separating medical cannabis from general cannabis use
depended on which other factors were at play.
“Our bill had nothing to do with cannabis legalization, which helped it
move forward. Under a previous administration however, the two were
linked and it almost passed even then. So it depends on the political
players, their level of support, and their level of courage” (G1-6, New
Mexico).
As discussed in Chapter Four, it is not always clear who supports what, and even
some advocates fail to make a clear distinction between medical cannabis and general
cannabis legalisation and sometimes tend to fluctuate between being medical cannabis
supporters only and supporting general legalisation. As two respondents also indicated,
the national organisations went through a lot of effort to make a clear distinction
between general cannabis legalisation and medical cannabis and selectively funnelled
their support for organisations that were able to keep the two issues separate.
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“The federal organization funding the statewide [sic] efforts were very
keen about keeping the broader legalization efforts quiet. Basically, to
the point of bringing myself (who was the main legalization voice for
cannabis in IL [Illinois]) on as a grant recipient to work on the medical
and not legalization” (G1-12, Illinois).
“Since both MPP and NORML advocate legalizing cannabis in general,
their support for the legalization of medicinal cannabis in IL and other
states can have both negative and positive effects to the extent that their
support is funnelled through individuals and groups who are able to keep
the two issues separate and not give fodder to anti cannabis groups that
claim that the medical cannabis movement is just a cover for the
legalization of cannabis” (G1-1, Illinois).
However, due to public perception, it is often difficult to separate the two issues.
This is also made more difficult by medical cannabis opponents, who attempt to portray
the two issues as one and the same.
“Opponents say they’re connected, we combat that. We’re usually able
to win” (G1-3, Michigan).
“The way the bill was introduced and written it was simply a gateway to
legalize cannabis in the future” (G1-14, Illinois).
“People in the general public see these two things as almost the same”
(G2-12, Kentucky).
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The influence of politicians. The majority of Group One participants believed
that politicians played a major role in the medical cannabis debate, but Group Two
participants believed that the politicians had some influence and that there were a
number of factors that influenced the support or opposition of politicians. According to
respondents, politicians could have a major influence on the passage or the failure to
pass medical cannabis legislation as they have the ability to carry bills and pass
legislation, therefore controlling the fate of the issue. However, in order for medical
cannabis legislation to pass, it is important to have the support of politicians, especially
in states with no initiative process.
“If the majority of legislators are in favour, it’s easy to pass. If a
majority is opposed, it’s next to impossible. It’s also important to have
key legislators on board such as committee chairs and those in
leadership positions” (G1-5, Louisiana).
“They control the fate of the issue; our state does not have a ballot
referendum or initiative process. So we have been working for so long on
it that we were actually advised to register as lobbyists, and thus I
registered a patient advocacy association so that we could legally lobby
our legislators to pass medical cannabis legislation” (G1-12, Illinois).
“They are important, and a few small advocacy groups are working
with them” (G2-2, Illinois).
While the respondent believed that medical cannabis legislation is easier to pass
if there is support from the politicians, especially those well known to the public, the
difficulty arises when legislators are unresponsive, or unwilling to introduce the

Medical Cannabis in the United States

276

legislation. This can occur either because they are not in favour of the legislation or
because there are other factors that they need to take into account.
“I have spent more than 2 years writing politicians all over our state,
and of the few who have responded, not one supports safe and legal
access to medical cannabis” (G1-21, Kentucky).
“Most legislators I’ve contacted don’t reply or are afraid to tackle
medical cannabis. Our legislature is stuck on creationism in class, which
indicates their level of sophistication” (G1-20, Illinois).
“Politicians from the rural portions of the state will block any effort to
pass medical cannabis laws” (G2-3, Illinois).
“Politicians in my state are largely quite conservative and generally not
supportive of legalization given the dire economic situation in our state
and nation; legalization is a very low priority right now” (G2-12,
Kentucky).
Influences on politicians’ decision making. Factors such as getting re-elected,
how they are perceived, political ideology and funding are very important in influencing
politicians’ decision of whether or not to support specific legislation. As suggested by
the respondents, the influences may differ between the political players, but include
personal opinion and perceived disapproval or approval by the public, political
ideology, political timing, or fear and unwillingness to tackle a difficult issue.
“Most are conflicted by their own opinions vs. perceived disapproval by
the constituents or fearful of Federal (DEA) backlash if they support the
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legislation but we are forever hopeful that we will succeed in this battle”
(G1-1, Illinois).
“It is hard for politicians to support something like legalization of
marijuana because it is such a polarizing topic, which might affect their
re-election” (G2-5, Illinois).
“Politicians lean any direction that gets them elected. The populace
needs educating & that’s difficult in a state that ranks 49th in education”
(G1-21, Kentucky).
As discussed in Chapter Four, the general notion in terms of medical cannabis is
that the dominant Democratic position is to support medical cannabis, while the
dominant Republican position is to oppose it. Respondents agreed that political
ideology could influence whether or not medical cannabis legislation is supported.
However, in some states, such as New Mexico, the support for medical cannabis is not
necessarily defined by political parties, and bipartisan support was believed to be one of
the reasons for the success of New Mexico’s medical cannabis law.
“...especially bipartisan support” (G1-6, New Mexico).
“Dems favour....Repubs don’t” (G1-11, Michigan).
“Republican Governor Johnson had fought for it, but he was blocked by
the Democratic legislature who wanted to pass it, but felt that
Republican legislators would use it against him. Having Democratic
Governor Richardson in office, who also supported the legislation,
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created a safer environment for legislators and Democrats got behind
the bill” (G1-19, New Mexico).
“Pretty straightforward- Dems [Democrats] are (mostly) in favour
though not all. Republicans are fairly adamant in their opposition” (G221, Illinois).
Rather than scientific evidence driving their decision making, medical cannabis
can be a personal issue for some politicians. Some support the legislation because they
have used medical cannabis themselves or know of someone who has, and their
personal experience rather than scientific evidence drives their support. As Black (2001)
said, policymakers can have their own goals for policies other than scientific evidence
and clinical effectiveness, and can focus on other types of evidence such as personal
experience.
“We have to deal with lots of politicians; we see their human side.
Cannabis gets personal, so the politicians do as well” (G1-20, Illinois).
The people as legislators: Influence of direct democracy. The state by state
review in Chapter Four indicated that using the initiative process helped pass medical
cannabis laws initially in some states and helped them gain momentum in other states.
To date 10 of 17 state medical cannabis laws were passed by a ballot initiative and in
some states may not have passed, or passed as quickly, if the attempts to pass a medical
cannabis law were only focused on the legislative process. In Michigan, for example,
several attempts to pass a medical cannabis law via the legislature were unsuccessful
until the issue was placed on the ballot and passed.
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The results from Groups One and Two indicated that a distinction needs to be
made between states with a direct democracy process (i.e. ballot initiative) where
constituents are given the power to pass laws, and the states where the legislative
decisions are left up to the legislators. The general consensus amongst participants was
that the two processes have a differing influence on medical cannabis policy.
Participants believed that ballot initiatives were important as they were able to take
politicians out of the equation, were easier to pass, helped move the issue along, and
allowed people to make a decision regarding a particular law. However, the difficulty
arises in states that do not have the initiative process, and the attempts to pass a medical
cannabis initiative need to occur at the legislative level.
“If the state has a hostile legislature but a ballot initiative process, you
can go around the legislature. It can be expensive though depending on
the number and size of media markets” (G1-3, Michigan).
“I think the ballot initiative was crucial for getting the medical
marijuana on the books. The legislature never would have gone for it”
(G2-16, Michigan).
“...they allow the issues to percolate to the top at the initiative of the
people rather than the legislators” (G2-6, Kentucky).
“It may assist with moving the legislature along” (G2-7, Illinois).
According to the respondents, states with ballot initiatives usually fare better on
passing legislation than states without, which must rely on the legislators to engage in a
medical cannabis debate. However, only 17 U.S. states and the D.C. have an initiative

Medical Cannabis in the United States

280

process, which means that 27 states must rely on their state legislatures to enact medical
cannabis laws.
“Without a ballot initiative process, Louisiana residents are left to
depend upon legislators to even engage in a debate regarding medical
cannabis. As a result, there is no debate” (G1-2, Louisiana).
“In initiative states, medical marijuana almost always passes. When it
must be approved by politicians, it’s always a struggle, and Illinois was
a classic example” (G1-9, Illinois).
“Obviously, states that allow voter initiatives fair [sic] much better on
passing this type of legislation” (G1-21, Kentucky).
“I feel that the initiative process is a much easier way to get medical
cannabis available to patients since politicians generally feel the issue is
too controversial and don’t want to take a tough vote like this” (G1-12,
Illinois).
However, as much as they can be beneficial, both processes are perceived as
having their disadvantages, such as being costly and prone to abuse, and can put wellfunded special interest groups at an advantage because of their access to campaign
professions, access to donor lists, and media strategies (Birkland, 2005; Braunstein,
2004; Cushman, 2005; Magleby, 1998).
“Ballot- Big money will be used to campaign for the passage of the
initiative, however it does allow the electorate to have a say as to what
will be passed. Drawback is there is not the big money to campaign
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against the initiative. Legislative branch- leaves the decision of millions
in the hands of a very few. They become educated as to the benefits this
cannabis will have for “patients”. They forget to look at the other side of
the debate from law enforcement, prosecutors, treatment and prevention
professionals” (G1-4, New Mexico).
A dubious method [ballot initiative] in some cases due to manipulation of
voters” [G1-25, Louisiana].
“As a former Californian, I’d say that ballot measures tend more often to
be harmful than helpful, so I would not advocate for them as a means of
passing legislation” (G2-15, Illinois).
The influence of national-level advocacy organisations on state-level policy.
State by state review in Chapter Four found that organised interest groups are more
likely to have greater access to resources and make campaign contributions in order to
advance their desired outcomes. Money was very important as it enabled the groups to
reach a wider audience and have a bigger impact. In the states with medical cannabis
laws, national organisations such as NORML were very prominent and engaged in a
range of activities from lobbying to organising television and radio advertisements to
support their cause. The majority of Group One and Group Two respondents agreed that
the involvement of national advocacy organisations, such as MPP and NORML, had an
impact on medical cannabis policy; mostly positive, some detrimental. The responses
indicated that one of the main contributions of the national organizations was money.
“They have a very strong presence in our state and funded staff to lobby
the Governor and legislature to pass the legislation. I imagine they also
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paid for some of the individuals who testified in support of the
legislation” (G1-4, New Mexico).
“They were important mainly in funding and keeping databases current.
Also providing qualified spokesmen” (G1-16, Louisiana).
“MPP played the leading role, financing and organizing the lobbying
campaign and media efforts” (G1-9, Illinois).
“Most states are convinced by the PR not the data. PR takes money,
hence national pro use groups are powerful” (G2-11, Michigan).
“These groups are very prominent in MI [Michigan]” (G2-17,
Michigan).
As discussed in Chapter Four, interest groups prefer to use direct initiatives and
carefully consider where they focus their efforts (Boehmke, 2002). The approach and
activities of most interest groups is determined by the group’s mission, strategic goals,
objectives, and strategies and tactics (Leiden, 1995). Research has found that states with
an initiative process have more interest groups (Boehmke, 2002). While they may have
contributed to the debate and passing of medical cannabis laws in some states, national
organisations such as MPP and NORML did not actively participate in all states and
appeared somewhat selective about the states they put their resources into. For example,
MPP played a large role in supporting the medical cannabis effort in Michigan, donating
money as well as organising television advertisements and being active in the
newspaper discussion of the issue, but were not very active in New Mexico. The
participants also noted that MPP and NORML put resources into states such as
Michigan, while they did not have a strong presence in other states.
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“MPP funded our initiative” (G1-11, Michigan).
“I was leader of the state office of DPA, we led the fight. NORML was
very helpful with information requests and behind-the scenes
background information. MPP did not play a role” (G1-6, New Mexico).
“There is no NORML office in Coonville, Kentucky anymore & I believe
they have not targeted Kentucky as a prudent place to spend their limited
resources” (G1-21, Kentucky).
“NORML played almost no role in Michigan. That law was written,
funded, and passed by MPP” (G1-3, Michigan).
“There are many of us who are either members of NORML Louisiana or
are advocates...we are in our infant stage, though, and need more
capacity-building and technical assistance from our national office”
(G1-13, Kentucky).
Interestingly, while Group One participants strongly believed that the national
organisations played a role in the medical cannabis legislation, Group Two participants
were not unanimous in this belief, some not even being aware of the presence of these
organisations. Notably, the respondents were from states such as Kentucky and Illinois
that do not have medical cannabis legislation or have not considered one. Also, the
medical cannabis debate in states such as Kentucky has not been very active.
“Probably very little except to the extent that they could influence local
politicians” (G2-6, Kentucky).
“Since I have not heard of them, perhaps very little” (G2-20, Kentucky).
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“None that I can see” (G2-21, Illinois).
The perception of the national organised groups can also have an influence on
the role that they play. That is, if they are perceived as negative or supporting a cause
not favoured by the general public, it may have a detrimental effect. More specifically,
if the organisations were perceived as supporting general cannabis legalisation, their
support detracted from the issue of medical cannabis:
“They pushed to convince people that they were being denied a real
treatment. It should be noted that the effort in California to make
personal use (not medical) failed because of the public’s views of these
organizations. They were simply too facile” (G2-11, Michigan).
“NORML’s primary focus on legalization in more progressive states
provides little support for efforts to advance medical cannabis law
reform in Louisiana” (G1-2, Louisiana).
“They are legalization activists talking medicine and are bad at it” (G117, Louisiana).
“They create problems because they are not reputable organizations”
(G1-30, Illinois).
Higher level opposition: The federal government. While the state by state
review in Chapter Four showed that the federal government, and more specifically the
ONDCP, were active in Michigan and New Mexico when the medical cannabis
movement in those states gained momentum, the federal government was not identified
as playing a major role in passing or failure to pass medical cannabis laws. The majority
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of Group One study participants, however, saw the federal government, and more
specifically the ONDCP, as having both positive and detrimental effects on the medical
cannabis legislation process. It was noted that while opposing the law, the federal
opposition to medical cannabis in states such as Michigan was not very effective.
“ONDCP opposition is always a problem. They work with the
opposition, both overtly and covertly. In Illinois, a former ONDCP
official, Andrea Barthwell, also played a visible role in opposition” (G19, Illinois).
“Diminishing effect, as most educated people realize that the War on
Drugs is actually a War on Drug Users and is propped up by what I call
“The Big Lie” that cannabis deserves to be a Schedule I narcotic and is
more harmful than legal intoxicants, such as alcohol or nicotine” (G1-1,
Illinois).
“They opposed the law, but weren’t terribly vocal or effective” (G1-3,
Michigan).
While participants believed that the federal government can influence state
politicians and their support of medical cannabis legislation, their direct involvement in
the state debate was reported by a number of Group One participants. Different tactics
such as using expert testimony, prominent public figures and threatening funding were
reported as being used by the federal government officials to oppose state medical
cannabis bills.
“ONDCP sent an expert witness to testify in opposition to the legislation.
Along with all the other experts, the policy makers turned a deaf ear to
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the realities of legalizing marijuana. ONDCP testimony was helpful”
(G1-4, New Mexico).
“We’ve had former DEA head Bensinger testify against us numerous
times over the years and even appearing on a televised debate against
myself. I recall Walters coming to Illinois to testify once too. Other than
brief appearances and working behind the scenes not much involvement
I’d imagine” (G1-12, Illinois).
Group Two participants reported that the federal offices have constantly opposed
medical cannabis legislation, but that their presence usually had little or no influence.
Participants from states such as Kentucky and Louisiana, in particular, did not believe
there was strong federal opposition to cannabis in their states.
“The ONDCP is pretty quiet on this issues [sic], even though they paid
the IOM for the Marijuana as Medicine study. The ONDCP’s real task is
to formulate drug abuse policy. General McAfree decided to let the
medical issue alone” (G2-11, Michigan).
“Slightly more than MPP, etc? not aware of their involvement in my
state either so practically zero effect” (G2-20, Kentucky).
“None to my knowledge but the federal offices have remained
consistently opposed to such legislation” (G2-6, Kentucky).
When they are active, participants in Group Two believed that federal offices
such as the ONDCP can act as a voice of authority and back up opposition groups in the
state.
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“Much- voice of authority” (G2-10, Louisiana).
“Provides cover for those in opposition” (G2-21, Illinois).
In some cases, while not having a direct impact and preventing legislation from
passing, the presence of the federal officials and federal offices such the ONDCP can
have a reverse effect, and ignite the efforts of the advocates. As one participant
described:
“He [the Drug Czar] and his entourage visited our statehouse; he spoke
to the panel; left the room before anyone on our side spoke; we lost the
vote. His presence (and his twenty person entourage) worked to motivate
our patients. He also, by his presence, let the statehouse know we must
really be a threat if a representative from the federal government came
to Springfield Illinois” (G1-20, Illinois).
The effectiveness and organisation of state-based organised groups. The
extent to which advocates for both sides are organised has been found to contribute to
the successful enactment of medical cannabis laws. The state by state review found that
in Michigan, state based organised groups had a persistent and prominent involvement
in the medical cannabis debate and lobbied for medical cannabis over a period of time,
while the only state based organised opposition group was not formed until shortly
before the medical cannabis issue went to ballot. The influence of state-based organised
lobby and advocacy groups had been frequently mentioned by the Group One
respondents, with eight out of 14 respondents believing that they played a role in
ensuring the passing of medical cannabis laws in some states.
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“These groups were effective in getting the legislation passed and spent
significant amounts of money to ensure its passage” (G1-1, Illinois).
“We won the debate, hands down. I don’t think it would’ve passed
without a well-organized group” (G1-6, New Mexico).
“It wouldn’t be possible to introduce legislation and have a chance to
pass this without lobby groups” (G1-24, Illinois).
However, respondents, and in particular those based in states with no medical
cannabis law, believed that state-based organised lobby groups had little to no
influence.
“It was minor. The ones that existed were largely funded by MPP. They
were useful allies, but have little impact without MPP’s resources. The
major thing they contributed was connections with local patients,
doctors and other visible supporters” (G1-9, Illinois).
The majority of Group Two participants was not aware of state-based organised
groups in their state, and, along with some Group One participants, believed that statebased organised groups were generally related to the national efforts, and would not
have been successful without the support of national organisations.
“If we lobby groups in my state, they seem pretty invisible” (G2-12,
Kentucky).
“They have not been well publicised in the media and so I am guessing
very little” (G2-21, Illinois).
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“Generally they are related to the national pro efforts” (G2-11,
Michigan).
However, both Group One and Group Two participants noted that it was
important for groups both supporting and opposing medical cannabis legislation to be
well organised and work strategically, as it can influence how they are perceived by the
public and the policymakers.
“...they need to work carefully and strategically. The more professional
the group the better” (G2-2, Illinois).
“...the more you organize the better your chances are of being
successful. It isn’t only the most important causes that get attention but
those that have publicity and money” (G1-24, Illinois).
“I don’t think it would’ve passed without a well-organized group” (G16, New Mexico).
Lack of good organisation can in turn be detrimental to a particular side of the
debate. For example, a respondent from New Mexico (a state with a medical cannabis
law) said:
“The opposition had more bodies (i.e. law enforcement) but they weren’t
as well organized” (G1-6, New Mexico).
The perceived presence of state-based organised groups. According to the
respondents, the effectiveness of state-based organised groups was limited by their level
of presence (or lack of) in the states and their perceived effort to pass medical cannabis
legislation. In states such as Kentucky, there are no state-based medical cannabis
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advocacy groups, and the student-run NORML chapter also experienced problems and
eventually ceased operation.
“I’m not aware of a single state lobby group in Kentucky lobbying for
cannabis law reform. There is no NORML chapter still in operation here
& no other organized group has considered Kentucky a favourable place
to spend their resources” (G1-21, Kentucky).
“There are none in Louisiana” (G1-12, Louisiana).
The role of money. While the state by state review found that the allocation of
money to support either side of the argument can affect the policy process, the
respondents were divided on how significant the influence of money was, as it differed
amongst states. This was also noted in the state by state review, which found that more
money was spent in Michigan which had the ballot initiative process than in New
Mexico which does not have a ballot initiative process and where the medical cannabis
debate occurred within the political system. The respondents also believed that medical
cannabis proponents spent more money than opponents, and this was also found to be
the case in the state review of Michigan.
“Not enough money is funnelled to effective advocates for medical
cannabis by either state or national organizations, such as MPP, DPA,
etc. NORML is basically a non-profit run by mostly volunteers and is of
limited effectiveness in this debate as described before. Philanthropists
are not yet supporting medical cannabis legalization in IL they [sic] way
they did in CA and other early MC states” (G1-1, Illinois).

Medical Cannabis in the United States

291

“Until a level playing field is established in terms of funding for
advocacy groups opposed to the legalization of cannabis, states will
continue to fall prey to the pro-cannabis funded movement” (G1-4, New
Mexico).
“I don’t believe much money is spent for OR against MMJ [medical
cannabis] in Ky [Kentucky]” (G1-21, Kentucky).
“It’s always about the money to be successful” (G1-11, Michigan).
“Whichever lobby has the most money rules the day” (G2-1, New
Mexico).
How money is used. Those respondents who believed that money did play or
continues to play a significant role in the medical cannabis debate frequently gave
consideration to how that money is used by individuals both supporting and opposing
the legislation. The respondents stated that some of the ways that money can be used is
to influence opinions and fund efforts to support or oppose the legislation.
“Money enabled the hiring of professional lobbyists and assembling an
effective lobbying and advocacy effort. Almost nothing gets passed in
U.S. state legislatures without some money behind it” (G1-9, Illinois).
“Money has been a crucial resource in many ways; the hiring of
lobbyists who have the relationship with legislators to get the bill
introduced, funding patients’ presence at the Capitol, and supporting
advocacy efforts” (G1-12, Illinois).
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“Key politicians are being bought off by marijuana advocates” (G1-7,
Illinois).
City and county-level change. As noted in Chapter Four, over the years local
governments have made it easier for the electorate to raise issues and voice their
opinions, and at times issues at the local level have been acted on more quickly than at
the state and federal level. In Michigan, first medical cannabis changes occurred at the
city level, and there was also city activity in Illinois and Louisiana. The majority of
respondents in this study believed that city-level change showed potential and helped
pave the way for future, larger-scale change, and are a good place to start in terms of
gaining momentum for the issue.
“I think they begin to open up the debate and they are a good place to
start” (G1-6, New Mexico).
“They clearly helped pave the way and illustrate public support. This
was most obviously the case in Michigan” (G1-9, Illinois).
“There is less money involved in terms of lobbyists and the cities have
been able to avoid any influence from either side. City councils are
smaller than the general assembly and that is easier to change too” (G112, Illinois).
“City-level changes can have a huge impact and did in our area” (G216, Michigan).
However, the city-level changes also appeared to be linked to states with an
initiative process and states where there is already medical cannabis activity at the state

Medical Cannabis in the United States

293

level. Those states where there was little medical cannabis movement at the state level
appeared to have little to no movement at the city level.
“In New Mexico this was not an issue. It was a top-down process. The
debate began with Johnson and gained momentum with Richardson”
(G1-19, New Mexico).
“No city in Louisiana has even addressed medical cannabis issues” (G12, Louisiana).
“I’m not aware of any city level initiatives in Kentucky, although I did
pose the question to our new Mayor. He, like most politicians, only
considered if the majority of voters would approve of a low enforcement
law” (G1-21, Kentucky).
Participants also believed that passing medical cannabis laws or ordinances at
different levels would make the medical cannabis issue more complex and city-level
changes would not necessarily lead to a successful implementation at the state level.
“It would be a good start. But what happens in Chicago sometimes does
not affect downstate but if a few smaller progressive cities would do it
that would help” (G2-7, Illinois).
“I think it’s ridiculous to make changes at the city level. It’s too
confusing and piecemeal” (G2-1, New Mexico).
“City law cannot override state law so little impact likely” (G2-20,
Kentucky).
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“I think it is highly unlikely to play a role in this state” (G2-6,
Kentucky).
On the other hand, seven participants did not think separating the two aims had
much (or any) influence for a number of reasons, including it being confusing and the
influence of state law.
“I think it’s ridiculous to make changes at the city level. It’s too
confusing and piecemeal” (G2-1, New Mexico).
Difference between states. As can be seen from the other themes mentioned
previously, medical cannabis advocates and opposition groups are more active in some
states than others and tend to choose where they will allocate their time and resources.
According to four Group One respondents, factors such as debate, public support and
perception, and the influence of other states may account for this. As mentioned in
Chapter Four, it is also generally believed that there is little interest in medical cannabis
in the Southern states, while the initiative process tends to be most popular in the
Western states, but is not exclusively a western phenomenon (Matsusaka, 2005).
“There is no NORML chapter still in operation here & no other
organized group has considered Kentucky a favourable place to spend
their resources…Kentucky is a rural, religious, and uneducated state.
Change is slow to non-existent. I’ve written my legislators numerous
times & have had no response” (G1-21, Kentucky).
“Louisiana lawmakers mirror those of other deep southern states, and
ignore medical cannabis as potentially beneficial to countless suffering
patients.” (G1-2, Louisiana).
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Need for activity. Lack of campaigning in a particular state generally leads to
lack of funds and debate on the issue. In the state by state review, limited campaigning
and debate was observed in states such as Kentucky and Louisiana, and as a result there
was little public support. Meanwhile, states such as Michigan had a well organised,
persistent medical cannabis effort, which eventually resulted in passing of the medical
cannabis law in the state.
“...there is little medical cannabis debate in Kentucky. There is no
television coverage except National Programming & the Newspaper
rarely covers stories or medical breakthroughs” (G1-21, Kentucky).
“I heard nothing- pro or con during the last election cycle” (G2-10,
Louisiana).
“Very little debate to my knowledge” (G2-20, Kentucky).
While there is need for activity and persistence in efforts, timing is also an
important factor to consider. In the state by state review, timing was an important factor.
It was noted that timing of political events does not happen by chance and politicians
attempt to influence the timing in order to maximise benefits and draw public attention
to a particular issue or draw it away. In New Mexico, for example, Gov. Johnson voiced
his support for medical cannabis in his last term as a governor, when he was not up for
re-election and the issue was not going to affect him being re-elected. As one Group
One participant wrote:
“The politicians don’t want to do anything closely controversial
anywhere near an election, and State Reps. in Illinois run for re-election
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every two years. Party leaders will only do it when it is the least
problematic for them in terms of losing seats” (G1-12, Illinois).
Media influence. The state by state review in Chapter Four found that how an
issue is framed in the media can shape how individuals interpret and evaluate the issue
(Lee et al., 2008). The media has also been found to be of particular influence in the
democratic process. In states such as Michigan, the media kept the public actively
involved in the issue. In terms of medical cannabis, the media was a forum where the
proponents and opponents could debate and present their opinions. Five Group One
respondents said that media presence and coverage can have an influence on the
outcome of medical cannabis policy. How a particular issue is covered and portrayed by
the media can also influence the outcome, with the media also having the ability to
“cherry-pick” scientific evidence that is presented. No Group Two participants
discussed media as a factor of influence in the medical cannabis debate.
“The mainstream media gives little attention to scientific evidence
regarding cannabis. I’ve written & had published numerous letters in Ky
[Kentucky] largest newspaper, the Courier-Journal, calling them out on
their lack of coverage. They didn’t even cover Dr Tashkin’s 2005 cancer
study(except for my letter) that should be front page news in a state with
one of the highest cancer rates” (G1-21, Kentucky).
“We end up losing momentum whenever there is significant media
coverage that distorts the aim of the effort and instead tries to paint it as
more of a drug legalization effort” (G1-24, Illinois).
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In terms of medical cannabis, the participants also indicated that the media can
work in reverse, with insufficient media coverage leading to less public support in
states.
“...there is simply not enough media coverage to even encourage public
debate, much less support” (G1-2, Louisiana).
The importance of knowledge/education. In Chapter One, it was discussed
that scientific evidence can have an impact on policymaking, but not necessarily in the
immediate or direct way that would be expected by the researchers (Black, 2001;
Brownson et al., 2009). It was also noted that it was not enough for relevant research to
just be available as evidence itself may not necessarily be used by the participants in the
process or influence decision making (Birkland, 2005; Brownson et al., 2009; Hanney et
al., 2003). Those involved in the medical cannabis debate in the states reviewed in this
thesis believed that both physicians’ and politicians’ lack of knowledge about the
medicinal properties of cannabis influenced the medical cannabis debate. The responses
indicated that it is not enough to simply have scientific evidence, but that it needs to be
actively used to educate individuals and groups involved in the policy process, such as
politicians and the general public.
“The biggest factor influencing the absence of implementable law in
Louisiana is lack of education regarding the medical value of cannabis...
Even doctors lack knowledge of its medical value. Because it is illegal,
they tend to ignore scientific/medical research study reports proving it to
be a reasonably safe and effective medicine” (G1-2, Louisiana).
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“We have had some decent progress in Illinois in attempting to
implement medical cannabis, largely due to an effective push by
advocacy groups that are supported by scientific and medical
professionals” (G1-24, Illinois).
However, the respondents also acknowledged that there were obstacles to
educating individuals involved in the process, such as the need for more comprehensive
studies and refusal by some physicians to share their data.
“I am also trying to organize a North American Community-Based
Clinical Cannabis Research Network to achieve the basic aims of
developing evidence based treatment guidelines...but encountering much
resistance from the major MC physicians, particularly in CA, who don’t
want to “share” their data, etc.” (G1-1, Illinois).
The influence of old laws. Four out of five states reviewed in Chapter One had
medical cannabis or therapeutic research laws passed in the 1970s, which have not been
effective. Some states such as New Mexico attempted to reinstate the old state law by
making amendments to it, while states such as Michigan did not attempt to reinstate the
old law but instead tried passing a new one. Group Two respondents did not discuss old
state laws, but Group One respondents believed that the focus should not be on creating
a new medical cannabis law, but reinforcing the already existing one.
“The problem isn’t making new laws, but honouring the current laws”
(G1-5, Louisiana).
“We’ve had an “inoperable” medical cannabis law in Illinois since
1978. It is only a lack of political will to create a workable law...We
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don’t need an initiative ~ we need Section 11 of the current law
enforced” (G1-20, Illinois).
However, there were also respondents who believed that the old laws were an
impediment to passing new medical cannabis legislation.
“...the State of IL DID pass a medical marijuana law in, I think, 1971,
but since it called for “prescription” of cannabis and was never enacted
through regulations, etc., it never went into effect. I think that having this
history in IL is a definite barrier to passing a reasonable MC law
currently and we would be better off if the earlier law had never been
enacted” (G1-1, Illinois).
The role of patient testimonies. It has been argued that the policy process can
sometimes be more influenced by anecdotal rather than by scientific evidence. In terms
of medical cannabis, the majority of evidence on cannabis as a medicine came from
personal and historical accounts (Mack & Joy, 2000). In Michigan, for example, patient
testimonies were prominent in the media, while in New Mexico patient testimonies
were heard in the Senate and House of Representatives when there were attempts to
pass a medical cannabis bill. There were also professionals and individuals testifying
against medical cannabis to support the opposition’s arguments of negative effects of
medical cannabis. Four Group One respondents said that patient and expert testimony
can play a role in determining the outcome of legislation. For example, the ONDCP
using professional/expert witnesses to testify against medical cannabis legislation. As
one respondent put it:
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“The Administrative Branch, Legislature, advocacy groups and patient
testimony were the most compelling efforts and support that lead to the
passing” (G1-4, New Mexico).
The opposition of the law enforcement lobby. While the law enforcement
lobby was not identified as one of the major factors in the medical cannabis debate in
the state by state review, four Group One respondents from states that do not currently
have a medical cannabis law believed it was one of the major factors preventing medical
cannabis laws from passing in their states as it had the potential to influence legislators.
“Cowardly legislators in fear of the law enforcement lobby (the latter
should have been named as a factor in the prior sections – it is the most
important source of opposition)” (G1-9, Illinois).
“Illinois Partners Providing Marijuana Education and the law
enforcement community were able to influence the legislators” (G1-30,
Illinois).
Public opinion and support. As can be observed through the themes discussed
previously, public opinion can have an influence on the legislators and their decision to
support or not support particular legislation. Public opinion can be particularly
influential in states with an initiative process. As noted in the state by state review,
medical cannabis opponents and proponents in Michigan frequently appealed to the
public to support their cause, especially in the months preceding the placing of the issue
on the ballot. Five Group One respondents believed that public support played a major
role in the medical cannabis policy process. However, they also believed that public
support played little role in states with only the legislative process.
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“Most important in Michigan was public support” (G1-3, Michigan).
“Legislation on this issue, sadly, is an illustration of how little role
public sentiment often plays in the legislative process” (G1-9, Illinois).
Religious organisations. While the involvement of religious organisations was
reported in the state by state review, especially in Kentucky and Louisiana, it was not
identified as a major factor. In this study, only one Group One respondent stated that
religious organisations had a strong influence on medical cannabis legislation. The
respondent also indicated that if the medical cannabis issue was brought up in the state,
there would be opposition from conservative religious organisations.
“If it were to be brought up by advocates, I would assume there would be
push back from opponents (particularly from conservative religious
organizations)” (G1-15, Louisiana).
While Groups One and Two were analysed and their findings reported, an
additional group, Group Three, was excluded from analysis. The following section will
describe the group and the reasons behind its exclusion.
Group Three
Group Three participants were drawn from individuals currently involved in the
state government sector (i.e. the governor, Representatives and Senators) in one of the
five states reviewed. The participants were identified through publicly available sources
such as government documents and state government websites, and online searches.
Participants were selected for their involvement in the government sector, and their
experience in the policy process. As they were not identified as being directly involved
in the medical cannabis debate, it was anticipated that Group Three participants would

Medical Cannabis in the United States

302

be able to provide an objective appraisal of the debate and factors influencing medical
cannabis legislation. A search of the literature did not provide a clear guideline for the
response rate in the interviews of politicians; therefore a specific response rate was not
expected. However, being guided by the response rate for Group One and Two
participants, a response rate of at least 10% would have been deemed acceptable to
discuss in this thesis.
A total of 625 potential participants with publicly available email addresses
were contacted via email and invited to complete the online Qualtrics survey. Of those,
three responded to the email invitation and stated that they would be unable to
participate. A total of 5 (0.8%) participants completed the online survey. As the number
of responses was low it was concluded that the sample would not be representative of
the group (politicians) as a whole, and Group Three was therefore excluded from further
analysis.
Perhaps an explanation for the low response rate can be found in the literature
which suggests that elites such as politicians are unwilling to reveal their true beliefs in
structured questionnaires because they feel that the differential nature of their political
views cannot be adequately captured by the questions with fixed-choice options
(Donsbach & Traugott, 2008). Politicians are busy people with time constraints and can
also have distrust in the purpose of the research or the trustworthiness of the researcher.
In this case, the researcher was from a relatively new university in a different country to
the participants, which may have impacted on the response rate. It was also difficult to
obtain direct contact details for the majority of participants, and the researcher had to
contact their office in hope of establishing direct contact with potential participants. It is
possible then that the questionnaire did not reach some potential participants. As noted
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in the previous chapters, there are also many factors that politicians need to take into
account when engaging in a public debate or taking a stance on a particular issue, and as
such may have been reluctant to participate in research on medical cannabis.
In hindsight, it may have been better to attempt to make direct contact with this
group of participants and establish rapport before interviewing them. Face-to-face
interviewing would have been preferred, as the participants may have been weary of
online surveys and may have held concerns about the security and data integrity
(Rivera, Kozyreva, & Sarovskii, 2002; Sax, Gilmartin, & Bryant, 2003). However, faceto-face interviewing was not possible for the purposes of this study due to money and
time constraints, and the location of the researcher.
Discussion
There were some underlying differences between the respondents in terms of the
demographic information. Just under half (48%) of Group one and 83 percent of Group
Two respondents identified as Democrat, which supports the earlier assertion that
Democrats generally tend to be in favour of medical cannabis, and the majority of
participants in both groups indicated that they supported medical cannabis. While Group
One participants were identified as participating in the medical cannabis process, the
findings indicate that a majority of Group Two participants were also aware of the
medical cannabis debate in their state. It indicates that even those that are not directly
involved in the process have some knowledge of it, and have formed opinions on the
issue.
As the medical cannabis movement keeps gaining momentum, it is possible that
a large percentage of the population will in some way be exposed to the medical
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cannabis debate or have personal experience with it. This makes it important for
evidence to be disseminated to the wider population, so that informed decisions can be
formed. However, as discussed in Chapter One, there are a number of factors that play a
role in the medical cannabis policy process, and evidence does not play as big a role as
one might assume. While it is acknowledged that the findings of Group One and Two
studies may be biased towards the views of medical cannabis supporters, some
underlying themes have been identified. While the findings in this chapter were
presented as themes, it should be noted that they are not independent of each other and
actually interact as part of the policy process.
The general consensus between research participants was that cannabis can be
used effectively as a medicine, but there were no elaborate discussions in relation to
specific disorders. An overwhelming majority of participants also agreed that further
research on cannabis as a medicine was needed, particularly research addressing
different routes of administration, appropriate dosage, side effects, and long-term
effects. While those involved in the research field, such as Group Two participants,
were more likely to call for more evidence on cannabis’ medicinal properties, it was
also noted that the results may not have enough impact unless they are reaching and
informing those involved in the policy making process. Group Two participants were
also less optimistic in terms of the role scientific evidence plays in passing medical
cannabis legislation, but this could be attributed to their belief that more evidence is
needed. However, it is important that the evidence being disseminated to the public and
those involved in the process remains objective, and that it be presented in a way that is
easy to understand.
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What also needs to be taken into consideration is the individual or the group,
such as politicians, who the evidence is distributed to and what sort of evidence they
require (Ritter, 2009). For example, Ritter (2009) found that politicians were interested
in simple, uncomplicated information. In relation to understanding who the evidence is
provided to, Davoudi (2006) stated that:
When it comes to influencing policy, it should be noted that new
evidence does not enter a pristine environment, it has to fit into the
policy-makers’ general understanding of how the world works. Such
understanding comes from a variety of sources ranging from scientific,
systematic research evidence to anecdotal experiences and tacit and uncodified knowledge. (p. 21).
While the notion that scientific evidence should play a major role in influencing
medical cannabis policy is ideal, it is also not realistic in the sense that there are other
factors which play a role in the process and which need to be taken into consideration.
The role of scientific evidence in informing policy also depends on a variety of factors,
such as the government; context; how it is used and for what purpose; how it is
presented and communicated; the direct policy process; and what individuals interested
in the policy make of the science. While it might be argued that policy should be
enacted on the basis of the scientific evidence, it needs to be understood that the
legislative process is essentially political. Advocates of medical cannabis, or other drug
law reform, while not losing sight of the evidence, also need to understand and engage
in the political process. A change in researchers’ attitudes is also required, so that the
sole focus is not just on generating research, but on making that research an influential
part of the policy process.
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The findings also indicate that there may be some differences between the
factors which play a role in passing medical cannabis laws in states with the initiative
process and those without. The results of this study indicate that a distinction needs to
be made between the factors playing a role in medical cannabis policy formation in
states with an initiative process and those without. While the participants thought that it
may be easier to pass medical cannabis laws in states with an initiative process, there
were also difficulties associated with it, such as cost and potential for the system to be
abused by those who have monetary and organisational power. The question of who set
the agenda and for what purpose is also another important question to consider with
regards to the initiative process, as, according to Kousser and McCubbins (2005) “it
does not allow for careful selection of those who set the agenda” (p. 20). Kousser and
McCubbins suggested that, due to the flaws in the process, initiatives have the potential
to lead to negative outcomes and poor implementation. This can be related back to the
poor implementation of medical cannabis laws in some states and the difficulties
experienced with implementing such laws which will be discussed later. Overall, while
using the initiative process has helped in the passing of medical cannabis laws where
they may not have passed otherwise, the ballot initiative process can also be abused. For
example, money from outside organizations can often have a disproportionate influence
on the process, which may or may not be consistent with what the evidence supports or
what the majority of the electorate desire.
The findings also indicate that influencing public opinion is a driver in
instigating policy change, especially when concerning a polarising topic such as medical
cannabis. Public support was rated as one of the top three factors of influence by both
Group One and Group Two participants. According to the findings, laws are not likely
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to work without the support of the public. As a result, influencing public opinion is one
of the major focus points for those who are attempting to get a law passed.
While the state by state review in Chapter Four showed that there were highprofile organisations supporting medical cannabis, Group One and Two participants did
not think that high-profile individuals played a significant role in the medical cannabis
policy process. They ranked it as eight and seventh respectively, and indicated that other
factors, such as legislative and public support, took precedence. Notably, Group One
participants rated advocacy groups as the second most important factor influencing
policy, while Group Two participants rated this as the second last. The difference could
be attributed to the fact that Group One participants had a direct involvement in the
process and possibly had had interactions with advocacy groups. Because Group One
participants were selected based on their involvement in the medical cannabis debate in
one of the five states under review, they may also have been medical cannabis
advocates and may have seen their involvement in the process as important. Because
Group Two participants were not involved in the medical cannabis debate, they may
have taken a more objective view of the importance of advocacy groups and other
factors.
Both Group One and Group Two participants placed the support in the
legislature as one of the most important factors influencing policy. This is also linked to
the influence of high profile individuals, as some politicians are very high profile and
were known to actively support or oppose medical cannabis policy. While it is
important to have support from the politicians, especially those well-known or wellliked by the public, the support does not come easily as there are many factors
politicians need to take into account when making policy-related decisions. If the aim is
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to make policy making more evidence-based and educate politicians, then scientists
should be aware of the political process and the factors, apart from scientific evidence,
that politicians need to take into account.
Patient testimonies were ranked by Group One participants as sixth out of nine
factors influencing medical cannabis policy creation and last by Group Two
participants. This could possibly be due to the fact that the evidence so far has been
limited and inconclusive. Those participants who were researchers may also have been
biased towards the role of scientific evidence. Nonetheless, as can be seen from a look
at the process of how medical cannabis laws were created, as discussed in Chapter Four
the role of anecdotal evidence should not be underestimated.
Notably, Group Two participants rated money as the number one factor
influencing medical cannabis policy. It was placed fourth by Group One participants,
who were directly involved in the process. This tendency could be explained by the fact
that only four (13%) Group One respondents participated in the medical cannabis debate
in Michigan, while most resided in New Mexico, Illinois and Louisiana, which have no
ballot initiative process or cannot put medical cannabis on the ballot. The results also
indicated that the reason why some organisations or individuals supported medical
cannabis policies was not due to science or compassion, but due to the belief that
medical cannabis is a business and there are profits available. The influence of funding
sources can then make it difficult for decision makers to remain objective.
Taking into account the many factors participants identified as playing a role in
the medical cannabis process, it can be said that the political process is composed of a
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number of different factors and influences. These include political timing, legislative
pressure, and party ideology.
Unrelated political conflicts and instances when other pieces of legislation are
used for a different purpose can also impact progress, as well as political “mind games”
such as threatening funding and adapting to a particular environment in order to send a
particular message. There are also different factors that policymakers need to take into
account, which can diminish the perceived importance and influence of the scientific
evidence. Overall, policy creation can be a long and difficult process, where persistence
and a well-organised effort are of importance, as well as the interplay of different
factors such as timing, political ideologies, and the context in which the policy creation
is occurring.
“One of the major issues that ultimately led to it being a 7 year fight
were all the unrelated political conflicts and instances when other pieces
of legislation were used to impact our progress, or when our bill was
used to further another bill. Hostage situations (taking the bill hostage in
exchange for another bill), timing issues, all unrelated to the merits of
the bill but part of the political process” (G1-6, New Mexico).
Study Limitations
As with any research, there were some unavoidable limitations with this study.
One noteworthy limitation was low response rates in the research groups. Although the
findings of the study were intended to inform the researcher and there were no
expectations in terms of acceptable response rates for the groups, previous research has
found that an average response rate for online surveys to be around 33 percent and 56
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percent for paper-based surveys. While the use of online surveys is increasing, little
research is identified which can suggest what an appropriate expected response rate may
be. According to Nulty (2008) “whether or not a response rate is adequate depends (in
part) on the use that is being made of the data” (p. 307). Participants for this study were
asked to provide their views on factors influencing the medical cannabis process, and it
was therefore decided that, although limited in the number of respondents, Group One
and Two participants were able to offer a valuable insight into the policy process from
the view of those directly involved in it and those involved in the science based aspect
of policy. The low response rate could be attributed to a number of reasons including an
increase in the number of research studies during the past few decades and the number
of requests participants may receive to participate in studies, overall decline in social
participation, and participation not being viewed as worthwhile (Galea & Tracy, 2007).
Research has shown that face-to-face interviews result in higher response rates, but this
was difficult to achieve for the purpose of this thesis due to the researcher’s location and
time and money constraints (Nulty, 2008). Future research may consider face-to-face
interviews and increasing the sample size to try and achieve a higher response rate.
There is also the issue of generalizability of the findings. In terms of Group One,
individuals involved in the medical cannabis debate in the five U.S. states reviewed here
are a unique sample, and the data obtained may not be applicable to other populations.
Group Two participants were all researchers and had varying degrees of familiarity with
the medical cannabis debate in the five U.S. states, and could be considered to have a
more objective view of the topic due to lack of direct involvement. It is not possible to
demonstrate that the sample was representative of the population; therefore caution
must be exercised in generalising conclusions beyond the medical cannabis policy field.
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However, it is important to note that this study was of an exploratory design and
generalisability was not the aim of the study. The aim of this study was not to test a
hypothesis, but obtaining an insight into the medical cannabis process and what
happened in the five states under review from the perspective of those participating in
the process and those observing it. This sample is therefore a very small proportion of
everyone involved in the medical cannabis process in the U.S., either directly or
indirectly, and research studies with a much larger sample size would be needed to
ensure generalisability of the findings. The data collection was limited to only five
representative U.S. states and future studies may want to look at replications of the
study in different U.S. states and in the general population.
There might be a potential for bias in the Group One sample of participants as
they already had formed views on the medical cannabis issue, which were expressed in
the public forum and identified in the literature review for each state. Nine (31%) of
Group One participants also used cannabis for medical purposes, and eight (28%) used
it recreationally. In contrast, no Group Two participant used cannabis for medical
purposes, but 11 (48%) used it recreationally. However, the majority of participants in
both groups supported medical cannabis legislation, and the sample may therefore be
biased toward medical cannabis. According to Galea & Tracy (2007), potential
participants are more likely to respond to surveys they are interested in and that have
some personal value to them, which may explain more medical cannabis supporters
completing the surveys. The sample was also biased in terms of political affiliation,
with 48 percent of Group One participants and 83 percent of Group Two participants
identifying themselves as Democrats. As discussed in the state by state review in
Chapter Four, Democrats generally tend to be supporters of medical cannabis while
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Republicans tend to oppose it. As such, the views of those involved in the study may
greatly differ from the views expressed by those not involved, as the supports of
medical cannabis legislation may have been more inclined to participate.
Another potential limitation of this study is that it relied on self-reported
responses, which can lead to potential bias in results (Donsbach & Traugott, 2008).
Biases can be derived from participants’ experience of medical cannabis or recreational
cannabis use, as well as their involvement in the debate; they may misreport their level
of involvement or the importance of certain factors based on their personal opinion and
experience, and may be inclined to provide socially accepted responses. Personal
perceptions and opinions of the participants in this study may therefore not reflect the
actual medical cannabis policy process and the importance of factors influencing such a
process. However, self-report methods were considered as the most appropriate and
realistic method for gathering the required information, due to the participants’ location,
and for gathering information about the process itself from the perspective of those
involved in it. It is therefore advisable that any future studies draw a random sample of
the population.
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Chapter 6- Group Four Study
This chapter will outline in detail how the Group Four study was undertaken,
provide details of the study design, and present Group Four findings. The purpose of
this study was to further explore the themes developed through earlier studies and the
state by state review, and obtain a general overview of the factors influencing alcohol,
other drug, and medical cannabis policy from the perspective of individuals involved in
the field.
Sample
Group Four participants were members of the ISSDP, and were chosen as
individuals who had an interest in, and participated in, the drug policy field. It was
anticipated that the participants would have sufficient experience to answer questions
relating to the drug policy field and the processes and factors involved in enacting
policy, without necessarily being directly involved in the medical cannabis debate.
Their opinions were sought as experts on the drug policy process and it was anticipated
that they would be able to provide an objective, informed view of the process. All
participants were identified through the ISSDP 2010 conference registration list
supplied to the researcher by ISSDP. All participants who were not personally involved
with this study through providing feedback on the study to the researcher, and whose
email addresses were available were invited to participate in a semi-structured telephone
interview.
A total of 90 potential participants were invited to participate in the study.
Nineteen individuals responded to say that they were unable to participate in the study
for several reasons, including insufficient knowledge of medical cannabis policy,
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insufficient knowledge of the drug policy field, and time constraints. The interviews
were conducted with participants in the order that participants were available for
interview. It was estimated that ten interviews would be able to provide a valuable
insight into expert view of the policy process, and data saturation was reached after ten
interviews. In qualitative studies, saturation is reached when no new or relevant
information emerges from the data, and the information obtained from participants
becomes repetitive (Given, 2008; Liamputtong & Ezzy, 2005; Mason, 2010; O'Leary,
2004).
In total, interviews were conducted over three months, with ten participants of
whom five resided in the U.S., three in Australia, one in the Czech Republic, and one in
France. Their occupations included professor, senior economist, consultant in social
research and evaluation, researcher, PhD student, lecturer, and assistant policy advisor.
All participants had research experience in drug policy, and five had studied policies on
the use of cannabis as a medicine.
Procedure
Approval for the study was obtained from the ECU Human Research Ethics
Committee prior to commencing the research. The following section will describe the
procedures used in the development of the semi-structured interview schedule and how
the interviews were conducted. The data collection period spanned from 16th February
2011 to 22nd April 2011.
According to Corbetta (2003), qualitative interviewing allows the researcher to
gain an understanding of a subject’s perspective, “understanding his mental categories,
his interpretations, his perceptions and feelings, and the motives underlying his actions”
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(p. 264). It was expected that Group Four participants would be able to present an
objective overview of the policy field and factors which play a role in influencing it,
along with their experiences of working in that particular field. Qualitative interviewing
also does not call for a representative sample, making it appropriate for Group Four
participants who were all from similar fields and were members of ISSDP (Corbetta,
2003).
Telephone interviews, specifically, allowed the researcher to obtain more indepth data than questionnaires did, and allowed respondents to discuss their
experiences, perceptions, and attitudes (Morrison et al., 2000; Stetson & Romeo, 1996).
Telephone interviewing is a cost-effective way to cover a greater geographical area,
which allowed the researcher to interview participants from four different countries and
obtain a wider perspective of the policy process (Musselwhite, Cuff, McGregor, &
King, 2007). It also allowed the researcher to arrange interview times across different
time zones, at a time convenient to participants, and allowed for a dynamic interchange
of information and allowed the researcher to clarify responses and discuss relevant
issues (O'Leary, 2004). Protection of participants’ anonymity was also considered when
selecting an appropriate interviewing method, and telephone interviewing allowed this.
According to Musselwhite et al. (2007) “the anonymity associated with telephone
contact may enable participants to be more forthcoming with their responses” (p. 1066).
Due to low participant response rates for Groups One to Three, telephone interviews
were utilised for Group Four interviews as they generally have better response rates
than questionnaires (Glogowska, Young, & Lockyer, 2011).
Interview questions. A semi-structured interview schedule (Appendix E)
containing nine open-ended questions was used. Semi-structured interviews are the
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most used interviewing format for qualitative research (DiCicco-Bloom & Crabtree,
2006). According to O’Leary (2004), semi-structured interviewing “gives both the
interviewer and the respondent ample freedom, while at the same time ensuring that all
the relevant themes are dealt with and all the necessary information collected” (p. 270).
The questions helped guide the interaction between the participants and the researcher,
while still allowing participants an opportunity to raise and discuss pertinent issues
(Liamputtong & Ezzy, 2005). Examples of questions included “What role do you think
scientific evidence generally plays in policy-making?” and “In your opinion, which
factors influenced the passing of medical cannabis legislation in 15 11 U.S. states (such
as California, Michigan, and New Mexico) since 1998?”
The questions were based on themes derived from the state by state review and
Phase I results. The questions sought to investigate the role of scientific evidence in
medical cannabis policy, and identify the factors influencing general drug as well as
medical cannabis policy. In semi-structured interviewing, the wording and order of the
questions can be changed, depending on the interview and the participant (O'Leary,
2004). Some questions were omitted due to participants’ lack of knowledge or inability
to answer a question, while in certain cases questions were added in order to facilitate
discussion. Probing (or prompting) was also used to encourage participants to provide
more information or to clarify an issue (O'Leary, 2004).
The interview process. Once the contact details of ISSDP members were
obtained, they were emailed an information letter which outlined the nature of the study
and invited them to voluntarily participate in it. The letter also informed participants
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At the time of the interviews being conducted, 15 U.S. states had enacted medical cannabis legislation.
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that the study looked at the policy process underlying medical cannabis laws in the U.S.,
how problems and issues are recognised and raised, and how and why governments
choose to act or not act on certain policies. The participants were advised that they had
been identified as someone who could comment on the policy process due to their
involvement with the ISSDP.
Participants were asked to indicate their willingness to participate in the study by
sending an email to the researcher stating their agreement. They were then contacted by
the researcher to arrange a suitable interview time. Participants were informed that they
were free to withdraw their consent and cease their involvement in the research project
at any time. Participants were provided with contact details of the researcher, two
supervisors, and an independent contact (ECU Research Ethics Officer) in case they had
any questions about the study. Prior to the interview taking place, participants were sent
a confirmation email, allowing them time to raise questions or concerns regarding the
study. If a date change was necessary, participants were asked to indicate their
availability and the interview was rescheduled to a more suitable time.
All Group Four interviews were conducted at a time convenient to the
participants and the researcher. The researcher obtained a quiet room with a speaker
telephone, and interviews were recorded and transcribed verbatim. All interviews were
completed in one sitting. Before interview questions were asked, the researcher
explained the purpose of the interview, addressed the terms of confidentiality, explained
the format of the interview, indicated how long the interview would take, and allowed
participants to ask questions to clarify any concerns they had (Musselwhite, et al.,
2007). The researcher also attempted to set participants at ease by reviewing the aims of
the interview and reassuring participants of their anonymity. Participants were also
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reminded that the interview would be voice recorded for later transcription, and their
consent was confirmed.
The interview was voice recorded in order to preserve the data in its purest form,
as it would have been difficult to write notes and keep track of the questions while
maintaining a conversation with the interviewee (Glogowska, et al., 2011). The
interviewer used a speaker telephone in a quiet room at ECU, and an audio-recording
device with high sensitivity. One participant preferred using Skype (www.skype.com)
for the interview and this was arranged. The Skype interview was recorded using audiorecording software on the researcher’s computer.
The interview began with generic questions in order to establish rapport with the
participants and set them at ease (Musselwhite, et al., 2007). The interviews were kept
at 30 to 40 minutes long, in order to minimise participant inconvenience (Glogowska, et
al., 2011). One interview had missing data due to technical difficulties with the voice
recorder. The participant invited the researcher to email them the missing questions, but
no response was received. After the interview took place, the researcher allowed
respondents time to add further information or discuss any pertinent issues.
After the interviews were completed they were transcribed by the researcher,
and audio files of telephone interviews were stored in a password protected computer in
the researcher’s office at ECU and all further work was done using the transcripts. Only
the researcher had access to the transcripts. All transcripts were numerically coded; each
participant was assigned a different numerical code, and no identifying information was
used. All transcripts were coded based on the participant’s group, and their interview
number. For example, if the participant belonged to Group Four and was the fifth
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participant interviewed, they were assigned the code “G4-5”. Transcripts and data were
stored in a locked filing cabinet at ECU.
Analysis
After the accuracy of the transcripts was verified, by checking them against the
audiotapes, they were analysed using thematic analysis, with a focus on maintaining the
essence of the participants’ accounts (Liamputtong & Ezzy, 2005). Thematic analysis
involves the identification of themes through reading and rereading of the data and
coding of recurring themes appearing throughout (Liamputtong & Ezzy, 2005). For
more information on thematic analysis and the steps used in the analysis process, please
refer to Chapter Five, “Analysis” section.
An audit trail consisting of how codes and themes are developed was kept in
order to enhance the credibility of the research. Providing an audit trail ensured the
rigour of the study, clearly and accurately documenting how the data were collected and
analysed and how interpretations were made. In order to check the validity, the
supervisors of the project reviewed the themes (Liamputtong & Ezzy, 2005). The
researcher used a reflective journal (memoing) in order to recognise any research bias,
which added to the authenticity of the information (Liamputtong & Ezzy, 2005). QSR
International’s computer-assisted qualitative data analysis software, Nvivo 9, was also
used to assist with the organisation and analysis of the data, and with keeping an audit
trail (QSR International Pty Ltd, 2010).
The following section outlines the findings from Group Four interviews,
presented according to emerging themes.
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Results
Moderate but increasing role of scientific evidence. One of the major themes
arising from the Group Four study was the influence of scientific evidence on general
drug policy. The general consensus amongst participants was that the scientific evidence
did and continued to play a role in the policy making process and the policy debate.
However, as noted in the previous chapters, that role was generally believed to be
limited and not to the level that researchers may have wanted. Those conducting
research also hoped that evidence did play a role as that meant that they were serving
their purpose and contributing to the process.
“You know, if you had a rating scale of 0 to 10 of how much role does
science play in it...I would put it currently at about a 4 or a 5 in general
alcohol and drug policy. We have seen, for example, increasing use of
medications in treatment over the last decade- in part because of science
and research, but it’s...I would put it maybe at a 4 ½ to 5...So I would
say a moderate amount that is done in alcohol and drug treatment in
general” (G4-4, U.S.).
“I mean, my life sort of depends on it having an effect; because if it
doesn’t, I’m just wasting my life. But it is kind of frustrating that....It
seems like you have an effect maybe, but it’s a small effect; and it could
really go either way” (G4-5, U.S.).
“I think it plays a minor role to a moderate role. It can definitely
motivate a change in policy, support a case for it, but in terms of
implementing the best policy it’s not always then used” (G4-10, U.S.).
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Participants also indicated that the impact of scientific evidence on policy had
increased over the years and attributed this to an increase in research and an improved
communication between researchers and policymakers.
“I do think it’s playing an increasing role. I do think in some areas of
medicine and health care it plays a substantial role” (G4-4, U.S.).
Scientific evidence: a range of roles. In regards to general policy making, roles
of scientific evidence were varied and depended on a number of factors. Scientific
evidence was found to motivate a change in policy and help shape policy; help get an
issue onto an agenda and lead to a recognition of an issue; be a part of the policy
discussion; influence and educate state legislators; and inform the process and the actors
in it. The question that arises, however, is whether scientific evidence is used to
implement the best policy, as this has not always been the case. As discussed in the
earlier chapters, while scientific evidence may not have a direct impact on policy
creation, it does enter the discussion and can help inform the policymakers. This
supports Weiss’ “enlightenment model” that the impact of research on policy is not
direct, but research is instead seen as one of several sources of information available to
policymakers (Weiss, 1977, 1979).
“It can definitely motivate a change in policy, support a case for it, but
in terms of implementing the best policy it’s not always then used....I
think what scientific research does more than anything is it helps modify
existing policies” (G4-10, U.S.).
“I think state legislators change their position based on the scientific
evidence....I think scientific evidence is a part of the discussion. I’ve seen
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legislatures go from incarceration to diversion treatment. I’ve seen
legislatures go to needle exchange programs as a way of fighting the
transmission of HIV. So, I have seen scientific evidence impact policy
decision at the local and state levels” (G4-1, U.S.).
Scientific evidence and agenda setting. According to Kingdon (1995) decision
makers will prioritise those problems where someone like the administration or the
scientific community can provide them with a constructive solution. However, three of
Group Four participants argued that even with scientific evidence available, this did not
play a significant role in agenda setting. The question that this view raises is, even if the
evidence is brought to the attention of policymakers, will it make any difference to
agenda setting?
“I think — generally speaking- scientific evidence is very low in the
hierarchy of influences on setting agenda. A low- fairly low- in hierarchy
of influences that lead to governments paying attention to an issue” (G42, Australia).
“I don’t think it influences agenda setting. So if you think about how
governments do business, the first thing is: it needs to be on their
agenda. The second thing is: they need to look for solutions. And then the
third thing is: they need to implement those solutions. So in terms of
agenda setting- research has a very small role to play in agenda setting;
that’s much more the area of public opinion, and media, and individual
political concerns” (G4-8, Australia).
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Factors influencing the role of scientific evidence. As discussed in Chapter
One, Weiss listed the reasons for the limited use of research in policymaking as
weaknesses in the research itself, conflicting demands on policy, and the discrepancy
between what knowledge is needed by policymakers and what is provided by
researchers (Weiss, 1977, 1979). Black (2001) listed these reasons as policymakers
having their own goals for policies other than scientific evidence and clinical
effectiveness, the dismissal of scientific evidence as irrelevant and not applicable, lack
of consensus about scientific evidence and its interpretations, focus on other types of
evidence such as personal experience, social environment not conductive to policy
change, and poor quality of knowledge purveyors. Group Four participants also
believed that there were a range of factors that influenced the use of science in policy
formation, and whether or not it is used to influence policy. How the evidence is
communicated to the public and other actors in the policy process was the most
discussed factor of influence. Five participants indicated that the way the evidence is
communicated can impact on whether or not it is used to influence a particular policy.
Other factors included access to evidence and the type of research accessed; the
availability of scientific evidence; who has access to the evidence and in what context;
connections within the political field (how scientists are connected with the political
field, who is responsible to whom, etc.); context and the time period; mass media and
how it presents the scientific evidence; public perceptions of what evidence is; interest
in scientific evidence; type of society the policy is made in; and the topic area. Overall,
the participants did not believe that a single factor influences the impact of evidence on
policymaking, but rather a number of different factors. However, all participants agreed
that what is lacking is getting the right type of research to the wider public, who
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generally tend to obtain their information from non-scientific sources, rather than
scientific journals.
“...There is a whole journal now here in the States about the therapeutic
benefits of cannabis and the various studies that show the clinical studies
of cannabis. And you can find lots of scientific articles in that journal.
But I think that most doctors would say that that journal is probably not
as well read or accepted as JMR or the New England Journal of
Medicine, and you don’t see articles there; but does the average person
know that? The quality of science is not dichotomous either and the
average person isn’t necessarily able to decipher that” (G4-10, U.S.).
“You know, we’ve been busy funding science in the U.S. for the last 50
years and we fund a ton of wonderful science, but there’s been almost
very little attention given to how to communicate that science to the
public....In fact, for those of us who get grants and research: we get the
grant to do the research; we do the research; we do the research
findings; if we’re lucky we get something that we can publish in a
professional journal; and then we’re onto the next grant. There’s never
any attention paid to get this information out to the public and try to
communicate it to the broader community. And I think that’s then part of
the problem in getting the public more aware of the science of alcohol
and other drug policy” (G4-4, U.S.).
Improving the use of scientific evidence in policy making. Bacci (2009)
suggested that in order for research evidence to be used effectively in the policy
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process, researchers and policymakers need to take a more collaborative approach
instead of working in isolation. Bacci also suggested that policymakers need to be
involved in all stages of research from the development of the research question to the
implementation of the results. Group Four participants thought that the first step in
improving the use of evidence is improving how the evidence is communicated to the
individuals involved in policy making (such as the public and the politicians). The
participants believed that scientific evidence needed to be reconciled so that it
encompassed both sides of the debate and presented results in an objective way. They
indicated that it was also important to make evidence easier to understand, and focus on
translating it into the political field. This could be done, as Bacci (2009) suggested, by
taking a more collaborative approach between researchers and policymakers.
“If science is supposed to be objective and get information and present
facts, we can’t force people to use those facts, unless we can educate
them. So I really, really believe that if science was to become more
important in affecting policy it needs to do a better job of communicating
not just to the politicians but also to the layperson what the essential
points are – and not doing it by overstating the findings, because that’s
where we get ourselves into a lot of trouble with drug policy is things
tend to get overstated...and be honest when the results aren’t clear” (G410, U.S.).
“It’s how that evidence is manipulated, is packaged, is communicated to
the people who can make use of it. In my view, we need to return to some
kind of arrangement whereby there are structures, and resources, and
known channels through which the research evidence can be- not just put
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together- but packaged, and communicated, and used in the policy
context at the national level” (G4-2, Australia).
“…I think in the future for us to get science to play a better role our
ability to communicate effectively, and to communicate in a way that the
public understands it, and to tailor the messaging so it’s something they
can relate to their own lives- THAT makes a difference” (G4-4, U.S.).
Other ways of improving the role of scientific evidence, as mentioned by the
respondents, included more studies, apart from ideology; drawing more attention to
science, “selling it”; making science more accessible; catering to policymakers’
interests; mixing science with politics by scientists becoming more aware of political
issues and the political process; and providing objective information.
“I think scientists and the organisations that promote science and that
think that science should have more influence need to do a better job and
invest more in communicating the science more effectively, and getting
the science out to the public in vehicles. And if you’re going to try to
communicate via mass media you have to be skilled at communicating in
a way people can understand and that they will continue to pay attention.
And I think that we haven’t done a lot of that. I think we’re moving in
that direction and I think that’s going to be one of the factors that will
determine how successful we are in making science more important in
setting policies and developing the whole policy side of things” (G4-4,
U.S.).
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“I think the first thing is to do the kind of research that matters to policy
makers. Most research that’s conducted in drug and alcohol is marginal
to policy makers’ interests. So that’s problem number 1 – we’re studying
the wrong things, because we’re not studying the things that policy
makers are interested in or need to make decisions about... Now, we do
efficacy trials all the time and we rarely do effectiveness trials. And
politicians aren’t interested in efficacy so much; they’re much more
interested in effectiveness. That is, if they rolled out this treatment, would
it actually be used in a way in which it’s intended and produce the
outcomes that the pollies were looking for?” (G4-8, Australia).
Science and democracy. As mentioned in Chapter Two, one of the more
prominent criticisms of the initiative process is that voters lack education and
competence to make policy decisions (Burnett & Parry, 2014; Matsusaka, 2005).
Research has shown that most voters are uninformed about public policy, politics and
government, which raises the concern that damaging policies may be adopted as a result
of voters lacking education. The question this raises is whether, in a democratic process,
science should play a more important role than public opinion, or vice versa? And how
restricting is the democratic process to evidence-based policy?
“…I think that there’s an optimisation here that hasn’t been done, and
that is: If science is providing information that’s counter to what the
general public wants to believe; and in democracy, should science be the
one thing directing policy? I would like to believe science is very
important and is more important than people that don’t understand the
facts – that’s not democracy” (G4-10, U.S.).
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Scientific evidence in the future: an increasing importance. Overall, Group
Four participants were optimistic that if steps were taken to improve its use, the role of
scientific evidence in the general policy making process will likely increase over time:
“You know, I couldn’t keep doing the work I do if I didn’t think it was
going to increase” (G4-4, U.S.).
“I tend to think that in the future it will get better. That overtime- as
people become more educated- they’ll have better scientific
understanding of the theme and a better appreciation for scientific
evidence, and a global willingness to defer to science when they need to”
(G4-5, U.S.).
Selective use of scientific evidence. The use and misuse of scientific evidence
by the people involved in the policy field was another theme frequently discussed by
Group Four participants. Participants addressed the issue of “cherry-picking” or the act
of selectively using data that conform to a particular position in order to promote it,
while ignoring cases or data that may contradict that position. Participants believed that
science was used by the individuals involved in the policy making process to “sell” their
position to the general public and gain support for the issue they were representing. This
was also a major theme in the state by state review in this thesis, as well as Group One
and Two studies. This was also described by Weiss (1991) as “research as arguments”,
representing research to which an advocacy position has been added. The difficulty lies
in overcoming the selective use of evidence, and Birkland (2005) and Ritter (2011)
argued that to do this it would be important to bridge the gap between what research
tells us and how citizens and government officials use that information.
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“I think that people prefer science that supports their position so it gets
selectively reviewed and presented on every side of the issue” (G4-10,
U.S.).
“Politicians, I believe, use the scientific evidence in the substance abuse
field primarily in the way that we do characterise as “cherry picking”.
In other words, selecting those bits of evidence that are consistent with a
predetermined position. And, unfortunately, many public servants now
find themselves taking the same approach” (G4-2, Australia).
“What’s very interesting is that sometimes the same scientific evidence
or the same scientific theory is used in two different ways by two
stakeholders, like lobbyists and politicians, that are actually opposed in
the drug policy creation” (G4-9, France).
Scientific evidence and medical cannabis. While not all participants were
familiar with medical cannabis research and medical cannabis policy in some of the
U.S. states, the majority agreed that there was insufficient scientific evidence supporting
cannabis’ use as a medicine to warrant policy change. The respondents indicated that
the evidence was usually mixed and could generally be considered limited. Similarly,
the research evidence reviewed in Chapter Three has shown that cannabis and its
constituents have therapeutic potential for a number of conditions, some for which the
evidence is mixed and unclear. Most of the research evidence supports the use of
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an
appetite simulant for AIDS-related wasting syndrome. The participants concluded that it
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is difficult to make effective policy on medical cannabis when research is mixed or
lacking.
“In the case of medical marijuana I think that there are certain areas
where there’s lots of research; and there are certain areas where there is
still a gaping hole. And so the science is not as developed as in other
areas” (G4-10, U.S.).
“So the scientific research on dosage, on impact, for what conditions,
really is not out there” (G4-1, U.S.).
“The science of cannabis and its effects as a medicine have been so
poorly studied up to this point. It’s hard to make policy on cannabis as a
medicine based on science because there’s so little science” (G4-4,
U.S.).
As a result, the participants believed that in the case of medical cannabis,
scientific evidence has not been a main motivating factor for policy change.
“But the rest of the scientific evidence just doesn’t stack up in terms of
the benefits of medicinal cannabis. So, given that states in America have
approved medicinal cannabis; I don’t think it’s on the basis of scientific
evidence, because if it was on the basis of that, they wouldn’t have
approved it” (G4-8, Australia).
“There was no such crisis in those 15 states, besides, I guess, the
gradual change in opinion in voters’ minds, where it eventually got to
the point where you had these laws from so long ago that they didn’t
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really match up with people’s opinions and their sense of compassion
towards sick people” (G4-5, U.S.).
While it was generally not considered to be the sole factor driving medical
cannabis policy, the participants suggested that scientific evidence did play a role in the
policy process by informing the process, rather than directly affecting it.
“It remains a very complicated process which the science informs, but
doesn’t really decide political polemics about legalising recreational
drug... intertwined with medicine and science....So, the science is a part
of it, but science I don’t think overwhelms it- I gave it less than half of
the contribution” (G4-1, U.S.).
“I think that in this case the research hasn’t been the motivating factor
for the policy change. No. I think it’s been used in the discussion, but it
has not been the motivating factor for policy change” (G4-10, U.S.).
One participant also discussed the need to educate people and gain knowledge as
something that should be the motivating factor for gathering evidence on medical
cannabis.
“I don’t think it’s been done to warrant a policy change; I think that we
generally need to know. In the U.S. there was a senate committee that
was funded to look at the medicinal value of marijuana using clinical
trials, and I think that that was completely appropriate and should have
been then” (G4-10, U.S.).
Factors influencing the use of science in medical cannabis policy. Similarly to
general policy formation, the participants believed that there were certain factors which
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influenced medical cannabis research, whether or not science was used in the medical
cannabis policy process, and how the evidence was used. No one particular factor was
identified, but rather a range of factors which were believed to influence the quality of
scientific research and its role. Politics and the political nature of medical cannabis
policy was the most frequently mentioned factor. Participants suggested that politics had
the potential to interfere with the role science had in informing policy and could prevent
medical cannabis research from occurring. Other factors mentioned by participants
included limited research funding, the priority given to research (participants believed
medical cannabis research was not seen as a priority by governments), restrictions
placed on medical cannabis research due to the drug’s scheduling and difficulty in
obtaining cannabis supplies for research purposes, communication between different
actors in the policy process, religious groups, special interest groups, and the type of
research conducted.
“I’d say it’s all political. I don’t think enough research has been done,
but, that’s a political issue because of the scheduling issue in the U.S.
...Unfortunately, because cannabis is classed as a Schedule I drug in the
U.S., not a whole lot of research has been done. I think the way
government sees it now is that it’s a non-issue because marijuanacannabis- is still classified as a Schedule I drug and so they’re not
funding research; people have a hard time getting any funding for
research legally and doing it ethically” (G4-6, Australia).
“First, on a political level, it’s easier to make the argument that
marijuana should remain illegal if there’s nothing good known about
it…With regards to the second one: the importance of the special interest
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groups. I do think that it will also kind of hinder the use of scientific
evidence, unless that scientific evidence can be framed in such a way as
being beneficial to those special interest groups; to the police, the prison
guards. In that sense, if it could be framed as their asset, then they could
gain some significant allies. But generally, I think those groups are
going to be against a lot of scientific evidence and also the use of
scientific evidence” (G4-7, U.S.).
“...there’s not a whole lot of priority in really funding research on
medical cannabis and what it can do. There is some, but it’s not going to
get a lot of federal funds, it’s not going to get a lot of state funds. These
are tough budget times; it’s not going to get a top priority.... And the
politics can really interfere with the science” (G4-1, U.S.).
“… in the United States, as an addiction researcher for 35 years, we
have not been able to research cannabis. It’s been impossible to get
supplies of it; the National Institute on Drug Abuse wouldn’t fund it...
until the last, I don’t know, 5 to 8 years, it simply was a topic you
couldn’t do research on and so we kind of ignored it” (G4-4, U.S.).
Improving the use of scientific evidence in medical cannabis policy. After it
was suggested that scientific evidence does not play a significant enough role in relation
to medical cannabis policies, participants suggested a total of six different ways of
improving medical cannabis research and giving it a more important role in medical
cannabis policy making. Conducting more definitive medical cannabis studies was the
most popular suggestion, discussed by six participants. This was closely followed by the
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need to improve upon how science is communicated to the general public and the
individuals involved in the policy process. Participants also mentioned the need to
conduct more studies, and conduct them away from ideology. Re-scheduling of
cannabis was also discussed, as one participant believed it would allow access to the
drug in order to conduct more studies and obtain more funding. Lastly, two participants
suggested that researchers needed to conduct research that is relevant to politicians and
policymakers:
“I think it would be very helpful to do some definitive scientific studies
that would look into medical marijuana, and in terms of the health
condition, in terms of what it is. You know, we think “Marijuana. What is
it, marijuana?” THC, I mean, the dosage levels, delivery...Is smoking the
best way to get the medicine to you?” (G4-1, U.S.).
“I think with cannabis as medicine there are a few steps before that that
we also need to be doing, which is documenting clearly what cannabis is
useful for, and documenting with carefully designed research trials to
articulate how cannabis produces whatever beneficial effects it does
produce, and what proportion of the population benefit from the pain
relief or which kinds of pain, why it produces pain relief. I mean, all of
those....With cannabis, we have the problem of: we don’t have the
science yet. And so...we need more basic, and applied, and clinical
science” (G4-4, U.S.).
However, despite acknowledging that re-scheduling cannabis at the federal level
is an important step towards improving medical cannabis science and its influence on
medical cannabis policy, it has to be acknowledged that re-scheduling is a difficult
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process. As suggested by one participant, the federal government would not reschedule
cannabis until there was sufficient evidence for its medicinal properties. However,
scientific evidence alone would not likely lead to cannabis’ re-scheduling, as the federal
government had to consider other factors, such as international treaties it is signed onto:
“In the U.S., while we have states changing laws the federal government
is not going to change its law until it has more scientific evidence. And
so perhaps this is just the way that evidence will come out” (G4-10,
U.S.).
“I think that a lot of other things have to happen for the federal
government to do it, because it wouldn’t just be an issue of science given
the international treaties it’s signed onto. The fact that cannabis has
been rated as a top ten dangerous drug internationally not just in the
U.S. — that would have to be addressed for the U.S. federal government
to change its policy because I don’t see it as being willing to change its
policy and go against the international laws, violate international
treaties. That doesn’t promote its other interests in seeking other people
to comply with international treaties” (G4-10, U.S.).
Selective use of medical cannabis research. While participant views regarding
the influence of scientific evidence in passing medical cannabis policies were mixed, it
was agreed that scientific evidence can be used in different ways by different
individuals in the field. Group Four participants indicated that the evidence can be used
selectively by individuals involved in medical cannabis policy to further or support a
position, as well as to influence public opinion. As discussed earlier in the chapter,
selective use of evidence, or “cherry-picking”, is not solely limited to medical cannabis,
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but is happening across the drug policy field. However, with cannabis being a
contentious issue, proponents and opponents selectively using the currently available
evidence was one of the major factors playing a role in the medical cannabis debate in
the states reviewed in Chapter Four.
“The public definitely heard that there is some evidence for medical
marijuana, and the IOM report provided some additional evidence that
there might be therapeutic benefits. It wasn’t that it said that definitively,
but there were a couple of statements that the advocacy groups could
pull out. And the other side of that too, because the IOM said we should
not make marijuana available for medicinal purposes, right now we
don’t have enough science... the people who were against policy change
pulled that line out. The people who wanted policy change pulled
different lines out. And both presented that information to the public, and
the question is: which one was the public listening to?” (G4-10, U.S).
“And on the other side of things- I think that this is a big enough issue
and it’s gotten enough attention- that I don’t think that advocates on
either side are basing their opinions on the scientific evidence. I think
that they’re picking their facts to fit their side…” (G4-7, U.S.).
Is cannabis a medicine? Participants also brought up uncertainties over medical
cannabis and whether or not it could be considered a medicine as well as the availability
of other medicine that could be used instead of cannabis. Undefined aspects of medical
cannabis, such as dose, purity, and distribution need to be explored further through
research in order for effective laws to be created. Participants also believed that medical
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cannabis policies in some states were not clearly defined, especially in terms of how the
medical cannabis program should be implemented. As discussed in the earlier chapters,
there are differences in state medical cannabis laws in terms of the conditions covered,
the amount of cannabis allowed for medical use, and how cannabis is distributed. One
of the themes that came up in this study was, if cannabis is a medicine, why is it not
treated as such. This would mean following the FDA approval process for new medicine
as well as having well-defined laws.
“If it’s a medicine, we aren’t really treating it like medicine....I think
most of medical marijuana policies are ludicrous. Because they don’t
give a good definition of disease, they don’t give good definition of
dosage, there’s really no way to know the purity and delivery...It’s
bizarre...through some clubs in California you ‘grow your own’ in some
states... you grow 3 or 4 plants.” (G4-1, U.S.).
“Whether or not marijuana is the preferred medicine is still debated
because of other issues such as route of administration and the
availability of other medicines that could meet the same goal” (G4-10,
U.S.).
Differences between medical cannabis and other areas of policy. It was
suggested by the participants that there was a difference between medical cannabis and
other drug policy, as well as medical cannabis and other medicines. The same rules did
not apply to cannabis as a medicine and other medicines, such as the required FDA
approval. The participants thought that there was a difference in the amount of research
available for medical cannabis and other drugs, and that people were more likely to be
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opinionated on the issue of medical cannabis. While some participants believed that
there was not enough scientific evidence to show cannabis can be effective as a
medicine, others believed that scientific evidence could play a more important role in
informing medical cannabis policy than other policy areas. Alternatively, it was also
suggested that science would not be as influential a factor in medical cannabis policy
formation as it is in other drug policy areas. There was also a notable difference in the
power the law enforcement lobby had in medical cannabis policy and other areas of
medical research.
“I would say one of the differences is in a lot of the cases where we try to
do a policy change, cigarettes for example, there were just volumes of
research to promote or substantiate a policy change. In the case of
medical marijuana I think that there are certain areas where there’s lots
of research; and there are certain areas where there is still a gaping
hole. And so the science is not as developed as in other areas” (G4-10,
U.S.).
“So, I think- in other areas of medicine in general- there’s a greater
potential for science to play a role... up to this point anyway. I mean
maybe it will change with cannabis as we get good studies – if we do.
And in other areas of medicine there is a more direct relationship. I
mean, there’s medicine where it’s equally as hysterical. Things like, in
the United States, the stem cell research and anything to do with
abortion. I mean those things generate the same kind of hysteria and
emotionality as cannabis. But, for the most part, in other areas of
medicine there’s more direct application of science” (G4-4, U.S.).
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“I don’t think you’d advocate growing penicillin. It’s a ridiculous way
they approach the matters. So I think the medical marijuana policy is not
a good medical policy; it’s not a good health policy” (G4-1, U.S.).
Framing the issue. Group Four participants also discussed different ways of
how the medical cannabis issue was portrayed by both supporters and opponents.
Generally, it was found that portraying medical cannabis as a human suffering and
compassionate issue contributed to the successful passing of some medical cannabis
laws. The participants also agreed that it was important to differentiate medical cannabis
from legalisation of recreational cannabis in order to pass medical cannabis laws.
Separating medical cannabis from the broader legalisation issue has played a major role
in the medical cannabis policy debate. This also has political importance as medical
cannabis can be seen as an issue of compassion and is generally more accepted by the
public, while drug legalisation is more controversial and there is generally less
acceptance.
“I think the attempt to make it a medical- human suffering- definition has
played a role...perhaps medical marijuana passing where
legalisation/decriminalisation did not. So I think the attempt to
differentiate them probably has played some success in medicalisation”
(G4-1, U.S.).
“Personally, I think that many of these advocates for legalisation of
marijuana are being a little disingenuous by saying “No, no, we’re not
necessarily going for legalisation of marijuana for everyone today;
we’re just going for medical marijuana.” And so I think that their

Medical Cannabis in the United States

340

arguments are a little disingenuous; whether they’re right or they’re
wrong. But, I do think it can be very effective” (G4-7, U.S.).
“Well, you know the saying, that with respect to drug policy, you should
probably restrain from using the term ‘legalisation’ in case you wanted
to push through something which is really useful and acceptable by the
public and decision makers....” (G4-3, Czech Republic).
Science vs. politics. Another common theme in the Group Four study was the
interplay of science and politics in the policy creation process. Politics can impede the
use of science in the policy process and can sometimes overwhelm it. As a result, it was
implied by some participants that scientists conducting research should be more aware
of political issues and the political process in order to make science an essential factor
in informed policy creation.
“I think right now there’s still a lot of fear and a lot of politics-driven
issues that are affecting policy; more so than scientific evidence” (G4-6,
Australia).
“I think that probably scientists have to be more aware of political
issues, political debates, and things like that. Because, in my PhD I
showed that the scientific evidence...that the translation of scientific
evidence in politics, how it’s framed and things like that, is done by
political actors. Rather, political actors translate scientific evidence
rather than scientists themselves” (G4-9, France).
Interest: who stands to win or lose? Participants also considered interest
groups, or who stands to win or lose if a particular law is passed or fails to pass, as one
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of the factors influencing policy formation. Group Four participants discussed the role
of interest groups and suggested that, especially in terms of medical cannabis, there
were various groups and organisations who stood to win if the law were passed as well
as those who stood to lose both power and financially. Interest groups can have political
significance when they try to influence public policy, propose new laws, or persuade
government officials to act in their interest. Over the years, the activism and influence
of interest groups has expanded, and they now play a significant role in the U.S.
political system (Singh, 2003). As discussed in the state by state review, pharmaceutical
groups also stood to lose money if cannabis was legalised and suggestions were made
that the reluctance to adopt new drug laws came mainly from the pharmaceutical
industry’s concern that they would suffer significant monetary loss should cannabis be
legalised (Andrews, 2007a; R. E. Martin, 2007).
“I think that the business- cannabis as a business- has definitely played a
role. The profits that are available... because the business has continued
to push forward a desire to see policies change and for them to operate
more freely. I think that there has been a huge role” (G4-10, U.S.).
“...it wasn’t so much an argument about medicine/no medicine; it was an
argument about economics of distribution” (G4-4, U.S.).
“Because the DEA agents with the police already have a position, and
they’re already powerful, and they already exist and have interests- they
are in a much better position to fight for those interests than people who
may have a benefit sometime in the future and don’t really have
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something concrete to grab onto, and don’t really have those levers of
power to work with” (G4-7, U.S.).
The influence of public opinion. The participants believed that, especially in
the medical cannabis field, public opinion was taken into account by the individuals
involved in policy creation. However, they also believed that the role could be reversed
and public opinion be influenced by those in the policy creation field. Public opinion
also had an effect on the use of evidence in policy formation, as sometimes public
support for a particular issue was seen as more important than the scientific evidence
available. As discussed in Chapter Four, public opinion is also likely to play more of a
role in states with an initiative process, while science tends to have more impact when a
law is being passed by the legislature.
“You know...they give you all the organising you want to and if the
public wasn’t crying out- then nothing would happen” (G4-5, U.S.).
“In my mind, in cases...once the public gets involved, evidence may be
wielded as a weapon by one side or the other; but they’re not making
their decisions based on the science. The only time that I really think that
science is going to be used by policy makers is when it’s the
policymakers who are making the decision; not when the politicians are
appealing to the people. And so...in cases where a committee is making a
decision pretty much behind closed doors, or if it’s something that
people [don’t] really care about or don’t really have an opinion about
most of the time; then science will play a large role. But, in cases where

Medical Cannabis in the United States

343

people are really excited and really fired up, I don’t think that science
plays that large of a role” (G4-7, U.S.).
Ballot initiative vs. legislature. The participants also agreed with previous
findings that there is a difference between factors involved in passing medical cannabis
laws via a ballot initiative and those passed by the legislature. The participants were
inclined to believe that giving constituents the power to pass laws contributed to the
success of passing medical cannabis legislation in some U.S. states, especially in the
early stages, as the voters were more willing to have policies changed. Five participants
believed that public support of an issue was important, but diminished the role that
scientific evidence played in influencing policy. Conversely, participants suggested that
medical cannabis laws passed by the legislative process were more thought out and
were more likely to be informed by scientific evidence.
“A real problem is that you can go through the state legislative process
where you may have some scientific evidence about medical marijuana.
Other states, since they went through a ballot initiative, it became more
of a popular referendum than a scientific discussion” (G4-1, U.S.).
“The fact that it happened initially through ballot initiatives is no
coincidence. There have been proposals in the legislatures- even in the
federal government- to decriminalise recreational use of marijuana or to
allow things for medicinal purposes, and none of that gets by legislature.
And it really was... it’s going directly to the populace and appealing to
the populace that caused some of these initiatives initially to pass, and
that gained momentum” (G4-10, U.S.).
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“I think that the states that adopted laws through voter referendum
initiative process, which was the first grouping of state medical
marijuana laws, they relied more on advocates using science to promote
a position. I think in the legislatures- when they were passed by
legislative bodies- there was an opportunity to consider a broader look
at science.... And some of the legislatures, such as Hawaii which passed
the law in 2000, saw this coming in their state and went about it more
judiciously through the legislature as opposed to allowing it to get
usurped and put on as a ballot initiative” (G4-10, U.S.).
The initiative process enables citizens to put an issue on the political agenda
which may not be seen as important by the decision makers, and allows the general
public to make decisions away from the influence of government. However, some may
think that with voter initiatives, all that has to be done in order to pass a law is convince
the public. This in essence reduces the use of scientific evidence as intended by
researchers, with scientific evidence potentially used as a means of convincing the
public to support a particular issue rather than informing it and increasing its
knowledge.
“So a lot of these things have happened by a voter initiative and so they
just sort of have to convince the public. So to the extent that scientific
evidence is used to help convince the public that there are people with a
medical need out there, then I suppose it’s having an effect; but it’s
probably an indirect one. There seems to be a lot of demagoguery on
either side in that kind of environment” (G4-5, U.S.).
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Factors politicians have to take into account. As discussed in the earlier
chapters, there are many factors other than evidence that politicians need to take into
account when making policy-related decisions. Factors such as getting re-elected, how
they are perceived, political ideology and funding are very important in influencing
politicians whether or not to support specific legislation. Group Four participants
mentioned that, in terms of medical cannabis, politicians usually look at more than just
proof of the therapeutic benefits of the drug, but instead consider other factors such as
efficacy, alternative medication, and economic advantages/disadvantages. Interestingly,
the most commonly mentioned factor was scientific evidence. However, the participants
concurred that scientific evidence plays a significant role when it is the policymakers
who are making the decision, such as when laws are passed by the legislative process,
rather than when a law is passed via the initiative process. Otherwise, the politicians
look to the decisions that are supported by the public and that will get them re-elected.
The participants also acknowledged the roles of various other factors, including funds,
extreme events, global perception of drugs and international standing, public perception,
ideology, lobby groups, laws in other states, policy advice that they receive,
politics/policy issues, and public health issues.
“The only time that I really think that science is going to be used by
policy makers is when it’s the policymakers who are making the
decision; not when the politicians are appealing to the people (G4-7,
U.S).
“What do I think they make their decisions based on? Whoever donates
to their political campaigns and whatever they need to do to get reelected is my cynical answer” (G4-4, U.S.).

Medical Cannabis in the United States

346

“The largest thing that comes into account for them is- can this come
back at them? If they make this decision, can there be something
concrete and high-profile, something with a perception of dread and the
unknown that really, really amplifies...that makes something coming out
of it to be really dramatic. The politicians’ perception that this could
come back to bite them. I think it definitely suggests that a politician be
cautious that they go to status quo, that they don’t try and allow more
medical trials because it’s a lot harder to be dinged for a nebulous
inaction that for a specific concrete action” (G4-7, U.S.).
“They need to take into account the various pressure groups who are
always trying to influence them in one direction or another....They need
to take into account the kind of policy advice they receive from the public
service; the quality and nature of which is incredibly variable, depending
on a lot of factors” (G4-2, Australia).
State differences. The responses of Group Four participants indicated that there
were differences between U.S. states that could determine whether legislation, such as
medical cannabis, was passed or not. These differences mainly focused on whether or
not a state had a ballot initiative process, as well as how the state attempted to pass
legislation. It was suggested that the U.S. allowed variety in terms of how policy is
made and implemented within a state, and the way that scientific evidence is used. As
seen in the state by state review, medical cannabis advocates and opposition groups can
be more active in some states than others and tend to choose where they will allocate
their time and resources. States were also found to be inclined to follow happenings in
other states and improve on previously passed legislation; such was the case in relation
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to medical cannabis legislation. As discussed in Chapter Four, policymakers should
look to other states to creating effective medical cannabis laws, which may then lead to
a more uniform approach to medical cannabis across the states.
“Dependent on the state, dependent on the time- some states would move
toward medical marijuana and then back off. Some states you grow your
own; some states you don’t. Michigan has a real problem in, it doesn’t
know how to deliver the medical marijuana....I think in some states it
may be one of those elements [influencing policy] may be stronger than
in others” (G4-1, U.S.).
“… I think that some knowledge was gained in the preliminary ones that
helped legislatures devise policies that meet the needs of all constituents,
not just the advocates for change” (G4-10, U.S.).
“I think the success that California has had- being the first state to pass
a medical marijuana proposition. So other states have seen that and said
“Oh, look! We can do that”. I think it’s greatly affected it. I don’t know
if any other state would have had the idea. I mean, 1998 was pretty
early. So, it’s been more reasonable than the past five to seven years, but
I think California’s passage greatly affected the rest of the states” (G4-6,
Australia).
Anecdotal evidence and testimonials. Another theme discussed by Group Four
participants was the use of anecdotal evidence and patient testimonials in the medical
cannabis debate. Participants believed that, in terms of medical cannabis policy,
anecdotal evidence was widely used and played an influential role. Participants also
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suggested that patient testimonies on the use of cannabis as a medicine were used to
portray a particular image of cannabis as a medicine and the individuals using the drug
for medical purposes, in order to influence policy.
“Lots of information was reported to the average person through the
newspapers and through the media. And the source of that information
was largely anecdotal. That doesn’t mean that it wasn’t valid or useful,
but from a scientific perspective it wouldn’t be viewed as rigorous as a
large informed study. But there were no large informed studies, so that’s
what they had to draw on” (G4-10, U.S.).
“.. I don’t think that, in the United States at least, we’re discussing
matters of medical fact very much. We’re using a lot of anecdote, but I
don’t know how much we’re using factual data....” (G4-7, U.S.).
“I think in all of those states, and certainly in California, you have these
testimonials of people who were in general community law abiding,
productive citizens, who use cannabis to control nausea or pain and
have gotten what they see as being great relief from it. And they give
emotional testimonials to the benefits of cannabis. I think those also play
a big role.” (G4-4-, U.S.).
Politics and policy. There are also politics-driven factors which can drive
policy, more so than scientific evidence. According to Kingdon (1995), the politics
stream comprises political issues such as election results, interest groups and public
opinion that need to be taken into account. Group Four participants also suggested that
the nature of politics and the political system can affect scientific evidence and its
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ability to inform policy. Issues such as political ideology are another aspect of the
process that was mentioned by participants who believed that medical cannabis policy
was driven and affected by ideology, more than by scientific evidence.
“Well, I think the cannabis policy is far more politicised and the result of
a 30, 40, 50 year battle of ideologies...” (G4-4, U.S.).
“I guess one of the really big impediments to using the scientific evidence
in thinking about medical cannabis is the highly political aspect of it. By
political, I’m thinking of party politics. And I’m also thinking of issues of
power more broadly- about who controls whom in society” (G4-2,
Australia).
“I think there’s also the political ideology that plays a major role. I
think...you have a bit of libertarian ideology in the United States. One of
the...political movements in the U.S. right now is libertarianism. In
which the governments should not interfere with the daily lives of its
citizens....And I think libertarianism has been an increasing force in
medical marijuana policy. That the government shouldn’t interfere; that
medical marijuana often becomes a part of the
legalisation/decriminalisation rubric. So, that kind of policy discussion
probably is stronger than the medical/scientific discussion” (G4-1,
U.S.).
The role of advocates. Similarly to Groups One and Two, Group Four
respondents rated advocacy groups as playing a major role in the creation of medical
cannabis policies. The respondents believed that advocacy groups for both sides were
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effective in raising the awareness of the issue and influencing public opinion. According
to participants, one of the reasons why advocates played an important role was their
ability to “sell” the issue to the public and policymaker. The question raised, however,
is how much of the advocacy groups’ stance is based on scientific evidence. As
previously mentioned, both medical cannabis opponents and proponents tend to
selectively use scientific evidence to support their arguments, ignoring the bigger
picture.
“I think that advocacy in this area makes a big difference; it clearly has
in the case of marijuana. Because things that people might do and talk
about at the federal level they can’t do, because of international
agreements or unwillingness, can be done at a more grassroots level,
and our structure of government at the States allows that. So advocacy
has definitely played a role. And when I say advocacy I should be clear;
I don’t just mean advocacy for people changing the law- I mean
advocacy for people opposed to the law” (G4-10, U.S.).
“I think...advocacy is very, very strong. Advocacy of medical marijuana
and drug policy is strong in the United States- as for being so extreme on
general drug policy laws....So in terms of taking the research out and
selling it to the media and to the public and to policymakers- I think
they’ve done a really good job” (G4-3, Czech Republic).
“I think that their dogged efforts are bearing fruit. I think that these
things take a long time, but...I think they’re having an effect on public
opinion; maybe using some scientific evidence- at least the scientific
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evidence that they favour. But some evidence anyway to change people’s
minds about things” (G4-5, U.S.).
While the participants believed that advocates play a role in the policy making
process, they suggested that they are not always necessarily basing their arguments on
scientific evidence. Additionally, participants stated that advocates sometimes used
scientific evidence to further their position, even if that position was not always based
on science.
“I think the science was used for advocacy purposes and not presented
by scientists per se. Some scientists were the ones presenting it, but
again it was used to promote a position as opposed to comprehensively
review everything we know and what we don’t know and whether it was
enough to make decisions” (G4-10, U.S.).
“And on the other side of things, I think that this is a big enough issue –
and it’s gotten enough attention – that I don’t think that advocates on
either side are basing their opinions on the scientific evidence. I think
that they’re picking their facts to fit their side” (G4-7, U.S.).
The importance of what is advocated. Participants suggested that some medical
cannabis advocates advocated for both medical and recreational use of cannabis. Not
making a distinction between medical and recreational use of the drug could hurt its
chances of being made legally available for medical purposes, as medical use of
cannabis is generally more accepted than general legalisation.
“But I think the groups that are advocating for medicalisation have also
tended to advocate for legalisation. I think that they have done some
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attempts to separate, and that has been successful for medical
marijuana…” (G4-1, U.S.).
“I find that many people who are on the pro-medical marijuana side
are...they make a strong argument for medical marijuana, but they also
make strong arguments for legalisation of marijuana for everybody…”
(G4-7, U.S.).
Perceptions, morals, and ideology. Apart from evidence, there are also factors
such as how an issue is perceived, people’s morals and ideology that those involved in
policy creation need to consider. Even factors such as how drug users are generally
perceived can influence whether or not a medical cannabis policy will be passed. Are
medical cannabis users seen as drug users or is a more compassionate stance taken and
they are viewed as people who are suffering and are in need of a medicine? Group Four
respondents mentioned the role of individual belief systems and their perceptions of
politicians and drug users. According to the respondents, even factors such as fear were
influential in passing or failing to pass medical cannabis policies. When we look at the
history of medical cannabis in the U.S., it has been viewed as different things at
different points in time, such as a medicine in the early 1900s, an evil drug in the 1930s,
and again as a potential medicine in recent times.
“Fear was a big part of it- if you smoke pot you’ll be a heroin addict.
Belief systems are still out there in the community and amongst some
conservative parents groups and all of that that you still heard...So there
are both of those” (G4-4, U.S.).
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“And so I still think that the first most important thing is the conception
or the construction of the people who use drugs. And the second thing is
the construction of the politicians, insofar as what makes a good leader.
And I think that construction of what makes a good leader is
changing....These constructions play a much larger role than the science
behind it....So I guess the main factor- one of the main factors- would be
how the users of drugs are viewed- are they constructed as the other, are
they constructed as good or bad, weak or strong?” (G4-7, U.S.).
“Now, linked to that is the issue of morals and values that different
people hold about the appropriateness or otherwise of using cannabis
under any circumstances. And that- those moral issues- don’t apply to a
lot of other medications” (G4-2, Australia).
The role of organised networks. The role of organised networks, such as
NORML, was also mentioned by Group Four participants who stated that organisations
played a role in the passage of medical cannabis legislation in some states. However, the
participants also believed that organised groups only had an effect when they worked in
conjunction with public opinion. It also depends on how well organised the networks
are and where they chose to focus their efforts.
“Well, I mean, the Soros Foundation, you know...I’m sure you’ve run
across that...has played a major role. As well as, of course, NORML, as
an organisation that played a major role” (G4-1, U.S.).
“...but also organised groups. Like, California in particular has a really
good organised network of people in the medical marijuana – or even
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marijuana generally – reform community. And these people are really
well organised and they’re really motivated, and they make things
happen in their state, in conjunction with the public opinion. ...they give
you all the organising you want to and if the public wasn’t crying outthen nothing would happen. So I think you need those things” (G4-5,
U.S.).
Overall, it was concluded that policy making is an ongoing, complicated process
depending on a number of different factors. The factors are required to come together in
order for a change to occur or a policy to be created and passed. It was also suggested
by Group Four participants that the process is multidisciplinary, and required
individuals in different fields and levels to work together.
“...it remains a very complicated process which the science informs, but
doesn’t really decide political polemics...I mean, there’s no clear
answer. It’s a very mixed bag of polemics. In some ways, yeah, you have
to always be a part of the political process. It’s a never-ending process”
(G4-1, U.S.).
“…that there are what I call a policy network or existing communities
that are ...in these networks there are scientists, there are lawyers, there
are politicians, there are also medical practitioners...that are working
together to do some research, to find some evidence to unearth, to
impact policies” (G4-9, France).
Discussion
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Group Four participants were sought for their expert opinion on the drug policy
process. One of the major themes to come out of the study is the need for further
research into medical cannabis. However, what is important when conducting such
research is that it is the type of research that matters to policy makers. Otherwise, it will
be difficult for the evidence to enter the policymaking arena and have major influence.
In order to identify the type of research required by the policymakers, a collaborative
approach between those involved in policymaking and the researchers is needed.
However, this is no easy feat.
While there has been a significant progress in the use of technology and social
media over recent years, ways of presenting and communicating the evidence has not
followed suit. Ritter (2006) found that politicians most commonly sourced information
by consulting an expert or technical reports, monographs and bulletins. Accessing the
internet and using statistical data were the other two most common sources of
information. A question then arises is why, with all the information available to them,
are the politicians not following the evidence? Researchers also need to make the
evidence more accessible, and to do this there needs to be a shift in how we
communicate with those we would like to inform, such as increasing the use of internet
and social media to promote research findings. If scientific evidence is to play a bigger
role in the policy making process, we need to look beyond the evidence into how we
can promote it and disseminate it effectively. As one Group Four participant said that
“the evidence alone never speaks for itself” (G4-2, Australia).
Another theme that was raised by Group Four participants was the issue of direct
democracy and whether policy decisions should be left up to the public, which can
oftentimes be uninformed but expected to make important decisions. In terms of ballot
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initiatives, care needs to be taken that they do not become more a popular referendum
than a scientific discussion. Most Group Four participants were also inclined to believe
that advocacy groups played more of a role in the laws passed via the ballot initiative.
The participants also felt that the legislative process met the needs of the constituents
rather than the advocates and also tended to be more influenced by the evidence. There
is also an indication that states which pass the laws through the legislature have more
scientific debate. The findings also suggest that, with the laws passed through the
legislative process, there was an opportunity to consider science more broadly. As one
participant stated:
And now it’s becoming more common to see these as legislative
processes which have thought through the implications of access and
supply, as well as how do you reconcile this with the prohibition on
recreational use. And those sorts of issues and the nuances were not so
well thought through in the initial ballot initiatives. (G4-10, U.S.).
The highly political aspect of medical cannabis can also be an impediment to the
use of evidence. There is the issue of federal versus state power, where direct
democracy measures have created a conflict between state and federal governments
(Ferraiolo, 2008; Hall & Degenhardt, 2003; McDonough, 2000; Pickerill & Chen,
2008). The question that arose is whether states should be able to decide for themselves
whether to legalise cannabis for medical use or if the federal government should
regulate this area of policy (Pickerill & Chen, 2008). There are also interest groups who
play a major role in states with the initiative process, and who have both monetary and
organisational power to have a big impact on public opinion as well as policy creation.
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In terms of politicians, evidence may not have a direct effect on agenda setting
or politician support. There are a number of factors politicians need to take into account,
with one of the most important being getting re-elected. As previously mentioned,
politicians need to carefully consider the timing of their decisions to support or oppose
particular legislation. Politicians also need to consider the impact and benefit of their
decisions, and what happens in the future. Other factors include, but are not limited to
campaign funding (who provides support for their re-election and how the decision to
support or oppose particular legislation will impact fund raising); how they are
perceived; international standing; lobby, pressure, and interest groups; political
ideology; what happened and is happening in other states; public opinion; scientific
evidence; and the policy advice they receive. Scientists interested in informing policy
need to consider these factors and create the sort of evidence that fits in with what
politicians need and are looking for. For example, one Group Four participant suggested
that:
They [politicians] are looking for the sound bites. And scientists
need to be aware of that. Sometimes you can only get a politician’s
attention for 5 or 10 minutes and need to reveal and tell a general gist in
that 5 to 10, and be OK with the fact that you can’t give all the qualifiers
and the nuances and you weren’t able to do this and that and that...We
as scientists sometimes want to provide all the situation, and we can’t
communicate that in the attention span of either the politicians or of the
average person. (G4-10, U.S.).
Findings also indicate that media can filter scientific evidence, and can be
selective as to what is or is not put forward to the public. One participant said that “the
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public does not have direct access to scientific evidence. It’s all filtered- primarily
through the mass media” (G4-2). What needs to be considered then is how well the
media filters the evidence and whether or not it is done in an objective way. Another
question to be considered is where the media gets its information from and what its
sources of “scientific evidence” are.
While a number of factors play a role it the policy process, in terms of medical
cannabis one question deserves significant attention: if cannabis is a medicine, why is it
not being treated as such? The evidence indicates that cannabis does have potential as a
treatment for some debilitating medical conditions. However, the findings of this study
indicate that cannabis is not treated as a medicine in the sense that the process of
making it legally available has been different from the process other medicines have to
go through, such as the FDA approval process. Medical cannabis is not obtained from a
normal drug store as other medicines are, but is instead grown by individuals or
distributed by special dispensaries. As a result, it is difficult to determine what “medical
grade” cannabis is and what appropriate dosages are, as it is left to the individual and
not a medical professional to determine these. In Los Angeles alone, it is estimated that
there are around 750 medical cannabis dispensaries (Linthicum, 2012). In order to
regulate the distribution of medical cannabis and after complaints and calls for
restrictions from the mayor, the police chief, the city’s attorney office, and the residents’
groups, a city ordinance was passed to shut down most of the dispensaries (Linthicum,
2012). The federal government also got involved and started issuing letters to
dispensaries stating that they are violating federal drug laws and that, despite the state’s
medical cannabis law, federal law takes precedence over state law. The potential
negative effect of this is that patients unable to grow their own cannabis or obtain it
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from a dispensary may expose themselves to risk by obtaining it from the black market,
where the quality of the drug is difficult to control. This would not be an issue if
cannabis were recognised as a medicine and obtained in the same way other medicines
are.
There is, however, a difference between medical cannabis and other medicines:
cannabis is not recognised as a medicine by the FDA. As previously discussed, all
medicines in the U.S. must be approved by the FDA; in order for cannabis to be
approved as a medicine, it needs to go through the FDA approval process. In order for a
medicine to be approved it needs to be proven that it is safe and effective, and that its
benefits outweigh the risks (Federal Food, Drug, and Cosmetic Act, 2000). So why is
cannabis not approved by the FDA? According to the FDA, evaluations by several
departments have concluded that “no scientific studies supported medical use of
marijuana for treatment in the U.S., and no animal or human data supported the safety
or efficacy of marijuana for general medical use” (FDA, 2006). The results from the
literature review conducted in Chapter Two indicate otherwise; there are clinical trials
which have shown that cannabis has medicinal value and potential to be used as a
medicine for some medical conditions.
However, the difficulties arise in relation to how the appropriate dosage would
be determined, what an appropriate route of administration would be, and what the
ingredients of medical cannabis would be. Moreover, as stated in Chapter One, there are
still many unidentified components of medical cannabis, making it difficult to approve
it as a medicine. The research so far has not clarified these issues, as one Group Four
participant put it:

Medical Cannabis in the United States

360

I think one of the major issues of medical marijuana is, if it is
going to be “medicalised” we really haven’t gone to the process of
defining dose, purity, how we manage and how we distribute it. Medical
marijuana rendered to a real problem of how you would distribute it,
how you would label it, define it, decide on a dosage level. In most
states, the delivery mechanism is difficult. In a few states, you grow your
own. Well, that’s kind of complicated. I mean, would you grow your own
penicillin? It has some real quality problems”. (G4-1, U.S.).
If medical cannabis laws are to be driven by science, then scientific research
needs to be enabled by re-classifying cannabis, providing funding for such research, and
allowing researchers access to medical-grade cannabis. Doctors need to be able to
prescribe the drug and determine the right dosage for the patient, and this will not be
possible as long as cannabis remains in Schedule I of the CSA. Cohen (2006) speculated
that, had cannabis not been included in the CSA and was taxed and regulated as are
alcohol and tobacco, “every ‘medical marijuana’ case would have been moot. And
under this scenario, as long as smoked marijuana was not advertised as a FDA-approved
pharmaceutical....it would undoubtedly have become one of this century’s premier
herbal medications” (p. 22).
Study limitations
As with the previous studies, there were some unavoidable limitations with the
Group Four study. One noteworthy limitation was generalisability. In Group Four, the
sample was varied and consisted of ISSDP members from three continents, the U.S.,
Australia, and Europe, who conducted drug policy research. The individuals had
varying degrees of familiarity with the medical cannabis debate, but all conducted
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research on drug policy. It is not possible to demonstrate that the sample was
representative of the population; therefore caution must be exercised in generalising
conclusions beyond the medical cannabis policy or policy field. Because it is such a
specific and somewhat controversial topic, there was also potential for bias, especially
due to a small sample size. However, the participants were chosen for a specific
purpose, and that is due to their expertise in the area of drug policy. As such, we cannot
make generalisations about the total population from this sample because it is not
representative.
The participants were identified through an ISSDP-supplied contact list and
were asked to participate due to their experience in the drug policy area. While the study
sample may have been biased due to non-random selection, as they were not identified
as being directly involved in the medical cannabis debate it was anticipated that Group
Four participants would be able to provide an objective appraisal of the medical
cannabis policy process. Literature suggests that elites such as politicians and experts
are busy people with time constraints and can also have distrust in the purpose of the
research or the trustworthiness of the researcher. The researcher therefore attempted to
make direct contact with this group of participants and establish rapport before
interviewing them. Face-to-face interviewing would have been preferred but was not
possible for the purposes of this study due to money and time constraints, and the
location of the researcher. As Nulty (2008) said, “whether or not a response rate is
adequate depends (in part) on the use that is being made of the data” (p. 307). In this
case, the data were treated as expert opinion on a particular topic, providing insight into
expert views of the medical cannabis policy process in addition to already established
findings. To decrease bias and to reach generalisability of data, future studies may want
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Chapter 7- Discussion
This study aimed to identify the main issues pertaining to the development of
medical cannabis policies in the U.S. This study was conducted in two stages. The first
stage was a state by state review of the medical cannabis debate in five representative
U.S. states to identify which factors played a role in the passing or failure to pass
medical cannabis laws in those states. The second part of the study involved using a
questionnaire and telephone interviews to further explore the factors which influenced
the medical cannabis policy process from the perspective of those directly involved in
the process, researchers not directly involved, and drug policy experts. This discussion
section is framed around the central research questions and the themes and sub-themes
that emerge from what has been presented in the previous chapters of this thesis. That
is, it will pull together the themes and sub-themes that emerge across the whole of the
study to discuss the overarching themes and answer the three research questions.
The literature review completed in Chapter Three indicated that cannabis has
medicinal properties, but further research is required to explore the efficacy and
effectiveness of cannabis in the treatment of specific medical conditions, identify which
conditions the use of cannabis is best suited for, the appropriate route of administration
and dosage, and the long-term consequences. While the long-term effects of medical
cannabis use are difficult to assess it was also noted that this can be experienced with
other conventional medication and is not considered a major problem in the medical use
of cannabis. For conditions which aren’t always successfully treated by other medicines,
medical cannabis may also be a beneficial addition to treatment or management of the
condition (Zajicek, et al., 2003). Therefore, further studies of medical cannabis are
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encouraged. In relation to the importance of increasing knowledge of medical cannabis,
Strang et al. wrote:
In its absence, public policy will continue to be made with
premature foreclosure of debate in the face of uncertainty by using
arbitrary rules about which side in the debate bears the burden of proofthose who defend the status quo or those who wish to reform our
cannabis laws. (p. 110).
One way to overcome the issue of mixed and unclear evidence would be to
conduct more research into cannabis as a medicine, especially smoked cannabis.
However, the difficulty lies in cannabis being a Schedule I substance in the CSA,
making it difficult to obtain research-grade cannabis and conduct studies. This issue is
discussed in detail throughout the thesis, and more specifically in Chapter Six. The
history of drug policy in the U.S. also shows that it is a complex process, and while
there were some shifts at the state level towards recognition of medical cannabis, the
attempts have largely been ignored by the federal government who maintain that there is
currently no evidence to support cannabis’ rescheduling. However, the fact that the drug
is placed in Schedule I creates a barrier to research. This has been summed up by the
Martin and Rashidian (2014) statement that “Cannabis is a Schedule I because there is
not enough federally approved research, but there is not enough federally approved
research because cannabis is a Schedule I” (p.29). Therefore, the first step towards
evidence playing a bigger role in medical cannabis would be for it to be rescheduled. In
the absence of that, other ways of giving evidence more prominence in the medical
cannabis debate need to be explored. As one Group Four participant put it:
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“I think in the future- especially if we can think about reclassifying or rescheduling drugs that are currently scheduled as
Schedule I- I think scientific evidence will play more of a factor....I would
say it’s got to be reclassed. It’s got to be rescheduled. People need to
have access to it in order to do studies, and studies need to be funded
and backed by policy or backed by U.S. federal government” (G4-6,
Australia).
What also needs to be addressed is the sort of research that is being done. In
terms of medical cannabis, it may be wise to separate the whole plant from its
compounds. It is highly unlikely that due to side-effects associated with it, smoked
cannabis will ever be approved as a medicine by the FDA, but there is potential for
other compounds to be made into pharmaceutical products (Hall & Degenhardt, 2009;
Martin & Rashidian, 2014). In the absence of a pharmaceutical product, the role of
whole plant cannabis also needs to be further explored, especially in the light of state
medical cannabis initiatives which have legalised smoked cannabis for medicinal use. It
is also important to consider how the use of evidence in policymaking can be approved,
and this is discussed next.
Kingdon (1995) described policy formation as the result of three processes or
“streams”; the problem stream, the policy stream and the politics stream. The problem
stream is related to matters requiring the attention of decision makers. It is important to
note that not all problems are given such attention. The policy stream involves proposals
for change. This implies that before a problem can reach the decision making agenda,
decision makers need to be given at least one solution to the problem. Kingdon states
that decision makers will prioritise problems where someone like the administration or
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the scientific community can provide them with a constructive solution. The politics
stream comprises issues such as election results, interest groups and public opinion that
need to be considered. The three streams are independent of each other and for the most
part operate independently, until they come together and a “window of opportunity”
opens for policy change. For scientific evidence to influence the policy agenda,
information would need to be readily available when “windows of opportunity” open
(Kingdon, 1995).
Another issue that needs to be recognised is that evidence is used in different
ways by the actors in the process. Cherry-picking, or selective use of evidence, was a
frequently occurring theme throughout this study and is discussed in more depth in
Chapter Four (p. 239). What this study found is that the three main arguments
frequently used for opposing medical cannabis legalisation were unproven safety and
effectiveness of cannabis as a medicine, cannabis as a “gateway drug” that leads to use
of more serious drugs, and sending the wrong message to the public that cannabis is safe
for recreational use. Medical cannabis opponents argue that there are already medicines
available that can treat symptoms and conditions for which cannabis has been shown to
be effective while supporters argue that cannabis can be used as a medicine for a range
of medical conditions including some which have not had strong scientific support.
Supporters also argue that cannabis has less abuse potential than drugs such as alcohol,
tobacco, and cocaine. In essence, evidence is used as ammunition in the fight, but there
is little acknowledgement by either side of the complexities and incompleteness of the
research evidence. As the debate tends to be oversimplified, what usually seems to be
omitted is the rational middle ground, one which objectively assesses the benefits and
costs of cannabis use.
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This lends support to Weiss’ (1991) assertion that one of the ways the research
enters the policy field is as research to which an advocacy position has been added and
used by policymakers and/or interest groups to support their position. The problem that
arises when research enters the policy field in such a way is that the some findings tend
to get selectively lost as they give way to findings that support a particular argument
(Weiss, 1991). This problem can be overcome by bridging the gap between what
knowledge is needed by policymakers and what is provided by researchers, as well as
what the research tells us and how the information gets used by the policymakers
(Ritter, 2011; Weiss, 1977, 1979). There are also concerns about what sort of evidence
is deemed “acceptable” by policymakers, who can select evidence that suits specific
political agendas and to seek justification for their decision on policy (Bacchi, 2009;
Nagel, 1990; Weiss, 1998, 1999). This is made more complex by the nature of evidence
available which is often vast, uneven in quality and inaccessible to policymakers
(Brownson et al., 2009; Davies et al., 2000). More medical cannabis research is also
needed to assist creation of more evidence-based policies and making the evidence more
accessible to policymakers and the public (Strang, Witton, & Hall, 2000).
However, having a debate about the evidence may not necessarily be a bad
thing. In an article that can still be applied to what we have seen in the medical cannabis
debate to date, Majone (1979) said that “The real problem facing regulating bodies
today is not the existence of conflicting expert opinions, but the inability of existing
procedures to channel disagreement toward constructive purposes” (p. 572). While
Majone recognised that regulatory decisions are increasingly based on arguments and
judgements about competing benefits and risks rather than facts, he also encouraged this
conflict as a way to educate the public. Because public opinion plays a significant role
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in influencing policy, it is important to consider how well informed the public is and
what sort of information they are getting.
Ideally, scientific evidence should always be incorporated in selecting and
implementing programs, developing policies, and evaluating progress (Brownson, et al.,
2011). The approval of any drug for medical use should also ideally be based on
evidence rather than political considerations (Cohen, 2010). However, this study is
consistent with the literature which finds that the policy process is inherently political
and does not rely solely on research evidence (Anderson, 2003; Brownson et al., 2009;
Brownson et al., 2011; Pentz, et al., 2004; Ritter, 2011). If research evidence was used
to drive policy, then cannabis would be recommended only for use as a medicine for the
conditions that the evidence supports, with some flexibility in relation to a conservative
or liberal interpretation of the research evidence. Smoked cannabis would also not be
the preferred route of administration. However, this is not the case in those states which
have enacted medical cannabis laws. For example, in New Mexico, medical conditions
included in the law go beyond the scope of currently available evidence and is also open
to adding other medical condition as approved by the NMDH. This supports Weiss’
“enlightenment model” that the impact of research on policy is not direct, but research
is instead seen as one of several sources of information available to policymakers
(Weiss, 1977, 1979). The other factors which were found to influence the medical
cannabis policy process are discussed next.
The findings of this study have indicated that scientific evidence does play a
role in the policy process, but not as significant a role as one may think, or as scientists
may like. While scientific evidence is one factor of influence, it is often not used in the
manner scientists would prefer but rather as ammunition to support an already adopted
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position. Contrary to what is generally believed, the medical cannabis process appears
to be less medically and more politically driven, and scientific evidence tends to fall
behind in its level of influence (Black, 2001). In this study, it is suggested that political
issues play a more central role than evidence. Factors such as the decoupling of medical
cannabis from wider moves to decriminalise or legalise cannabis are important, as are
anecdotal reports of those who have or could potentially benefit from medical cannabis,
and organised, well-funded advocacy groups. National advocacy groups can play an
important role, especially in states with a ballot initiative process. The success or failure
of a law can also depend upon context, timing, and persistence. As the U.S. is a
democratic republic, it is important to consider public opinion, which tends to play more
of a role in the states with a ballot initiative process. Public opinion is also taken into
account by politicians making policy decisions, amongst other factors that they need to
take into account, such as whether making a certain decision will work in their favour or
against them. While the support of powerful politicians can be important, as in the case
of New Mexico, lack of such support does not prevent such laws being enacted, as the
case of Michigan illustrates.
There are many factors which need to be taken into consideration when looking
at the political process and how certain laws are enacted. When questioned about the
factors influencing the medical cannabis process, there was no major difference noted in
terms of the importance of the factors. Depending on the person and the context,
generally all the factors identified in this thesis were rated as important. While the
factors mentioned in Chapters Four to Six can affect the policy process, they are not
free-standing and there is a relationship between the factors. There is a complex
relationship between science, public opinion, and political action and the decisions in
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the policymaking process are the cumulative result of interactions between the many
actors involved in the process (Kingdon, 1995; Sabatier, 1999; Speck, 2010; Wolf,
2000). In the case of medical cannabis, media coverage can influence public opinion,
which in turn can influence political actors. For example, the review of the five states
indicated that there was significant media coverage of the medical cannabis debate in
Michigan.This resulted in national organisations putting their efforts into passing a
medical cannabis law in that state. As the law was passed by a ballot initiative, the
public had to be informed in order to make a decision and vote for or against the issue.
The national advocacy organisations used media in order to promote their stance, and
while the opposition attempted the same, it did not do it on a large scale. In New
Mexico, there was a similar relationship between the media and the public, except that
New Mexico does not have the ballot initiative process, and the focus there was on
getting the support of the politicians. It is evident, based on the previous discussion of
what politicians take into account, that they took heed of public opinion whilst deciding
whether or not to pass a medical cannabis law. While it is difficult to conclude that had
media portrayed the issue differently or not portrayed it at all, it would not affect the
public’s perspective on the issue and that the laws would have been passed anyway, it is
also possible that the interplay between the three factors positively influenced the
outcome.
Kingdon (1995) viewed the three policy streams in his model as separate until
they come together to create a policy “window of opportunity”. Kingdon viewed these
three streams as largely independent of each other. While going beyond agenda setting,
the findings of this study indicate that the different factors co-exist and interact in
multiple ways. Some argue that a single framework cannot explain all its facets and it is
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difficult to reach consensus on which is the “best” or most satisfactory approach
(Anderson, 2003; Weible et al., 2012). This thesis did not focus on a particular
framework instead adopted the approach of the Institute of Medicine (IOM) (1999)
study which recommend commencing policy analysis by describing what happened with
no predetermined framework identified. However, future studies may use a framework
to attempt to explain the policy process. One framework, based on Kingdon’s (1995)
policy stream model, that could potentially prove a good explanation for the medical
cannabis policy process is described by Howlett, McConnell, and Perl (2013) as “A
Five Stream ‘Confluence’ Model”. This incorporates five different streams and involves
thinking about policymaking as a sequence of stages of the policy process, and sees the
streams as interacting and nested within others.
It would be difficult for the factors identified in this thesis not to interact. For
example, in relation to scientific evidence and limited access to it by the general public,
the media plays a role by filtering the evidence and presenting it to the public who then
make their opinions known, and these opinions are then taken into account by
politicians. Advocates also play a role in disseminating the evidence, as do the
researchers themselves. This then creates a set of interactions, which, although not
entirely predictable in terms of the outcome, have the ability to change the policy
making process. However, timing is important and can determine the success or failure
of the interaction. Researchers should understand that these factors should not be
interpreted individually as they do not make the policy process on their own, but are
rather part of a complex, interactive, and ongoing process, dependent on context and
time. The goal is to draw lessons from each of the factors and their interactions and
identify how science can best be part of the interplay.
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The context in which a law change is proposed, finding the right timing, and
most importantly, persistence, are also important factors to consider. In the states with
medical cannabis laws reviewed here, the advocacy efforts have been widespread.
Medical cannabis laws were not created overnight and were the result of persistent
effort by medical cannabis supporters to put the issue in the public arena, raise public
support and, in the case of Michigan, get the issue on the ballot. In the case of New
Mexico, medical cannabis supporters were constantly introducing medical cannabis
bills, sometimes more than one at a time. However, while the efforts in Illinois have
been just as persistent, a medical cannabis law is yet to be passed. Kentucky and
Louisiana have never had such efforts.
This is where the question of timing comes in. Throughout the literature, there
are references made to the importance of timing in the political context: when a
particular issue is introduced, when announcements are made and when bills are
introduced (Gibson, 1999; Kingdon, 1995). Gibson (1999) argued that the timing of
political events did not happen by chance, with politicians attempting to influence the
timing in order to maximise benefits and draw public attention to a particular issue or
draw it away if needed. In the case of New Mexico, this was evident in Gov. Johnson’s
decision to support medical cannabis in his last term as a governor, when he was not up
for re-election. His views continued to cause controversy, and an article published in the
Chicago Tribune noted that Gov. Johnson did not make his position on drug use clear
until his second term as a governor. This decision, however, had consequences as his
approval rating dropped by 11 points. It is therefore not enough to just put an issue
forward but to identify the right time to do so, based on careful consideration of factors
such as public support and sentiment and likelihood and desire of being re-elected. The
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findings in this thesis support Kingdon’s assertion that policy change occurs when a
“window of opportunity” opens for policy change. Timing was therefore an important
factor in medical cannabis policy creation.
Also related to timing is the change in the perceptions of medical cannabis. As
discussed in Chapter One’s history of medical cannabis, the public perceptions of the
drug have undergone change in the past 100 years. For example, previous to 1914,
cannabis was readily available in the U.S. (Grinspoon, 2000; IOM, 1999; Ruiz, et al.,
2007). Then, gradually, in the context of major social reforms, the Harrison Act saw the
federal government not only collecting taxes and ensuring registration of drug users, but
also the prosecution of doctors that prescribed the drugs (McBride, et al., 2009; Musto,
1999). Cannabis’ recreational use increased and it became popular among minorities,
including African-Americans and Mexican immigrants, who were feared as a source of
crime and deviant social behaviour (Musto, 1999). This saw the emergence of reports of
negative effects of cannabis and the drug being viewed as evil, which subsequently led
to cannabis use being prohibited in every state by 1937 (Gieringer et al., 2008; Mack &
Joy, 2000; Marshall, 2005; Musto, 1999). Despite an increase in cannabis use in the
1960s, which was also a period of economic growth in the U.S. and the drug becoming
a political issue, associated with anti-war protests, it remained legal under federal law
until the CSA was created in 1970 (Musto, 1999). What then followed is an attempt by
activists to portray the use of the drug as a medical necessity, starting with Robert
Randall's use of the "medical defence to defend himself against cannabis charges
(Gieringer et al., 2008), followed by the creation of the NORML organisation. One
Group Two participant said:
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“My impression is that the medical cannabis movement (i.e.
smoked cannabis, not THC pills) is partly an effort to show that cannabis
is a benign substance…” (G2-3, Illinois).
Since then the federal government has maintained that cannabis deserves its
Schedule I classification, and that there is no evidence to show otherwise. However,
there were shifts in 1978 when New Mexico became the first state to pass legislation
recognising cannabis as a medicine and subsequently 34 states had enacted legislation
which allowed their health departments to conduct research on the effectiveness of
cannabis as a medicine under the IND program (Koch, 1999; Werner, 2001). However,
the IND program was terminated and has not been revived since. Despite the lobbying
effort, it was not until 1996 that California became the first state to legalise the
cultivation, possession and use of cannabis for medical purposes that the medical
cannabis movement gained momentum and the public recognised the need for cannabis
as a medicine (MPP, 2013; Zeese 1999).
Michigan and New Mexico’s medical cannabis laws came to pass following the
first such law passed in California in 1996. States such as Michigan and New Mexico
also had ineffective medical cannabis and therapeutic research laws from 1978 which
they were trying to revive. Some medical cannabis laws are similar to that of California
while there are also variations in the state laws. New Mexico’s law was the first in the
country to specifically instruct the state to develop and implement a cannabis production
and distribution system, in response to criticism of the California law which led to
difficulties in medical cannabis production and distribution. In New Mexico, there were
regular calls from the medical cannabis proponents and the Department of Health to
model New Mexico’s medical cannabis program on Hawaii and Oregon’s, as they were
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deemed to be the most effective. Due to the states being subjected to similar pressures
and the expanding amount of information available, it can be said that policymakers are
looking to other political systems for knowledge and ideas that they can apply to their
jurisdictions, as was the case with New Mexico’s legislature (Dolowitz & Marsh, 2000;
Wolf, 2000). Wolf (2000) noted that there is no such thing as “best public
administration” but there are instead good and better practices which need to be
identified on the basis of national needs and the requirements for adaptation to the
political and administrative context in which they are to be applied. While there are
variations in state approaches to medical cannabis issues, policymakers should look to
other states to determine those parts of medical cannabis laws that have proven to be
effective, and apply it to their law. This will then, perhaps, lead to a more uniform
approach to medical cannabis laws across the states. However, policy transfer is not an
“all or nothing” process and the type of transfer likely to occur is subject to a number of
factors such as the actors involved in the process, the resources and time available to
them, and the nature of the problem they face (Dolowitz & Marsh, 2000).
Some may argue that it was not by coincidence that the first medical cannabis
law was passed by the ballot initiative process. As Watts (2010) notes, the past two
decades saw an increase in initiatives in the U.S. The initiative process is useful in cases
where law makers are unwilling to enact or consider a law that the citizens want, and in
the case of medical cannabis, after the attempts to reschedule cannabis since the CSA
have failed, attention turned to state measures (Watts, 2010). As discussed in Chapter
Two, the initiative process has largely become influenced by money and large interest
groups, but ultimately must involve mass audiences in order to place an issue on the
ballot and win on election day (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby,
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1998). The issue, however, is that the literature has found that voters often lack
education and competence to make policy decisions which allows for the elites to
influence voters’ choice (Burnett & Parry, 2014; Matsusaka, 2005).
So if the voters are uninformed about public policy, politics and government,
damaging policy may be adopted as a result. If the goal is to make more evidence-based
policy, then it is important to consider, especially in states with the initiative process,
the role science plays in informing the public and how scientific information can be
made more accessible to them. This view is also supported by Sabatier (1988) who
encouraged policy debates in order for policymakers to broaden their perspectives
beyond the ideological concerns and self-interest. Sabatier (1988) said that exposure to
competing views and justifying one’s position in a public forum would lead to a more
thought out policy. Therefore, as suggested by Majone (1979) steps need to be taken
encourage conflict about the evidence and a process where alternatives are encouraged,
particularly when the evidence is mixed. As Majone (1979) concluded:
By ensuring the representation of conflicting opinions and the
examination of a wide range of alternatives, well-designed procedures
can greatly improve not only the rationality but also the legitimacy of
regulatory decisions. (p. 580).
The results from the group studies discussed in Chapters Five and Six indicate
the participants’ beliefs that scientific evidence enters the debate more when the medical
cannabis laws are passed by the legislature than by the initiative process. The
participants also noted a difference in the factors influencing the debate at the legislative
and initiative level. They can also lead to different outcomes and improvements upon
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the laws in other states, such as New Mexico’s law being the first in the country to
specifically instruct the state to develop and implement a cannabis production and
distribution system, in order to assist patients in obtaining the drug (Lynn and Erin
Compassionate Use Act, 2007; MPP, 2013). Based on the findings in this study, a better
way of approaching medical cannabis policy may be to move the debate to the
legislature. There has already been an increase in states passing medical cannabis laws
through the legislative process, and this may be the way to go in order to increase the
use of science in the medical cannabis policy field (MPP, 2013). After all, government
elites tend to be more reflective of their constituents’ views because of their greater
electoral accountability and exposure to opponents’ views, whereas interest groups, who
largely influence the initiative process, tend to be more extreme in their views than their
constituents (Sabatier, 1988).
Conclusion
This thesis looked at the medical cannabis process in five representative U.S.
states and sought to identify the role of scientific evidence in the medical cannabis
policy process and other factors of influence. It provided an in-depth view of the
medical cannabis process in five representative states, and individual experiences of the
medical cannabis policy process through the eyes of those who were directly involved
in it. It also examined the process from the views of those not directly involved in the
process but conducting research in the alcohol and other drug field, and those
individuals who have expertise in drug policy research. This thesis also drew attention
to areas that need to be addressed by future research, such as the limitations of the
currently available scientific evidence, the need for further studies, and increasing the
role of scientific evidence in what is essentially a medical field.
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The study found that, despite the expectation that the same rules would apply to
cannabis as other medicine, the medical cannabis process appears to be less medically
and more politically driven, and scientific evidence tends to fall behind in its level of
influence. Factors such as political ideology, the initiative process in some states,
political timing, and interest groups tend to play a role in the process and more so than
scientific evidence. While this study recommended more research into cannabis as a
medicine, it is recognised that this is made difficult by cannabis being placed in
Schedule I of the Controlled Substances Act. Cannabis’ rescheduling would potentially
lead to more studies, especially long-term studies which are lacking. However, it is
unlikely that cannabis will be rescheduled in the near future, so the attention needs to be
turned to how the evidence can be used to assure that effective medical cannabis laws
are passed and that there is a more uniform approach across the states passing such
laws. There are also opportunities to improve the laws and how they are implemented,
through taking a more evidence-based approach. This study suggests that the first step
to doing this is for the debate to shift to the legislative process and for more systematic
effort being dedicated to educating the public and the policymakers. A collaborative
approach between researchers and policymakers is also recommended.
Although a controversial issue and still in the early stages of scientific
exploration, the topic of cannabis and its role as a medicine is nonetheless an important
one. It is an issue which should be further explored on both an individual and political
level, in order to develop successful laws which would benefit society and increase
knowledge of what it takes to create an effective law. It should also be questioned why,
if cannabis is a medicine, it is not treated as such, and what could be done to enable its
treatment as a medicine, such as undergoing the FDA approval process, giving
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physicians the ability to prescribe it, and controlling it in the same way other medicines
are controlled.
It is hoped that this thesis will be viewed as an observation of the medical
cannabis process, not only from the researcher’s point of view but from the views of
those who participated in the process, researched the process, or observed the changes
in medical cannabis laws over the years. It is anticipated that, by reporting the results of
this research, the main factors influencing the policy formation process can be identified
and that information used by researchers and those involved in the policy process as a
guide to improving the role of evidence in the medical cannabis movement. Ideally,
scientific evidence would be incorporated into all levels of policy decision-making and
the researchers would work collaboratively with policymakers to provide the knowledge
that is needed by the policymakers, while not losing sight of the best evidence.
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Appendix A- Questionnaire for Group One

Factors Influencing Medical Cannabis Policy Development in the United States
Dear participant,
Thank you for agreeing to take part in this study of the processes that led, or did
not lead, to the enactment of medicinal cannabis legislation in Michigan, New Mexico,
Illinois, Kentucky, and Louisiana.

Please note that you will remain anonymous and no responses will be
attributed to any individual.

Through the review of the published media reports relating to medical cannabis,
you have been identified as having actively participated in the medical cannabis debate
in one of the following states: a) Michigan; b) New Mexico; c) Illinois; d) Kentucky; or
e) Louisiana.
Please indicate which state you were MOST ACTIVELY participating in during
the 2000-2010 time period (select ONE).
___ Michigan
___ New Mexico
___ Illinois
___ Kentucky
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___ Louisiana
___ More than one state *
* Because of the nature of these questions, we ask that you specify one state
where you had most involvement by selecting it below:

___ Michigan

___New Mexico

___ Illinois

___ Kentucky

___Louisiana

As you answer the following questions, could you please answer in relation to
the state you specified. Should you wish to make additional comments in relation to
other states, please refer to Section 3 “Additional comments”.

This section relates to your opinions on medical cannabis and the medical
cannabis debate in your state. For the following statements, please indicate if you
strongly agree, agree, disagree, strongly disagree or do not know by circling the
letter (a, b, c, d, or e) that best reflects your view.
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SECTION 1

1. I support legislation to make cannabis legally available for medicinal purposes
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
2. Cannabis can be used effectively as a medicine
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
3. Cannabis is a gateway to the use of other illicit drugs
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
4. More research is needed on cannabis as a medicine
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
5. Scientific evidence plays an important role in the passing of medical cannabis
legislation
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
6. Laws to allow the use of cannabis as a medicine should be implemented in all
U.S. States
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
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7. Laws to allow the use of cannabis as a medicine should be implemented at the
federal level
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
8. It is important to separate medical cannabis legalization from the broader drug
legalization agenda
a) Strongly Agree
b) Agree
c) Disagree
d) Strongly Disagree
e) Don’t know
For Items 9-17, consider how important each of the following is to whether
medical cannabis legislation is enacted or not:
9. Advocacy groups
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
10. The extent to which advocacy groups are well organized
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
11. Politicians
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
12. The amount of money available to both legalization advocates and opponents
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
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e) Don’t know
13. Testimonies from people who have used cannabis as a medicine
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
14. The support of the executive branch of the state government (i.e., the governor)
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
15. The support of the legislative branch of the state government (Senate and the
House of Representatives)
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
16. Public support
a) Very Important
b) Somewhat Important
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
17. The media
a) Very Important
b) Very Unimportant
c) Somewhat Unimportant
d) Very Unimportant
e) Don’t know
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The following set of questions will enable us to group responses and to sort
the data collected. Please note that you will remain anonymous and no responses
will be attributed to any individual.
18. In the table below, please rate (by marking the corresponding box) the following
in terms of the level of influence you believe they have on medical cannabis
legislation (0= no influence, 5= some influence, 10=very high influence).
No
Influence
0

Very Little
Influence
1

2

3

4

Some
Influence
5

6

7

Very
High
Influence
8

9

Advocacy groups
High-profile individuals
Money
Lobbyists
Opposition groups
Patient testimonies
Support in the legislature
Public support
Media support

19. Have you or anyone you know used cannabis for medical purposes or
recreational use? (You can give more than one response).
a) Yes, I have personally used cannabis for medical purposes
b) Yes, I know someone who has used cannabis for medical purposes
c) No
d) Yes, I have used cannabis for recreational purposes
e) Yes, I know someone who has used cannabis for recreational purposes
f) I opt not to disclose this information
20. Which of the following most accurately describes your political affiliation?
a) Democrat
b) Republican
c) Other ____________ please specify
You have now completed the first section of the questionnaire.

10
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SECTION 2
The following section will provide you with an opportunity to expand on the
answers you provided in the first section of this questionnaire. There is no limit on
the length of your answer. If more space is required, simply attach as many pages
as you need. Please answer to the best of your ability.

The first part of this section contains general questions relating to the
medical cannabis debate and the factors influencing medical cannabis legislation.
1) In your opinion, which factors influenced the passing or failure to pass medical
cannabis legislation in your state?

2) Does scientific evidence play a role in the medical cannabis debate in your state?
If so, what role does it play?

3) Does the separating of medical cannabis from the broader aim of cannabis
legalization have an impact on the medical cannabis debate in your state? If so,
what impact does it have?

4) Please describe the role politicians played or are playing in the medical cannabis
debate in your state.
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The second part of this section consists of more specific questions relating to
factors influencing the medical cannabis debate in Michigan, New Mexico, Illinois,
Kentucky, and Louisiana.
5) What effect did or does the involvement of national advocacy organizations,
such as the Marijuana Policy Project (MPP) and the National Organization for
the Reform of Marijuana Laws (NORML), have on the medical cannabis debate
in your state?

6) What effect did or does the involvement of the Office of National Drug Control
Policy (the “Drug Czar”) have on the medical cannabis debate in your state?

7) What are your views on the way money was or is used in your state, in relation
to the medical cannabis debate?

8) Some U.S. states have a ballot initiative process for proposing a new law or a
constitutional amendment at the state level. Other states do not have the
initiative process and rely on the legislative branch of government.
What are your views on the effect these differing processes have on the medical
cannabis debate in your state?

9) What are your views on the role state-based organized lobby groups had on the
medical cannabis debate in your state?
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10) In some U.S. states, city-level changes to medical cannabis legislation preceded
changes at the state level.

What are your views on the effect city-level changes have on the state-level
medical cannabis legislation?

END OF QUESTIONNAIRE
Thank you for taking your time to participate in this study. We appreciate
your responses.
If you would like to leave comments regarding this questionnaire or would
like further information, please contact Jelica Grbic (researcher) by telephone
(+61 86304 2654 or +381 61 422 345 397) or email (jgrbic@our.ecu.edu.au).
If you would like to obtain further information regarding the results of the
study, a summary will be made available to you by the researcher upon request.

SECTION 3
Additional Comments
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Appendix B- Additional Questions for Group Two

Dear participant,

Thank you for agreeing to take part in this study of the processes that led, or did not
lead, to the enactment of medicinal cannabis legislation in Michigan, New Mexico,
Illinois, Kentucky, and Louisiana. You have the option of saving your answer and reopening the site to complete the questionnaire at a later time (no later than January
14th 2011).

Please note that you will remain anonymous and no responses will be attributed to any
individual.

Through the review of publicly available data, you have been identified as a researcher
in the alcohol and other drug field, currently receiving a grant from the NIAAA, NIDA,
or SAMHSA* in one of the following states: a) Michigan; b) New Mexico; c) Illinois;
d) Kentucky; or e) Louisiana.

* Please disregard this survey if you are not currently or have not in the
past conducted research funded by NIAAA, NIDA or SAMHSA.

Please indicate which state you currently conduct alcohol and other
drug related research in (select ONE).
Michigan
New Mexico
Illinois
Kentucky
Louisiana

Medical Cannabis in the United States

Please indicate your awareness of the medical cannabis debate in your state
Very aware
Somewhat aware
Neither aware nor unaware
Somewhat unaware
Very unaware

Please indicate the level of your involvement in the medical cannabis debate in
your state
Very involved
Somewhat involved
Neither involved nor uninvolved
Somewhat uninvolved
Very uninvolved
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Appendix C- Informational Email

Subject name: Factors Influencing Medical Cannabis Policy Development in the United
States

Dear (Potential Research Participant’s Name)
My name is Jelica Grbic, and I am a PhD student in the Faculty of Computing,
Health and Science at Edith Cowan University (ECU), Western Australia. I am
conducting research under the supervision of Dr. David Ryder (Faculty of Computing
Health and Science, ECU) and Professor Perilou Goddard (Department of Psychology,
Northern Kentucky University).
You are invited to participate in a research study looking at the policy process
underlying medical cannabis laws in the U.S.A, aiming to identify how problems and
issues are recognized and raised, and how and why governments choose to act or not act
on certain policies. Through a review of the literature, you have been identified as
someone who could comment on the policy process, and we are interested in hearing
about your experiences.
As a participant in this study, you will be asked to answer questions through an
internet survey. The survey can be accessed on the following link
http://ecupsych.qualtrics.com/SE/?SID=SV_0HCbC6H8BbrdRQM .
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The questions will ask you about the medical cannabis policy process which lead
to laws being passed or not passed.
Participation in this research project is voluntary, and will take approximately 1
hour of your time. You will not be asked to provide any personally-identifying
information. There are no anticipated risks or discomforts related to this research,
except for the time you take to answer the research questions. You may decline to
answer any questions presented during the study if you wish to do so. You will be free
to withdraw your consent and cease your involvement in the research project at any
time.
Due to the nature of your involvement in the policy creation field, you will be
identified in the research project, but not identified by the questionnaire. However,
should you wish to do so, you will be able to request anonymity, upon which the
researcher will remove all the identifying information relating to you from the project,
and your information will be presented using numerical codes. The data with identifying
information will be kept for a period of five years following the completion of the
research, after which it will be destroyed. The data will be securely locked in an office
in Edith Cowan University, to which only the researcher and the supervisors will have
access.
The benefits of participation in this study include an opportunity to raise issues
relevant to you, and offer your perspective on the medical cannabis policy process. You
will also gain insight into what challenges helped shape your experiences and ways in
which this occurred. You will also be able to express your wishes for future policy
development.
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If, after receiving this email, you have any questions about this study or would
like additional information to assist you in reaching a decision about participation,
please feel free to contact me or either of my supervisors using the information supplied
below. If you would like to obtain the final results of this research, you may also contact
me on the numbers/email supplied below. If you wish to speak to someone independent
of this research, please contact the Postgraduate Coordinator in Public Health (ECU)
Kim Clark, whose contact details are supplied below.
This research has been approved by the Human Research and Ethics Committee
at Edith Cowan University.
If upon reading the information presented here you wish to participate in this
research project, please reply to this email and indicate your consent by writing the
following into the e-mail message: “I have read the above information regarding this
research study on medical cannabis policy in the U.S, and consent to participate in this
study”.

Thank you for your interest in this research and for your assistance.

Regards
Jelica Grbic
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Researcher’s contact details
Jelica Grbic
PhD Candidate
Faculty of Computing, Health and Science
Edith Cowan University
Telephone: (08) 6304 2654
Mobile: +61422345397
Email: jgrbic@student.ecu.edu.au

Supervisors
Dr David Ryder
Coordinator of Clinical Psychology Courses
School of Psychology and Social Science
Edith Cowan University, JOONDALUP
Telephone: (08) 6304 5452
Facsimile:
(08) 6304 5834
Email: david.ryder@ecu.edu.au

Professor Perilou Goddard, Ph.D.
Department of Psychology
Northern Kentucky University
BEP 355, Nunn Drive
Highland Heights, KY 41099
Telephone: 859 572 5463
Facsimile: 859 572 6085
Email: goddard@nku.edu

Independent Contact
Kim Gifkins
Research Ethics Officer
Edith Cowan University, JOONDALUP
Telephone: (08) 6304 2170
Facsimile: (08) 6304 2661
Email: research.ethics@ecu.edu.au
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Appendix D- Information Letter

Subject name: Factors Influencing Medical Cannabis Policy Development in the United
States
Dear
My name is Jelica Grbic, and I am a PhD student in the Faculty of Computing,
Health and Science at Edith Cowan University (ECU), Western Australia. I am
conducting research under the supervision of Dr. David Ryder (Faculty of Computing
Health and Science, ECU) and Professor Perilou Goddard (Department of Psychology,
Northern Kentucky University).
You are invited to participate in a research study looking at the policy process
underlying medical cannabis laws in the U.S.A, aiming to identify how problems and
issues are recognized and raised, and how and why governments choose to act or not act
on certain policies. Through a review of the literature, you have been identified as
someone who could comment on the policy process, and we are interested in hearing
about your experiences.
As a participant in this study, you will be asked to answer questions included in
this letter. After completion we ask that you return the questionnaire to us in an
envelope provided by December 10th 2010. The questions will ask you about the
medical cannabis policy process which lead to laws being passed or not passed.
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Participation in this research project is voluntary, and will take approximately 1
hour of your time. You will not be asked to provide any personally-identifying
information. There are no anticipated risks or discomforts related to this research,
except for the time you take to answer the research questions. You may decline to
answer any questions presented during the study if you wish to do so. You will be free
to withdraw your consent and cease your involvement in the research project at any
time.
Due to the nature of your involvement in the policy creation field, you will be
identified in the research project, but not identified by the questionnaire. However,
should you wish to do so, you will be able to request anonymity, upon which the
researcher will remove all the identifying information relating to you from the project,
and your information will be presented using numerical codes. The data with identifying
information will be kept for a period of five years following the completion of the
research, after which it will be destroyed. The data will be securely locked in an office
in Edith Cowan University, to which only the researcher and the supervisors will have
access.
The benefits of participation in this study include an opportunity to raise issues
relevant to you, and offer your perspective on the medical cannabis policy process. You
will also gain insight into what challenges helped shape your experiences and ways in
which this occurred. You will also be able to express your wishes for future policy
development.
If, after receiving this mail, you have any questions about this study or would
like additional information to assist you in reaching a decision about participation,
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please feel free to contact me or either of my supervisors using the information supplied
below. If you would like to obtain the final results of this research, you may also contact
me on the numbers/email supplied below. If you wish to speak to someone independent
of this research, please contact the Postgraduate Coordinator in Public Health (ECU)
Kim Clark, whose contact details are supplied below.
This research has been approved by the Human Research and Ethics Committee
at Edith Cowan University.
If upon reading the information presented here you wish to participate in this
research project, please indicate your consent by writing the following statement on the
tear-off docket below: “I have read the above information regarding this research
study on medical cannabis policy in the U.S, and consent to participate in this
study”.
Thank you for your interest in this research and for your assistance.
Regards
Jelica Grbic

Please write your consent here and return with the questionnaire.
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Researcher’s contact details
Jelica Grbic
PhD Candidate
Faculty of Computing, Health and Science
Edith Cowan University
Telephone: (08) 6304 2654
Mobile: +61422345397
Email: jgrbic@student.ecu.edu.au

Supervisors
Dr David Ryder
Coordinator of Clinical Psychology Courses
School of Psychology and Social Science
Edith Cowan University, JOONDALUP
Telephone: (08) 6304 5452
Facsimile:
(08) 6304 5834
Email: david.ryder@ecu.edu.au

Professor Perilou Goddard, Ph.D.
Department of Psychology
Northern Kentucky University
BEP 355, Nunn Drive
Highland Heights, KY 41099
Telephone: 859 572 5463
Facsimile: 859 572 6085
Email: goddard@nku.edu

Independent Contact
Kim Gifkins
Research Ethics Officer
Edith Cowan University, JOONDALUP
Telephone: (08) 6304 2170
Facsimile: (08) 6304 2661
Email: research.ethics@ecu.edu.au
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Appendix E- Group Four Interview Questions

Semi-Structured Interview Schedule
Demographic information
What is your current occupation?
Have you ever conducted research into drug policy?
Prompt: Please tell me a bit more about your research. What did your
research mainly focus on?
Have you ever studied policies on the use of cannabis as a medicine?

1) What role do you think scientific evidence generally plays in policy-making?
Prompt: How do you think scientific evidence influences government
recognition of a particular issue as requiring consideration and / or action?
Prompt: More specifically, what role do you think scientific evidence plays
in policies related to alcohol and other drugs?
Prompt: What role do you think scientific evidence plays in passing medical
cannabis policies?
2) How do you think scientific evidence is used by individuals directly or indirectly
involved in policy creation (e.g. politicians, lobbyists, and the voting public)?
Prompt: Can you please give specific examples to illustrate the view you
have just given?
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3) It is a belief held by some medical cannabis opponents that insufficient research
has been conducted on medical cannabis to warrant a policy change. What is
your opinion on this?
4) Which factors influence the policy making process? And specifically, drug
policy related process?
Prompt: Which factors are important for politicians to take into account
when making policy-related decisions?
5) What are some of the notable differences between the role scientific evidence
plays in general and medical cannabis-related policy making?
6) In your opinion, which factors influenced the passing of medical cannabis
legislation in 15 US states (such as California, Michigan, and New Mexico)
since 1998?
7) What role do you think the scientific evidence played in passing medical
cannabis laws in 15 US states?
8) In your opinion, what role will scientific evidence play in the future in relation
to policy making?
9) It has been said that scientific evidence does not play a significant enough role in
informing alcohol and other drug policies. Do you agree with this statement and
if you do, what do you think we can do to improve its significance?
Prompt: Can you suggest how we might give scientific evidence a more
significant role in informing policy on the use of cannabis as a medicine?

